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Paediatric B-cell non-Hodgkin Lymphoma (B-NHL), namely Burkitt lymphoma and 
diffuse large B cell lymphoma, is successfully treated in the majority of patients in the 
UK at the cost of debilitating toxicity. For patients who undergo disease progression 
the prognosis is dire, with salvage rates as low as 20%. Previous studies have 
identified putative markers of disease progression, but none are currently used in the 
clinic. There is a clear need for usable markers of relapse/refractory disease at 
diagnosis for paediatric B-NHL with the aim to stratify patients and identify new 
potentially targetable genes and pathways.  
 
Copy number analysis of 162 patients from the CCLG and published data identified 
genomic aberrations associated with disease progression: 17p copy number neutral 
loss of heterozygosity (CNN-LOH), 3q29 amplification and 17q CNN-LOH. 17p CNN-
LOH was a prognostic marker with a hazard-ratio of 5.6 (95% CI 2-16, p=0.001, Cox 
proportional hazard method). TP53 was investigated further using a combination 
Sanger sequencing and whole-exome sequencing. TP53 aberrations were present in 
52/95 cases, with biallelic abnormalities conferring poorer outcomes. Biallelic TP53 
aberrations were also associated with complex chromosomal abnormalities, including 
a novel aberration termed 13qplex. Copy number analysis of 105 endemic BL patients 
treated in Malawi showed that prognostic aberrations in sporadic BL are present but 
not prognostic in endemic BL. TP53 aberrations were identified in endemic BL and 
were not associated with relapse, however biallelic cases had an inferior overall 
survival.  
 
Investigating 11 diagnostic and relapse pairs demonstrated that TP53 status drives 
evolution of chemo-resistant disease. BLs with TP53 aberrations at diagnosis 
exhibited linear evolution, while TP53 normal cases had early-diverging patterns of 
progression and acquired TP53 aberrations at relapse. We report TP53 as an 
important prognostic marker in paediatric B-NHL that confers higher risk of disease 
progression and may help inform treatment decisions allowing for the possibility of 
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Chapter 1: Introduction 
 
B cell non-Hodgkin Lymphoma (B-NHL) is a solid haematological malignancy of B 
lymphocytes that presents in lymphoid tissue and other extranodal sites. Currently 34 
types of mature B cell neoplasm are recognised by the World Health Organisation 
(WHO) (Swerdlow et al., 2016) and these vary widely in incidence, median age at 
diagnosis, clinical presentation and prognosis. The fastest growing and most 
aggressive forms of mature B-NHL are Burkitt Lymphoma (BL) and diffuse large B 
cell lymphoma (DLBCL), while follicular (FL) and marginal zone lymphomas, for 
example, are considered indolent, or less aggressive.  
 
The expected incidence of haematological neoplasms in the UK is 38,090 cases per 
year, of which 9620 are B-NHL based on data for 2001 recorded by the 
Haematological Malignancy Research Network Census (HMRN, 2019). Slightly more 
than half of B-NHL cases in the UK are diagnosed as DLBCL (4980 cases). The 
relative incidences of new B-NHL diagnoses are not consistent in all age groups 
(Figure 1.1). In younger patients, BL is the most common diagnosis of B-NHL until 
the adolescent years, where the incidence of DLBCL increases and remains the most 




Figure 1.1 - Number of UK cases of NHL subtypes per year by age. Data from 
HMRN, 2019. 
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1.1 The Germinal Centre 
 
The germinal centre (GC) is a transient lymphoid histological structure formed as a 
result of T cell-dependent antigen presentation, and many of the mechanisms driving 
lymphomagenesis play a role in normal GC biology (Basso and Dalla-Favera, 2015). 
The major role of the GC is to produce and select B cells with high affinity antibodies 
through somatic hypermutation. The GC is comprised of the dark one  and the 
light one . B cells (CXCR4hiCD83lowCD86low) in the dark zone are highly 
proliferative and undergo somatic hypermutation here (Victora et al., 2010). 
Conversely, light zone B cells (CXCR4lowCD83hiCD86hi) are accompanied by 
dendritic cells, macrophages and T cells, and are activated and selected for based 
on their receptor affinity (Figure 1.2). MYC is an important regulator of the GC 
physiology, both in lymphomagenesis and normal function. MYC is highly expressed 
early in the GC initiation stages but it is then suppressed in dark zone B cells by 
BCL6. Light zone B cells that return to the dark zone by cyclic re-entry are known to 
re-express MYC (Basso and Dalla-Favera, 2015).  
 
 
Figure 1.2  A summary of the activity and cellular composition of the germinal 
centre. Taken from Basso and Dalla Favera (2015). 
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BCL6 is a major regulator of the GC, inhibiting target gene expression via DNA 
binding and recruitment of histone deacetylase complexes (Hatzi et al., 2013). The 
BCL6 gene is responsible for modulation of a large and complex network of genes 
associated with multiple related pathways including DNA damage response, somatic 
hypermutation, cell cycle arrest and apoptosis (Basso and Dalla-Favera, 2015). 
BCL6 is crucial to adaptive immune response mechanisms and BCL6-deficient mice 
have been shown to lead to a complete absence of GC formation (Dent et al., 1997). 
E2A, encoded by the TCF3, gene is expressed in the dark zone, driving cell cycle 
progression via cyclin D3 (CCND3) and E2F2 induction and downregulation of RB1. 
ID3 functions to inhibit active E2A, forming a vital axis of regulation. The interaction 
between TCF3, ID3 and CCND3 has been shown to be important in Burkitt 
Lymphoma, where 74% of cases were shown in one study to have a mutation of 
either ID3 or TCF3 (Lopez et al., 2019).  
 
B cells undergo somatic hypermutation in the dark zone of the GC, then migrate to 
the light zone for antigen selection. Exit of the light zone relies on the downregulation 
of BCL6 in B cells driven by BLIMP1 (PRDM1) expression.  
 
The MYC proto-oncogene is implicated in the initiation and maintenance of many 
cancer types (Dang, 2012). In fact, MYC was the first gene to be shown to be 
associated in GC-derived lymphomagenesis (Dalla-Favera et al., 1982). Expression 
of MYC is required for initiation of the GC and then is repressed in dark zone cells as 
a result of BCL6 expression (Calado et al., 2012). MYC re-expression is then only 
observed in B cells re-entering the dark zone from the light zone.  
Translocations involving immunoglobulin genes are frequently observed in mature B 
cell lymphomas, and this is linked to normal processes involved in B cell 
development including class switch recombination, V(D)J recombination and somatic 
hypermutation. In V(D)J recombination, induction of the recombinant activation genes 
RAG1 and RAG2 leads to cleavage of the DNA between recombination signal 
sequences (RSS). This mechanism in healthy cells drives antibody antigen 
specificity. However this machinery can lead to the juxtaposition of oncogenes 
adjacent to an immunoglobulin locus, usually IGH. The frequent involvement of IGH 
and other IG loci is due to its propensity to harbour double strand breaks. One of the 
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earliest detectable genetic events in B cell lymphoma is the t(14;18) translocation 
involving the BCL2 and IGH genes often seen in follicular lymphoma and less 
frequently in GCB-DLBCL (Blombery et al., 2015). This is thought to take place 
during the pro-B cell stage as a result of D-J rearrangement. Further translocations 
identified in BL and DLBCL arise within the germinal centre. The hallmark BL 
translocation t(8;14) involving the MYC and IGH genes occur in the dark zone as a 
result of aberrant class switch recombination at a time when MYC expression is still 
high (Dominguez-Sola et al., 2012). Further evidence implicating class switch 
recombination is the fact that the breakpoints of in the MYC gene are clustered at the 
AID (activation induced cytidine deaminase) hotspots adjacent to exon 1 of the gene. 
Further alterations to the MYC gene are regularly observed as a result of AID-
induced somatic hypermutation (Dominguez-Sola et al., 2012). With the exception of 
high MYC expression in the germinal centre driven by MYC rearrangement, BL cells 
share a gene expression profile with normal dark zone germinal B cells. This pattern 
of expression is implemented by activating mutations in TCF3 and inactivating 
mutations in ID3.  
 
Ectopic MYC expression drives proliferation and progression through the cell cycle 
which supports lymphomagenesis, but also activates pro-apoptotic pathways, 
including via TP53. Genetic aberrations involving the TP53 gene or its regulators are 
required to inhibit these pro-apoptotic signals and maintain lymphoma development 
(O'Leary et al., 2004). Overexpression of MDM2 has been reported in BL (Capoulade 
et al., 1998), and MDM4 expression is believed to be high in almost all BL cases 




1.2 Subtypes of B-NHL 
 
This thesis focuses primarily on two common subtypes of B-NHL: BL and DLBCL. 
Both present similarly but pathologists are able to differentiate between the two 
primarily though immunohistochemistry (IHC) and fluorescence in-situ hybridisation 
(FISH) for MYC-rearrangement with an immunoglobulin locus. Despite this there is 
still ambiguity in some B-NHL diagnoses where a firm subtype cannot be determined. 
In addition, intermediate diagnoses do exist, which are not fully characterised 
currently. For example, many paediatric B-NHL express markers that resemble BL 
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when queried by IHC, but lack a detectable MYC-rearrangement (Leucci et al., 
2008). Some of these cases are determined to be BL, some would have been 
considered Burkitt-like  or B cell l mphoma, unclassified (BCLU) in previous WHO 
classifications but would now be classified as either the high grade B cell lymphoma, 
not otherwise specified (HGBL, NOS) or Burkitt-like lymphoma with 11q aberration 
(BLL-11q) which are both new to the WHO 2016 classification (Swerdlow et al., 
2016) (Table 1.1). 
 
 
Table 1.1  A table summarising the main B-NHL subtypes and their associated 
genetics. Information collated from Blombery et al. (2015) and Swerdlow et al. 
(2016).  
 
1.2.1 Burkitt lymphoma 
 
B-NHL Subtype Abbreviation Genetic Lesions
Burkitt lymphoma BL
Hallmark IG-MYC  translocation. Activating 
CCND3  and TCF3  mutations. 
Inactivating ID 3 mutations
Germinal centre DLBCL GCB-DLBCL
Frequent IGH-BCL2 translocations. 
BCL6 deregulation through mutations in 
BCL 6, FBXO1 1, MEF2 B, CREBB P and 
EP30 0. 
Activating EZ H2 mutations. 
MYC upregulation through P TEN loss. 
Dysregulated inhibition of centroblast 
migration and Akt signalling via inactivating 
mutations of RHOA, GNA13  and S1 PR2. 
Activated B cell DLBCL ABC-DLBCL
NF-kB activation via activating MYD88 
mutations and biallelic loss of TNFAIP3. 
BCL6 deregulation via IGH-BCL6 
translocations and translocations with non-
IGH partners. 
Failure of post-GC differentiation through 
PRD M1 mutation or loss. 
Burkitt-like lymphoma with 
11q aberration BLL-11q
Lack of detectable IG-MYC translocation. 
Copy number aberration involving telomere 
of 11q.
High grade B cell 
lymphoma, not otherwise 
specified
HGBL, NOS
Lack of detectable IG-MYC , IG-BCL2  and 
IG-BCL6  translocations
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There are three subtypes of Burkitt Lymphoma recognised by the WHO: endemic BL 
(eBL), sporadic BL (sBL) and immunodeficiency-associated BL (Swerdlow et al., 
2016). Endemic BL is primarily found in sub-Saharan Africa, accounting for 
approximately 50% of all childhood cancers in Africa (Molyneux et al., 2012; 
O'Callaghan-Gordo et al., 2016). Sporadic BL is the subtype found primarily in the 
western world, including Western Europe and the United States of America, but is 
diagnosed globally. The third form is associated with immunodeficiency and is 
recognised and specific to individuals with compromised immune systems due to 
transplant related immunosuppressant therapy, HIV virus infection, congenital 
immunodeficiency disorders or various iatrogenic causes. The hallmark of Burkitt 
Lymphoma, regardless of subtype, is a translocation that places the MYC proto-
oncogene under the regulation of an immunoglobulin chain locus (most commonly 
IGH) leading to constitutive, high level expression, but less than 5% have no 
detectable rearrangement of the MYC gene (Swerdlow et al., 2016). Burkitt 
Lymphoma is the most common aggressive lymphoma in children, but incidence 
decreases with age (Figure 1.1). Paediatric BL is treated successfully in a paediatric 
setting with over 90% 5 year event free survival (Giulino-Roth and Goldman, 2016; 
Minard-Colin et al., 2016). Conversely, adult Burkitt Lymphoma has been reported to 
have 2 year event free survivals as low as 37% (Perkins and Friedberg, 2008).  
 
1.2.2 Diffuse large B cell lymphoma 
Diffuse large B cell lymphoma makes up the largest proportion of B-NHL overall and 
encompasses neoplasms with a wide spectrum of clinical and pathological features. 
DLBCL usually presents as a rapidly growing mass at a lymph node or extra-nodal 
site. The vast majority of DLBCL diagnoses are made in adults but the disease is 
found in children and adolescents. As a large and heterogeneous group of 
lymphomas it has been difficult historically to find subgroups to stratify patients as no 
method of subdivision, including morphology, was found to be reliable or reproducible 
by the REAL (Revised European-American Lymphoma) classification. The WHO 
recognises many subtypes of DLBCL including ALK+, EBV+, plasmablastic and IRF4 
rearranged while cases that do not fit into an existing category are deemed to be 
DLBCL, NOS (not otherwise specified). More recently, gene expression profiling by 
microarray analysis has been utilised to identify three distinct DLBCL, NOS subtypes 
with expression profiles that correspond to germinal centre B cells (GCB), activated B 
cells (ABC) and type 3/unclassifiable (Alizadeh et al., 2000), with ABC-DLBCL being 
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associated with a significantly poorer prognosis. The 2016 WHO classification takes 
elements of these previous classifications into account (Swerdlow et al., 2016) and is 
generally adopted by clinicians and researchers across the world. GCB-like DLBCL is 
the most common DLBCL subtype and has a generally superior prognosis (Alizadeh 
et al., 2000). Conversely, ABC-like DLBCL is less common and has a worse 
outcome. ABC-like DLBCL is also significantly less frequent in the paediatric disease 
compared to GCB-like. In addition to ABC-like gene expression pattern, expression 
of MYC (Chang et al., 2000), BCL2 (de Leval and Harris, 2003) and Ki67 (Miller et 
al., 1994) are all associated with inferior outcome. However, in paediatrics these 
markers are not associated with prognosis (Miles et al., 2008). The most recently 
proposed subgroup is large B cell lymphoma with IRF4 rearrangement. The subtype 
is characterised by a high expression pattern of IRF4/MUM1, usually but not 
exclusively with an IRF4 rearrangement. It is an uncommon subgroup, present in 
approximately 0.05% of DLBCL diagnoses and has been observed in both adult and 
paediatric disease (Swerdlow et al., 2016).  
 
1.2.3 Burkitt-like Lymphoma with 11q aberration 
The WHO Classification for 2016 introduced a new subtype of B-NHL characterised 
by a lack of IG/MYC translocation, Burkitt-like morphology and a chromosomal 
abnormality on 11q (BLL-11q) (Swerdlow et al., 2016). Originally characterised by 
Salaverria et al. (2014) the subtype describes a subset of cases which would 
previously have been described as either a MYC-negative BL or BCLU (B cell 
lymphoma, unclassified) with Burkitt-like features. They are typically CD20+, CD10+, 
BCL2- and Ki67+ near 100%. The hallmark abnormality on 11q involves a gain most 
commonly between 11q13 and 11q23 followed by a loss of 11qter and the 
abnormality is most frequently described as a tandem duplication. The subtype 
strongly resembles a form of post-transplant Burkitt Lymphoma with no detectable 
MYC rearrangement and proximal gain of 11q paired with telomeric deletion (Ferreiro 
et al., 2015). It is important to note that the inclusion of the BLL-11q subtype in the 
2016 WHO Classification is provisional as there is still controversy regarding the true 
nature of the subtype, with some believing it is a BL-like subtype while others 
consider it a form of DLBCL or HGBL (Ferreiro et al., 2015; Havelange et al., 2016a). 
This highlights the need for better characterisation of this rare subgroup of B-NHL so 
that the most appropriate therapy can be given to patients and new targeted 
 8 
therapies can be implemented based on robust biological understanding of these 
cases. Relatively little is known about the prognosis of BLL-11q as few cases have 
been characterised to date, however in the adult setting it is believed that BL-like 
cases with no detectable MYC rearrangement have a better prognosis on BL 
regiments rather than R-CHOP in the adult setting (Sevilla et al., 2007). Cases of this 
subtype are usually EBV negative and have relatively quiet genomes, comparable to 
MYC-rearranged BL (Gonzalez-Farre et al., 2019). BLL-11q cases have been 
reported to have frequent 5q21.3-5q32 copy number gain and deletions on 6q, but 
lack the 1q gains frequently seen in MYC-rearranged BL. Mutations in typical driver 
genes in BL, namely ID3, TCF3 and CCND3, were not identified in BLL-11q cases, 
instead a GCB-DLBCL-like mutational landscape was observed, with mutations of 
BTG2, ETS1, EP300 and GNA13 identified more frequently. Further analysis in the 
same study showed that the mutational profile of BL patients without MYC 
rearrangement or 11q aberration resembled neither MYC-rearranged BL nor BLL-11q 
(Gonzalez-Farre et al., 2019).  
 
1.3 Genomic and Molecular Landscape of B-NHL 
 
1.3.1 Burkitt Lymphoma 
 
Burkitt Lymphoma is defined by a hallmark MYC translocation, predominantly 
t(8;14)(q24;q32) involving the immunoglobulin heavy chain (IGH) locus. In a smaller 
percentage of cases MYC translocations involve the immunoglobulin light chain loci 
lambda (IGL) by a t(8;22)(q24;q11.2) translocation or kappa (IGK) by t(2;8)(p12;q24) 
rearrangement to the same effect. Other than this primary translocation the BL 
genome is generally quiet, without additional translocations and few other major 
cytogenetic abnormalities (Hummel et al., 2006). Burkitt Lymphoma cells resemble 
normal germinal centre B cells in terms of gene expression profile (Dave et al., 
2006). By a combination of sequencing and staining techniques, it has been shown 
that BL cells are most comparable to dark zone centroblastic cells, while the majority 
of other B cell lymphomas resemble light zone centrocytes. Very few differences in 
gene expression have been found between these two cell types. A notable exception 
is the finding that TCF3 is upregulated in dark zone cells compared to light zone, and 
mutations of the gene are implicated in BL pathogenesis (Schmitz et al., 2012). 
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IGH/MYC translocation in sporadic BL is believed to be a result of aberrant class 
switch recombination (CSR), the process by which the B cell uses double stranded 
breaks in the IGH region to change the arrangement of heavy chain genes to switch 
the immunoglobulin class that the cell produces (Burmeister et al., 2013). Both BL 
and normal GC B cells express AID, an enzyme that deaminates cytosine bases 
converting them to uracil. This leads to a base mismatch, which will be bound by 
proteins of the mismatch repair (MMR) pathway, which in turn recruit an exonuclease 
to excise the aberrant uracil base and create a single strand break. Binding sites for 
AID are abundant in the IGH locus, leading to frequent deamination of cytosine 
bases (Ramiro et al. 2004). Double stranded breaks occur when two deaminated 
bases are close to one another on different strands. This is utilised by the B cell to 
excise heavy chain genes that code for now-redundant heavy chain classes (Kumar 
et al., 2014). However it is well known now that AID has many off-target effects in loci 
outside the IGH region, including PAX5, BCL6 and MYC (Kato et al., 2012) which 
have been shown to lead to translocations (Lieber et al. 2016).  
 
MYC acts as a transcription factor for many genes, many of which are involved in cell 
survival, proliferation and apoptosis, resulting in its implication in a plethora of human 
cancers. It was first identified as a viral gene in the genome of the acute transforming 
retrovirus which caused tumours in chickens (Duesberg and Vogt, 1979). The 
identification of MYC at the breakpoint of t(8;14) translocations in BL led to the 
confirmation of its role as a proto-oncogene. Transgenic mouse experiments show 
that MYC is transforming in vivo, but that cessation of MYC expression leads to 
regression of tumours, suggesting that continuous expression is required to maintain 
the tumour state, and that inactivation of MYC could be a viable therapeutic target. 
Additionally, due to the clonal nature of transgenic models with ectopic expression of 
MYC it is suggested that secondary abnormalities are required in BL for malignant 
transformation to occur. Additionally, transgenic Eµ-MYC mouse models of 
lymphoma are distinctly different to BL, often being lymphoblastic (Harris et al., 
1988). Eµ-MYC mouse models have been used extensively to investigate the 
pathogenesis of MYC-driven lymphomagenesis. A study using these mouse models 
showed that constitutive activation of MYC accompanied with deregulated PI3K 
activity gives rise to BL-like tumours (Sander et al., 2012).  
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Several studies have investigated the genomic landscape of Burkitt Lymphoma using 
a range of low- and high-resolution techniques. The vast majority of studies have 
primarily described sporadic BL. Poirel et al. (Poirel et al., 2009) collected karyotype 
data from 238 BL and DLBCL patients treated on the FAB/LMB 96 trial (French, 
American British/Lymphomes Malins B). The most frequently identified abnormality in 
BL, other than MYC translocation was gain of 1q (29% of patients), followed by gain 
of 7q (14% of patients) and deletion of 13q (14% of patients). Copy number gains 
involving chromosome 1q have been reported in several studies as the most frequent 
secondary abnormality in BL (Lones et al., 2004; Onciu et al., 2006; Toujani et al., 
2009; Scholtysik et al., 2010) with conflicting conclusions regarding prognostic value. 
Poirel et al. had the largest patient cohort but did not detect any significant difference 
in prognosis between 1q gained and 1q normal BL patients. However, sample size 
and varying therapeutic regimens may go some way to explain the differences in 
outcome.  
 
Chromosome 13 is frequently aberrant in B cell lymphoma, including BL. Cytogenetic 
studies have identified deletions of 13qter in BL. Lones et al. (2004) detected loss of 
13q32-qter in two patients (2/18, 11%) and both of these patients relapsed while the 
abnormality was not detected in any of the patients who did not relapse. Poirel et al. 
(2009) detected 13q loss in 38/238 (16%) cases, with the most commonly deleted 
region mapped to 13q34. Remarkably, 13q loss did not differ significantly in 
incidence between BL and DLBCL cases, suggesting involvement of a pathway 
common to both disease subtypes. An investigation utilising FISH (fluorescence in 
situ hybridiation) to characterise chromosome 13 and 7 abnormalities in Burkitt 
Lymphoma and evaluate their prognostic significance identified 13q deletions in 42% 
of patients, considerably more frequently than the Poirel study (Poirel et al., 2009; 
Nelson et al., 2010). The study observed 20% of cases (18/90) with deletion of both 
13q14.3 and 13q34 and an additional 8% harboured a loss of 13q34 alone (7/90). 
Karyotyping data was available for 18 of the cases investigated, and 44% of these 
(8/18) showed loss of 13q compared to 78% by FISH of the same 18 samples. This 
partial lack of consistency between techniques may explain the difference in 
frequency of 13q loss between studies. 13q14.3 deletion was associated with 
significantly inferior prognosis and it was hypothesised that deletion of DLEU1 and 
DLEU2 conferred the poor outcome in these patients (Lee et al., 2017). 
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The increasing resolution of microarray technology enabled greater understanding of 
13q abnormalities in B cell lymphoma. Array CGH analysis of 15 BL cell lines and 13 
patient samples (Toujani et al., 2009) identified a small minimal common region 
(MCR) of amplification at 13q31.3-q32.1. The authors identified this amplified region 
in five cell lines and two tumour samples. The region contained 12 genes and one 
microRNA cluster, and it was postulated that ABCC4 was the driver gene in this 
region. ABCC4 is a member of the ATP-binding cassette gene superfamily of 
transporter proteins and is part of the MRP (multi-drug resistance-associated protein) 
subfamily, which is known to be involved in multiple drug resistance in cancer that is 
reversed when the gene is silenced by RNAi (Zhang et al., 2015). However later 
genomic studies with higher resolution SNP arrays refined the region of amplification 
of the 13q31.3 region of amplification in BL and postulated that it was the 
amplification of miRNA cluster MIR17HG that was most significant within this region 
(Scholtysik et al., 2010; Schiffman et al., 2011). Schiffman et al. (Schiffman et al., 
2011) reported that of 28 paediatric Burkitt Lymphoma samples analysed by SNP 
array, three harboured amplification of MIR17HG and of them two relapsed (Figure 
1.3). This raised the possibility of a prognostic role for MIR17HG amplification in 




Figure 1.3 - Copy Number Gain of MIR17HG in three paediatric BL cases. Adapted 
from Schiffman et al. 2011.The top panel shows the size and nature of copy number 
gains and deletions on chromosome 13q. Green bars represent copy number gain 
and red bars represent deletion. Panels 2-4 show the processed 13q copy number 
data for the three patients.  
 
A recent study further investigated the amplification of MIR17HG in BL using 
Affymetrix Mapping 100K SNP arrays and Fluorescence in Situ Hybridisation (FISH). 
A cohort of 24 patients (13 children and 11 adults) was screened for the abnormality 
(Havelange et al., 2016b). MIR17HG amplification was detected in five patients 
(20.8%). Interestingly, four of the five patients were children and the one adult was 
22 years old, suggesting that the abnormality may be an age-associated abnormality 
in Burkitt Lymphoma. However, they did not include enough patients in the study to 
meaningfully investigate the prognostic impact of the abnormality. Other than the 
incidence of MIR17HG amplification no significant differences in copy number 
profiles between adult and paediatric BL have been reported (Klapper et al., 2012).  
 
As described earlier, gain of chromosome 7 is a frequent abnormality in BL and has 
been shown to have a significant negative effect on event-free survival (83.6% vs 
72.2%) (Poirel et al., 2009). The region contains 64 genes and, notably, the mir106b-
25 miRNA cluster, a paralog of the MIR17HG miRNA cluster. Like MIR17HG, 
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MIR106B is involved in proliferation and resistance to apoptosis and has been shown 
to induce doxorubicin resistance in breast cancer cells. Nelson et al. (2010) 
investigated the incidence and prognostic value of chromosome 7 gains in 68 BL in 
patients from the COG (Children s Oncolog  Group) CCG-5961 study. 10% of 
patients (7/68) investigated by FISH for CEP7 (centromere of chromosome 7) 
harboured a gain of the region. This result is consistent with the findings of Poirel et 
al. despite investigating a different region of the chromosome. Results from the Poirel 
study suggested that smaller regions of copy number gain were detected proximal to 
7q21-q22 which would not be identified by a CEP7 probe. Nelson et al. did not detect 
a significant difference in overall survival or event-free survival in patients with 
chromosome 7 gains compared to the rest of the cohort, conflicting with previously 
published studies (Lones et al., 2004; Poirel et al., 2009). A possible explanation for 
this is that both studies treated patients using different therapy protocols: the Poirel 
study incorporated patients treated as part of the FAB/LMB96 trial with COPADM, 
CYVE/CYM while the Nelson paper studied patients treated with the much less 
intensive CHOP regimen. This would not explain the conflicting incidences of 
abnormalities between studies but may explain difference in prognostic value. 
 
Four studies investigating the mutational spectrum of Burkitt Lymphoma were 
published in 2012 using next generation sequencing approaches (Love et al., 2012; 
Richter et al., 2012; Schmitz et al., 2012; Giulino-Roth and Goldman, 2016). The 
results of these studies, as well as two subsequent sequencing studies (Abate et al., 
2015; Havelange et al., 2016b) are summarised in Figure 1.4. 
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Figure 1.4 - Summary chart displaying the incidence of specific mutations in BL from 
6 studies that were identified in over 10% of patients using a combination of Whole 
Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing 
approaches. 
 
MYC and ID3 mutations were the most frequent mutations in BL and were identified 
in all studies. Mutations in several other genes were identified in >10% of patients, 
namely CCND3, TP53, SMARCA4, GNA13, TCF3 and RHOA. Over 70% of BL 
cases had mutations in either ID3 or TCF3. ID3 (inhibitor of DNA binding 3) functions 
by binding E proteins including E2A which is coded by the TCF3 gene. Silencing 
mutations of exon 1 of ID3 were shown to abrogate the ability of ID3 to bind and 
inhibit E2A and lead to loss of regulation of cell cycle progression in B cells (Richter 
et al., 2012). Uninhibited activation of TCF3/E2A by mutant ID3 or activating 
mutations of TCF3 itself leads to activation of PI3K kinase pathway and antigen-
independent constitutive activation of the B cell receptor. TCF3 mutations frequently 
affect the E47 transcript at the B-HLH (basic helix-loop-helix) domain, removing 
binding affinity for ID3. CCND3 encodes cyclin D3 and mutations were frequently 
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reported in BL that lead to overexpression and protein stabilisation. Additionally, 
increased TCF3 expression as a result of ID3 or TCF3 mutations can transactivate 
the CCDN3 gene leading to deregulation of the G1 to S phase transition (Figure 1.5) 
(Schmitz et al., 2012). However, none of these sequencing studies presented 
associated clinical data to identify prognostic markers.  
 
Figure 1.5 - Deregulated pathways in Burkitt Lymphoma. Schmitz et al. 2012. 
 
Recent studies of sporadic and endemic BL have highlighted genomic events that 
were enriched in specific subtypes of BL. The primary driver of genetic differences 
between subtypes is thought to be EBV status (Grande et al., 2019). AID activity was 
significantly higher in EBV positive cases. Regions enriched for non-coding mutations 
were regularly identified at transcription start sites in EBV positive BL patients that 
were associated with somatic hypermutation. These genes were the highest 
expressed in BL tumours of both subtypes, but expression was not associated with 
mutation at that locus. The same study identified recurrent mutations in apoptotic 
genes, including TP53, in EBV negative BL more frequently than in EBV positive BL, 
supporting the hypothesis that EBV infection drives inhibition of apoptosis in BL 
(Grande et al., 2019). Additionall , the incidence of Burkitt-associated genes  was 
significantly lower in EBV positive BL than those without EBV involvement. These 
genetic differences between EBV groups, and strongly associated with tumour 




A study involving whole genome sequencing of 101 BL samples representing all 
three subtypes reported that the genomic profiles of immunodeficiency-associated 
and sporadic BL were very similar while endemic BL, particularly the EBV positive 
cases, were distinct from other subtypes. Mutations in MYC were most frequently 
observed across BL subtypes, with 72 driver genes identified across the cohort 
(Panea et al., 2019). Genes thought to play roles as oncogenes including BCL6 and 
MCL1 were shown to harbour a series of missense mutations and amplification 
events while putative tumour suppressor genes such as DDX3X, ARID1A and ID3 
were repeatedly deleted or harboured truncating mutations. As the first whole 
genome sequencing study of a large BL cohort, the study reported the novel finding 
that non-coding events occurred in the majority of driver genes and over 90% of 
cases had at least one non-coding mutation in a driver gene. For a subset of genes 
this was proven to be associated with somatic hypermutation, which complements 
the findings of Grande et al. (2019). Further validating their findings, a strong 
association was observed between EBV positive endemic BL and dysregulation of 
AID function (Panea et al., 2019). Remarkably, ID3 abrogation was one of the most 
common events in all three disease subtypes, and investigation in cell lines showed 
that ID3 synergised with MYC in BL pathogenesis. The authors postulated that due to 
the similarities in genetic profiles between BL subtypes that clinical trials and new 
therapeutics identified in sporadic BL will be relevant in the endemic and 
immunodeficiency-associated subtypes. This may be broadly true, but it is important 
to remember the significant differences between clinical settings in the Europe/USA 
compared to sub-Saharan Africa. Vastly different treatment protocols will likely exert 
unique selection pressures onto the progressing disease, resulting in the acquisition 




1.3.2 Germinal Centre-like B cell DLBCL (GCB-DLBCL)  
 
When the GCB and ABC subtypes were first reported by Alizadeh et al. (Alizadeh et 
al., 2000), two primary oncogenic events were identified in the GCB subtype; 
IGH/BCL2 translocation and REL amplification. Up to 40% of GCB-DLBCL cases 
have t(14;18)(q32;q21) IGH/BCL2 translocations which leads to constitutive 
overexpression of BCL2, a feature common to both ABC and GCB-DLBCL subtypes, 
but more commonly due to BCL2 amplification or upregulation in ABC-DLBCL. 
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However high expression of BCL2 is not solely a result of translocation or 
amplification, as high expression has been observed in patients with no detectable 
BCL2 abnormalities. This would suggest that other mechanisms are necessary for 
increasing BCL2 expression in these patients, such as NF- B activation, loss of mir-
15 and mir-16 expression (Cimmino et al., 2005) or changes to epigenetic regulation 
of the BCL2 gene. Patients with IGH/BCL2 translocation have been shown to 
express significantly higher levels of BCL2 and CD10 than their non-translocated 
counterparts (Iqbal et al., 2004).  
 
Resistance to apoptosis is recognised as one of Hanahan and Weinberg s (Hanahan 
and Weinberg, 2011) Hallmarks of Cancer. BCL2 plays an important role in the 
inhibition of apoptosis and as such is known to be important in the pathogenesis of 
multiple cancer types (Yip and Reed, 2008) after originally being identified by the 
t(14;18)(q32;q21) translocation in non-Hodgkin Lymphoma. The BCL2 family of 
proteins consists of pro-apoptotic and anti-apoptotic members that share one or more 
BH domains (BCL2 homology), and mutation or dysregulation of pro-apoptotic 
members also occurs in cancer. High BCL2 expression reduces the ability of 
cytotoxic therapy to kill tumour cells by inhibiting apoptosis. As BCL2 inhibits 
apoptosis at the mitochondrial membrane by abrogating cytochrome c release, it is 
able to block apoptotic stimuli originating from almost any source, including the vast 
majority of cytotoxic drugs utilised in cancer treatment. The t(14;18)(q32;q21) 
translocation has been shown to be associated with a significantly poorer prognosis 
in GCB-DLBCL (Figure 1.6) (Visco et al., 2013).  
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Figure 1.6 - Kaplan Meier plot showing overall and progression-free survival of 
DLBCL patients with and without BCL2 translocation stratified by GEP defined 
subgroups.(Visco et al., 2013). 
 
EZH2 (enhancer of zeste homolog 2) is mutated in approximately 20-30% of GCB-
DLBCL cases. Wildtype EZH2 is a histone methyltransferase with a SET domain that 
plays a role in the Polycomb Repressive Complex 2 (PRC2) and is required for 
normal embryonic development and VDJ recombination in pre-B cells (Su et al., 
2003) before being downregulated. EZH2, as part of the PRC2, methylates histone 3 
at lysine 27 (H3K27) leading to repression of specific genes. While EZH2 has 
important functions in embryonic stem cells, in germinal centre B cells the list of 
target genes of EZH2 are not entirely identical, suggesting that the function of the 
gene in GC cells is different. It has been demonstrated that EZH2 is required for the 
formation of the germinal centre and that mutant EZH2 can cause hyperplasia in the 
germinal centre (Béguelin et al., 2013). The most common variant of EZH2 found in 
GCB-DLBCL is EZH2Y641N which leads to increased methylation of H3K27. It is 
believed that this change drives growth in B cell lymphoma cells, but the precise 
mechanism by which this occurs remains elusive. Beguelin et al. (2013) also showed 
that EZH2-mutant cell lines have higher levels of proliferation as a result of 
repression of CDKN1A. CDKN1A is normally activated in a p53-dependent manner to 
halt cell cycle progression (Bendjennat et al., 2003). Another role of EZH2Y641N is to 
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block differentiation of DLBCL cells, just as GCB-DLBCL cells are locked at the GC 
phenotype. EZH2Y641N but not wildtype EZH2 was shown to do this through the 
suppression of PRDM1 (Béguelin et al., 2013), a gene frequently deleted in ABC-
DLBCL. Additionally, ChIP-seq experiments showed that other genes important for 
terminal differentiation including BCL6, HOXA7 and IRF4, as well as PRDM1, were 
co-occupied by trimethylated H3K27. Altogether, EZH2 mutants have the propensity 
to cause GC B cell hyperplasia, suppress genes required for GC B cells to leave the 
germinal centre stage of development and provide an ideal state for additional events 
to transform a GC B cell into a GCB-DLBCL cell. 
 
PTEN (phosphatase and tensin homologue deleted on chromosome 10) gene 
deletion is observed in about 10% of GCB-DLBCL cases, but loss of PTEN 
expression has been detected in up to 55% of cases. In an extended cohort of 214 
DLBCL cases, 44% of GCB-DLBCL cases were shown to express PTEN by IHC 
(>5% cells staining) in contrast to 87% in non-GCB-DLBCL (Pfeifer et al., 2013). The 
results were corroborated by Western blotting in cell lines. Curiously, out of 18 GCB-
DLBCL patient samples investigated by quantitative PCR, deletion of PTEN was only 
detected in 3 cases (16.7%), suggesting alternative mechanisms that lead to loss of 
PTEN expression are involved. Sanger sequencing of the samples revealed an 
acquired 3bp deletion of PTEN in one GCB-DLBCL patient with no PTEN expression. 
While the incidence of PTEN mutation appears to be low, somatic mutations are able 
to abrogate expression of the gene. PTEN functions to negatively regulate the 
PI3K/AKT pathway. The PI3K/AKT pathway is implicated in DLBCL as a driver of 
proliferation and survival of tumour cells and is activated by phosphatidyl-inositol-3,-
4,-5-triphosphate. PTEN dephosphorylates this molecule, thus abrogating the 
pathway. Loss of functional PTEN leads to the pathway being activated and supports 
tumour growth. This has been supported by detection of an inverse correlation 
between PTEN expression loss and levels of phosphorylated AKT (Pfeifer et al., 
2013) and the discovery that PTEN-deficient GCB-DLBCL cells respond well to PI3K 
inhibitor treatment. Outside of the PI3K/AKT pathway, PTEN is important for genome 
stability through upregulation of RAD51 to prevent double strand breaks (Shen et al., 
2007).  
MYC translocation is the hallmark of BL but also occurs in GCB-DLBCL patients at 
lower incidence. These patients have a significantly inferior prognosis compared to 
their MYC- counterparts and have been associated with a higher proliferation rate 
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with 50% of MYC+ having a Ki67 above 90% compared to 7.5% of MYC- cases 
(Savage et al., 2009). 
 
Amplification of the REL gene, coding for the REL proto-oncogene of the NF- B 
transcription factor family, has been reported in approximately 30% of GCB-DLBCL 
cases (Scholtysik et al., 2015). REL plays an important role in normal lymphocyte 
biology as it is the predominant NF- B dimer after B cell maturation (Table 1.2) 
(Gilmore and Gerondakis, 2011). B cell division and survival in response to stimuli is 
vital to initiation of an adaptive immune response and REL is required by B cell 
receptor activated B cells to progress from G1 to S phase of the cell cycle (Grumont 
et al., 1998), as well as for MYC upregulation in G1. c-Rel also plays an anti-
apoptotic role in BCR activated cells by activating Bcl-2 family proteins A1 and Bcl-
XL, each playing a different role in B cell survival as evidenced by their different 
response kinetics to c-Rel activation. c-Rel is also required for successful isotype 
switching from IgG to IgE (Kontgen et al., 1995). Despite NF- B e pression being 
highest in ABC-DLBCL, REL amplification is more frequently reported at higher 
incidences in GCB-DLBCL (Scholtysik et al., 2015) and as a result it has been 
suggested that REL amplification is required early in the development of GCB-
DLBCL, but not in disease progression. Despite the high incidence of REL 
amplification in DLBCL, no DLBCL cell lines exist with the abnormality. It is possible 
therefore that REL amplification aids growth of GCB-DLBCL cells in vivo only, and 
additional unknown factors are required for in vitro cell growth.   
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GENE/PROTEIN PROTEIN FUNCTION 
CELL PROLIFERATION/CELL GROWTH 
 C-REL Transcription factor 
 C-MYC Transcription factor 
 IRF-4 Transcription factor 
 E2F3A Transcription factor 
 EP300 Histone acetyltransferase 
 CD21 Complement receptor 
 CD40 Cell surface receptor 
 SFN 14-3-3 protein 
 GM-CSF Hematopoietic growth factor 
 TGFß Growth factor 
 IL-2 Cytokine 
 IL-4 T cell cytokine 
APOPTOSIS/CELL SURVIVAL 
 BCL-2 Anti-apoptotic 
 BFL-1/A1 Anti-apoptotic 
 BCL-XL Anti-apoptotic 
 MIR-21 Pro-apoptotic for ß cells 
ADHESION/CELL ARCHITECTURE 
 ICAM-1 Cell adhesion 
 SELECTIN Cell adhesion; binds sugars 
 MMP-1 Metalloproteinase 
 EPHB2 Receptor tyrosine kinase 
(repressed) 
IMMUNE CELL FUNCTION 
 GAMMA1 Ig heavy chain 
 GAMMA4 Ig heavy chain 
 TNF-A Cytokine 
 IL-12 p35 cytokine 
 IL-13 Cytokine 
 IL-21 Cytokine 
 IL-23 Cytokine 
 CD40L CD40 ligand 
 BLYS/BAFF TNF-like cytokine 
 IP-10 Chemokine 
 LIGP1 GTPase 
 MIG Macrophage cytokine 
 FOXP3 Transcription factor 
DNA REPAIR/DAMAGE 
 ATM Protein kinase 
 CLASPIN Cell cycle kinase 
 SKP2 S-phase kinase- associated factor 




Genomic aberrations in a large DLBCL cohort of 148 cases were investigated by 
Scholtysik et al. (2015) using high-resolution Affymetrix Mapping 250k Sty2 SNP 
arrays. Figure 1.6 displays the genomic aberrations identified by the investigation for 
all DLBCL cases pooled, ABC subtype only, GCB subtype only and a comparison 
between subtypes. As might be expected due to the similar cell of origin of BL and 
GCB-DLBCL, abnormalities identified in BL such as gain of 1q, gain of 7 and 
abnormalities of 13q were common in GCB-DLBCL (Scholtysik et al., 2015). 
Additionally, GCB-DLBCL harboured copy number changes such as 2p15 
amplification involving the REL gene and 6q loss involving PRDM1 (Figure 1.7).  
 
 
Figure 1.7 - Genomic Abnormalities detected by high-resolution SNP arrays in 
DLBCL, separated by subtype. Adapted from Scholtysik et al. 2015. 
 
 
1.3.3 Activated B cell-like Diffuse Large B cell Lymphoma (ABC-DLBCL)  
 
The cell of origin of ABC-DLBCL is thought to be plasmablastic B cells that have not 
left the germinal centre, based on gene expression profiling (Alizadeh et al., 2000). 
The block on differentiation of these cells gives them an activated B cell phenotype 
without fully differentiating to plasma cells. This may be due to several different 
mechanisms. BCL6 (B Cell Lymphoma protein 6) is highly expressed in GC B cells 
but not in activated plasma B cells. Differentiation to plasma cells requires BLIMP1, 
coded by the PRDM1 gene on chromosome 6q and BCL6 and BLIMP1 mutually 
inhibit each other, so for successful differentiation of a GC B cell to a plasma B cell 
downregulation of BCL6 is required. BCL6 expression is dependent on a number of 
factors, most notably BCL6 mutation, CD40 signalling, growth factors including IL-21 
and STAT5, and signalling from the B cell receptor. BCL6 translocations with various 
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partners are present in approximately one quarter of ABC-DLBCL cases leading to 
deregulation of the gene, but has not been shown to correlate with expression (Iqbal 
et al., 2007).  
 
ABC-DLBCL cases are much more dependent on NF- B signalling than GCB-
DLBCL. Constitutive activation of NF- B is a hallmark of ABC-DLBCL, leading to cell 
proliferation and resistance to apoptosis, and therapeutic targeting of IKK has been 
shown to kill ABC-DLBCL but not GCB-DLBCL cells (Lam et al., 2005). shRNA 
screening showed that NF- B activation in ABC-DLBCL is dependent on the 
CARD11, BCL10 and MALT1 (CBM) complex (Ngo et al., 2006). This complex is 
important for IKK activation in normal biology, but in ABC-DLBCL the pathway is 
activated by alternative methods including CARD11 mutation. Constitutive activation 
of IKK leads to abnormall  high levels of I B ubiquitination and degradation and as a 
result nuclear translocation of NF- B famil  members. CARD11 (caspase recruitment 
domain-containing protein 11) is a scaffold protein for NF- B and is e pressed in B 
cells. Missense mutations have been detected in approximately 10% of ABC-DLBCL 
cases (Lenz et al., 2008). Additional CBM-independent mechanisms of NF- B 
activation have been identified including deletion or inactivation of A20 (Kato et al., 
2009). A20 is a protein that acts to negatively regulate NF- B famil  members and is 
located at 6q23.3. A20 induction occurs as a result of stimulation by TNF-  (Dixit et 
al., 1990).  
 
Figure 1.6 displays the results of copy number analysis of 148 DLBCL cases, 
including 49 ABC-DLBCL. GISTIC, a statistical tool used for detecting significantly 
aberrant genomic regions in cancer, revealed 13 recurrent gains and 25 recurrent 
deletions in ABC-DLBCL (Scholtysik et al., 2015). Deletions of chromosome 6 were 
most common in the ABC subtype and three minimal regions were identified by 
GISTIC: 6p21.23, 6q21 and 6q23.3. 6p21.23 harbours the HLA region which is 
commonly variable by copy number analysis. PRDM1 resides at 6q21, and deletion 
of this region would support existing evidence that PRDM1 is required for terminal 
differentiation to plasma cells and that ABC-DLBCL cells are blocked before this 
stage. Deletion at 9p21.3 involved the two genes CDKN2A and CDKN2B, both of 
which are involved in cancer-related pathways. CDKN2A codes for two transcripts, 
p16INK4, which is a MDM2 binding protein, and p14ARF1 which is a CDK inhibitor. 
 24 
CDKN2B encodes p15INK4B, which has been shown to inhibit cell growth in response 
to TGF-  (Stone et al., 1995).  
 
Additional differences between ABC- and GCB-DLBCL subtypes detected by array 
were a higher incidence of gains of chromosomes 3 and 18 in the ABC group and 
gain of chromosome 18 in GCB-DLBCL. Chromosomes 3 and 18 harbour the BCL6 
and BCL2 genes respectively and the difference in BCL2 copy number gain 
frequency reflects previously reported data as translocations are the primary cause of 
overexpression of BCL2 in GCB-DLBCL and would not be detectable by SNP array.  
 
1.3.4 Paediatric DLBCL 
 
Paediatric DLBCL makes up approximately 10% of non-Hodgkin lymphomas 
diagnosed in patients aged up to 14 years in the UK (HMRN, 2019). Paediatric 
DLBCL is almost exclusively of the GCB subtype (Iqbal et al., 2004). However unlike 
adult GCB-DLBCL the t(14;18) translocation that places the BCL2 gene under control 
the IGH promoter is extremely rare in paediatric patients (Oschlies et al., 2006) and 
BCL2 expression is less common. In contrast, IRF4/IGH translocations have been 
identified as more common in paediatric DLBCL cases (Salaverria et al., 2011). Few 
studies exist examining the molecular characteristics of paediatric DLBCL. The Poirel 
study of cytogenetic data collected within the FAB/LMB96 trial highlighted MYC 
rearrangement was more frequent than reported in adults at approximately 33% of 
paediatric cases compared with 10% in adults (Poirel et al., 2009). A recent study 
attempted to characterise the paediatric disease using gene expression and CGH 
microarray analysis, FISH and IHC (Klapper et al., 2012). They reported that 
amplifications of 2p16 (REL), a common abnormality in adult DLBCL, were not 
detected in the childhood cases. Elucidation of a clear cut-off between paediatric and 
adult lymphoma was then attempted using known molecular markers. By plotting the 
incidence of these abnormalities against patient age (Figure 1.8), visual inspection 
suggested that many of these abnormalities differ in frequency with age. Rather than 
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a stark cut-off between age groups, a spectrum of continuous change was 
suggested, with the most notable transition observed between ages 24 and 36.   
 
 
Figure 1.8 - Scatter plot displaying incidence of abnormalities against patient age for 
aggressive B cell lymphomas other than Burkitt Lymphoma. Klapper et al. 2012. 
 
 
Statistical analysis confirmed that the significantly superior prognosis of paediatric 
DLBCL compared to the adult form was independent of GCB/ABC subtype bias and 
that age was an independent factor for predicting outcome. BCL2 expression by IHC 
and an ABC-type gene expression signature were separately confirmed to be 
prognostic factors independent of age. The results of the study strongly suggest 
there is no biological rationale for the current dichotomous treatment strategies. It 
was demonstrated that the paediatric disease differs in its molecular profile to the 
adult disease, but that it is not currently possible to determine an age cut-off between 
the two to guide therap , and an age evolution model  was suggested instead. This 
leaves a therapeutic no-mans-land of teenagers and young adults who are 
insufficiently treated by adult regimens and may benefit from more aggressive 
chemotherapy regimens administered to paediatric cases.   
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1.4 Current treatment 
 
Treatment of BL and DLBCL in patients below the age of 18 is routinely according to 
the FAB/LMB96 trial protocol which delivers intensive multi-agent chemotherapy 
including cyclophosphamide, vincristine, prednisolone, doxorubicin, methotrexate, 
cytarabine and etoposide (Patte et al., 2007). Within this regimen patients are further 
stratified into group A, B or C. Group A comprises completely resected stage I and 
abdominal stage II patients, who are considered to be at the lowest risk and receive 
just two courses of COPAD chemotherapy. Group C patients have stage IV disease 
or Burkitt s ALL (L3ALL), as well as patients with CNS involvement and represents 
the most advanced stage patients. Group B encompasses all patients not eligible for 
groups A or C. Group B and C patients receive an induction phase of two courses of 
COPADM, followed by a consolidation phase of two courses. Group B patients 
receive two CYM consolidation courses and stop. Group C patients receive two 
courses of high dose cytarabine and etoposide, followed by two maintenance 
courses. Disease status is reassessed following CYM1 (group B patients) or CYVE2 
(group C patients) and any residual mass >2cm must be biopsied/resected to confirm 
histological remission. Failure to confirm histological remission results in escalation of 
therapy. For adults with Burkitt lymphoma, those who are adequately fit will receive a 
protocol similar to FAB/LMB96  R-CODOX-M-IVAC. For frailer adults not able to 
tolerate the intensity of R-CODOX-M-IVAC, an alternative strategy will be used. 
 
The recent Inter-B-NHL-Rituximab trial established in 2010 has significantly improved 
the outcome of paediatric B-NHL patients. Patients in group B with more than double 
the upper normal range of LDH are now given rituximab upfront at the point of initial 
diagnosis, as well as all group C patients. This has led to an event-free survival of 
over 94% in paediatric BL and DLBCL cases (Minard-Colin et al., 2016).  
 
Treatment for DLBCL in the UK (as well as in the Klapper et al. study of German 
patients (Klapper et al., 2012) is uniform across subtypes for adults. R-CHOP is a 
regimen of chemotherapy combined with the anti-CD20 antibody Rituximab. CHOP 
has been shown to be the gold standard in first-line treatment of DLBCL in adults 
(Messori et al., 2001). However, it is associated with a degree of toxicity to the 
patient and is difficult for some older patients to tolerate. One study of 135 
aggressive NHL patients receiving standard CHOP reported that 27 patients (20%) 
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suffered congestive heart failure within 1 year of treatment, three of whom died as a 
result (Limat et al., 2003). Additionally, approximately 40% of patients treated with R-
CHOP will go on to relapse or their disease will become refractory (Sehn, 2012). 
Therefore there is a clear clinical demand for targeted therapies that manipulate the 
biology of B cell lymphoma to improve patient outcome and reduce the debilitating 
toxicity that current approaches cause (Minard-Colin et al., 2016).  
 
1.5 Development of chemotherapy resistant B-NHL 
 
Cancer is known to progress and evolve in a similar manner to Darwinian evolution. It 
has recently been postulated that disease progression and treatment resistance arise 
as a result of clonal selection from an inherently heterogenous tumour (intrinsic 
resistance), or ongoing genomic evolution of the tumour reacting to selection 
pressures caused by frontline therapy, or indeed a combination of the two methods 
(Asic, 2016). Intrinsic resistance arises early during tumorigenesis, while acquired 
resistance occurs on or after treatment. Studying the genomic changes throughout 
the development of disease progression may provide clinical solutions to intrinsic 
resistance. Acquired resistance is a more complicated clinical challenge, as it has 
been shown that targeted therapies can drive malignancies to acquire resistance to 
the targeted agent (Asic, 2016). In fact, most FDA-approved targeted therapies used 
in cancers not driven by a single, dominant oncogene lead to resistance to therapy 
within one year of salvage therapy (Ellis and Hicklin, 2009). This is particularly 
prevalent in DLBCL, where it has been shown that rituximab treatment reduces 
salvage rates of patients who go on to receive autologous stem cell transplants if 
they relapsed within 12 months of frontline therapy (Gisselbrecht et al., 2010).  
 
In BL, relapse occurs much quicker than in DLBCL patients, particularly in 
paediatrics, with relapse usually occurring within one year of diagnosis. Rapid 
recurrence allows less time for the tumour population to diversify, suggesting that the 
pattern of evolution in BL disease progression is likely to be linear, with late 
divergence of clones (Juskevicius et al., 2017). A second model of clonal evolution in 
B-NHL was recurrently seen in DLBCL where there are genomic aberrations in 
common between the diagnostic clone and the major clone at disease progression, 
but that the clones diverged earl , representing a more branched  pattern of 
evolution. Both patterns are seen in DLBCL, with late-divergent/linear evolution 
occurring most frequently (65%) and early divergent/branching progression occurring 
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in approximately 30% of cases (Juskevicius et al., 2016). Both patterns of clonal 
evolution are summarised in Figure 1.9. 
 
 
Figure 1.9 - A cartoon demonstrating the two patterns of evolution observed in 
DLBCL. Adapted from Juskevicius et al. (2017) 
 
The only study of sequential karyotypes from BL relapse/refractory patients was 
performed using traditional karyotyping methods (Aukema et al., 2015). The 
investigation revealed that while BL has a relatively quiet genomic landscape at 
diagnosis, there was a significant increase in the number of cytogenetic aberrations 
identified in sequential samples (Aukema et al., 2015) (Figure 1.10). Karyotyping of 
tumour cells is a very low-resolution technique that may have significantly under-




Figure 1.10 - A heatmap of recurrent secondary abnormalities in (A) diagnostic and 
(B) sequential BL samples. 
 
In this study, the pattern of evolution was shown to be primarily linear in 20/25 BL, 
but more studies are needed to better understand the pattern of clonal evolution in 
this malignancy. It was also reported that clonal aberrations seen in sequential 
samples were present in a subclonal population of cells studied at diagnosis, 
particularly trisomy 12 and dup(1q). Mathematical modelling of BL relapse supported 
the presence of primarily early linear relapses, and showed that even later relapses 
were primarily linear (Aukema et al., 2015). To better unravel the clonal evolution of 
paediatric B-NHL it is important to identify putative prognostic genomic markers. 
Evaluation of these prognostic events in paediatric B-NHL may reveal genomic 
drivers of intrinsic therapy resistance. Alternatively, these markers may simply drive 
genomic instability in the tumour and lead to an increased likelihood of acquired 







1.6 Aims and Hypothesis: 
 
Despite improvements in outcome of patients diagnosed with aggressive B-NHL, 
relapsed and refractory disease remains a major clinical challenge. The failure to fully 
respond to treatment suggests a fundamental difference in the underlying biology of 
relapsed/refractory disease. The central hypothesis for this project is that by 
interrogating the largest UK dataset of B-NHL patients it will be possible to identify 
genomic abnormalities which drive resistance to chemotherapy and highlight genes 
and pathways that could be used to stratify patients into clinically significant 
subgroups or targeted by therapeutics to improve patient outcome and overcome 
resistance to chemotherapy.  
 
Current research into aggressive B cell lymphoma and identification of prognostic 
markers is regularly hindered by small sample sizes and insufficient clinical 
information. The majority of published studies focus on adult B-NHL and little is 
known about BL and DLBCL in children and adolescents. This analysis will reveal 
which abnormalities promote survival of malignant cells through current intensive 
chemotherapy regimens and remain in the resistant tumour at point of disease 
progression. The patient cohort will form the basis of this PhD project and will be 
integrated with published datasets in order to:  
 
1. Model paediatric B-NHL by integrating copy number arrays from in-house 
datasets and data from the literature to identify putative prognostic markers.  
2. Further identify and characterise potential prognostic markers with integrated 
whole-exome sequencing analysis, evaluating the clinical relevance of 
identified markers.  
3. Investigate diagnostic and relapse paired samples to investigate the clonal 
evolution of disease progression.  
 
The hypothesis of this thesis is that high resolution copy number array analysis when 
compared with exome sequencing data will identify prognostic markers in paediatric 
B-NHL. These markers can then be further validated in a trial cohort and used to 








2.1.1 Laboratory Equipment 
 
Equipment Manufacturer 
Precellys Homogeniser Bertin 
Thermobrite Hybridiser Fisher Scientific 
SureCycler 8800 Thermal Cycler Agilent 
Water Bath Grant Instruments 
Coplin Jars Thermofisher Scientific 
Qubit 3.0 Fluorometer Thermofisher Scientific 
Nanodrop 2000 Thermofisher Scientific 
DNA Gel Tank Engineering and Design Plastics Ltd. 
Electrophoresis Powerpack BioRad 
ChemiDoc Visualiser BioRad 
Tapestation 4200 Agilent 
Bioanalyzer 2100 Agilent 





Copy Number Analysis software Developer 
Nexus Copy Number 10.0 Biodiscovery 
Integrative Genome Viewer (IGV) Broad Institute 
Oncoscan Console Affymetrix 
GISTIC Broad Institute 
GISTIC2.0 Broad Institute 
 
Sanger Sequencing Analysis  Developer 
FinchTV Geospiza Inc. 
BLAT Ensembl, EMBL-EBI 
 
Whole exome sequencing Developer 
GATK3.8 Broad Institute 
Samtools Heng Li (Li et al., 2009) 
FastQC Babraham Institute 
Bedtools Quinlan Lab (Quinlan and Hall, 2010) 
Variant Effect Predictor Ensembl, EMBL-EBI 
 
Statistical Analysis Developer 
RStudio RStudio Inc. 
Excel 16 Microsoft 
 















GitHub Repository URL 
Scripts written for use in this thesis https://github.com/anewman66/phd-
thesis-2020 





2.1.3 Chemicals and reagents 
 
Reagent Supplier 
Fixogum Rubber Cement 
 
Generon 
















20X SSC Fisher Scientific 
 
2.1.4 Experimental kits 
 
Kit Supplier 








QIAquick PCR Purification kit 
 
Qiagen 
Cytocell Tissue Pre-treatment kit 
 
Cytocell 





Agilent RNA 6000 Nano kit 
 
Agilent 




Applied Bios stems AmpliTaq Gold  
DNA Polymerase with Buffer II and 
MgCl2 
 
Life Technologies  
Thermo Scientific dNTP set 
 
Fisher Scientific 
Ambion DNA-free Turbo DNAse kit 
 
Life Technologies 
Precellys Ceramic kit 2.8mm 50x2 ml 




2.1.5 Oligonucleotide sequences 
 
Primer oligonucleotide sequences for TP53 exons 5-8 are presented in Table 2.1. 
 
Exon Forward sequence Reverse sequence 
Exon 5 CTCTGTCTCCTTCCTCTTCC GCAATCAGTGAGGAATCAGAGG 
Exon 6 GCCTCTGATTCCTCACTGAT GGAGGGCCACTGACAACCA 
Exon 7 AGGCGCACTGGCCTCATCTT CAGGGGTCAGAGGCAAGCAGA 
Exon 8 GAGCCTGGTTTTTTAAATGG TTTGGCTGGGGAGAGGAGCT 
Table 2.1 - Primer sequences for TP53 exons 5-8 used for Sanger sequencing. 
 
2.1.6 FISH Probes 
 
Probe Supplier 




IGL/cMYC Dual Fusion Probe 
 
Cytocell 
IGK/cMYC Dual Fusion Probe 
 
Cytocell 









2.2.1 Ethics approval for studies using CCLG Biobank tumour material 
 
Tumour samples were collected from patients diagnosed with paediatric lymphoma 
with informed written consent obtained from each participant or their parent/legal 
guardian as per CCLG (Children s Cancer and Leukaemia Group) guidelines and 
protocols at local centres. Original consent forms are held by the CCLG. Fresh frozen 
tumour samples were stored in accordance with the Human Tissue Act (2006). 
Project and ethics approval were granted via the CCLG Biological Studies Steering 
Group (REC 18/EM/0134; Biological Study 2012 BS 08).  
 
2.2.2 Ethics approval for studies using patient tumour FNAs from Queen 
Elizabeth Central Hospital, Malawi 
 
Tumour samples were collected from patients diagnosed with suspected lymphoma 
at QECH, Blantyre, Malawi, between October 2009 and March 2014. This study was 
approved by the Malawi College of Medicine Research and Ethics Committee 
(COMREC:P.07/12/1249) and the Newcastle University Ethics Committee 
(3314/2016) and written informed consent for the use of tumour samples for research 






2.3.1 Patient Cohorts 
 
Distinct patient cohorts were used for each chapter, with some overlap of patients 
analysed between chapters. There were three primary sources of patient samples 
and data: CCLG cohort, literature search of data repositories and Malawi cohort. 
Summaries detailing the patients of each cohort involved in chapter of results are 
detailed in Figures 2.1-2.5. 
 
Analysis in Chapter 3 was performed on patients from the CCLG biobank with 
existing copy number array data generated on the Affymetrix Genome-Wide Human 
SNP6.0 array platform and cases identified from the literature (Figure 2.1). Raw copy 
number array data from seven studies identified via the Gene Expression Omnibus 
(GEO) data repository was downloaded for analysis. Additional segmented data from 
one study was taken from the supplemental data of a paper in the British Journal of 




Figure 2.1 - Consort diagram detailing the makeup of the cohort used for the Pilot Project described in Chapter 3. Some data from 
some accession numbers had one or more cases with no associated age data: GSE11318: 10 cases (6.9%), GSE12906: 62 cases 
(100%), GSE54303: 142 cases (100%), GSE57612: 1 case (0.7%). 
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The patient cohort of 162 cases used in Chapter 4 is detailed in Figure 2.2. Running 
parallel to the copy number analysis in Chapter 3, new samples were prepared for 
copy number analysis through DNA extraction and QC. DNA samples were sent for 
copy number array hybridisation to either Affymetrix Cytoscan HD arrays or 
Affymetrix Oncoscan v2 MIP arrays. If sufficient DNA was available for the 25 CCLG 
cases with existing Affymetrix Genome-Wide Human SNP.60 array data then the 
samples were re-analysed on the Affymetrix Cytoscan HD array kit.  
 
 
Figure 2.2 - Consort diagram detailing the makeup of the cohort used for analysis in 
Chapter 4.  
 
The patient cohort analysed in Chapter 5 was made up of a subset of the cohort from 
Chapter 4. 95 patients with both copy number array data and TP53 sequencing data 
were selected for analysis. Cases from the literature were excluded from analysis as 
large numbers of these cases were lacking mutation data. There were 15 cases 
without exome sequencing data that could not be analysed by Sanger sequencing 
due to a lack of DNA and these cases were excluded from the analysis. The 




Figure 2.3 - Consort diagram detailing the makeup of the CCLG cohorts analysed in 
Chapter 5. 
 
Two patient cohorts were analysed in Chapter 6 to compare the endemic and 
sporadic BL. The sporadic cohort was comprised of a subset of BL patients from the 
cohort analysed in Chapters 4 and 5 with four additional locally diagnosed cases 
added. The four additional cases were diagnosed and treated at the Great North 
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Children s Hospital at the RVI, Newcastle. Tumour DNA from the patient samples 
was kindly supplied by Dr Simon Bomken. 
Endemic BL patients were acquired from a collaboration with the Queen Elizabeth 
Central Hospital in Blantyre, Malawi. The makeup of both cohorts are detailed in 




Figure 2.4 - Consort diagram detailing the makeup of the sporadic BL and endemic BL cohorts used in for analysis in Chapter 6. 
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11 patients who underwent disease progression were analysed in Chapter 7. Nine 
patients were from the CCLG cohort and copy number arrays from their diagnostic 
samples had already been analysed as part of Chapters 4 and 5, including 7 BL 
patients and 2 DLBCL patients. Two patients were acquired from the Queen 
Elizabeth Central Hospital, Blantyre, Malawi. One was diagnosed with endemic BL 
and the other was considered to be a BCLU patient. The cohort is described in 
Figure 2.5 
 
Figure 2.5 - Detail of the patients analysed in Chapter 7 of this thesis. 11 diagnostic 
and relapse pairs were investigated.
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2.3.2 Pathology Review of patient samples acquired from the CCLG Biobank 
 
As part of a larger study in the Rand Lab and with the support of Children Cancer 
and Leukaemia Group (CCLG) Tissue Bank, we established the largest cohort of 
clinically annotated paediatric B-NHL tumour samples taken from children diagnosed 
and treated in the UK. As expected from current survival data, 15% of children had 
relapsed/refractory disease, of which 9 have matched relapse samples. A pathology 
review was conducted to confirm that samples included in the study were from B-
NHL patients and appropriate for use in the study, as well as confirming the 
diagnosis of the B-NHL subtype. Patients diagnosed with the following B-NHL 
subtypes were included in the analysis: Burkitt lymphoma (BL), diffuse large B cell 
lymphoma (DLBCL), Burkitt-like Lymphoma with 11q aberration (BLL-11q) and high 
grade B cell Lymphoma, not otherwise specified (HGBL, NOS). Patients that could 
not be confidently prescribed to a B-NHL subtype were considered B-NHL, NOS (not 
otherwise specified). Pathology review was performed on patient samples with 
available formalin-fixed paraffin-embedded (FFPE) material. Where available, 
unstained sections were cut from FFPE blocks and IHC (immunohistochemistry) 
stained for CD10, CD20, CD3, BCL2, BCL6 and Ki67 by the Cellular Pathology 
Department of the Royal Victoria Infirmary (RVI), Newcastle. Haematoxylin and eosin 
(HE) staining was also requested if fresh frozen (FF) material was available. The 
review of material was performed by three haematopathologists from the RVI: Drs 
Christopher Bacon, Despina Televantou and Katrina Wood and consensus 
diagnoses were reported. Confirmation of MYC status was performed when possible 
by fluorescence in-situ hybridisation (FISH). Cases with no consensus on diagnosis 
between three pathologists but confirmed to be B-NHL were reported as B-NHL, 
NOS (B cell non-Hodgkin lymphoma, not otherwise specified). For cases with no 
available FFPE material for pathology review, Dr Christopher Bacon performed a 
review of the original pathology report from the local treatment centre to ensure that 
the initial diagnosis was appropriate. Patients diagnosed prior to publication of the 
2016 WHO Classification of Lymphoid Neoplasms were reviewed to determine 
whether the initial diagnosis was still appropriate, including new diagnoses of HGBL, 






2.3.3 Pathology Review of patient samples acquired from QECH, Malawi 
 
A collaboration between Newcastle-upon Tyne Hospital Trust/RVI and the Queen 
Elizabeth Central Hospital in Blantyre, Malawi has allowed us to generate a cohort of 
105 paediatric BL cases from the endemic subtype. Pathology review of the endemic 
BL cohort acquired from the Queen Elizabeth Central Hospital in Blantyre, Malawi 
had previously been performed within the group. Diagnoses were confirmed by 
pathology review according to the World Health Organisation criteria using 
immunocytochemistry for CD20, CD3, CD10, BCL2, BCL6 and Ki67, in situ 
hybridization for Epstein Barr Virus-encoded small RNA (EBER) and Fluorescence 
in-situ hybridisation (FISH) for the presence of a MYC translocation. 
 
2.3.4 Fluorescence in-situ hybridisation (FISH) on unstained imprints from 
fresh frozen material 
 
FISH was performed to determine the MYC-rearrangement status of patients with 
tumour material. Superfrost glass slides with tumour imprints that were received from 
the Cellular Pathology department of the RVI were marked using a diamond point 
marker to highlight the location of the imprint on the slide. Slides were marked from 
underneath so as not to damage the tumour imprint. Slides were already marked with 
patient samples and the date of set-up and probe name were written onto the slides 
in pencil. 2µl of FISH probe was pipetted onto the slide within the marked area. The 
area was covered with a 10mm diameter coverslip and sealed using a rubber 
cement. The slides were loaded onto a Thermobrite Hybridiser and the foam pads in 
the chamber were dampened to keep the environment humid. The Thermobrite 
Hybridiser was programmed to denature for 2 minutes at 80°C and then hybridise at 
37°C overnight.  
 
A water bath was prepared at 72°C before removing slides from the hybridiser the 
next morning. A plastic Coplin jar was filled with wash solution (0.4xSSC/0.003% NP-
40) and left to heat to 72°C in the water bath. The coverslip was removed from the 
slide using needle point tweezers, removing any residue of rubber cement along with 
it. The slides were immediately submerged and washed in the 72°C wash solution for 
2 minutes. Slides were then subsequently transferred directly to another Coplin jar of 
2xSSC at room temperature for 2 minutes. Slides were removed from the 2xSSC 
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solution and 8µl of Vector Shield Mounting Medium with DAPI was applied to the 
slide and covered with a 22x50mm coverslip (0.13mm thickness). Slides were then 
viewed after 15 minutes or stored in a dark box at 4°C for scoring at a later date.  
 
2.3.5 Fluorescence in-situ hybridisation (FISH) on unstained sections from 
FFPE material 
 
The protocol for performing FISH analysis on samples with FFPE material required 
additional steps compared to the preparation of fresh frozen imprints. Slides were 
received from Cellular Pathology on Superfrost glass slides. Slides were submerged 
in a Coplin jar of Xylene for 10 minutes inside a fume hood. Xylene was then 
discarded and the wash was repeated with fresh Xylene. After the second Xylene 
wash, slides went through a rehydrating gradient of ethanol preparations. The slides 
were submerged in a Coplin jar of 100% ethanol for 1 minute at room temperature, 
followed by 85% ethanol for 1 minute, 70% ethanol for 1 minute and washed in 
distilled water for 1 minute. After the wash with water, another 1 minute wash with 
distilled water was performed.  
 
200µl of Cytocell Tissue Pre-treatment kit reagent 1 was pipetted onto each slide and 
they were covered with a 22x50mm coverslip (0.13m thickness) and sealed with 
rubber cement. Slides were then placed on the Thermobrite Hybridiser at 99°C for 15 
minutes. Once removed from the hybridiser, coverslips were removed with a pair of 
needle point tweezers and the slides were washed again in distilled water for 1 
minute, twice. 2 drops of Cytocell Tissue Pre-treatment kit reagent 2 were applied to 
the slide and covered with 22x50mm coverslips (0.13mm thickness), sealed with 
rubber cement and incubated at room temperature for 30 minutes before being 
washed in distilled water for 1 minute, twice.  
 
The slides were then dehydrated by being submerged in 70% ethanol for 1 minute, 
85% ethanol for 1 minute and then 100% ethanol for 1 minute. Once removed from 
the Coplin jars, slides were left to air dry on paper towels. 4µl of FISH probe was 
pipetted onto the slide and covered with a 19mm diameter round coverslip, sealed 
again with rubber cement. The slides were then placed on the Thermobrite Hybridiser 
and the foam pads were soaked in water. The Thermobrite Hybridiser was 
programmed to denature at 75°C for 2 minutes and then incubate at 37°C overnight.  
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The following morning the coverslips were removed from the slide with needle point 
tweezers and the slides were incubated in a Coplin jar with 0.4xSSC/0.003% NP-40 
for 2 minutes in a 72°C water bath. The slides were transferred to another Coplin jar 
of 2xSSC for 2 minutes at room temperature before 8µl of Vector Shield Mounting 
Medium with DAPI was dropped onto the slide and a 22x50mm (0.13mm thickness) 
coverslip was applied. The slides were left to incubate for 15 minutes before being 
visualised, or were stored at 4°C for later scoring. 
 
2.3.6 FISH slide Scoring 
 
FISH slides were scored on an Olympus BX61 fluorescence microscope. At least 50 
cells were scored with the fluorescent patterns recorded in a lab book and tallied. 
Each slide was scored by a minimum of two trained researchers independently. A 
panel of normal bone marrow preparations hybridised with the same probe as the 
tumour sections/imprints were scored by each researcher. This was performed to 
calculate a minimum cut off of aberrant cells reported for each individual, which is 
required to ensure that results were consistent between researchers. Five normal 
bone marrow samples were scored and the mean + 3 standard deviations of 
abnormal patterns across all five marrow preparations was calculated as a cut-off. If 
the ratio of abnormal cells identified by an individual in a case was above cut-off then 
it was considered a positive case. Results were then compared between both 
scorers, and discrepancies were re-scored by both individuals.  
 
 
2.3.7 Nucleic Acid Extraction from Fresh Frozen Tumour Samples 
 
DNA and RNA were extracted from fresh frozen tumours using the Qiagen Allprep 
DNA/RNA/Protein mini kit (50 samples) at the beginning of the study. Later, 
additional samples were extracted instead with the Qiagen Allprep DNA/RNA/miRNA 
Universal kit according to the manufacturer s guidelines to achieve total RNA 
extraction from limited fresh frozen material. The DNA extraction method was 
identical in both protocols. RNA extractions were treated with the Ambion Turbo 
DNA-free DNAse kit to remove residual genomic DNA. This allowed the RNA aliquots 
to be used for RNA sequencing in the future. Total RNA was eluted into nucleic acid-




2.3.8 Nucleic Acid Extraction from FFPE Tumour Samples 
 
DNA and RNA were extracted from FFPE tumour material using the Qiagen 
DNA/RNA FFPE kit. Deparaffinisation was performed initially on FFPE curls cut by 
Cellular Pathology on a microtome. In 1.5ml microcentrifuge tubes curls were treated 
with 800µl of Xylene. Tubes were vortexed thoroughly and incubated for 5 minutes at 
room temperature. The tubes were then spun down in a centrifuge at 12,000G for 2 
minutes. The supernatant was discarded by pipette. The deparaffinisation step was 
repeated once more per sample. After removing the supernatant for the second time, 
800µl of 100% ethanol was added to the microcentrifuge tubes and vortexed 
thoroughly. Without incubation, the tubes were then spun down using a centrifuge for 
2 minutes at 12,000G. The tubes were then left to incubate on a heat block set to 
55°C with the caps off to allow residual liquid to evaporate off. From this point 
onwards the standard protocol for the Qiagen AllPrep DNA/RNA FFPE kit was 
followed.  
 
2.3.9 DNA Quality Control and Quantification 
 
DNA concentration was measured by Qubit 3.0 Fluorometer (ThermoFisher, USA). 
The Thermofisher Scientific Qubit dsDNA Broad Range Assay was used to calculate 
the concentration of double stranded DNA specifically. A new standard curve was 
created for every batch of 10 samples. RNA concentration and integrity (RIN score) 
were determined by Agilent Bioanalyzer 2100 using the Agilent RNA 6000 Nano kit 
and later the Agilent Tapestation 4200 using the Agilent RNA ScreenTape kit 
according to the manufacturer s protocols. DNA and RNA were stored at -80°C in 
1.5ml microcentrifuge tubes.  
 
2.3.10 Polymerase chain reaction (PCR) of patient DNA for Sanger sequencing 
 
Patient DNA was diluted to a stock concentration of 10ng/µl. A minimum quantity of 
50ng of patient DNA was added. A PCR master mix was made up using the 






Master Mix  x1 
10X PCR Buffer 5µl 
dNTPs 0.4µl 
MgCl2 3µl 
AmpliTaq Gold Polymerase 0.25µl 
5µM Forward primer 1µl 
5µM Reverse primer 1µl 
Nucleic acid-free water Up to 45µl 
TOTAL 45µl 
Table 2.2  Components of the PCR master mix for one reaction. 
 
The AmpliTaq Gold Polymerase was taken out of the freezer as the last step to 
preserve the quality of the polymerase. 45µl of master mix was aliquoted to each well 
of a 200µl 96-well skirtless PCR plate per sample with a water control. 5µl of patient 
DNA (at 10ng/µl) was added to each plate well, as well as 1µl of 5µM Forward primer 
and 1µl of 5µM Reverse primer. 5µl of nuclease-free water was added instead of 
DNA to the water control well.  
 
The plate was sealed with strip tube lids before being vortexed and spun down briefly 
to ensure the reaction volume was well mixed by pipetting. The plate was run on an 
Agilent SureCycler 8800 thermal cycler. A pre-made PCR program was selected as 
specified in Table 2.3. 
 
Step Temperature Time 
Initial Denaturation 95 °C 10 minutes 
35 Cycles 
95 °C 20 seconds 
54 °C 1 minute 
72 °C 1 minute 
Final Extension 72 °C 5 minutes 
Hold 10 °C Indefinitely 





2.3.11 Gel electrophoresis of PCR products 
 
The presence of successful PCR product amplification was confirmed by gel 





Tris Base 242g (dissolved in 750ml of water) 
Glacial acetic acid 57.1ml 
0.5M EDTA (adjusted to pH 8.0) 100ml 
Nuclease-free water (top up) Adjust to final volume of 1L 
Table 2.4 - Protocol for making up 1000ml of 50X TAE buffer for DNA gel 
electrophoresis. 
 
Analytical grade agarose powder was weighed out appropriately to make up a 1.2% 
agarose gel. 0.84g of electrophoresis-grade agarose powder was added to 70ml of 
1X TAE buffer in a conical flask. After the powder was dissolved via microwave 
heating in short bursts for 2.5 minutes, 7µl of GelRed (10,000x concentrated) was 
added to the mixed 1.2% agarose solution and the mixture was poured into a pre-
assembled DNA gel tank with 16-well combs in place inside. The agarose gel was 
left to set for approximately 20 minutes, making the sure gel was completely set. 1X 
TAE buffer was poured over the gel until the electrodes in the tank were sufficiently 
submerged. The combs were removed after the 1X TAE had been added. 4µl of PCR 
product per sample was combined with 1µl of DNA loading dye on a sheet of parafilm 
and then carefully pipetted into each well on the gel. 2µl of DNA Hyperladder (100bp) 
was added to the first and last well of each row. Once the lid was placed on the tank 
it was connected to a BioRad powerpack and run for 40 minutes at 70 volts. The gel 
was then visualised under ultraviolet light using a BioRad ChemiDoc machine. The 
size of the bands on the gel were compared to the predicted product size to ensure 
the right region of genome was amplified. Negative water controls were checked to 
ensure nothing had been amplified in them, and patient samples were checked to 
ensure that only one band had been amplified.  
 
 
2.3.12 Purification of PCR products 
 
PCR products in 96-well plates were purified by Eurofins Genomics, Germany. 
Purification of products that were amplified in 8-well strip tubes was performed in-
house using the QIAquick PCR Purification kit as per the manufacturer s protocol. 
Purified products were aliquoted and sent to Eurofins Genomics, Germany for 





2.3.13 Analysis of Sanger sequencing data 
 
When Sanger sequencing results were received the data was visualised using 
FinchTV software. In FinchTV, Sanger chromatogram files (.ab1 file format) were 
checked manually to determine whether any nucleotides exhibited two peaks on top 
of each other, indicating that more than one nucleotide was detected at that locus. 
This would represent a heterozygous mutation or a mutation that was present in a 
subclone of the patient sample (either heterozygous or homozygous). DNA 
sequences generated from the Sanger chromatogram were next screened using 
BLAT against sequences on Ensembl to detect mutations that were homozygous 
(Cunningham et al., 2019). 
 
2.4 Bioinformatics Methods 
 
 
2.4.1 Copy Number Data Processing of Affymetrix SNP 6.0 array 
 
25 paediatric B-NHL fresh fro en samples provided b  the Children s Cancer and 
Leukaemia Group (CCLG) were investigated using a high-resolution SNP microarray 
platform. Tumour DNA was extracted using the Qiagen All Prep DNA/RNA/Protein 
extraction kit and sent to AROS (Applied Biosystems, Denmark) to be hybridised to 
an Affymetrix Genome Wide SNP 6.0 Array. The raw cel probe intensity files were 
analysed using the SNP Rank segmentation algorithm and manually annotated to 
exclude obvious artefacts. Five cases were not re-analysed using Affymetrix 
CytoScan HD or OncoScan v2 MIP arrays for analysis in Chapters 4 onwards and 
the original SNP6.0 data was used for copy number analysis. 
 
2.4.2 Copy Number Data Processing of Affymetrix CytoScan HD array 
 
DNA from 79 diagnostic samples of B-NHL patients acquired through the CCLG 
biobank were sent to AROS (Applied Biosystems, Denmark) to generate copy 
number data using the Affymetrix CytoScan HD array. Raw cel intensity files were 
analysed using Nexus Copy Number 10.0 with the SNPRank segmentation 




2.4.3 Copy Number Data Processing of Affymetrix OncoScan 2.0 MIP array 
 
DNA from 26 diagnostic samples of B-NHL patients acquired through the CCLG 
biobank and 105 diagnostic samples from the endemic BL Malawi cohort were sent 
to AROS (Applied Biosystems, Denmark) to be analysed on the Affymetrix OncoScan 
2.0 molecular inversion probe array. Raw pairs of cel intensity files were analysed 
using Affymetrix OncoScan Console version 1.3 to generate OSCHP files with 
normalised log2 ratio data and segmentation data produced via the proprietary 
TuScan algorithm using the default settings. Due to the nature of the algorithm and 
the fact that it calculates an estimate of the proportion of aberrant cells in a sample, 
hard coded thresholds for gain and loss calling are not possible. Segmented copy 
number calls generated by the TuScan algorithm were viewed and manually checked 
in Nexus Copy Number 10.0. The TuScan algorithm was favoured due to its reliability 
when calling subclonal events or events in samples with low tumour content. This 
was particularly important when working with fine needle aspirations taken from 
patients in Malawi when the tumour content was expected to be lower.  
 
2.4.4 Copy Number Data Processing of External Data from GSE57612 and 
GSE21597 
 
Both studies were performed on subsets of the same cohort dataset looking at BL 
(GSE21597) and DLBCL (GSE57612). Data was processed from raw CEL files using 
Nexus Copy Number 10.0 using the SNP Rank segmentation algorithm. Both 
Affymetrix GeneChip Human Mapping 250K Nsp array and Affymetrix GeneChip 
Human Mapping 250K Sty array data was available for 30/39 cases within 
GSE21597, which do not share probe IDs. In these 30 cases the data was merged 
using Nexus Copy Number 10.0 to give a final resolution of 500K. A systematic 
correction file for the Affymetrix GeneChip Human Mapping 500K array was applied 
to both data types. Due to the noisy nature of the data the segmentation settings 
were changed to decrease the threshold for copy number gain from 0.15 to 0.1 and 
the significance threshold was set to 5.0x10-9. Clinical data, including patient age, 
follow up and relapse status was made available by the authors (Scholtysik et al., 
2010; Scholtysik et al., 2015) and additional clinical information for both datasets was 
kindly provided by the authors on request.  
 
2.4.5 Copy Number Data Processing of External Data from GSE19459  
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The dataset is associated with a study into noise reduction on aCGH arrays (Lepretre 
et al., 2010). 20 DLBCL patient samples were hybridised on an IRCL Human 
Genome CGH Microarray 44B G4410B against Promega control DNA. Data was 
processed from raw text files using Nexus Copy Number 10.0 using FASST2 
segmentation. Segmentation thresholds for gain and loss were increased to 0.2 and -
0.23 respectively to reflect the noise level of the samples from this study.  
 
2.4.6 Copy Number Data Processing of External Data from GSE11318  
 
The dataset was associated with a study investigating copy number abnormalities in 
different DLBCL subtypes (Lenz et al., 2008). 203 DLBCL patients were analysed 
using an NCI NimbleGen Homo sapiens HG17 Whole Genome 385K Tiling Set 
(version 1). Of the 203 samples published, 27 were unclassifiable as to their DLBCL 
subtype, and 31 were primary mediastinal DLBCL so were excluded from analysis. 
Segmentation thresholds for gain and loss were increased slightly to 0.17 and -0.20 
respectively.  
 
2.4.7 Copy Number Data Processing of External Data from GSE12906  
 
The dataset was published alongside a Letter to Nature by Kato et al. (Kato et al., 
2009). 62 DLBCL samples were used in our investigation. The platforms used in the 
studies were a combination of Affymetrix SNP arrays; Affymetrix GeneChip Human 
Mapping 250K Nsp arrays and Affymetrix GeneChip Human Mapping 250K Sty 
arrays and the lower resolution Affymetrix GeneChip Mapping 50K XbaI arrays and 
Affymetrix GeneChip Mapping 50K HindIII arrays. Only site of disease and diagnosis 
by histology was made available. Data analysis was performed from raw .cel files 
using the SNP-FASST2 algorithm. Segmentation thresholds for gain was increased 
slightly to 0.1. 
 
2.4.8 Copy Number Data Processing of External Data from GSE56884  
 
The dataset comprised of 81 tumour samples from 21 follicular lymphoma patients, 
31 transformed DLBCL patients and 29 de novo DLBCL patients. Only de novo 
DLBCL patients were included in our investigation. The data was published to 
accompany Kwiecinska et al. (2014) and was accessed from GEO. Extensive clinical 
data was published including patient age at diagnosis, gender, DLBCL subtype, 
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tumour stage, outcome, follow-up time, relapse status and treatment strategy. 
Diagnosis was made by immunohistochemistry according to WHO 2008 
classification. Processed log ratio data was made available in the form of tab-
delimited text files. The array used was a custom-made CGH array with an 
approximate resolution of 1Mb manufactured by the Wellcome Trust Sanger Institute, 
Hinxton, UK. The processed data was visualised in Nexus Copy Number 10.0 using 
0.2 and -0.2 as gain and loss segmentation thresholds respectively.  
 
2.4.9 Copy Number Data Processing of External Data from GSE54303  
 
The dataset involved 332 untreated lymphoma patients. Only 117 DLBCL and 24 BL 
patients were used in this investigation, totalling 141 samples. The dataset was 
published as part of a publication by Suguro et al. (2014) in Cancer Science. This 
study investigated the prognostic role of clonal heterogeneity in lymphoma using a 
custom-made BAC array with approximately 2000 probes. Raw log ratio data was 
available via GEO and clinical information was available for survival status, follow up 
in years and IPI score. No information about patient age was made available. 
Patients were diagnosed at the Aichi Cancer Center Hospital and Nagoya University 
Hospital, Japan according to the WHO classification. Thresholds for segmentation 
were set at 0.15 and -0.15 for gain and loss respectively.  
 
 
2.4.10 Copy Number Data Processing of External Data from Havelange et al. 
2016   
 
Although copy number array files were not available for the samples investigated in 
this publication, the authors of the study published the start and end positions of 
regions of genomic aberration in the supplementary information, and these were 
used to create segmented data files that could be loaded into Nexus Copy Number 
10.0 and analysed alongside data from other studies. The study performed copy 
number detection using Affymetrix Mapping 100K-XbaI arrays.  
 
 
2.4.11 Inclusion/Exclusion criteria 
 
Samples from in-house and external datasets were chosen based on available 
diagnostic information. This investigation focused only on Burkitt lymphoma, diffuse 
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large B cell lymphoma, Burkitt-like lymphoma with 11q abnormality and cases which 
are known to be B-NHL but where the subtype was not determined. Patients 
presenting with post-transplant disease, lymphoblastic lymphoma, T cell (or T cell-
rich) lymphoma, mediastinal lymphoma, pre-B cell lymphoma, unspecified lymphoma 
and those with no tumour sample available were excluded from our analysis.  
 
2.4.12 Data Analysis with Nexus Copy Number 10.0: Segmentation algorithms 
 
Several factors determined the analysis and segmentation parameters used in our 
investigation. Two segmentation algorithms included in Nexus were used: Rank 
segmentation and fast adaptive states segmentation technique (FASST2). Both 
algorithms use log-ratio values and genomic positioning of probes to segment data 
into regions of statistically significant copy number change. Rank segmentation is 
based on the circular binary segmentation (CBS) algorithm but is significantly faster 
to run than standard CBS. FASST2 is a Hidden Markov Model (HMM) based 
algorithm and uses this method to estimate segment values between expected copy 
number states, and further processing this information to assign these values to 
events. Both segmentation algorithms incorporated into Nexus Copy Number 10.0 
also exist as a SNP  version, designed specifically for copy number arrays with 
allelic frequency data for SNPs associated. The algorithm works in fundamentally the 
same way in each case, but the SNP form uses allelic information to complement 
log-ratio values in copy number detection and ploidy calculation for the sample.  
 
2.4.13 GISTIC1.0 analysis to detect driver aberrations 
 
Developed by the Broad Institute, Genomic Identification of Significant Targets in 
Cancer (GISTIC) is a tool designed to identify regions within copy number data that 
are significantly aberrant. The first iteration of GISTIC is implemented into Nexus 
Copy Number 10.0 and calls peaks at locations of the genome with the most frequent 
aberrations across a group of samples. Both frequency of the abnormality and the 
magnitude of the copy number change are taken into account by the algorithm to 
produce a G-score. The software identifies a tight peak using this G-score, and a 
wide peak using a leave-one-out method to ensure the tight peak is not defined 
purely based on one sample (Beroukhim et al., 2007). The functionality of GISTIC 
relies on the assumption that driver events caused by copy number variation occur 
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more frequently than passenger events in a cohort of patient samples. Therefore, the 
most significant regions identified by GISTIC should theoretically be disease drivers.  
 
2.4.14 GISTIC2.0 analysis to detect driver aberrations 
 
As successor to GISTIC1.0, GISTIC2.0 was developed to more reliably detect 
significant targets in cancer from somatic copy number data. The second iteration of 
GISTIC2.0 splits genomic events into focal and arm-length events to further 
characterise genomic events (Mermel et al., 2011) (Figure 2.6).  
 
 
Figure 2.6 - A flow diagram describing the differences between GISTIC1.0 and 
GISTIC2.0. Taken from Mermel et al.(2011). 
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While GISTIC1.0 generates a G score for recurrent copy number aberrations 
calculated from the amplitude of the log ratio multiplied by the frequency of the 
aberration within the cohort, GISTIC2.0 uses a more advanced method. The updated 
algorithm used by GISTIC2.0 computes a G score based on the negative log 
probability of the region being part of the background pattern. Depending on the 
settings provided to GISTIC2.0 on the command line, this can be either on a gene 
basis or a marker basis. As markers are surrogates for probes, and the cohort being 
analysed is comprised of multiple array platforms with different probe sets, it was 
decided that gene-based scoring was more appropriate. A function new to GISTIC2.0 
then allows the tool to distinguish between multiple peaks/targets within a segmented 
region (i.e. a chromosome arm) using a peel-off function. This functionality is most 
useful when there are multiple recurrent peaks on a single chromosome that may be 
covered by the same copy number event in some samples.  
 
Another improvement on the previous algorithm allows the minimal common region 
of gain or loss to be more appropriately defined using a probabilistic method. This 
result gives both a wide peak, which is the more conservative estimate of the true 
bounds of the region of interest, while the narrow peak region is the genomic region 
that GISTIC2.0 is confident to be focal to the true aberration.  
 
GISTIC2.0 requires segmented copy number data with log ratio values for the entire 
genome, even if no events are called. Regions with missing data in any sample are 
excluded from the entirety of the cohort analysis. Centromeric regions were covered 
inconsistently by different array platforms so this ensured that events around the 
centromere were called appropriately regardless of the degree of coverage.  
 
GISTIC2.0 analysis was performed as part of Chapter 4 and Chapter 6, while the 
original iteration was utilised in Chapter 3. Parameters for each separate GISTIC2.0 
analysis are available Appendix A and in the shell scripts run by the docker container 
in the GitHub repository associated with this thesis 
(https://github.com/anewman66/phd-thesis-2020). The dockerfile used to generate 
the docker container was acquired from GitHub (https://github.com/sandertan/docker-
gistic2) and the version of GISTIC2.0 was GISTIC2.0.23. The container was run with 
a local file mounted to allow uploading of data to the container without stopping and 
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resetting the container each time an edit was made to a script. Plotting GISTIC2.0 
focal regions against G score was performed using maftools in R for analysis in 
Chapter 4.  
 
 
2.4.15 Whole exome sequencing analysis 
 
Whole exome sequencing data was analysed to screen the protein coding regions of 
the cancer genome for mutations. Wherever possible both the tumour and matched 
normal DNA were sequenced. In total, whole exome sequencing data was available 
for 90 B-NHL cases from the CCLG cohort. Of these, matched normal DNA was 
sequenced in 41 cases and tumour alone was sequenced for 49. A number of whole 
exome sequencing capture kits were utilised in this study and library prep was 
performed either at AROS (Applied Biosystems, Denmark) or the Genomics Core 
Facility (Centre for Life, Newcastle, UK). Kits used were Agilent SureSelect Human 
Exome v4 kit, Illumina Nextera DNA Exome and the Twist Human Core Exome kit. 
Sequencing was performed on Illumina HiSeq 4000 at AROS and either the Illumina 
MiSeq instrument or the Illumina NovaSeq 6000 at the Genomics Core Facility. All 
sequencers generated paired end reads of 100bp. 
 
The analysis pipeline involved quality control (QC) of the raw reads, alignment to a 
reference genome, aligned read processing, variant calling and functional annotation 
of variants. Fastq files containing raw reads from the sequencer were the starting 
point for the analysis. Quality control was performed by applying the FastQC tool to 
each fastq file. The most important metric to check at this stage was that the base 
quality score was not associated with a particular base position on the read. Even 
high quality Illumina sequencing data often exhibits lower base quality scores toward 
the end of the read, but this can be more pronounced in poor quality sequencing 
(Andrews, 2010; Opitz et al., 2019). After checking the per base sequence quality 
using FastQC it was sufficiently high across all samples so no cases were excluded.  
 
Bioinformatics processing and analysis of sequencing data was performed using the 
FMS Cluster at Newcastle University. The cluster uses the Son of Grid engine (SGE) 
as a job scheduler and all scripts were written to be scheduled by SGE. Alignment, 
processing and variant calling were all performed using a pipeline written by Dr Matt 
Bashton at Newcastle Universit . The scripts are available from Dr Bashton s GitHub 
 57 
page (https://github.com/MattBashton/MB-GATK-SGE). Scripts were written in the 
bash language and process NGS data using GATK3.8. The pipeline took pairs of raw 
fastq files and aligned the reads using the Burrows-Wheeler aligner, maximal exact 
matches (BWA-MEM). BWA-MEM is an alignment tool based on the Burrows-
Wheeler transform, and the -MEM iteration of the algorithm is designed specifically 
for aligning Illumina paired end sequencing data with reads over 70bp, which was 
appropriate for our data. Reads were aligned to the hg19 1000 Genome Project 
Decoy genome (b37). BWA-MEM outputted sequencing alignment mapping (SAM) 
files which were converted to binary alignment mapping (BAM) files and were sorted 
and indexed. At this point the aligned reads could be viewed in Integrative Genomics 
Viewer (IGV) developed by the Broad Institute. Further processing was required 
before variant calling could be performed.  
 
Duplicate reads were marked using Picard, but not removed. Marked duplicates were 
retained as they can still be helpful. Marking duplicate reads is important to ensure 
that errors are not overrepresented when calling variants. The next step was to 
perform realignment target creation, where indels (insertions and deletions) are 
highlighted as targets for indel realignment. As somatic indels are not present in the 
reference genome, realignment must be performed to ensure that the reads 
surrounding these indels are correctly mapped and that the indels are not artefacts 
(Li and Durbin, 2009). Base Q score recalibration (BQSR) was performed as there 
are inherent biases in the way that Illumina sequencers assign quality scores. 
Adjustment of these scores is required as inaccurate scores are known to have an 
effect on variant caller results (Tian et al., 2016). Reads were printed with 
recalibrated quality scores to new BAM files for further analysis.  
 
The next step involved variant calling with MuTect for tumour only data and Mutect2 
for cases with matched tumour and normal sequencing data.  
 
The original MuTect tool was utilised for tumour only analysis. The tool detects 
variants using four primary steps (Cibulskis et al., 2013). Step one is to remove low 





Read Quality Filters for MuTect 
(a)  Mapping Quality score > 0 
(b)  Base qualit  score  5 
(c)  If there is an overlapping read pair, and both reads agree the read with the highest 
quality score is retained otherwise both are discarded. 
(d)  Sum of the qualit  scores of the mismatches  100 
(e)  < 30% of bases have been soft-clipped 
(f)  Reads that have not been mapped b  mate rescue  of BWA1,2 (BAM XT tag = M ) 
Table 2.5 - A table listing quality control filters for input reads to MuTect. Adapted 
from Cibulskis et al., (2013). 
 
 
Step two is to detect variants using a Bayesian classifier. This function compares two 
models for each locus: a reference model where there is no variant at the locus and 
any calls are due to sequencing errors, and a variant model where a true variant is 
found at the locus. An allelic fraction value is calculated to determine the proportion 
of reads that support the variant model. This value is used instead of assuming 
heterozygosity so that the tool is more sensitive in cases where tumour purity is lower 
or subclonal events exist (Cibulskis et al., 2013). The variant is considered a 
candidate true variant if the log odds value exceeds a predetermined value based on 
other criteria, namely a predefined false discovery rate and the expected frequency 
of mutations.  
 
Step three involves filtering called variants based on known parameters associated 
with false positive calls. Six filters are implemented, as well as comparison against a 




Name Class Description and Default Thresholds 
Proximal 
Gap HC 
Remove false positives caused by nearby misaligned small insertion and 
deletion events. Reject candidate site if there are  3 reads with insertions 
within an 11-bp window centered on the candidate mutation, or if there are 
 3 reads with deletions within the same 11-bp window 
Poor 
Mapping HC 
Remove false positives caused by sequence similarity in the genome, 
leading to misplacement of reads. Two tests are used to identify such sites: 
(i) Candidates are rejected if  50% of the reads in the tumor and normal 
have a mapping quality of zero (although mapping quality zero reads are 
discarded in the short-read preprocessing this filter reconsiders those 
discarded reads); (ii) Candidates are rejected if they do not have at least a 
single observation of the mutant allele with a confident mapping (i.e. 
mapping qualit  score  20). 
Triallelic 
Site HC 
Reject false positives caused by calling tri-allelic sites where the normal is 
heterozygous with alleles A/B and MuTect is considering an alternate allele 
C. Although this is biologically possible, and remains an area for future 
improvement in mutation detection, calling at these sites generates many 
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false positives and therefore they are currently filtered out by default. 
However, it may be desirable to review mutations failing only this filter for 
biological relevance and orthogonal validation and further study the 
underlying reasons for these false positives. 
Strand 
Bias HC 
Reject false positives caused by context specific sequencing errors where 
the vast majority of the alternate alleles are observed in a single direction 
of reads. We perform this test by stratifying the reads by direction and then 
applying the core detection statistic on the two datasets. We also calculate 
the sensitivity to have passed the threshold given the data. Candidates are 
rejected when the strand specific LOD is < 2.0 in directions where the 
sensitivit  to have passed that threshold is  90%. 
Clustered 
Position HC 
Reject false positives caused by misalignments hallmarked by the alternate 
alleles being clustered at a consistent distance from the start or end of the 
read alignment. We calculate the median and median absolute deviation of 
the distance from both the start and end of the read and reject sites that 
have a median  10 (near the start/end of the alignment) and a median 
absolute deviation  3 (clustered) 
Observed 
in Control HC 
Eliminate false positives in the tumor by looking at the control data 
(typically from the matched normal) for evidence of the alternate allele 
beyond what is expected from random sequencing error. A candidate is 
rejected if, in the control data, there are (i) 2 observations of the alternate 
allele, or they represent  3% of the reads; and (ii) their sum of qualit  





Reject artifacts and germline variants by inspecting a panel of normal 
samples and rejecting candidates that are present in two or more normal 
samples 
Table 2.6 - A table describing variant filters utilised in the high confidence method of 
MuTect analysis. 
 
Step four involves determination of somatic and germline variants based by another 
Bayesian classifier. All variants were designated as either somatic , germline  or 
variant . The variant call is used for variants that are confirmed to be present in the 
tumour but where the status in the matched normal is undeterminable. This call was 
not required in our cohort as all samples with matched normals were analysed via 
Mutect2.  
 
Mutect2 is incorporated in GATK3.8 and is run on processed BAM files to produce a 
list of variants (Benjamin, 2019). Sharing a lot of code with the existing Haplotype 
Caller (HC), Mutect2 identifies active regions where somatic variation is likely to 
occur by comparing tumour and normal log odds. If the log odds value for a variant 
exceed the threshold set in Mutect2 then the intervals around the active site are 
considered for realignment. A series of haplotypes are generated and ranked based 
on their score. A pair-Hidden Markov Model (HMM) function for pairwise sequence 
alignment assesses the likelihood of each read to have been sequenced against 
each candidate haplotype for both the tumour and normal samples. A likelihood ratio 
for each allele is generated using this tool and potential variants are filtered based on 
calls made by Mutect2. The risk of variants being present in the germline is 
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determined using TLOD (tumour log odds) and NLOD (normal log odds) values. If a 
variant NLOD was above 2.2 and TLOD was above 6.3 then the variant was not 
considered to be a germline risk. The NLOD threshold was set to a higher value of 
5.5 if the variant was present in the COSMIC database of somatic variants in cancer 
(Tate et al., 2019). NLOD is the likelihood that a variant is not present in the normal 
sample from the patient and the TLOD is the likelihood that the variant is present in 
the tumour sample. A panel of normal was not utilised in this analysis but the option 
exists within Mutect2.  
 
Once variant calls were made using MuTect and Mutect2 functional annotation was 
performed to identify mutated genes and the predicted impact of variants on the gene 
function. This was performed using Variant Effect Predictor (VEP) from Ensembl with 
the ever thing  option added. The bash function grep  was used to pull lines from 
the VEP output files of interest. In Chapter 4 this was done to identify variants in a 
given genomic region. In Chapter 5 this was performed to create one file containing 
all variants in the cohort for a given list of genes of interest. An R script was used to 
manually filter results for coding mutations, recurrent variants and for specific 
predicted impacts using tools such as PolyPhen and SIFT (Adzhubei et al., 2013). 
 
2.4.16 Statistical analysis 
 
Chi-squared and Fisher Exact tests to compare the incidence of events in patient 
subgroups were performed using the base package of R. All R scripts used in this 
thesis are included in the associated GitHub repository 
(https://github.com/anewman66/phd-thesis-2020). Data for comparisons was either 
loaded into R from a text file or manually edited into the script for smaller 
comparisons. Comparisons of continuous variables within the cohort was performed 
using a student t-test in R.  
 
Survival analysis was performed in R. A tab-delimited text file was read into R 
containing the sample name, follow-up data (time to event/last follow up) for 
appropriate survival parameters (Time to Progression, Risk of Relapse or Overall 
Survival) and covariates to test. For analyses where subsets of the cohort were 
analysed separately a column specifying inclusion and exclusion criteria was added 
for filtering via R. Univariate survival analysis was performed using the Cox 
Proportional Hazard method. Cox Proportional Hazard modelling makes the 
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assumption that the effect that a covariate has on the hazard ratio of a cohort is 
constant across time (Singh and Mukhopadhyay, 2011). This assumption test was 
performed in R to ensure that this assumption held true in each cohort analysed in 
this study.  
 
Covariates with univariate p values below 0.1 were included in multivariate modelling 
by a forward selection method of statistical regression. The most significant covariate 
from univariate analysis (i.e. with the lowest p value) was included in the first model. 
The second model was generated from the first model alongside one of the other 
covariates. All possible second models were compared to the first model using a 
likelihood ratio test to determine if the addition of the second covariate had improved 
upon the first model. If more than one model significantly improved upon the 
previous, then the model with the most significant p value by likelihood ratio test was 
taken forward to the next stage of the forward selection. This process continued until 
no models significantly improved upon the last model by likelihood ratio test.  
 
The Kaplan-Meier survival estimate function was performed to visualise the 
difference in relative risk between two patient subsets. Kaplan-Meier plots were 
generated in R using the survminer package. Input data for Kaplan-Meier plots was 
the same as used for Cox Proportional Hazard survival analysis. Scripts for 
producing Kaplan-Meier plots are saved to the GitHub repository associated with this 
thesis (https://github.com/anewman66/phd-thesis-2020).  
 
 
2.4.17 Data visualisation 
 
Copy number data figures were generated using Nexus Copy Number 10.0, R and 
IGV. Aggregate plots were generated in Nexus Copy Number 10.0 and reformatted 
using Inkscape. Cohort heatmaps presented in Chapter 4 and Chapter 6 were 
generated in IGV using a seg file generated from Nexus Copy Number 10.0. The 
image was saved as a vector-based image in .svg format and then reformatted and 
annotated in Inkscape. GISTIC2.0 plots were generated using the maftools  R 
package. 
 
Figures presenting whole exome sequencing reads were generated using IGV and 
reformatted and annotated using Inkscape. Lolliplots presented in Chapter 5 and 
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Chapter 6 displaying TP53 mutations were generated in R using the GenVisR  
package. Scripts used to generate plots are available at the GitHub repository 
associated with this thesis (https://github.com/anewman66/phd-thesis-2020). Circos 
plots presented in Chapter 4 were generated using the Circos tool in the perl 
language by Dr Masood Zaka. The input files were aggregate plot files generated 
from Nexus Copy Number 10.0.  
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Relapse is a significant clinical challenge in treating paediatric B-NHL, with salvage 
rates as low as 17% (Fujita et al., 2008). While the introduction of rituximab into 
frontline therapy has reduced rates of relapsed/refractory disease significantly 
(Minard-Colin et al., 2016), treatment is still highly intense and toxic to the patient 
(Anoop et al., 2012). Until salvage therapy is improved to be consistently successful 
then de-escalation of high-dose chemotherapy is not going to be possible. Currently 
there are no markers that can predict disease progression used in the clinic, despite 
previous studies identifying gain of 7q, deletion of 13q and amplification of 13q31.3 
as putative prognostic markers (Poirel et al., 2009; Nelson et al., 2010; Schiffman et 
al., 2011). The reason for these prognostic markers failing to reach the bedside is 
unclear, but the clinical need for translatable prognostic markers is still strong. It is 
possible that validation of prognostic markers could not be performed due to the low 
number of patients for phase II clinical trial recruitment. 7q gain and 13q loss were 
identified in the context of a large clinical trial cohort with extensive clinical data 
involving 238 cases (Poirel et al., 2009) and validated in an additional cohort of 28 
patients by FISH analysis (Nelson et al., 2010). In contrast, 13q31.3 amplification 
was identified in a small cohort of 28 patients (Schiffman et al., 2011) and has not yet 
been validated as a prognostic marker in a larger cohort. A recent study has 
suggested that 13q31.3 amplification is associated with paediatric disease and is 
significantly less frequent in the adult disease (Havelange et al., 2016b). The study 
did not investigate the prognostic value of the abnormality, but the suggestion of 
MIR17HG gain being associated with paediatric disease is potentially incompatible 
with it being prognostic, as the childhood cases do better than adults.  
 
Age is an important factor in the outcome of B-NHL, with adult patients doing 
significantly worse when compared to their paediatric counterparts (Pfreundschuh et 
al., 2006; Poirel et al., 2009). A significant factor driving this will be the use of 
different treatment protocols, and when treated uniformly in the past the outcomes in 
both age groups were comparable (Magrath et al., 1996). However, important 
differences in disease biology between adult and paediatric B-NHL also exist 
(Sandlund and Martin, 2016). Treatment protocols in adults differ to those given in 
the paediatric setting, opting instead for a CODOX-M-IVAC regimen. The 
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FAB/LMB96-based protocols given to children are not as well tolerated by adult 
patients, and this is also an issue for older, more frail adult patients who cannot 
safely be treated on CODOX-M-IVAC and are generally given less intensive 
protocols such as dose adjusted EPOCH-R (Zhu et al., 2018).  
 
In the paediatric setting, B-NHL is a relatively rare haematological malignancy and 
studies investigating the genomic characteristics of the disease are hampered by 
small sample sizes (Poirel et al., 2009; Scholtysik et al., 2010; Schiffman et al., 2011; 
Salaverria et al., 2014; Havelange et al., 2016b). These smaller studies often publish 
their raw data allowing for re-analysis of their cases, as well as larger meta-analysis 
of all previously published cases. At the start of this project, relatively few of our in-
house cases had copy number array data or were clinically annotated for powerful 
survival analysis. To address this, data from our in-house cohort was combined with 
those of cases from the literature to perform a pilot study.  
 
3.2 Chapter Aims 
 
The specific aims of the work detailed in this chapter were as follows: 
x To identify copy number data from the literature and optimise analysis of data 
from different platforms together.  
x To process in-house copy number array data and evaluate bioinformatic tools 
to analyse results. 
x To perform a preliminary investigation into recurrent copy number 
abnormalities in B-NHL in a combined cohort and identify aberrations 
associated with age and subtype.  
x Investigate the prognostic value of previously-published markers associated 







3.3.1 Literature search for B-NHL copy number data 
 
A data search was performed using online data repositories Gene Expression 
Omnibus (GEO), ArrayExpress and the Database of Genotypes and Phenotypes 
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(dbGaP). The search was performed to find datasets that were generated on copy 
number platforms, including copy number/SNP arrays or aCGH (array comparative 
genome hybridisation) microarray datasets with raw or processed data available to 
download. Datasets had to include tumour material with a diagnosis of de novo 
DLBCL or BL. Nine studies were initially identified, but two were excluded before 
analysis due to the nature of the investigation. Of these, one study identified was 
excluded due to only constitutional germline array data being made available 
(GSE58718 (Conde et al., 2014)) while another study was excluded as it only 
investigated post-transplant DLBCL diagnoses, which are known to differ genetically 
to de novo DLBCL (GSE69440).  
In total, seven studies were identified which met the inclusion criteria (Table 3.1). 
Additional copy number data was obtained from a paper published in the British 
Journal of Haematology in 2016, after the search was performed (Havelange et al., 







Citation Samples Platform 
GSE19459 DLBCL Lepretre et al. 
2009 
20 IRCL Human Genome CGH Microarray 
44B G4410B (probe version) 
GSE11318 DLBCL Lenz et al. 
2008 
145 NCI NimbleGen Homo sapiens HG17 
Whole Genome 385K Tiling Set 
GSE57612 DLBCL Scholtysik et 
al. 2015 
148 Affymetrix Mapping 250K Sty2 SNP 
Array 
GSE12906 DLBCL Kato et al. 
2009 
62 Affymetrix Mapping 250K Sty2 SNP 
Array, 250K Nsp, 50K Hind240, 50K 
Xba240 
GSE21597 BL Scholtysik et 
al. 2010 
39 Affymetrix 250K Nsp and 250K Sty 
GSE56884 DLBCL Ichimura et al. 
2014 
29 Array CGH (Custom) 1Mb resolution 
GSE54303 BL, 
DLBCL 
Suguro et al. 
2014 
142 Array CGH (Custom) ACC human 2K 
ver6.0. 
N/A BL Havelange et 
al. 2016 
24 Affymetrix Mapping 100K 
Table 3.1 - Summary of genomic datasets used in this study. 
 
 
3.3.2 Patient Cohort 
 
At the beginning of the project copy number data for 634 samples was collected from 
existing in-house and external datasets. A total of 25 diagnostic patient samples were 
included in the analysis (12 BL, 4 DLBCL and 9 B-NHL, NOS) and 609 were acquired 
from the literature (88 BL and 521 DLBCL). Age data was available for 410 samples 
allowing for age stratification. Table 3.2 details the breakdown of patients with age 
information by diagnosis. 18 years of age was used as the cut off between paediatric 













Paediatric 49 19 9 77 
Adult 26 316 0 342 
Unknown 25 190 0 215 
Total 100 525 9 634 
Table 3.2 - A summary table showing the age group and B-NHL subtypes of samples 
with copy number data. 
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3.3.3 Genomic abnormalities in B-NHL associated with age 
 
Investigation of copy number aberrations in adult and paediatric B-NHL showed 
distinct differences between the two age groups. 410 samples with clinical data 
regarding age and disease type were analysed together using Nexus Copy Number 
10.0 software and split into four groups based on diagnosis and age. A comparison 
of age and subtype diagnosis is displayed in Figure 3.1 and summarised in Table 
3.2. Common abnormalities in paediatric Burkitt lymphoma included gain of 1q 
(24/49, 49.0%), amplification of 13q31.3 (14/49, 28.6%) and 7q gain (16/49, 32.7%).  
 
The most frequently observed abnormalities in adult DLBCL were deletion of 6q 
(145/316, 45.9%), gain of chromosome 3 (103/316, 32.6%), gain of chromosome 18 
(82/316, 25.9%) and REL amplification at 2p15 (52/316, 16.5%). Other frequently 
identified copy number aberrations were 9p21.3 loss, gain of chromosome 11q, gain 
of chromosome 12, deletion of 15p and deletion of 17p.  
 
 
Figure 3.1 - Copy number profile for B-NHL subtypes separated by age and analysed 
by array. Blue peaks represent copy number gain and red peaks represent copy 
number loss at the region. A higher peak represents a higher incidence of 
abnormality. aBL = adult Burkitt Lymphoma, aDLBCL = adult Diffuse Large B Cell 
Lymphoma, pBL = paediatric Burkitt Lymphoma, pDLBCL = paediatric Diffuse Large 
B Cell Lymphoma. 
 
The GISTIC1.0 algorithm implemented into Nexus Copy Number 10.0 identified 42 
regions of significantly altered copy number in 634 B-NHL samples. 16 regions were 
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removed from analysis due to overlapping 100% with known CNVs and a further 7 
were removed as they appeared to be caused by anomalous artefacts at the probe 
level. It was common for regions of copy number gain or loss to be identified by 
GISTIC1.0 that had low or uneven probe coverage, leading to inappropriate 





Cytoband Event G-Score 
% of CNV 
Overlap Genes of interest within region 
1q23.3 CN Gain 52.2 0 PBX1 
1p36.32 CN Loss 30.7 0 TP73 
2p16.1 CN Gain 38.3 0 REL 
4q21.22 CN Loss 22.2 10.4 None 
6q21 CN Loss 66.3 0 PDSS2, FOXO3, PRDM1 
7q21.3 CN Gain 40.6 18.0 Mir106b-25 
7q12.2 CN Gain 32.2 0 ABCA13, CDC14 
9p21.3 CN Loss 59.9 100 CDKN2A, CDKN2B 
11q23.3 CN Gain 36.7 0 CD3, KMT2A, TMPRSS4, IL10RA 
11p13 CN Gain 23.8 0 CD44 
11q25 CN Loss 21.2 40.5 None 
12q15 CN Gain 36.1 0 IFN- , MDM1, IL26, IL22 
12p11.23 CN Gain 24.8 0 ITPR2, SOX5 
13q31.3 CN Gain 34.6 6.2 MIR17HG 
14q11.2 CN Gain 30.7 4.1 SUPT16H, SNORD9, SNORD8, CHD8, RAB2B, TOX4, METTL3, SALL2 
15q15.1 CN Loss 27.1 3.1 SNF106, CAPN3 
17p11.2 CN Loss 41.4 100 TP53 
18q21.32 CN Gain 55.2 4.8 CCBE1 
19p13.3 CN Loss 28.5 12.0 CD70, VAV1, SH2D3A 
Table 3.3  Regions and genes identified by GISTIC 1.0 analysis of all 634 B-NHL 
cases. Genes of interest were selected using Kegg Ontology Mapper (Kanehisa et 
al., 2019). 
 
Additionally, GISTIC1.0 analysis was performed on a subset of the cohort comprised 
of 49 paediatric BL cases to identify recurrent abnormalities specific to pBL (Table 
3.4).  
 
Cytoband Event G-Score 
% of CNV 
Overlap 
Genes of interest within 
region 
7q21.3-
7q22.1 CN Gain 3.3 23.7 MIR106B 
11q23.2 CN Gain 3.2 1.8 HTR3A, HTR3B 
12q15 CN Gain 2.7 6.4 MDM2, FRS2 
13q31.3 CN Gain 6.2 65.0 MIR17HG 
17p11.2 CN Loss 5.8 100 * TP53 
18q21.2 CN Gain 2.5 54.5 * POLI, MBD2, C18ORF54, DYNAP, RAB27B, CCDC68 
Table 3.4 - GISTIC 1.0 analysis of paediatric Burkitt Lymphoma samples. *Gene 
situated within wide peak region. Genes of interest were selected using Kegg 
Ontology Mapper (Kanehisa et al., 2019) 
 
In paediatric BL, 36 regions of copy number change were identified to be significant 
by the algorithm. Of these, 29 were excluded as they were due to array-specific 
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artefacts, regions of known germline copy number variation or were situated on sex 
chromosomes. The remaining 6 regions are summarised in table 5. Previously 
reported abnormalities including chromosome 1q gain, 7q21-q22 gain (mir106b-25 
locus), 13q31.3 amplification (MIR17HG locus) and TP53 loss were identified by the 
algorithm. Additionally, copy number gain of MDM2 and FRS2 on chromosome 12q 
was reported in the minimal common region of 12q gains in paediatric BL.  
 
Table 3.5 summarises the incidence of recurrent genomic abnormalities in B-NHL by 
subtype and age, demonstrating the difference in genomic landscape between 






events        % 
pBL 
events        % 
Fisher exact p 
value 
aDLBCL 
events        % 
pDLBCL 
events        % 
Fisher exact p 
value Observation 
1q gain 14/26 53.80% 24/49 49.00% 0.809 119/316 37.70% 9/19 47.40% 0.468  
REL amp 0/26 0% 0/49 0% 1 52/316 16.50% 2/19 10.50% 0.749  
Chr3 gain 4/26 15.40% 7/49 14.30% 1 103/316 32.60% 7/19 36.80% 0.802  
6q loss 1/26 3.90% 9/49 18.40% 0.150 145/316 45.90% 4/19 21.10% 0.055  
7q gain 3/26 11.50% 16/49 32.70% 0.054 92/316 29.10% 3/19 15.80% 0.296  
Chr9 gain 3/26 11.50% 6/49 12.20% 1 54/316 17.10% 7/19 36.80% 0.058  
CDKN2A 
loss 0/26 0% 4/49 8.20% 0.291 66/316 20.90% 3/19 15.80% 0.774  
11q gain 2/26 7.70% 12/49 24.50% 0.119 94/316 29.70% 3/19 15.80% 0.297  
Chr12 gain 3/26 11.50% 12/49 24.50% 0.234 98/316 31.00% 9/19 47.40% 0.203  
MIR17HG 
amp 2/26 7.70% 14/49 28.60% 0.042 29/316 9.20% 5/19 26.30% 0.033 
Significantly more common in paediatric 
cases than adult. 
13q34 loss 1/26 3.90% 7/49 14.30% 0.249 17/316 5.30% 0/19 0% 0.611  
17p loss 1/26 3.90% 7/49 14.30% 0.249 74/316 23.40% 5/19 26.30% 0.783  
Chr18 gain 2/26 7.70% 5/49 10.20% 1 72/316 22.80% 1/19 5.30% 0.087  
Table 3.5 - Incidence of frequent abnormalities in B-NHL stratified by patient age and disease subtype. 
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Amplification of the REL gene was not detected in BL and was found at a higher 
incidence in adult DLBCL than paediatric DLBCL. This observation is expected as 
REL amplification is typically seen in GCB-like DLBCL and not ABC-like DLBCL 
(Lenz et al., 2008). Amplification of REL was identified in 2/19 pDLBCL cases in 
contrast to a previously published study (Klapper et al., 2012) in which no paediatric 
patients aged below 15 years of age harboured this abnormality. The two pDLBCL 
cases with REL amplification were 7 and 14 years old. However, incidence of REL 
amplification in aDLBCL in our investigation was 16.14%, consistent with 17% 
observed in published data (Rosenwald et al., 2002). Other abnormalities previously 
reported as being associated with DLBCL rather than BL were, as expected, 
observed at higher incidences in DLBCL including chromosome 3 gain, 6q loss, 
CDKN2A loss, and chromosome 18 gain. 6q loss and chromosome 18 gains were 
shown to be more frequent in adult than paediatric DLBCL. The genomic landscape 
of adult BL appeared similar to that of the paediatric subtype, but with fewer 
additional abnormalities (Figure 3.1) and lower incidences of reported recurrent 
abnormalities (Table 3.5) with the exception of 1q gain. Chromosome 12 gains were 
reported at a higher frequency in DLBCL than BL but also at a higher incidence in 
paediatric than adult disease in both subtypes. 
 
MIR17HG amplification was identified as a significant abnormality by our GISTIC 
analysis in BL and it has been shown recently to be more common in paediatric 
disease than adult disease (Havelange et al., 2016b). Our analysis determined that 
the incidence of MIR17HG amplification is higher in paediatric DLBCL as well as in 
BL. This suggests that it is a paediatric-associated abnormality in B-NHL regardless 
of disease subtype. 14/49 (28.6%) paediatric BL patients and 5/19 (26.3%) paediatric 
DLBCL cases harboured a gain of MIR17HG. In contrast, the incidence of MIR17HG 
amplification was significantly lower in adult patients, at 2/26 (7.7%) and 29/316 
(9.2%) in adult BL and DLBCL respectively (BL p=0.042, DLBCL p=0.033, Fisher 
exact test) (Figure 3.2). This suggests that MIR17HG may be useful for creating a 




Figure 3.2 - Incidence of MIR17HG amplification in adult and paediatric BL and 
DLBCL. Blue denotes copy number gain and red denotes copy number loss. The 
higher the amplitude of the peak, the higher the frequency of aberration. 
 
3.3.5 Teenagers and Young Adults 
 
The age range of 15 and 24 years of age was used to define the teenager and young 
adult subset of patients. This was based on results from other studies that defined 
15-18 as adolescent patients and 24 as the age at which abnormalities common in 
adult patients become more frequent (Klapper et al., 2012). This group of patients 
had generally quiet genomes with recurrent gains of 1q and chromosome 12. Of the 
17 patients aged 15-24, four out of 17 patients had gains of 12p and 12q, with an 
additional patient harbouring gain of 12q alone. Two patients, aged 17 (MPI-757) and 
18 (MPI-122), harboured gains of chromosomes 9 and 12 together. MPI-757 also 
had a 1.5Mb deletion on 3p that involved RHOA and a 1.8Mb amplification involving 
MIR17HG. MPI-122 had only chromosome 9 and 12 gains and a small deletion on 2p 
involving DCDC2C and ALLC. The rest of the cohort with age data was then 
screened for this combination of whole chromosome gains. Twelve cases aged 
between 7 and 87 were identified with copy number gains of at least one 
chromosome arm of both chromosome 9 and 12.   
 
By splitting all B-NHL samples with patient age available into age groups spanning 5 
years it was possible to visualise the change in the genomic landscape. Using this 
method, a subset of patients between the ages of 16 and 20 years of age were 
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identified with gains of chromosome 9 and chromosome 12 concurrently. This 
combination of abnormalities is previously unreported in B-NHL, and is present at a 
much higher incidence in this age group (Figure 3.3). 
 
Figure 3.3 - Incidence of concurrent chromosome 9 and chromosome 12 gains in all 
B-NHL cases stratified by age. 
 
This analysis also confirmed that the frequency of MIR17HG amplification was lower 
in adult patients (Figure 3.4). 
 









































































































































































As this analysis shows that the incidence of MIR17HG gain is more frequent in 
children than adults, MIR17HG may be used as a marker to define a cut-off age 
between paediatric and adult B-NHL. A Chi-squared test showed that the age cut-off 
with the most significant difference in incidence of MIR17HG amplification was age 
25.  
 
3.3.6 Genomic abnormalities associated with outcome 
 
In total, 292 of 634 B-NHL patients analysed in this study had associated outcome 
and follow up data allowing for analysis of genomic aberrations by patient survival. Of 
49 pBL cases identified in this cohort there were 36 patients with follow up time and 
outcome information. By integrating this clinical data with copy number data it was 
possible to evaluate the impact of abnormalities on patient survival. Of the six 
frequently observed abnormalities identified by GISTIC analysis (Table 3.4), 17p loss 
was associated with a significantly altered outcome by Cox proportional hazard 
method (HR 7.7 95% CI 1.3-46.0, p=0.026, Cox proportional hazard method). 17p 
loss was associated with an inferior overall survival at 3 years, demonstrated in 
Figure 3.5. There were insufficient cases for analysis of time to progression or 
association with relapse/refractory disease.  
 
 
Figure 3.5 - Kaplan-Meier analysis of the prognostic significance of 17p deletion in 36 
paediatric Burkitt Lymphoma patients. (p=0.009, Log rank test) 
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The most well-characterised tumour suppressor gene, TP53, is situated at 17p13, 
which was deleted in all cases with 17p loss. These preliminary findings suggest that 
the TP53 gene is important in disease progression in paediatric BL.  
 
Kaplan Meier analysis was performed on the subset of BL patients with outcome data 
to determine whether previously identified prognostic markers were indicative of poor 
outcome in this cohort. In keeping with the analysis performed by Schiffman et al, 
gain of 13q31.3, involving MIR17HG was associated with a poorer outcome 
(p=0.024, Log rank test) which seemed to validate the results of the previous 




Figure 3.6 - Kaplan Meier Analysis was performed to evaluate the effect of previously 
identified putative prognostic markers on overall survival in paediatric BL. (P values: 
p=0.024, p=0.59 and p=0.91 respectively, Log rank test). 
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7q gain was not associated with an inferior overall survival (p=0.59, Log rank test). 
Equally, deletion of 13q, as reported to be prognostic in the Poirel (2009) and Nelson 
(2010) studies was not associated with poorer outcome (p=0.91, Log rank test). This 
apparent disparity in prognostic power between our analysis and those previously 
published may be explained by the small sample size in this analysis. Investigation 
with an expanded cohort will allow for more comprehensive analysis of putative 





Initial copy number investigation utilising existing data from in-house datasets 
successfully identified recurrent copy number abnormalities that were enriched in 
age-associated subgroups. Analysis of copy number array data from 634 B-NHL 
patients has enabled detailed analysis of genomic abnormalities in the disease. 
Abnormalities reported in the literature in Burkitt Lymphoma including gain of 1q, gain 
of 7q and 13q abnormalities were identified in this investigation. We report gain of 1q 
in 49% of paediatric BL cases, a higher incidence than observed in the Poirel study 
(Poirel et al., 2009). This difference in frequency is most likely explained by increased 
sensitivity of array platforms compared to traditional karyotyping and the ability to 
detect smaller regions of copy number change. Gain of 7q was detected in 32.7% of 
paediatric BL which is also considerably higher than the 10% reported by Nelson et 
al. (2010) and Poirel et al. (2009). Deletion of 13q, in contrast, was found in a lower 
proportion of paediatric BL cases than has been previously reported by Nelson et 
al.(2010). We detected 7 cases (14.3%) with deletions on 13q and all involved 
13q34. No deletions of 13q14.3 were detected. The frequency of 13q deletions in our 
study correlates with the findings of Poirel et al. (2009). No adult-specific 
abnormalities were detected in BL and samples in this group appeared to have much 
quieter genomes than the paediatric cases. Loss of 6q and gain of chromosome 18 
were both most strongly associated with adult DLBCL and were observed at lower 
incidences in BL. This reflects the increase in ABC-subtype DLBCL with age reported 
in the literature (Deffenbacher et al., 2012).  
 
Our copy number analysis confirmed the finding reported by Havelange et al.(2016b) 
that MIR17HG amplification is found at higher frequencies in paediatric Burkitt 
lymphoma than in the adult disease. Remarkably, investigating paediatric cases and 
separating out disease subtypes revealed that MIR17HG is associated with patient 
age in B-NHL regardless of subtype, with similar incidences in paediatric BL and 
DLBCL, and adult BL and DLBCL respectively. Stratifying patients into 5-year age 
groups showed the trend of MIR17HG amplification being at a high frequency in 
paediatric cases before reducing in frequency after age 25. We did not, however, find 
MIR17HG in paediatric and young adult cases exclusively, as we detected MIR17HG 
gain in 29/316 (9.2%) adult DLBCLs up to the age of 84 years. The oldest BL patient 
with MIR17HG gain was 35, suggesting that the abnormality may not occur in older 
adults. This would need validation with a larger cohort of BL patients however. 
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Despite data from previous studies (Klapper et al., 2012) amplification of REL was 
detected in both adult and paediatric DLBCL cases at similar frequencies, suggesting 
that the abnormality is not age specific. Gain of chromosome 9 and gain of 
chromosome 12 were both observed as being most frequent in paediatric DLBCL. 
Three paediatric DLBCL patients harboured both abnormalities concurrently, and two 
these patients were adolescents aged 17 and 18. Additional data from paediatric and 
TYA cases is needed to further investigate whether these co-occurring events are 
significant.  
 
Identification of a potential TYA-specific abnormality suggests that a subgroup of 
patients in this age group may be biologically distinguished from paediatric and adult 
type B-NHL. Further investigation with a higher number of patients between 16 and 
30 may allow us to determine which genes and pathways are involved with a view to 
developing a novel therapeutic strategy for this group. Unfortunately, as diagnosis of 
patients at this age group is very low, it is difficult to find enough samples for 
meaningful analysis with statistically significant results. Klapper et al. (2012) suffered 
similar setbacks, as in their cohort of 364 patients, onl  5 fell within their adolescent  
cut-off. Our investigation had 7 patients aged between 16 and 20 years of age with 
strikingly quiet genomes when compared to typical adult and paediatric B-NHL cases 
with the notable exception of concurrent chromosome 9 and 12 gains. TYA cases are 
under-represented in this and other studies due to the reduced incidence of disease 
in these patients, primarily as a result of fewer cases being diagnosed in these age 
groups. Meaningful characterisation of the TYA genomic landscape in B-NHL would 
require more patients in this age group with array data and/or next-generation 
sequencing data.  
 
Deletion of 17p involving TP53 was shown to be significantly associated with a 
poorer overall survival in paediatric BL. However, no other abnormalities were 
significantly associated with a poor prognosis. Although reported by Poirel et al. 
(2009) there was no significant effect of 7q gain or 13q loss on outcome in paediatric 
BL in our combined analysis. While MIR17HG gain was shown to be a prognostic 
marker in paediatric BL as part of our study, this was only in a very small subgroup of 
BL cases with outcome. This analysis highlighted the need for a larger cohort for 
meaningful survival analysis with better annotated clinical data. The majority of B-
NHL data available in the literature was either from adult studies or were of an 
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unknown age, and no further copy number data from paediatric B-NHL was 
identified.  
 
The primary aim of the study summarised in this chapter was to determine whether 
combining existing in-house data could be analysed in combination with previously 
published data generated on numerous different array platforms. There were more 
samples available from the CCLG cohort for paediatric B-NHL, so in light of the low 
numbers in this study 110 cases were sent to AROS (Applied Biosystems, Denmark) 
for analysis with Affymetrix Cytoscan HD array kit and Affymetrix Oncoscan FFPE 
array kit. However, many cases had not had their pathology reviewed to confirm the 
diagnosis from the treatment hospital. This is a significant issue in paediatric B-NHL 
as the subtype is not used to drive treatment decisions currently; DLBCL and BL 
patients all receive FAB/LMB96 protocol chemotherapy, as do newer subtypes 
including HGBL, NOS and BLL-11q. The identification of prognostic genomic markers 
in paediatric B-NHL will likely reflect the underlying biology of different disease 
subtypes, making robust pathological diagnosis of subtype important. Indeed, newly 
defined subtypes of B-NHL that were included in the 2016 revision of the WHO 
Classification of Lymphoid Neoplasms (Swerdlow et al., 2016) were not in use when 
many of these cases were diagnosed. Great effort was made to perform a thorough 
pathology review led by pathologist Dr Chris Bacon, which successfully confirmed the 
diagnosis of 74/110 (67.2%) patients in the new cohort. Lack of FFPE material was 
the primary reason for path review not being completed. On top of this, additional 
data requests were made to the CCLG for clinical data required for reliable survival 
analysis. Patient age, gender, bone marrow involvement status, CNS involvement 
status, CSF involvement status, date of diagnosis, date of end of treatment, date of 
relapse, relapse status, date of last follow up, treatment type, FAB/LMB96 treatment 
group and rituximab treatment status were requested from CCLG centres for cases in 
the study. Response rates from centres were high, and we received sufficient data 
for 101/110 CCLG patients to perform survival analysis for overall survival and time 
to progression. This cohort of 110 patients was combined with the 52 paediatric 
cases identified from the literature during this pilot project. This new combined 
paediatric cohort was 162 patients was taken forward for a more comprehensive 
analysis detailed in Chapter 4.  
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IG-MYC rearrangement is the hallmark of BL and is observed in 90-95% of BL cases 
(van Rijk et al., 2008). However, the co-operating cytogenetic and molecular genetic 
abnormalities are less well defined in BL, particularly those associated with outcome. 
Early cytogenetic studies using traditional karyotyping reported that additional copies 
of chromosome 1q and 7q were common in BL patients, as well as deletion of 13qter 
and 17p (Lones et al., 2004). However, most of these studies were conducted on 
small numbers of patients and/or used early, lower resolution CGH arrays. Cohort 
size is a major hurdle to overcome in the study of prognostic markers in B-NHL, 
which is a rare disease in the paediatric setting. Small patient numbers limit our 
ability to understand the impact of B-NHL genomic abnormalities and limit the 
significance of statistical analysis.  
 
With the advent of high resolution copy number arrays several studies were 
published investigating copy number changes in BL (Scholtysik et al., 2010) and 
DLBCL (Scholtysik et al., 2015). In BL the most common aberrations reported were 
gain of 1q, gain of 7q and gain of 13q31.3 with deletions on 6q and 17p. In DLBCL, 
1q gain, chromosome 7 gain and 6q loss were also recurrent while abnormalities on 
chromosome 3 and 18 were more common than in BL. ABC- and GCB-like DLBCL 
had distinct copy number patterns, with gain of chromosomes 3 and 18 and loss of 
6q involving BACH2 being more common in the ABC-DLBCL subtype while REL 
amplification has been frequently shown to occur in GCB-like DLBCL (Scholtysik et 
al., 2015). CDKN2A deletion was significantly more frequent in ABC-like DLBCL. As 
CDKN2A deletion has been shown to be associated with poorer outcome in adult 
DLBCL, this may go some way to explain the inferior survival rates of ABC-like 
DLBCL compared to the GCB-like subtype (Jardin et al., 2010). In contrast, CDKN2A 
deletion is seen in BL in a small population of patients, but has not been shown to be 
associated with poor outcome (Scholtysik et al., 2010; Schiffman et al., 2011). 
However, these studies involve primarily adult patients, which highlights the 
importance of clinical context to prognostic markers in B-NHL. Treatment protocols 
differ between BL and DLBCL subtypes in the adult setting, but not in paediatrics, 
where patients are primarily treated with FAB/LMB96 protocols (Patte et al., 2007). It 
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remains to be seen whether prognostic markers identified in BL would apply to 
DLBCL, and vice versa.  
 
Chemotherapy resistance represents the most pressing challenge in treating B-NHL 
and clinically actionable prognostic markers are urgently needed. A retrospective 
study of karyotypes from 33 children and 37 adults with BL suggested that 
abnormalities involving 13q and 17p were associated with poor outcome in children 
and adults respectively (Onciu et al., 2006). Low resolution cytogenetic analysis of 
238 patients enrolled on the FAB/LMB trial revealed that additional copies of 
chromosome arm 7q and del(13q) were associated with a significantly poorer EFS in 
BL and DLBCL patients (Poirel et al., 2009). Subsequent work using copy number 
arrays have reported amplification of the MIR17HG miRNA cluster on chromosome 
arm 13q as a putative prognostic marker, observed in 3/28 patients (10.7%)  
(Schiffman et al., 2011). However, this study was conducted on only 28 BL patients 
with only three relapse patients and was not powered to identify markers of relapse. 
Despite putative prognostic markers being identified as early as 2009, none of these 
have been translated to the clinic or been the focus of clinical trials. A significant 
contributor to this disconnect between research and the clinic is the relative rarity of 
paediatric B-NHL. Traditional clinical trial designs are unrealistic in paediatric B-NHL 
as recruitment would need to run for years. Similarly, small patient cohorts in 
genomic studies are not sufficient to change opinions in the field regarding treatment, 
meaning that larger studies are required. This was achieved in this study by 
collecting data from the literature to complement the cases from our in- house cohort. 
This facilitated creation of the largest paediatric B-NHL cohort with copy number and 
clinical data which was analysed to determine whether genomic aberrations 
detectable by copy number array can be used to stratify patients at the point of 
diagnosis and used to direct clinical management of the disease.  
 
4.2 Chapter Aims 
 
The specific aims of the work detailed in this chapter were as follows: 
x Identify and characterise copy number aberrations in a large paediatric B-NHL 
cohort using integrated bioinformatics. 
x Evaluate the prognostic value of recurrent genomic abnormalities by univariate 
and multivariate modelling.  
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x Further investigate statistically significant prognostic genomic markers using 









4.3.1 Clinical Characteristics of the Cohort  
 
Copy number analysis of 162 paediatric B-NHL samples was performed to identify 
recurrent genomic abnormalities. The cohort comprised 109 BL, 36 DLBCL, 5 BLL-
11q, 1HGBL, NOS and 11 B-NHL, NOS. Of these, 110 cases were acquired from the 
CCLG Tissue Biobank and the remaining 52 were taken from eight existing studies in 
the literature as described in Chapter 3 (Lenz et al., 2008; Kato et al., 2009; Lepretre 
et al., 2010; Scholtysik et al., 2010; Kwiecinska et al., 2014; Suguro et al., 2014; 
Scholtysik et al., 2015; Havelange et al., 2016b). The distribution of age, sex, disease 
stage and BM/CNS involvement were similar between cases with and without 




Table 4.1 - Clinical characteristics of 162 paediatric B-NHL patients. F=Female, 
M=Male, U=Unknown, BL=Burkitt lymphoma, DLBCL=Diffuse large B-cell lymphoma, 
Characteristic No Progression Disease Progression Unknown
Total Number of Cases 119 18 25
Sex
F 22 (18.5) 6 (33.3) 1 (4)
M 93 (78.2) 11 (61.1) 7 (28)
U 4 (3.4) 1 (5.6) 17 (68)
Age at Diagnosis
0-5 29 (24.4) 7 (38.9) 6 (24)
6-10 40 (33.6) 7 (38.9) 12 (48)
11-14 35 (29.4) 3 (16.7) 3 (12)
15-18 15 (12.6) 1 (5.6) 4 (16)
Median 8 6.5 8
Range 2-18 0-16 2-18
Tumour Stage
1 2 (1.7) 0 (0) 0 (0)
2 12 (10.1) 1 (5.6) 0 (0)
3 18 (15.1) 4 (22.2) 0 (0)
4 10 (8.4) 1 (5.6) 1 (4)
U 77 (64.7) 12 (66.7) 24 (96)
BNHL Subtype
BL 84 (70.6) 15 (83.3) 10 (40)
DLBCL 22 (18.5) 2 (11.1) 12 (48)
BLL-11q 4 (3.4) 0 (0) 1 (4)
HGBL, NOS 1 (0.8) 0 (0) 0 (0)
B-NHL, NOS 8 (6.7) 1 (5.6) 2 (8)
CSF Involvement
Y 2 (1.7) 0 (0) 0 (0)
N 60 (50.4) 10 (55.6) 2 (8)
U 57 (47.9) 8 (44.4) 23 (92)
CNS Involvement
Y 7 (5.9) 1 (5.6) 0 (0)
N 73 (61.3) 11 (61.1) 2 (8)
U 39 (32.8) 6 (33.3) 23 (92)
BM Involvement
Y 11 (9.2) 4 (22.2) 1 (4)
N 58 (48.7) 9 (50.0) 1 (4)
U 50 (42.0) 5 (27.8) 23 (92)
MYC translocation
MYC-R (IG) 75 (63.0) 15 (83.3) 8 (32)
MYC-R (non-IG) 1 (0.8) 0 (0) 0 (0)
No MYC-R 30 (25.2) 2 (11.1) 2 (8)
NA 13 (10.9) 1 (5.6) 15 (60)
Treatment Protocol
FAB/LMB-based 86 (72.3) 14 (77.8) 2 (8)
UKCCSG NHL-based 3 (2.5) 0 (0) 1 (4)
R-CHOP 0 (0) 1 (5.6) 0 (0)
ALL-like 14 (11.8) 1 (5.6) 0 (0)
CHOP-like 1 (0.8) 0 (0) 2 (8)
NHL BFM-90 1 (0.8) 0 (0) 1 (4)
Unknown 13 (10.9) 2 (11.1) 19 (76)
None 1 (0.8) 0 (0) 0 (0)
Rituximab Treatment
Y 4 (3.4) 6 (33.3) 1 (4)
N 58 (48.7) 4 (22.2) 1 (4)
U 57 (47.9) 8 (44.4) 23 (92)
Dead*
N 104 (87.4) 5 (27.8) 13 (52)
Y 6 (5.0) 13 (72.2) 4 (16)
U 9 (7.6) 0 (0) 8 (32)
Median time to death (mo) 1.4 7 4.38
Range (mo) 0.07-5.00 3.58-17.05 1.87-24.0
Outcome
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BLL-11q=Burkitt-like Lymphoma with 11q aberration,HGBL,NOS=High Brade B-cell 
Lymphoma not otherwise specified, B-NHL,NOS= B-cell non-Hodgkin lymphoma not 
otherwise specified, N= No, Y=Yes, MYC-R=MYC rearrangement, 
IG=Immunoglobuli, NA=not available. * censored at 3 years follow-up. 
 
18 cases had disease progression and 119 were in remission without progressive 
disease and in total, 128/162 (79%) had sufficient follow up data for survival analysis 
with a median follow up time of 5 years (range 0.01-22.5 years). Of the 18 cases with 
progressive disease, 12 patients achieved remission and six did not achieve 
remission prior to disease progression. There was no statistical significance between 
disease progression and subtypes (BL 15/109 13.8% vs 2/36 DLBCL 5.6%; p=0.24, 
Fisher exact test). Notably, all disease progression occurred within one year of 
original diagnosis (mean 5.01 months, range 2.80-8.25 months).  
 
4.3.2 Analysis of Copy Number Abnormalities 
 
The genomic profiles of 109 BL, 36 DLBCL, 5 BLL-11q, 1HGBL, NOS and 11 B-NHL, 
NOS cases were analysed (Figure 4.1). The mean number of copy number 
abnormalities (CNAs) and regions of copy-number neutral loss of heterozygosity 
(CNN-LOH) per sample were 40.43 (range: 0-618) and 1.72 (range: 0-30), 
respectively. Samples from the CCLG cohort were processed and segmented using 
Affymetrix arrays as detailed in Chapter 2. Of the 110 CCLG cases in this study, 79 
were analysed using the Affymetrix Cytoscan HD array kit, 26 on the Affymetrix 
Oncoscan 2.0 MIP array kit and 5 on the Affymetrix Genome-Wide Human SNP6.0 
array kit. Segmentation was performed using the proprietary Nexus Copy Number 10 
software. Affymetrix Cytoscan HD and Genome-Wide Human SNP6.0 array cases 
were segmented using the SNP Rank algorithm incorporated in Nexus Copy Number 
10, which is based on the Circular Binary Segmentation (CBS) algorithm. Affymetrix 
Oncoscan MIP arrays were segmented using the TuScan algorithm. All array types 
were segmented to generate calls for copy number gain, deletion and CNN-LOH.  
 
Copy number calls were manually checked for over-segmentation, noise and 
recurrent germline CNVs. Over-segmentation occurs when the threshold set for the 
segmentation algorithm is close to the probe median of a region of copy number 
change, resulting in uneven segmentation across the true abnormality (Rieber et al., 
2017). Suspected germline CNVs were checked against the Database of Genomic 
Variants (MacDonald et al., 2014).  
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Figure 4.1 - Heatmap displaying segmented copy number data for 162 paediatric B-
NHL patients. Age group, MYC status and diagnosis are shown. Sex chromosomes 




4.3.3 GISTIC2.0 Analysis of Significant Targets 
 
Significant regions of copy number alteration were detected using the GISTIC2.0 
algorithm. GISTIC2.0 is the second iteration of a tool developed by the Broad 
Institute. The tool takes segmented copy number data and identifies regions that are 
likely to be driver events in cancer based on the frequency and amplitude of the 
aberration. This tool was utilised to highlight potential driver events in paediatric B-
NHL which could then be evaluated through survival analysis to uncover potential 
prognostic markers and drug targets. In total, 26 focal recurrent regions of focal CNA 
or CNN-LOH were detected by the GISTIC2.0 algorithm in the 162 paediatric B-NHL 
cases identified; including eight regions of copy number gain, 10 of loss and eight of 
CNN-LOH (Figure 4.2A, Table 4.2).  




(mb) q value 
residual q 
value wide peak boundaries 
13q31.3 Gain 0.28 2.3163e-19 2.3163e-19 chr13:91778876-92062330 
11q23.3 Gain 1.17 1.8438e-05 1.8438e-05 chr11:117745876-118920452 
3q29 Gain 2.30 0.00015311 0.00015311 chr3:195718766-198022430 
1p12-1q21.3 Gain 33.88 0.00078668 0.00078668 chr1:119258849-153139036 
18q21.2-
18q21.31 Gain 3.53 0.0077145 0.0077145 chr18:51649814-55175432 
14q24.3 Gain 0.16 0.016323 0.016323 chr14:73869638-74029913 
2p16.1-2p15 Gain 3.21 0.020563 0.020563 chr2:60281930-63491437 
10q21.1-10q21.3 Gain 5.49 0.058425 0.058425 chr10:60382406-65875657 
9p21.3 Loss 0.59 1.0925e-09 1.0925e-09 chr9:21860429-22448736 
11q24.1-11q25 Loss 11.20 1.0925e-09 1.0925e-09 chr11:123801732-135006516 
13q33.1-13q34 Loss 12.39 1.0925e-09 1.0925e-09 chr13:102776066-115169878 
3q13.31-3q13.32 Loss 2.50 7.7413e-07 7.7413e-07 chr3:116150887-118646958 
2p22.2-2p16.3 Loss 12.70 0.00018371 0.00018371 chr2:37887965-50591552 
6q13-6q22.1 Loss 42.69 0.00082233 0.00082233 chr6:74521195-117212533 
19p13.3-19p13.2 Loss 0.63 0.0034498 0.0034498 chr19:6470214-7103541 
4q12-4q22.3 Loss 43.82 0.027997 0.028188 chr4:54669141-98489305 
8p23.3-8p23.2 Loss 2.82 0.028448 0.028188 chr8:1-2822739 
1q25.1-1q44 Loss 75.32 0.084717 0.077888 chr1:173932804-249250621 
1p36.33-1p34.3 CNN-LOH 35.90 4.0217e-07 4.0217e-07 chr1:704575-36603389 
17q22-17q24.1 CNN-LOH 10.03 0.00069264 0.0053824 chr17:53498472-63525564 
1q25.3-1q44 CNN-LOH 68.79 0.0067764 0.0067595 chr1:180465542-249250621 
9p24.3-9p21.3 CNN-LOH 21.80 0.034211 0.034211 chr9:199493-22001547 
17q11.2-
17q21.32 CNN-LOH 18.72 0.052759 0.20588 chr17:26213681-44931930 
6p25.3-6q11.1 CNN-LOH 62.40 0.23951 0.23951 chr6:1-62399484 
15q13.1-15q23 CNN-LOH 42.62 0.23951 0.23951 chr15:28331173-70954036 




Figure 4.2 - GISTIC2 results for 162 paediatric B-NHL patients with copy number data. (A) Focal GISTIC2 scores representing 
recurrent smaller copy number aberrations. (B) - An ideogram showing recurrent broad arm-length aberrations. Blue denotes copy 





GISTIC2.0 improves upon the previous iteration of the tool in its ability to separate 
out focal events and larger, arm length events. Figure 4.2A shows the focal events 
identified in the cohort of 162 paediatric B-NHL patients. Focal gain of 13q31.3 (0.28 
Mb) and deletion of 9p21.3 (0.59 Mb), were the most GISTIC2.0 significantly gained 
and lost regions occurring in 25% (40/162) and 13% cases (21/162), respectively. 
Broad analysis of chromosome arm-length aberrations identified seven gained arms, 
two lost arms and 11 arms with recurrent CNN-LOH (Figure 4.2B, Table 4.3). 
 
Arm Abnormality # Genes Amp q-value 
1q Gain 1955 0 
7q Gain 1277 0 
12p Gain 575 7.82E-13 
7p Gain 641 5.28E-10 
12q Gain 1447 1.03E-08 
13q Gain 654 1.25E-07 
11q Gain 1515 0.00564 
17p Loss 683 0 
6q Loss 839 2.83E-07 
6p CNN-LOH 1173 0 
9p CNN-LOH 422 0 
17p CNN-LOH 683 0 
17q CNN-LOH 1592 0 
13q CNN-LOH 654 2.09E-08 
22q CNN-LOH 921 2.54E-06 
18q CNN-LOH 446 0.00488 
15q CNN-LOH 1355 0.0144 
7p CNN-LOH 641 0.0199 
2q CNN-LOH 1556 0.0251 
6q CNN-LOH 839 0.0475 
Table 4.3 - GISTIC2.0 Broad regions identified in 162 paediatric B-NHL patients 
 




The most significant region of gain detected by GISTIC2.0 was on 13q31.3 spanning 
0.28Mb and involved the MIR17HG locus (Figure 4.3). This microRNA cluster gene 
has previously been studied in B-NHL and has been shown to be significantly more 
common in paediatric cases compared to adults (Havelange et al., 2016b). Another 
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study identified amplification of MIR17HG in 2/3 relapse cases and suggested that 
the aberration was associated with disease progression (Schiffman et al., 2011). The 
region also overlapped with the GPC5 gene which codes for a cell surface 
proteoglycan, but evidence from the literature strongly suggests that MIR17HG is the 
region of interest within 13q31.3 copy number gain. Expression of MIR17HG 
polycistron was shown to synergise with MYC expression in nude mice to accelerate 
tumour growth (Tagawa et al., 2007). Tumours that arose in mouse models of co-
expression of MYC and MIR17HG were B cell lymphomas (He et al., 2005).  
 
 
Figure 4.3. - A plot showing copy number data for 13q from 41 patients with 13q31.3 
copy number gain. Blue denotes copy number gain and red denotes copy number 
loss. 
 
Present in 41/162 (25.3%) patients, 13q31.3 gain was most strongly associated with 
BL, appearing in 31/109 (28.4%) of patients 7/36 (19.4%) DLBCL, 2/11 B-NHL, NOS 
and the only HGBL, NOS case. All 41 cases had gain of MIR17HG (Figure 4.3). 16 
cases with MIR17HG copy number gain on 13q also harboured 13qter deletion. 
Cases with gain-loss patterns on 13q regularly had complex patterns of gain with 
MIR17HG at the peak copy number.  
 
13q33.1-13q34 deletion was found in 23 cases, of which 21 were BL. One DLBCL 
case had telomeric deletion of 13q, as did one B-NHL, NOS case. 16/21 cases had 
deletion of 13qter in association with copy number gain involving 13q31.3, which was 
a significant GISTIC2.0-identified region. Others were small abnormalities under 
100kb within the GISTIC2.0 region with the exception of two cases with 8.0Mb and 
5.6Mb deletions respectively. The region identified by GISTIC2.0 contained 63 
genes. While the deleted region contained the IRS2 gene which is important in 
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signalling, it was hypothesised that the 13qter deletions identified in these patients 
were primarily passenger events associated with the pattern of gain followed by 
telomeric loss identified in 16 cases. The gained region of 13q associated with this 
abnormality always involved the MIR17HG locus, which has been previously shown 
to be important in lymphoma (Scholtysik et al., 2010; Schiffman et al., 2011; Dal Bo 
et al., 2015; Havelange et al., 2016b).  
 
A region of copy number gain at 11q23.3 was identified in 22 cases. In 12/22 (54.5%) 
cases with this abnormality this was associated with a complex 11q abnormality 
involving deletion of the 11q telomere (Figure 4.4). This abnormality is the hallmark of 
a B-NHL subtype comprised of MYC-negative Burkitt-like cases with 11q aberrations. 
The region spanned 36 genes, most notably including KMT2A which is a recurrent 
translocation target in multiple subtypes of leukaemia and DLBCL (Gindin et al., 
2015). In BLL-11q cases this gene has been shown to be repeatedly amplified 
beyond the copy number of the adjacent gained region (Salaverria et al., 2014).  
 
 
Figure 4.4 - A plot showing copy number data for chromosome 11 from 22 cases with 
gain of 11q23.3. Blue denotes copy number gain and red denotes copy number loss.   
 
11q24.1-11q25 deletion was frequent in the paediatric B-NHL cohort with an 
equivalent q-value to 9p21.3 deletion (q=1.1x10-9) and the same incidence (21/162 
patients). The abnormality was primarily associated with BLL-11q cases, with 5/5 
harbouring the deletion as part of the characteristic 11q aberration that defines the B-
NHL subtype. Additionally, 11q24.1-11q25 deletion was seen in 12 BL cases 
(11.0%), of which seven had the same 11q aberration pattern as seen in BLL-11q. 
Other deletions were small in three cases but were contained within the GISTIC2.0-
identified region, and two cases had larger telomeric deletions without an associated 
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region of copy number gain. The 11.2Mb region of deletion highlighted by GISTIC2.0 
analysis contained 94 genes, most notably including ETS1, FLI1 and CHEK1.  
 
3q29 gain was observed in 17/162 paediatric cases in this cohort. The region 
identified by GISTIC2.0 was 2.3Mb in size and encompassed 37 genes. The region 
of recurrent copy number gain involved the telomeric region of the 3q arm in multiple 
different genomic contexts (Figure 4.5). High copy number gain/amplification was 
observed in four cases while three cases had copy number gain of the majority of 
chromosome 3. One case (21/153) harboured a chromothripsis-like event of 
chromosome arm 3q involving a gain of 3q29. The most frequently gained region 
within 3q29 included 25 genes, most notably TFRC and PAK2 present in 16/17 
cases. Remarkably, 6/17 cases with 3q29 gain experienced disease progression, 




Figure 4.5 - A plot showing copy number data for chromosome 3 from 17 patients 
with 3q29 gain. Blue denotes copy number gain and red denotes copy number loss. 
 
 
GISTIC2.0 identified a region of recurrent gain spanning 1p12-1q21.3 that was 
observed in 66/162 (40.7%) cases, including 49 BL patients. GISTIC2.0 did not 
separate a series of small copy number gains observed at the 1p side of the 
centromere from other frequent gains of 1q, meaning that in some samples the 
region of copy number gain appears to include the centromere (Figure 4.6). In reality 
as the centromere is not covered by the arrays the presence of an additional copy of 
the centromeric DNA cannot be confirmed by this method.  
 
The recurrent gains on 1q represent the most frequently observed copy number 
change in BL. 21/162 (13.0%) cases had copy number gain of more than half of the 
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length 1q which is consistent with previous studies  findings (Lones et al., 2004; 
Onciu et al., 2006; Scholtysik et al., 2010) (Figure 4.6).  
 
Figure 4.6 - A plot showing copy number data for 1q from 66 cases with gain of 1q. 
Blue denotes copy number gain and red denotes copy number loss. 
 
Analysis of the aggregate plot for 1q copy number gain shows two separate 
centromeric peaks of amplification. These are not likely to be separate events but 
represent the fact that there are gaps in the probe coverage in this region due to the 
fact that 1q21.2 is repetitive. In multiple cases seen in figure 4.6 the segmentation 
algorithm did not bridge these two segments as the gap was larger than the defined 
maximum contiguous probe spacing considers and is considered too large to bridge 
the adjacent segments. There was nothing to suggest that these segments are 
separate. Interestingly, samples that were hybridised using the Affymetrix Cytoscan 
HD array kit did not experience this issue. This copy number array kit had fewer gaps 
in coverage within this cytoband and the coverage was sufficient for segmentation to 
be performed correctly, without over-segmentation. Cases taken from the literature 
that were hybridised to older Affymetrix Mapping 250K (both Nsp and Sty versions) 
and Affymetrix Mapping 500K array data had particularly pronounced gaps in 
coverage in this region. The MCL1 gene resides within the region identified by 
GISTIC2.0 at 1p12-1q21.3 within the minimum common region of amplification and 
the gene was gained in 49/66 (74.2%) cases. The MCL1 gene is a BCL2 family 
member and is highly expressed in the majority of high grade non-Hodgkin 
lymphomas including BL and DLBCL (Cho-Vega et al., 2004). High expression of the 
Mcl1 protein has been shown to drive haematological malignancies and specifically 
MYC-driven lymphomagenesis in mouse models (Campbell et al., 2010) and 
reducing expression of MCL1 is known to sensitise B-NHL cell lines to the selective 
BCL2 inhibitor Venetoclax (Phillips et al., 2015).  
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18q21.2-18q21.31 copy number gain was seen in 15 cases. The 3.5Mb GISTIC2.0 
region contained 16 genes and all cases had copy number gain of the genes 
RAB27B and CCDC68. 14 cases also had gain of TCF4 within the region highlighted 
by GISTIC2.0. This region did not include the BCL2 gene which was 5.7Mb telomeric 
to the region. 8/15 cases with gains in the GISTIC2.0 region also had gain of BCL2. 
The region was significantly more frequently gained in DLBCL patients than BL 
patients (6/36, 16.7% vs 5/109, 4.6%; p=0.03, Fisher exact test). The region 
identified at 14q24.3 was determined to be an artefact. 14q gain was seen in 3 
cases, but the focal region was defined by recurrent small amplification segment 
found only in cases analysed using the Affymetrix Cytoscan HD array kit.  
 
Gain within 2p16.1-2p15 was found in 10 cases and spanned 24 genes. The putative 
gene of interest here is the REL gene, which is part of the NFNB family of genes. 
Copy number gain of REL was seen in eight cases, with high level amplification in 
three cases, of which two were BL and one was DLBCL. It has previously been 
reported that while REL amplification is frequent in adult DLBCL of the GCB-like 
subtype, it is not seen in paediatrics. However, the one DLBCL case in this cohort 
with a REL amplification was aged 7 at diagnosis. The 3.2Mb region also included 
BCL11A, overexpression of which has been shown to play a role in 
lymphomagenesis and resistance to apoptosis (Gao et al., 2013).  
 
Copy number gain at 10q21.1-10q21.3 was seen in eight cases. Three cases shared 
a complex pattern of copy number gain between 10q21.1-10q21.3 paired with a 
deletion of the centre of 10q. Two cases harboured small gains in the region, but the 
other 6 had gains that spanned the majority of the GISTIC2.0 region. The CDK1 
gene sits within the gained region, which is vital for G1/S transition regulation.  
 
The most significant deleted region identified by GISTIC2.0 analysis was deletion at 
9p21.3 with a q-value of 1.1x10-9 computed by GISTIC2.0, denoting high 
significance. (Figure 4.7A). Deletion in this region was identified in 21/162 cases. The 




Figure 4.7 - A plot showing copy number data for (A) chromosome 9 and (B) the 
CDKN2A gene from 21 patients with deletion at 9p21.3. Blue denotes copy number 
gain and red denotes copy number loss. 
 
In three of these cases deletions were small and only involved exon 1 on CDKN2A 
while the other 18 covered both CDKN2A and CDKN2B (Figure 4.7B). The deletions 
ranged from 14.9kb to 38.8Mb with a mean size of 6.0Mb. 9p21.3 deletion was 
present in both BL and DLBCL cases at similar incidences (BL 11.9% vs DLBCL 
16.7%). CDKN2A codes for both p16INK4a and p14ARF, the latter of which is an 
important inhibitor of MDM2. Deletion of the CDKN2A tumour suppressor gene is 
frequently reported in multiple cancers and is a known mechanism of p53 abrogation 
(Agrawal et al., 2006).  
 
A 2.5Mb significantly deleted region of 3q13.31-3q13.32 observed in 19 cases 
(q=7.7x10-7). The majority of these cases were diagnosed with BL (12/19, 63.2%). 




Figure 4.8 - A plot showing copy number data for (A) chromosome 3 and (B) the 
3q13.31-13q31.32 GISTIC2.0 region of loss in 19 patients. Blue denotes copy 
number gain and red denotes copy number loss.   
 
Deletion of the TUSC7 gene has been identified in renal cell carcinoma (Chen et al., 
2003) and osteosarcoma (Kresse et al., 2009) previously, and low expression is 
prognostic in ovarian cancer (Ntougkos et al., 2005). Two BL cases harboured 
biallelic deletion of the TUSC7 gene at diagnosis.  
 
Loss of 2p22.2-2p16.3 was observed in 15 cases. The region was 12.7Mb in size 
and spanned 75 genes, most notably the mismatch repair family genes MSH2 and 
MSH6 as well as the F-box family gene FBXO11, which has a role in BCL6 
degradation (Duan et al., 2012). Two BL cases had smaller, focal biallelic deletions of 
the overlapping region between the 3  ends of the MSH6 and FBXO11 genes. 
Deletions within the 12.7Mb region were identified in 11 BL cases, 3 DLBCLs and 
one B-NHL, NOS. The deletions identified in the B-NHL, NOS case and one BL case 
(4/830 and 1/49 respectively) were part of a larger complex chromosomal 
abnormality spanning the rest of 2p. Both complex abnormalities also harboured a 
copy number gain of REL, also found on 2p.  
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6q13-6q22.1 deletion was detected in 44 cases. The 42.7Mb region covered the 
majority of the 6q, while only 15 cases had deletions that spanned the more than half 
of the arm. 6q harbours several genes that have previously been associated with 
lymphoma and deletion of the 6q arm has been reported frequently in the past. 
Deletions in GRIK2 (Sinclair et al., 2004), PRDM1 (Pasqualucci et al., 2006) and 
BACH2 (Swaminathan et al., 2013) have all been seen in haematological 
malignancies, with the latter two reported in B cell lymphoma. PRDM1 deletions were 
only seen in cases without disease progression (0/18, 0.0% vs 18/119, 15.1%, 
p=0.13, Fisher exact test).  The incidence of deletions within the 6q GISTIC2.0 focal 
region were consistently similar between BL and DLBCL subgroups (23/109, 21.1% 
and 8/36, 22.2% respectively). 
 
19p13.3-19p13.2 deletion involved a small 0.6Mb region with 17 genes. Eight cases 
were found to have this deletion, of which six were DLBCL cases (75%). The other 
two cases harbouring the deletion were a BL case and a B-NHL, NOS case.  The 
TNFSF14, TNFSF9 and TNFSF7 (CD70) genes were lost in eight, seven and eight 
cases respectively. A study has reported loss of these genes in DLBCL and BL 
previously (Scholtysik et al., 2012). Two cases harboured homozygous deletions of 
the focal region involving TNFSF7 and TNFSF14. One such deletion was standalone 
with no other abnormalities while the other occurred within a larger 7.4Mb region of 
deletion. Of the six hemizygous-only deletions, one spanned the entirety of 
chromosome 19, three were small and ranged from 500kb and 990kb in size while 
remaining focal to the TNFSF family genes, and two were more complex with 
immediately adjacent regions of copy number gain.   
 
A 43.8Mb region spanning cytobands 4q12 to 4q22.3 detected GISTIC2.0 analysis. 
The region is adjacent to the centromere on 4q and deletions in this locus was 
identified in 32 cases, however most were small focal deletions of UGT2B17. The 
UGT2B17 gene has been shown in prostate cancer (Gallagher et al., 2007) but the 
relevance of the gene in lymphoma is unclear. Larger deletions were identified in ten 
cases with a 3.5Mb minimal common region involving 26 genes, none of which had 
previously been associated with lymphoma pathogenesis.  
 
8p telomeric deletion was observed in nine cases, four of which spanned the rest of 
the arm. The 8p23.3-8p23.2 GISTIC2.0 region was infrequently observed in both BL 
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(5/109, 4.6%) and DLBCL (3/36, 8.3%) as well as one B-NHL, NOS. The region 
includes the large gene CSMD1, which is known to inhibit classical complement 
pathway activation and has been proposed as a tumour suppressor gene in breast 
cancer (Escudero-Esparza et al., 2016). Low expression and deletion were shown to 
be associated with a poorer overall survival in breast cancer. Although rare, deletions 
of 8p23.3-8p23.2 were found in two BL cases who underwent disease progression. 
There were too few cases to perform conventional survival analysis, however.   
 
GISTIC2.0 identified a recurrent region of deletion between 1q25.1-1q44. 30 cases 
had deletions within these cytobands, but the majority were small. Larger deletions 
were observed in eight cases with a mean size 30.0Mb and ranged between 1.6Mb 
and 64.7Mb in size. Six of these deletions were observed as part of complex 
abnormalities involving centromeric gain followed by telomeric loss similar to those 
seen on 11q and 13q.  
 
4.3.5 Recurrent regions of copy number neutral loss of heterozygosity (CNN-
LOH) 
 
Analysis of regions of CNN-LOH within the cohort revealed potential sites of 
recurrent mutation. CNN-LOH is not well characterised in B-NHL, with relatively few 
studies investigating recurrent CNN-LOH. A copy number investigation of 148 
DLBCL identified no recurrent CNN-LOH events in their cohort (Scholtysik et al., 
2015). In contrast, a study of 39 BL cases found CNN-LOH in nine cases, with 17p, 
17q and 6p CNN-LOH being recurrent (Scholtysik et al., 2010). Due to the 10Mb filter 
for regions of copy number neutral allelic events the results of focal and broad 
analysis from GISTIC2.0 were very similar, particularly on smaller chromosome 
arms.  
 
Recurrent CNN-LOH of 1p36.33-1p34.3 was identified as the most significant region 
of CNN-LOH in this paediatric B-NHL cohort with a q-value of 4.0x10-7. The region 
was large at 35.9Mb and contained 553 genes. 9/11 cases with CNN-LOH in this 
region were BL. The abnormalities began at the 1p telomere in all cases. The most 
notable of these genes was ID3 which is frequently mutated in up to 58.5% of BL 
cases but is not associated with DLBCL (Schmitz et al., 2012). The TCF3-ID3 axis is 
known to be important in BL, with 70% of BL patients in one study having a mutation 
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in one or both of these genes. Also, in this region was the TP73 gene, a member of 
the p53-like gene family. TP73 plays a role in DNA-damage mediated apoptotic 
signalling and is considered a tumour suppressor in medulloblastoma (Castellino et 
al., 2007).  
 
17q CNN-LOH was observed frequently in our cohort, with 20 cases having at least 
one region of CNN-LOH larger than 10Mb. Two focal regions were identified by 
GISTIC2.0 analysis. The first, and most significant (q=6.9x10-4) spanned a 10Mb 
region from 17q22-17q24.1. CNN-LOH in this region was found in 18 cases and 
contained 127 genes, notably including GNA13 (Figure 4.9).  
 
 
Figure 4.9 - a plot showing CNN-LOH calls on 17q in 19 patients with 17q22-17q24.1 
CNN-LOH. Yellow denotes CNN-LOH. 
 
 
GNA13 is known to be mutated recurrently in BL cases. Frequency of mutation 
ranges in the literature from 17.1% to approximately 30% (Love et al., 2012; Schmitz 
et al., 2012). The GNA13 gene codes for a guanine nucleotide-binding G protein and 
abrogating mutations are thought to be an oncogenic driver event in germinal centre 
B-like lymphomas and BL (Love et al., 2012). Abnormalities in GNA13 are usually 
inactivating mutations or deletion. While deletion was seen in 5/162 (3.1%) cases, 
and none were focal to the GNA13 gene, CNN-LOH involving the gene occurred in 
19/162 (11.7%) cases. 14/19 cases with abnormality in this region were diagnosed 
as BL, with 4 DLBCL and one B-NHL, NOS case.  
 
The second region on 17q identified by GISTIC2.0 involved part of the chromosome 
nearer the centromere between 17q11.2-17q21.32. The region was larger at 18.7Mb 
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and harboured 444 genes (Figure 4.10). This region was less frequently observed 
than the other region on 17q, being seen in only 15/162 cases (9.3%, q=0.053). In a 
similar manner to the 17q22-17q24.1 region, the majority of cases were BL (13/15) 
while it was observed in one DLBCL and one B-NHL, NOS.  
 
 
Figure 4.10 - A plot showing CNN-LOH calls on 17q in 15 patients with 17q11.2-
17q21.32 CNN-LOH. Yellow denotes CNN-LOH.   
 
CNN-LOH involving 1q25.3-1q44 was seen infrequently in nine patients. 
Chromosome 1q is regularly altered in paediatric B-NHL, with both copy number 
gains and losses also being reported by GISTIC2.0. CNN-LOH of the arm was less 
frequent than gain or loss and no region of 1q was aberrant in all nine cases. More 
than half of 1q underwent CNN-LOH in six of the cases and all of these aberrations 
involved the 1q telomere. The other three cases had smaller aberrations 11.4Mb, 
19.4Mb and 21.1Mb in size respectively that did not overlap in any two cases. The 
GISTIC2.0 region on 1q contained 521 genes, of which 15 were identified in 
Pathwa s in Cancer  within KEGG Mapper (Kanehisa et al., 2019). Two genes of the 
WNT family were found within this region, WNT9A and WNT3A. MDM4 was also 
identified in the region, which has a similar function to MDM2 in chelation and 
ubiquitination of p53 protein. Previous studies in BL have suggested that up 
regulation of MDM4 may functionally inhibit p53 in cases without TP53 or MDM2 
abnormalities (Leventaki et al., 2012).  
 
A large region of CNN-LOH on chromosome 9p was detected spanning 21.8Mb 
which also encompassed the CDKN2A/B locus, which could suggest the presence of 
driver mutations in this locus. The region encompassed 99 genes in total and was 
observed in nine cases. The locus also included the JAK2 gene which frequently 
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harbours a V617F mutation in haematological malignancies, however rarely in non-
Hodgkin lymphomas (Lee et al., 2006).  
 
CNN-LOH at 6p25.3-6q11.1 was seen in 13 cases. 11 cases showed CNN-LOH 
across 6p only, with two cases having 6q CNN-LOH and whole chromosome 6 CNN-
LOH respectively. The region most frequently observed to undergo CNN-LOH 
involved 243 genes in a 21.7Mb stretch of genome. Three genes associated with 
EBV infection are found in the region, of which two were HLA genes (HLA-F, HLA-G) 
as well as the transcription factor E2F3.  
 
15q CNN-LOH was seen in 6/162 cases with three BL, one DLBCL, one BLL-11q 
and one B-NHL, NOS cases affected. The minimal common region of abnormality 
was 6.1Mb in size and covered 79 genes while the wide peak identified by GISTIC2.0 
was significantly larger at 42.6Mb with 383 genes. Of the genes in the common 
region, B2M was considered a candidate gene for mutation due to a known role in 
evading immune recognition in DLBCL when combined with CD58 inactivation 
(Challa-Malladi et al., 2011).  
 
17p13.3-17p11.2 CNN-LOH affected 14 cases that were primarily diagnosed BL 
(12/14, 85.7%) (Figure 4.11). The region identified spanned the majority of the p arm 
of chromosome 17 and involved 314 genes. 210 of these genes lost heterozygosity 
in all 14 cases affected and included TP53.  
 
 
Figure 4.11 - A plot showing CNN-LOH calls on chromosome arm 17p in 14 cases. 
Yellow denotes CNN-LOH. 
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TP53 is commonly perturbed in many human cancers and is reported to be mutated 
in approximately 20% of BL cases (Love et al., 2012; Schmitz et al., 2012; Havelange 
et al., 2016b). TP53 aberration is a prognostic marker in several tumour types, 
including another B cell malignancy, chronic lymphocytic leukaemia (CLL) (Li et al., 
2019) and is known to have numerous important roles in cell proliferation and 
evasion of senescence, DNA damage response and resistance to apoptosis.  
 
 
4.3.6 GISTIC2.0 Broad Analysis to detect large scale copy number 
abnormalities 
 
Broad analysis identified gain of seven chromosome arms, loss of two and CNN-LOH 
of four with gain of 1q, 7q and loss of 17p as the most common regions of CNAs 
occurring in 13% of cases each (21/162). Most regions detected by broad analysis 
aligned with regions detected by focal analysis, while 7p, 7q, 12p and 12q large gains 
were not picked up by GISTIC2.0. Gain of chromosome 7 was common in both BL 
and DLBCL but BL cases tended to have gain of 7q only. 7q gain was most common 
as 21/162 cases had gain of more than half of 7q. A minimal common region of gain 
seen in 30/162 (18.5%) cases at 7q21.3-7q22.1 containing 67 genes. The region 
contained MCM7, a component of DNA replication machinery and correct assembly 
of replication forks, amplification and overexpression of which is prognostic in 
prostate cancer (Ren et al., 2006). The region also harbours the MIR106B microRNA 
cluster and functional paralogue of MIR17HG. 
 
Gains on chromosome 12 were most common in DLBCL (12p gain 10/36 vs 4/109, 
p=0.0001; 12q gain 6/36 vs 2/109, p=0.003, Fisher exact test). No peak or high copy 
number amplification was observed on chromosome 12. 16 cases in the cohort had 
gain of MDM2 at 12q15 which is a common abnormality in cancer. High copy number 
amplification involving multiple additional copies of MDM2 is associated with 
upregulation of MDM2 protein, which ubiquitinates p53 protein and targets it for 
degradation. p53 is abrogated in many tumours where the TP53 gene is wildtype by 
high expression of MDM2 (Olivier et al., 2010).  
 
4.3.7 Comparison of aberrations in BL and DLBCL 
 
Abnormalities in paediatric B-NHL were most frequent on chromosome arms 1q, 6q, 
7q and 13q, with recurrent aberrations of 11q and 17p (Figure 4.12). Broadly, BL-
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associated abnormalities were consistent with those found in the literature previously. 
1q gain was the most frequently observed abnormality in BL, with 49/109 (45.0%) 
harbouring copy number gain within the region identified by GISTIC2.0, compared to 
9/24 (37.5%) and 10/39 (25.6%) reported in previous copy number array studies 
(Scholtysik et al., 2010; Havelange et al., 2016b). The higher reported incidence in 
this study is likely a result of the large proportion of the cohort analysed using higher 





Figure 4.12 - A Circos plot showing copy number profiles for 109 paediatric BL 
patients. Blue denotes copy number gain, red denotes copy number loss and yellow 




Considering copy number abnormalities not highlighted by GISTIC2.0, multiple 
regions were identified that were enriched in one disease subtype compared to the 
others. Gain of chromosome 7 has been repeatedly reported as recurrent and 
potentially prognostic in BL (Poirel et al., 2009; Nelson et al., 2010; Scholtysik et al., 
2010). 11/109 (10.1%) BL patients in our cohort had large gains on 7q which 
correlates with previously reported incidences of 6/39 (15.4%) (Scholtysik et al., 
2010) and 36/238 (15.1%) (Poirel et al., 2009) (Figure 4.12). The most commonly 
gained region was 7q21.3-7q22.1 and was seen in 14.7% (16/109) of BL tumours 
investigated. The region encompassed the MIR106B miRNA cluster, which is 
paralogous to the recurrently amplified MIR17HG gene. 13q abnormalities were 
common in the BL subgroup with recurrent MIR17HG amplification (31/109, 28.4%) 
and telomeric deletion (21/109, 19.3%). Of these, 16 patients had both amplification 
of MIR17HG at 13q31.3 and subsequent telomeric deletion.  
 
Overall, the genome of DLBCL was more complex than that of BL (Figure 4.12, 
Figure 4.13), with significantly more of the genome altered (BL 7% vs DLBCL 15%, 
p<0.001, student t-test) and a higher mean number of CNAs per sample (24 BL vs 31 
DLBCL, p=0.040, student t-test)(Figure 4.13). The mean number of regions of CNN-
LOH, however, were similar (1.7 BL vs 2.3 DLBCL, p=0.610, student t-test).  
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Figure 4.13 - A Circos plot showing copy number profiles for 36 paediatric DLBCL 
patients. Blue denotes copy number gain, red denotes copy number loss and yellow 
denotes CNN-LOH.   
 
In BL, recurrent abnormalities were largely restricted to six chromosomal arms (1q, 
6q, 7q, 11q, 13q and 17p), whereas most chromosomes were altered in at least one 
DLBCL case. Of note, gain of 1q was only observed in DLBCL cases with an IG-MYC 
translocation (3/6, 50.0% IG-MYC positive vs 0/15, 0.0% IG-MYC negative, p=0.015, 
Fisher exact test).  
 
Several abnormalities were detected at similar frequency in both BL and DLBCL, for 
example 17p loss (14/109, 12.8%% BL vs 6/36, 16.7% DLBCL, p=0.582, Fisher 
exact test), however differences were observed between subtypes. Deletion of 
13q33.1-13qter was more frequent in BL compared to DLBCL (21/109, 19.3% BL vs 
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1/36, 2.8% DLBCL, p=0.015, Fisher exact test), whilst gain of the MYC locus on 
chromosome 8q24.21 was more common in the DLBCL cohort (4/109, 3.7% BL vs 
4/36, 11.1% DLBCL, p=0.105, Fisher exact test), as well as gain of chromosome 7 
(3/109, 2.8% BL vs 7/36, 19.4% DLBCL, p=0.002, Fisher exact test). In BL, deletions 
of 6q were large, whereas in DLBCL these were more focal, with the minimal region 
of loss defined as 6q23.2-6q24.2 (11/109, 10.1% BL vs 8/36, 22.2% DLBCL, 
p=0.085, Fisher exact test), although this comparison was not statistically significant.  
 
4.3.8 Burkitt-like lymphoma with 11q aberration (BLL-11q) 
 
In total five cases were diagnosed as BLL-11q, a recently characterised subset of B-
NHL cases defined by Burkitt-like morphology with the absence of a MYC 
rearrangement, and an 11q abnormality involving copy number gain adjacent to 
11qter loss (Salaverria et al., 2014; Gonzalez-Farre et al., 2019). The BLL-11q cases 
shared a common breakpoint within a 0.6 Mb region on 11q23.3 spanning 
118,605,127-119,240,071 bp involving 31 genes including CBL, FOXR1, BCL9L, 
CXCR5, and DDX6. In comparison the breakpoint of seven BL cases with a similar 
pattern of 11q abnormalities, were less focal and spanned a much larger 29.2 Mb 
region spanning 11q22.1-11q24.3 from 98,895,212-128,124,434 bp, encompassing 
322 genes. Analysis of the genomic profiles revealed that 4/5 (80%) of the BLL-11q 
cases had loss of 6q while 1/7 (14%) BL patients with 11q abnormalities had 6q loss 
(p=0.072, Fisher exact test). The 13.2 Mb minimal region of 6q loss in BLL-11q 
patients included MAP3K7, BACH2 and 60 other genes. In BL, 1q gain and 
MIR17HG amplification were the most frequent abnormalities, while in contrast no 
BLL-11q cases had either abnormality. The copy number profiles of BLL-11q cases 






Figure 4.14 - A Circos plot showing copy number profiles for 5 patients diagnosed 
with BLL-11q. Blue denotes copy number gain, red denotes copy number loss and 




4.3.9 Univariate Survival Analysis 
 
Survival estimates at 3 years for Time to Progression and Overall Survival were 
85.2% (CI 95% 79.2-91.8) and 85.1% (CI 95% 79.4-91.2) respectively. This is 
representative of the survival rates reported in the FAB/LMB96 trial, although slightly 
lower (Patte et al., 2007). The slightly lower estimates for TTP and OS may be 
explained by treatment protocols varying between studies. A subset of patients from 
both Scholtysik et al. (Scholtysik et al., 2010; Scholtysik et al., 2015) studies are 
described as being treated on AML-like therap  and man  of the patients 
 109 
investigated in this analysis, both from the literature and the CCLG cohort, pre-date 
the FAB/LMB96 protocols being adopted as the gold standard therapy.  
 
Survival analysis by Cox proportional hazards method was performed to understand 
which copy number abnormalities detected by SNP array were associated with 
superior or inferior overall survival or time to progression. Univariate factors were 
assessed individually to determine which factors should be included in multivariate 
analysis and modelling. All GISTIC2.0-identified focal and broad regions of copy 
number gain, loss and CNN-LOH were included in the analysis. Clinical parameters 
were also investigated including bone marrow and central nervous system 
involvement, diagnosis, age at diagnosis, MYC rearrangement status, disease stage, 
treatment protocol, gender and also number of copy number alterations and genome 
percentage of the genome changed.  
 
Univariate analysis with TTP and OS outcome data highlighted one region of copy 
number gain and two regions of CNN-LOH that were significantly associated with 





Time to progression (TTP) Overall survival (OS)   
HR (95% CI) p value HR (95% CI) p value 
No. cases with 
abnormality 
(%) 
Univariate analysis      
3q29 gain 6.2 (2.3-17) < 0.001 4.7 (1.9-11) < 0.001 17 (10.5%) 
17p13.3-17p11.2 CNN-LOH 5.6 (2-16) 0.001 3.1 (1.1-9.2) 0.038 14 (8.6%) 
17q11.2-17q21.32 CNN-LOH  4.5 (1.5-14) 0.008 4.6 (1.8-12) 0.002 15 (9.3%) 
17q22-17q24.1 CNN-LOH 3.4 (1.1-10) 0.031 3.4 (1.3-8.5) 0.011 18 (11.1%) 
No. CNA 1 (1-1) 0.026 1 (0.99-1) 0.340 NA 
Age at Diagnosis 0.89 (0.79-1) 0.057 0.94 (0.85-1) 0.220 NA 




3q29 gain was the third most significant region of copy number gain detected by 
GISTIC2.0 and was shown by univariate analysis to be associated with an inferior 
time to progression. 3q29 gain occurred in 17 cases throughout the cohort of which 
six (6/119, 5.0%) were cured by frontline therapy and another six (6/18, 33.3%) 
underwent disease progression (with 5 having insufficient outcome data). 3q29 gain 




Figure 4.15 - Kaplan Meier plots demonstrating the risk associated with 3q29 gain by 
(A) Time to Progression (p<0.001) and (B) Overall survival (p<0.001) analyses. 
 
The focal region of 17p CNN-LOH was shown to be associated with a poorer time to 
progression (HR 5.6 95% CI 2-16, p=0.0011, Cox proportional hazard method) 
(Figure 4.16A-B). Broad 17p CNN-LOH was also significant by the same analysis 
(HR 5.2 95% CI 1.5-18, p=0.0097, Cox proportional hazard method). CNN-LOH of 
the region was present in a higher proportion of cases who underwent 
relapse/refractory disease (5/18, 27.8% vs 8/119 6.7%, Fisher exact test). All 
aberrations in all cases involved the TP53 gene locus which suggests that it may play 
an important role in outcome and tumour resistance to therapy. Further investigation 




Figure 4.16 - Kaplan Meier plots demonstrating the risk associated with 17p CNN-
LOH by (A) Time to Progression (p<0.001, Log rank test) and (B) Overall survival 
(p=0.029, Log rank test) analyses. 
 
Both regions of 17q CNN-LOH were significant markers of inferior time to 
progression. The centromeric region spanning 17q11.2-17q21.32 CNN-LOH was 
most significant with the highest hazard ratio (HR 4.5 95% CI 1.5-14, p=0.008, Cox 
proportional hazard method) (Figure 4.17A-B). The alternative 17q CNN-LOH region 
at 17q22-17q24.1 had a lower hazard ratio than the region focal to the centromere 
(HR 3.4 95% CI 1.1-10, p=0.031, Cox proportional hazard method) but was still a 
significant survival factor. This region contained the GNA13 gene which may suggest 
that mutations may confer an inferior prognosis and higher risk of disease 
progression. This warrants further investigation of mutation data with a focus this 
region to determine whether GNA13 mutations are associated with disease 
progression or outcome. All 15 cases with CNN-LOH at 17q11.2-17q21.32 also had 
CNN-LOH at 17q22-17q24.1 and all 19 cases with CNN-LOH on 17q had aberrations 
involving GNA13.  
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Figure 4.17 - Kaplan Meier plots demonstrating the risk associated with 17q CNN-
LOH by (A) Time to Progression (p=0.003, Log rank test) and (B) Overall survival 
(p=0.001, Log rank test) analyses. 
 
 
4.3.10 Multivariate Prognostic Modelling 
 
Multivariate survival modelling was performed using a forward selection method. 
Factors included in the model had univariate Cox proportional hazards p values 
below 0.1. Several factors were assumed to represent the same genomic aberration, 
most notably broad 17p CNN-LOH and focal 17p CNN-LOH. In cases where this 
occurred only the focal region was included as this better represented the minimal 
common region and nature of the abnormality in the setting of B-NHL. The first factor 
included in the model was the most significant (3q29 gain) which made up Fit1, 
followed by the first round of selection in which all other univariate factors where 
p<0.1 were assessed in the model alongside 3q29 gain separately. A likelihood ratio 
test was performed on each model as part of the first forward selection to determine 
the strength of the model compared to Fit1. Five factors were tested in the first 
forward selection: 17p13.3-17p11.2 CNN-LOH, 17q11.2-17q21.32 CNN-LOH, total 
number of copy number abnormalities, 17q22-17q24.1 CNN-LOH and patient age. 
Three models were significantly stronger than Fit1: 17p13.3-17p11.2 CNN-LOH, 
17q11.2-17q21.32 CNN-LOH and 17q22-17q24.1 CNN-LOH. The most significant 
was the addition of the focal region of CNN-LOH on 17p to 3q29 gain (p=0.012, 
Likelihood ratio test) and this model was taken forward to second forward selection 
as Fit2.  
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The second forward selection compared Fit2 against itself alongside one of four 
additional factors. Only one model was significantly stronger than Fit2, which 
included 17q11.2-17q21.32 CNN-LOH and this model was taken to forward selection 
three as Fit3.  
 
The third round of forward selection involved one genomic factor (17q22-17q24.1 
CNN-LOH) as well as patient age at diagnosis and number of copy number 
abnormalities. Only the addition of patient age to Fit3 improved the model and this 
was taken to the fourth round of forward selection as Fit4.  
 
Round four of forward selection determined whether addition of the number of copy 
number aberrations or 17q22-17q24.1 CNN-LOH would add to the Fit4 model. 
Neither model was significantly superior to the previous model of Fit4 which is 
considered the most appropriate model (Table 4.5, Figure 4.18A-B).  
 
 
Risk Factor Time to progression (TTP) 
Hazard ratio (95% CI) p value 
3q29 gain 4.8016 (1.72-13.37) 0.003 
17p13.3-17p11.2 CNN-LOH 4.3298 (1.51-12.40) 0.006 
Age at Diagnosis 0.8836 (0.78-1.00) 0.049 
17q11.2-17q21.32 CNN-
LOH  4.5577 (1.42-14.64) 0.011 
Table 4.5 - Multivariate survival analysis by Forward Selection Method revealed Fit4 
to be the best predictive model of poor outcome in the cohort. 
 
Within this model all four factors were independent significant prognostic markers. 
The three genomic markers of 3q29 gain, 17p CNN-LOH and 17q CNN-LOH all 
warrant further investigation to determine what gene within the region is driving 




Figure 4.18 - Kaplan Meier plots demonstrating the Fit 4 multivariate risk model by 
(A) Time to Progression (p<0.001) and (B) Overall survival (p<0.001) analyses. 
 
Applying the model to the cohort, 39 cases fit the criteria for the high-risk group of the 
model in having 3q29 gain, 17p13.3-17p11.2 CNN-LOH or 17q11.2-17q21.32 CNN-
LOH. While a younger patient age was determined to be a significant factor in 
disease progression, with 14/18 cases who experienced relapsed/refractory disease 
being aged 10 or under, this cut-off led to 71.0% (115/162) cases being in high risk 
arm of the model, of which only 15.7% (18/115) had relapsed/refractory disease. This 
did however cover all cases that underwent disease progression. Removing patient 
age from the model reduces the number of patients in the high-risk group to 39 
(24.1% of the cohort), including 12 cases with disease progression (Figure 4.19). 
Further validation in a larger cohort of patients is required to better tune the model so 
it is sensitive enough to pick up all cases with disease progression but specific 
enough to exclude the majority of cases that would be cured by frontline therapy. 
Investigating mutations within the regions of interest in the model, particularly regions 
of CNN-LOH on chromosome 17, may allow for improvement of the model. This is 





4.3.11 Investigation of previously identified genomic prognostic markers 
 
In addition to regions highlighted in our cohort by GISTIC2.0 analysis, prognostic 
markers reported by previous studies were investigated to determine whether their 
prognostic relevance was validated in our patients. Three genomic abnormalities 
were investigated: 7q21-7q22 gain, 13q34 deletion and 13q31.3 gain. Remarkably, 
no previously identified prognostic markers were associated with patient outcome or 
disease progression in our cohort (Appendix B). 7q22.1 gain reported in both Poirel 
et al. (2009) and Nelson et al. (2010) were present in 37/162 patients but were not 
enriched for in the disease progression group. Equally, while 13q34 loss was seen in 
19/162 (11.8%) patients, the majority of these were associated with 13q complex 
aberrations which were not associated with survival. Equally, 13q31.3 gain involving 
the MIR17HG miRNA cluster was recurrent in the cohort but not associated with poor 
outcome or disease progression.  
 
Explaining the disparity in prognostic markers between our cohort and those 
previously published is difficult. All three markers investigated were identified in 
patients uniformly treated with FAB/LMB96-based protocols, so it is unlikely that the 
disparity arose through different selection pressures through treatment. The 
abnormalities were also initially identified as prognostic in paediatric cohort, meaning 
that age is unlikely to play a role. 7q21-7q22 gain and 13q34 deletion were identified 
through traditional karyotyping, while 13q31.3 was identified by copy number array, 
as used in this study. It is possible that the small cohort size in the Schiffman et al. 
study led to MIR17HG gain being called a prognostic marker inappropriately. Our 
findings in this study validate the presence of 13q31.3 copy number gain in paediatric 
B-NHL, but dismiss the possibility of being a prognostic marker. Differences in the 
limitations of traditional karyotyping and copy number arrays may go some way to 
explaining the differences between studies. 7q21-7q22 gain was usually the result of 
a gain of the whole arm, but several events were smaller and might not have been 
picked up by karyotyping. These differences highlight how important it is to secure a 
clinical trial to validate putative prognostic markers in a large cohort of uniformly 
treated patients with complete clinical data.  
 
4.3.12 Whole-exome sequencing analysis of 3q29 and 17q 
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39 cases with whole-exome sequencing data from tumour and matched normal DNA 
were processed and aligned as described in the methods section. Variants were 
called from the aligned BAM files using MuTect2 as part of GATK3.8 as described in 
Chapter 2 (Cibulskis et al., 2013). The output files from variant effect predictor (VEP) 
were merged for 39 paired samples and variants were filtered for mutations on 17q 
and 3q29.  
 
On chromosome 17q a total of 780 somatic variants were identified in 25/39 patients. 
After filtering out non-coding and synonymous variants, a total of 283 mutations in 13 
patients were observed. 188 unique genes were mutated within the cohort and 57 
were mutated more than once. The most frequently mutated gene on 17q was 
RNF213, with 12 variants called in seven unique cases. The RNF213 gene on 
cytoband 17q25.3 codes for an E3 ubiquitin-protein ligase and has been implicated in 
cancer previously. The gene is a known fusion partner of ALK in anaplastic large cell 
lymphoma (van der Krogt et al., 2017) and plays a role in hypoxia sensitivity in 
HER2+ breast cancer (Banh et al., 2016). RNF213 has not been implicated in B-NHL 
previously, and is not located within one of the two regions of 17q identified as having 
recurrent CNN-LOH by GISTIC2.0. 
 
One BLL-11q case, 12/854 harboured 5 unique missense variants in RNF213 of 
which one was present in the COSMIC database (Tate et al., 2019). Despite this, all 
variants were predicted to be benign by PolyPhen, a tool which evaluates the effect 
of amino acid changes caused by somatic variants on protein function from a 
structural and evolutionary perspective (Adzhubei et al., 2013) (Appendix C). BL 
patient 14/325 had two somatic missense mutations, of which one was flagged as 
probably damaging by PolyPhen, suggesting that the variant had a significant effect 
on RNF213 protein function. 
 
GNA13 at cytoband 17q24.1 was recurrently mutated in the cohort, as would be 
expected given the established role for mutations in the gene in B-NHL (Love et al., 
2012; Schmitz et al., 2012; O Ha re et al., 2016). 9/39 (23.1%) patients were shown 
to harbour mutations of the GNA13 gene including 8 single nucleotide variants and 
one 10bp deletion leading to a frame shift. No patient harboured more than one 
variant in the GNA13 gene. Of eight single nucleotide variants identified three were 
nonsense mutations introducing a stop codon. Of the five missense mutations, four 
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were flagged as probabl  deleterious  b  Pol Phen while one was considered 
benign by PolyPhen. SIFT, an alternative functional predictor of non-synonymous 
mutations, considered all five missense mutations to be deleterious. This is 
consistent with the literature, where GNA13 inactivating mutations have repeatedly 
been reported (Love et al., 2012; O Ha re et al., 2016). Of two patients with paired 
exome sequencing data and 17q CNN-LOH of the region spanning GNA13, one had 
a mutation. Investigation of the association between 17q CNN-LOH and GNA13 
mutation was performed in an additional cohort of 34 cases without exome 
sequencing data from matched normal DNA. Seven non-synonymous GNA13 
mutations were observed in the cohort in 7/34 (20.6%) cases, including three 
nonsense mutations. It was not possible to eliminate the possibility of germline 
mutations being identified in this cohort, however only one of seven mutations 
observed was present in dbSNP, a database of previously reported variants (Sherry 
et al., 2001). When considering all identified GNA13 mutations and integrating the 
data with 17q CNN-LOH events it was determined that of six cases with 17q CNN-
LOH spanning GNA13, four had mutations within the gene. This suggests that 
GNA13 may be the driver gene within 17q CNN-LOH conferring poor outcome in this 
B-NHL cohort. Cox Proportional Hazard and Kaplan-Meier analysis was performed to 
determine whether GNA13 mutations were associated with poor outcome (Figure 
4.19). Cox Proportional Hazard method confirmed that GNA13 mutations were not a 
prognostic in this cohort by TTP or OS (TTP: HR 1.4 95% CI 0.4-5.3, p=0.59, OS: HR 




Figure 4.19 - Kaplan Meier plots demonstrating the risk associated with GNA13 
mutation by (A) Time to Progression (p=0.587) and (B) Overall survival (p=0.674) 
analyses. 
 
Conversely to GNA13, 55 coding mutations in RNF213 were observed in the 
unpaired cohort of 34 cases, but only two were considered to be real as one was not 
present in dbSNP, while the other was present in dbSNP but also reported in 
COSMIC. No other genes were sufficiently recurrently mutated in the matched 
tumour-normal cohort for survival analysis on 17q. Expansion of the cohort with new 
samples is required for further investigation of genetic mutations associated with the 
prognostic marker 17q CNN-LOH.  
 
3q29 gain was shown to be a significant prognostic marker by TTP and OS analysis. 
Present in 17/162 (10.5%) cases, 3q29 represents an opportunity for the 
identification of drug targets as well as being a prognostic marker with potential 
clinical relevance. Analysing exome sequencing data from 39 cases with matched 
tumour and normal DNA, 67 coding mutations were identified in 24 patients. After 
filtering out non-coding and silent mutations the number of mutations was 24 in 17 
cases. A total of 15 genes were mutated in at least once case in this cohort, and four 
genes were mutated more than once: ATP13A4 (n=2), MUC4 (n=2), PAK2 (n=4) and 
OPA1 (n=5). Unlike 17q CNN-LOH where the aberration would be expected to co-
occur with mutations, as 3q29 was amplified it is possible that mutations may drive 
the expression of a driver gene which would otherwise be overexpressed by a gene 
dosage effect as a result of additional copies of the gene. Out of the 39 cases with 
paired exome data, four harboured 3q29 gain. Of these, 2/4 had mutations of one of 
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the four recurrently mutated genes. Both cases underwent disease progression, 
including one BL with an OPA1 mutation, and one DLBCL with a PAK2 mutation 
(Appendix D).  
 
Expanding this analysis to the remainder of the samples with exome sequencing 
data, MUC4 was recurrently mutated in these samples, with 34/34 (100.0%) of cases 
having at least one mutation. Recurrent variants at chr3:195515594 (rs13095016) 
and chr3:195517258 (rs1106502) were seen in 32 and 33 patients respectively, and 
so they were removed from analysis as they likely represented germline mutations. 
PAK2 and OPA1 mutations were not observed in this cohort. One mutation in 
ATP13A4 was observed in BL patient 11/634. It is noteworthy that the two most 
recurrently mutated genes in the paired samples were not observed in the unpaired 
cohort and so coding mutations in these genes of interest were not frequent enough 
to investigate via survival analysis. It is possible that non-coding mutations on 3q29 
drive progressive disease in paediatric B-NHL, therefore whole-genome sequencing 
should be performed to screen for the presence of these variants and better 







Despite increasingly high cure rates in paediatric B-NHL using intensive multi-agent 
chemotherapy, the outcome for patients who are not cured with frontline treatment is 
dire. Relapse and refractory disease are extremely difficult to predict at diagnosis, 
and salvage therapy for those who have undergone disease progression is largely 
ineffective. High resolution copy number analysis of large, clinically annotated 
datasets is required to identify significant markers of poor outcome in this particularly 
small, high-risk subgroup of patients.  
 
The results from this study represent the largest copy number investigation of 
paediatric B-NHL to date, taking into account clinical data and patient outcome. 
Previous studies have identified recurrent abnormalities which may play a role in 
disease progression and relapse but none of these have been successfully translated 
into the clinic (Poirel et al., 2009; Nelson et al., 2010; Schiffman et al., 2011). This 
study successfully identified three significant markers of disease progression that can 
be detected at diagnosis and further research into these aberrations may shed light 
on important drug targets.  
 
Copy number gain of 3q has been reported in B-NHL before but studies have 
previously assumed that BCL6 gain at 3q27.3 is the driver gene within this aberration 
(Scholtysik et al., 2010). However, BCL6 was gained in only 13/17 (76.5%) patients 
with gain at 3q29. Instead, it believed that other previously characterised oncogenes 
such as PAK2 within the 3q29 locus drive disease progression in paediatric B-NHL 
patients with 3q29 gain. Mutations were recurrently identified in PAK2, MUC4 and 
OPA1 but at low frequencies. There was no association between 3q29 gain and 
mutations in genes within the region, suggesting either that amplification of a 
candidate gene drives disease progression alone, or that variants involved with 
progressive disease could not be picked up by whole exome sequencing alone.  
 
17q CNN-LOH has not been thoroughly investigated in paediatric B-NHL previously 
despite the relatively high frequency identified in this study. Unlike in 17p CNN-LOH 
analysis, 17q does not immediately suggest the role of a particular tumour 
suppressor or oncogene. The most likely candidate from consideration of the 
literature was GNA13, which is found within the most frequently observed region of 
17q CNN-LOH and the gene has a known role in both BL and GCB-DLBCL 
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pathogenesis. GNA13 mutations are largely nonsense mutations which correlates 
with the findings of exome sequencing analysis in this study. Nonsense mutations 
and frameshift mutations cause abrogation of the gene, resulting in no detectable 
expression of the GD13 G protein coupled receptor (GPCR) subunit it encodes. 
Aberrations involving the GNA13 are present in between 10-25% of BL and GCB-like 
DLBCL cases (Healy et al., 2016; O Ha re et al., 2016) but mutations were not 
associated with inferior TTP or OS. Whole-genome sequencing analysis should be 
performed to investigate the prognostic value of GNA13 mutations and determine 
whether non-coding mutations are recurrent on 17q that confer an inferior prognosis.   
  
The significant association between 17p CNN-LOH and disease progression is a 
strong indicator for a pathogenic role for TP53 mutations and aberrations in 
paediatric B-NHL. This finding warrants further investigation of TP53 by sequencing 
to determine whether mutations alone could be used as a clinical test for patient risk, 
which is detailed in the next chapter. TP53 is an important tumour suppressor gene 
that is aberrant in about half of all cancer diagnoses and has been shown to be 
associated with poor outcome across multiple cancer subtypes (Robles et al., 2016). 
Despite this, aberrant TP53 status does not represent a clinically viable drug target. 
Establishing TP53 status at diagnosis may be useful in stratifying patients into 
clinically relevant subgroups in the future. The role of TP53 in paediatric B-NHL is 








Copy number analysis of 162 paediatric B-NHL cases highlighted that abnormalities 
involving chromosome arm 17p, namely deletion of the arm and copy number neutral 
loss of heterozygosity (CNN-LOH), are recurrent in the disease, as demonstrated in 
Chapter 4. CNN-LOH of 17p has been reported previously (Sobol et al., 2002; 
Scholtysik et al., 2010; Schiffman et al., 2011), as have deletions of 17p involving the 
TP53 gene (Poirel et al., 2009; Scholtysik et al., 2010; Schiffman et al., 2011). 
Schiffman et al. reported an association between amplification at 13q31.3 involving 
the MIR17HG miRNA cluster and 17p aberrations, with 3/3 cases harbouring either 
17p deletion or CNN-LOH. Strikingly, 17p CNN-LOH was associated with significantly 
inferior time to progression (TTP) and overall survival (OS). Given that 17p 
harboured the TP53 gene locus it was postulated that aberrations affecting the TP53 
gene may drive resistant disease in paediatric B-NHL. 
 
The TP53 gene has been shown to act as both a tumour suppressor gene and an 
oncogene (Soussi and Wiman, 2015). The gene is deleted and/or mutated frequently 
in most cancer subtypes and in about half of all cancer cases (Hollstein et al., 1991), 
lending to the consideration that the gene acts as a tumour suppressor gene in some 
contexts. However, several mutant p53 proteins have been shown to be active as a 
result of gain-of-function mutations in the TP53 gene (Yamamoto and Iwakuma, 
2019), and mutations in the gene are most frequently missense and rarely frame shift 
or nonsense mutations, which is atypical of a tumour suppressor gene (Baugh et al., 
2018).  
 
The p53 protein plays multiple roles in inhibiting inappropriate proliferation and 
initiating apoptosis in response to cell stress and extrinsic signalling. TP53 gene 
mutations are predominantly missense mutations, in contrast to the vast majority of 
tumour suppressor mutations which are typically nonsense frameshift mutations 
(Petitjean et al., 2007). Missense mutations in TP53 are recurrently identified in 
multiple loci, another distinction from mutational patterns seen in many other tumour 
suppressors where a small number of mutation hotspots are observed. Analysis of 
the comprehensive TP53 database maintained by the International Agency for 
Research on Cancer (IARC) (Bouaoun et al., 2016) highlights that the most common 
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missense variants identified in cancer have a dominant-negative effect (DNE) in 
which the mutated transcript acts antagonistically against the wild type resulting in a 
loss of function. The vast majority of TP53 mutations sit within the DNA-binding 
domain between codons 101 and 292 (Petitjean et al., 2007). Mutations within this 
region are overwhelmingly missense mutations while these only make up 
approximately 40% of variants outside this region with a higher proportion of 
nonsense and frameshift variants. There are 22 CpG dinucleotide sites in the DNA 
binding domain of TP53 and mutations of three codons make up 60% of missense 
variants reported in TP53 CpG sites: R175, R248 and R273. In addition, p53 function 
can be abrogated indirectly, independent of TP53 gene mutation. Amplification of 
MDM2 and deletion of CDKN2A are both frequently reported in cancer and both are 
known to inhibit the p53 pathway (Alhejaily et al., 2014).  
 
Somatic TP53 mutations in cancer has been studied for a long time (Hollstein et al., 
1991), however in recent years there has been a growing interest in germline TP53 
alterations. Li-Fraumeni Syndrome (LFS) was formally described in 1988 and 
characterised by a familial autosomal-dominant inherited pattern of various cancers 
in young patients (Li et al., 1988). The increased susceptibility to cancer was later 
shown to be caused by germline mutations in TP53 in five identified affected families 
(Malkin et al., 1990). LFS differs from other hereditary cancer syndromes in the wide 
range of cancer diagnoses observed, primarily brain, bone and breast tumours. 
Patients with LFS are also more likely to acquire radiotherapy-associated secondary 
malignancies, highlighting a clinical consideration for treatment and monitoring of 
affected patients. Additional families with Li-Fraumeni-like syndromes (LFL) have 
been identified with germline TP53 mutations but different clinical characteristics to 
classical LFS (Olivier et al., 2003). In characterising these syndromes an association 
between TP53 DNA binding domain and cancer diagnosis was observed, with DNA 
minor groove-binding mutations being associated more strongly with brain tumours 
(Olivier et al., 2003). The study of the LFS/LFL using the IARC TP53 database did 
not find specific germline mutations that were strongly associated with predisposition 
to lymphoma.  
 
Leventaki et al. have previously reported that many paediatric BL patients harbour no 
aberrations in the TP53 other than increased expression of MDM4. The investigators 
used CDKN1A immunohistochemistry (IHC) to measure impairment of the TP53 
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pathway and showed that CDKN1A as expressed in no cases. The authors 
hypothesised that while TP53 mutation and MDM2 overexpression and amplification 
acted to impair TP53 function in a number of cases, overexpression of the MDM4 
gene achieved the same effect in the remainder of the cohort. MDM4 has been 
shown to downregulate CDKN1A expression by abrogating the transactivation 
function of TP53 (Marine et al., 2006). TP53 mutations were identified in 18% of 
cases in the study which was consistent with the 20% of cases identified in a 
sequencing study of the same year (Love et al., 2012; Schmitz et al., 2012).  
 
TP53 status is assessed and used clinically in several cancers to guide treatment 
decisions, most notably in chronic lymphocytic leukaemia (CLL) (Campo et al., 2018). 
In CLL both TP53 mutation and deletion of 17p involving the TP53 gene are 
independent prognostic markers of chemotherapy resistance. TP53 aberrations were 
only observed in 10% of treatment-naïve CLL patients at diagnosis, but were more 
common in CLL samples that were refractory to fludarabine (Zenz et al., 2009). It 
was determined that TP53 aberrant CLL cases are effectively treated by BCL2 
inhibitor Venetoclax (Stilgenbauer et al., 2016), PI3K inhibitor Idelalisib (Brown et al., 
2014) and BTK inhibitor ibrutinib, leading to a marked improvement in the survival of 
these patients. The relevance of these inhibitors outside in TP53 aberrant cancer 
outside of CLL has not been characterised, however. TP53 status has been shown to 
be a prognostic factor in multiple other cancer subtypes, highlighting an opportunity 
to improve outcome in a large number of patients. TP53 status stratification in CLL is 
a recent success story in the field of personalised therapy for cancer, following in the 
wake of initiatives such as screening for somatic mutations in EGFR and ALK fusions 
in lung cancer and BRAF mutations in melanoma patients (Kelleher et al., 2012). The 
major distinction between these examples and TP53 stratification is that TP53 
mutation is not targetable in itself, but instead defines a subgroup of patients who 





5.2 Chapter Aims 
 
The specific aims of the work detailed in this chapter were as follows: 
x Investigate and characterise copy number aberrations and mutations affecting 
the TP53 gene in paediatric B-NHL. 
x Investigate the association between TP53 abnormalities on disease 
progression individually and in an integrated analysis.  
x Identify recurrent genomic abnormalities associated with TP53 status and test 




5.3.1 Patient and Clinical Demographics 
 
The TP53 status of the diagnostic tumour samples from 95 UK paediatric B-NHL 
patients with copy number and mutation data for the TP53 gene was analysed 
(Appendix E). Due to a lack of TP53 mutation data cases from the literature that were 
analysed in Chapter 4 were excluded from analysis in this section of the project.  
Clinical follow-up data were available for 88/95 (92.6%) cases. IG-MYC 
translocations were detected in 68 of 95 (71.6%) cases, including 60 BL, 4 DLBCL 
and 4 B-NHL, NOS. Six cases failed FISH or had no available material and 21 had 
no detectable MYC translocation. In total, 88 of 95 (92.6%) patients had complete 
clinical follow-up data; 77/88 (87.5%) were treated on FAB/LMB 96 protocols (trial or 
interim guidelines), one received no treatment, four were treated with alternative NHL 
protocols and treatment data were unavailable for 6 cases.  
 
5.3.2 Copy number aberrations involving the TP53 locus 
 
Following on from copy number analysis performed on 162 patients in Chapter 4, 
abnormalities involving 17p were interrogated in this cohort of 95 patients. 17p 
deletion involving TP53 was identified in 15/95 (15.8%) cases with median region of 
loss of 20.6 Mb (range 17.9-22.2 Mb), resulting in deletion of >80% of 17p in all 
cases. Median log ratio of deleted cases was -0.40 (range -0.14--0.79). All cases with 
17p loss had one copy deleted and there were no homozygous deletions of 17p. 
Additionally, 8/95 cases (8.4%) showed CNN-LOH with a median region of CNN-LOH 
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of 19.5 Mb (range 12.9-22.3 Mb) covering >80% of 17p (Figure 5.1). All 17p deletions 
and CNN-LOH involved the TP53 locus.  
 
 
Figure 5.1  (A) Deletion and (B) Copy Number Neutral Loss of Heterozygosity of 
chromosome arm 17p in 95 paediatric B-NHL diagnostic samples. P  Progression, 
NP  No Progression. 
 
17p CNN-LOH was shown to be a highly recurrent abnormality in this cohort, strongly 
suggesting that mutations in a gene on this chromosome arm plays a role in driving 
therapy resistance in paediatric B-NHL.  
 
5.3.3 Genomic Analysis of the TP53 locus 
 
The TP53 mutation status of all 95 cases was determined by whole-exome 
sequencing (n= 90) or Sanger sequencing (n=5). Variants were called by MuTect and 
Mutect2 variant callers and manually validated by in the Integrative Genomics Viewer 
software. For patients that did not have whole exome sequencing data but for whom 
there was patient DNA still available, Sanger sequencing of exons 5-8 was 
performed as described in Chapter 2.   
 
In all, 56 variants were identified in the cohort of 95 paediatric B-NHL patients. Non-
synonymous TP53 mutations were found in 46/95 (48.4%) cases: 37 had a single 
non-synonymous somatic mutation, 8 had two mutations and one had a germline 
R248Q mutation inherited variant that was observed in the tumour and constitutional 
DNA which corroborated clinical data showing the patient had Li-Fraumeni 
Syndrome. One case harboured a single R213R mutation that was excluded for 
being a silent variant, while another harboured the same mutation as well as a 
missense E258D variant and was considered to have a monoallelic TP53 
abnormality as the silent mutation is assumed to have no functional consequence.  
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Published data from the UMD and IARC TP53 Databases showed all but 2 of the 54 
non-synonymous mutations to be functionally deleterious (Leroy et al., 2014; 
Bouaoun et al., 2016) (Appendix E). As seen in other cancers (Bouaoun et al., 2016; 
Donehower et al., 2019), the most frequently mutated residues were R175 (n=6), 
G245 (n=5), R248 (n=7) and R273 (n=4) (Figure 5.1). Of the 56 mutations identified 
in this cohort, 55 appeared to cluster into one of three regions within the DNA-binding 
domain: 1. V122-R158, 2. V173-V126, 3. S241-L289 (Figure 5.2).  
 
Figure 5.2 - TP53 Mutations identified in 46/95 paediatric B-NHL patients. 
 
 
5.3.4 Integrated Analysis of TP53 Abnormalities in Paediatric B-NHL 
 
Integrating the mutation and copy number array data showed that abnormalities 
involving the TP53 gene were common at presentation with 52/95 (54.7%) cases 
harbouring at least one abnormality involving TP53 (Figure 5.3). Cases with TP53 
aberration events that were believed to affect both alleles (termed biallelic ) made up 
half of these, being present in 26/95 (27.4%) cases (Figure 5.4). Among 26 cases 
with biallelic abnormalities at diagnosis, 17 had mutation together with deletion or 
CNN-LOH, two had homozygous mutations without CNN-LOH and seven had two 
heterozygous mutations that were assumed to be compound heterozygous, affecting 
both alleles (Figure 5.3, Figure 5.4). Compound heterozygous mutations of TP53 
have been reported in the literature and are shown to be situated on alternate alleles 
(Havelange et al., 2016b; Sande et al., 2018). Of the 26 diagnostic samples with 
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monoallelic TP53 abnormalities, 20 had a single somatic heterozygous mutation 
(median variant allele frequency (VAF) 39%, range 18-50%), four had a deletion and 
two had CNN-LOH (Figure 5.3). Two cases with CNN-LOH were identified without a 
detectable mutation of the TP53 gene, it was assumed that an undetected subclonal 
TP53 mutation was present at a low level in a small subclone but could not be 
considered to have biallelic abnormalities of TP53. This does not explain the clonal 
distribution of 17p CNN-LOH, however. It is possible that non-coding mutations may 
contribute to disease progression in a similar manner to missense mutations in 
coding regions. Non-coding regions of the TP53 were not covered by the whole 
exome sequencing kits used in this study. Non-coding variants affecting the TP53 
gene have been reported in cancer previously (Gyorffy et al., 2018).  
 
 
Figure 5.3  A pie chart representation of co-occurrence of TP53 abnormalities in 95 
paediatric B-NHL patients. 
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Figure 5.4 - Integrated analysis of TP53 abnormalities in paediatric B-NHL. An oncoplot showing TP53 status with clinical and 
molecular factors as described in the key. Data is plotted from left to right according to the presence of biallelic, monoallelic or no 
TP53 abnormality. Unavailable data is indicated with a cross. 
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Two cases had mutations that were less than 100bp apart and therefore could be 
covered in the same read (Figure 5.5). Both cases showed that the mutations were 
on alternating reads, with no reads containing both variants in either case. Based on 
this information, we could determine that these mutations affected both alleles, and 
therefore both cases had biallelic TP53 abnormalities. The further six cases with 
compound heterozygous mutations were considered to have biallelic TP53 
aberrations based on this finding. Compound heterozygous cases are broken down 
in Table 5.1. 
  







14/325 R158H R175H 52, 17 Yes 
14/414 R175H G245S 209, 70 No 
15/156 S241Y G245S 12, 4 Yes 
15/314 R158H P278S 359, 120 No 
15/353  R248Q R273C 74, 25 No 
21/257 Y126H G245S 357, 119 No 
4/830* L257P R282W 74, 25 No 
5/686 R248Q T256K 24, 8 No 
Table 5.1 - Table showing the locations of variants in cases with compound 





Figure 5.5 - Whole Exome Sequencing Data viewed in IGV showing two cases with compound heterozygous TP53 mutations. Grey 
horizontal bars represent individual whole exome sequencing reads covering the TP53 locus. Each case harboured two 
heterozygous mutations in the TP53 gene which could be covered by the same reads. In both cases there were no reads exhibiting 
both variants which strongly suggests they occurred on separate molecules.
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Mutations in patient 14/325 both presented at high VAFs (54%, 36%) suggesting a 
high tumour content and that close to 100% of cells in the sample had both 
mutations. In contrast patient 15/156 presented with low VAFs (32%, 22%) which 
suggests that either the tumour content was low or that the compound heterozygous 
mutations were found in a subclone of the tumour sample. Patient 15/156 was 
designated in the pathology review as a B-NHL, NOS case, but was found to be 
100% IG-MYC positive by FISH (100/100 cells, performed previously in lab).  
 
5.3.5 Prognostic investigation of TP53 aberrations in paediatric B-NHL 
 
Survival estimates at 3 years for overall survival (OS) and time to progression (TTP) 
were 85.2% (95% CI 78.1-93.0) and 82.4% (95% CI 74.6-90.9), respectively. For 
those patients with primary refractory or relapsed disease, the median time from 
initial diagnosis to disease progression was 4.8 months (range 2.8-8.2 months). Bone 
marrow (BM) and Central nervous system (CNS) involvement were associated with 
an inferior overall survival; BM involvement reached our significance threshold (HR 
4.5 (CI 95% 1.3-16.0), p=0.018, Cox proportional hazard method) while CNS 
involvement almost achieved significance (HR 4.6 (CI 95% 1-22.0), p=0.057, Cox 
proportional hazard method).  
 
Investigating the prognostic relevance of TP53 in all 95 B-NHL cases by univariate 
cox modelling revealed that deletion of 17p did not confer an inferior TTP or OS 
independently (TTP HR 1.3 95% CI 0.4-4.8, p=0.650 and OS HR 0.4 95% CI 0.1-3.2, 
p=0.390, Cox proportional hazard method). However, 17p CNN-LOH was 
significantly associated with worse outcome (TTP HR 7, 95% CI 2.4-21.0, p<0.001 
and OS HR 5.6, 95% CI 1.7-18.0, p=0.005, Cox proportional hazard method). 17p 
deletion involving TP53 was observed twice as often as CNN-LOH of the same 
region (14/95, 15.9% vs 7/95, 8.0%, p=0.164, Fisher exact test) despite having no 
significant effect on TTP or OS. This suggested that mutations of the TP53 gene may 
play a more important role in resistance to therapy than deletion.  
 
Survival analysis by Cox Proportional Hazard model method demonstrated that TP53 
mutated cases had a significantly inferior TTP and OS than non-mutated cases (TTP 
HR 8.1, 95% CI 1.8-36.0, p=0.006 and OS HR 6.4, 95% CI 1.4-29, p=0.015, Cox 




Time to progression (TTP) Overall survival (OS) 
HR (95% CI) p value HR (95% CI) p value No. cases with abnormality (%) 
Univariate analysis      
CNS involvement 1.58 (0.2-12.4) 0.660 4.60 (0.95-22.0) 0.057 5/72 (6.9%)* 
BM involvement 2.17 (0.7-7.2) 0.207 4.50 (1.3-16.0) 0.018 15/74 (20.3%)* 
TP53 deletion 1.30 (0.4-4.8) 0.650 0.41 (0.1-3.2) 0.390 14 (15.9%) 
TP53 CNN-LOH 7.00 (2.4-21.0) 0.00042 5.60 (1.7-18.0) 0.0045 7 (8.0%) 
TP53 mutation 8.10 (1.8-36.0) 0.0058 6.40 (1.4-29.0) 0.015 43 (48.9%) 
Any TP53 abnormality 14.00 (1.8-100.0) 0.012 11.00 (1.4-85.0) 0.021 48 (54.5%) 
TP53 monoallelic abnormality 9.90 (1.2-85.0) 0.036 11.00 (1.4-94.0) 0.025 23 (26.1%) 
TP53 biallelic abnormality  16.00 (2.1-130.0) 0.0081 10.00 (1.2-86.0) 0.031 25 (28.4%) 
Table 5.2  Univariate survival analysis of TP53 abnormalities in paediatric B-NHL. * Data for BM and CNS involvement was not 
available for all cases with follow-up data. 
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Strikingly, when these variables were combined, the presence of any TP53 
abnormality was strongly associated with a poor outcome (TTP HR 14 (95% CI 1.8-
100.0), p=0.012, OS HR 11 (95% CI 1.4-85.0), p=0.021, Cox proportional hazard 
method) when compared to those without any abnormalities of TP53 with higher 
hazard ratios by both survival metrics. The presence of a biallelic TP53 abnormality 
at presentation was shown to be associated with a significantly inferior TTP than 
TP53 normal cases (TTP HR 16.0, 95% CI 2.1-130.0, p=0.008, Cox proportional 
hazard method). Similarly, monoallelic aberrations of the TP53 gene were also 
associated with a dire outcome (TTP HR 9.9, 95% CI 1.2-85.0, p=0.036, Cox 
proportional hazard method). This demonstrates that cases with TP53 aberrations 
affecting both alleles represent the absolute worst genetic risk group in paediatric B-
NHL identified to date. Kaplan Meier plots for TTP and OS demonstrate the poorer 
prognosis of biallelic TP53 cases in comparison to monoallelic and normal cases 
(Figure 5.6).  
 
Figure 5.6 - Kaplan Meier plots showing the (A) Time to progression (Biallelic vs 
Normal p<0.001, Biallelic vs Monoallelic p=0.002, Monoallelic vs Normal p=0.010, 
Log rank test) and (B) Overall survival analysis of TP53 status in paediatric B-NHL. 
(Biallelic vs Normal p-0.007, Biallelic vs Monoallelic p=0.137, Monoallelic vs Normal 
p=0.005, Log rank test) 
 
It is remarkable that only one patient who underwent disease progression resided 
within the TP53 normal group (Figure 5.6A). This patient was analysed as a 
diagnostic and relapse pair in Chapter 7 and was shown to have biallelic TP53 
aberrations in the relapse biopsy, specifically deletion of 17p and a hemizygous 
R248W mutation. This means that all BL cases that underwent disease progression 
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harboured a TP53 aberration. It is possible that the case with no detectable TP53 
abnormality at diagnosis harboured an undetected subclonal TP53 mutation. Of 
those patients without any TP53 abnormality at initial diagnosis had an OS of 97.5%, 
with one patient dying early during treatment (Figure 5.6B).  
 
It was hypothesised that specific residues within the DNA-binding domain conferred 
different degrees of protection to the tumour against chemotherapy, and mutations 
within these residues may confer a poorer prognosis. Survival analysis did not show 
a significant association between disease progression or patient outcome for any 
cluster of mutation sites in particular.  
 
5.3.6 Multivariate survival analysis investigating TP53 aberrations in paediatric 
B-NHL 
 
Multivariate analysis was performed to assess the impact of TP53 abnormalities 
alongside established high-risk clinical factors (BM and CNS involvement). 
Importantly, the presence of any TP53 abnormality emerged as an independent 
prognostic marker in the paediatric B-NHL cohort (TTP HR 11.69 (95% CI 1.49-
91.57), p=0.019, Cox proportional hazard method) (Table 5.3), in contrast to 
established clinical factors of BM and CNS involvement. Furthermore, biallelic TP53 
abnormalities were even more strongly associated with disease progression (TTP HR 
14.43 (1.76-118.02), p=0.013, Cox proportional hazard method), than monoallelic 





Table 5.3 - Multivariate survival analysis of TP53 abnormalities in paediatric B-NHL.  
 
 
5.3.7 TP53 abnormalities by B-NHL subgroup 
 
Hazard ratio (95% CI) p value
B-NHL (n=88 B-NHL cases with genomic and survival data)
Multivariate analysis - Biallelic and monoallelic abnormalities
TP53 monoallelic abnormality 8.20 (0.85-79.83) 0.068
TP53 biallelic abnormality 14.43 (1.76-118.02) 0.013
CNS involvement 1.37 (0.16-11.78) 0.771
BM involvement 1.47 (0.36-5.90) 0.590
Risk Factor
Time to progression (TTP)
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Subsequent survival analyses were performed to investigate whether the prognostic 
relevance of TP53 abnormalities were associated with a specific subtype of B-NHL. 
The cohort in this part of the study was primarily made up of BL cases, and univariate 
analysis confirmed that both biallelic abnormalities and any TP53 mutations were 
associated with a significantly poorer time to progression (Biallelic HR 8.80 (95% CI 
1.1-70), p=0.041, any TP53 mutation HR 8.30 (95% CI 1.1-64), p=0.043, Cox 
proportional hazard method) in this subgroup (Appendix F). The presence of any 
abnormalities involving TP53 was not a significant prognostic marker in paediatric BL 
but bordered on significance (HR 7.00 (95% CI 0.91-54), p=0.062, Cox proportional 
hazard method). The reduction in significance is likely attributed to the reduced 
statistical power as a result of a smaller cohort size. Kaplan Meier analysis by Log 
Rank highlighted that there is a correlation between TP53 abnormalities and poor 
outcome by overall survival and time to progression analysis (Figure 5.7). The TP53 
normal group still do remarkably well in the BL subset, and the one case that 
underwent disease progression that was TP53 normal at original diagnosis acquired 





Figure 5.7 - Kaplan Meier plots showing cumulative survival of BL patients with TP53 abnormalities.(A) TTP Survival of CNN-LOH 
involving TP53 gene (p<0.001, Log rank test) (B) TTP Survival of TP53 Mutation (p=0.001, Log rank test) (C) TTP Survival of any 
TP53 abnormality (p=0.001, Log rank test) (D) TTP Survival of TP53 Status in BL (Biallelic vs Normal p<0.001, Biallelic vs 
Monoallelic p=0.002, Monoallelic vs Normal p=0.010, Log rank test) and (E) Overall Survival of TP53 Status in BL (Biallelic vs 




In an investigation of 19 DLBCL patients with outcome and copy number data there 
were four cases with TP53 mutations, one of whom had Li-Fraumeni syndrome, with 
an inherited R248Q mutation. Out of the three cases with somatic TP53 mutations, 
one was a heterozygous R248W mutation, one was a hemizygous R213Q mutation 
alongside a single deletion of 17p, and the other was a case that experienced 
disease progression and had a single heterozygous G187S mutation. The other 
DLBCL case with disease progression harboured 17p CNN-LOH that involved the 
TP53 gene, but no mutations were identified in either the diagnostic or relapse 
samples via whole exome sequencing. There were too few cases to perform formal 
survival analysis, however of two patients who underwent disease progression, one 
had 17p CNN-LOH involving TP53 albeit without a detectable mutation and the other 
harboured a G187S mutation.  
 
5.3.8 p53 Pathway Defects and Abnormalities 
 
A panel of genes commonly aberrated in cancer and associated functionally with p53 
was identified using KEGG Ontology (Kanehisa et al., 2019) and screened using both 
copy number arrays (in all 95 patients) and whole exome sequencing (in 39 patients 
with paired tumour and normal DNA sequencing) to determine whether additional 
defects in the p53 pathway were associated with or contributed to poor outcome in B-
NHL (Table 5.4).  
Gene Gain  Loss CNN-LOH Coding 
Mutation 
TP73 1/95 (1.1%) 3/95 (3.2%) 6/95 (6.3%) 0/39 (0.0%) 
MDM4 15/95 (15.8%) 2/95 (2.1%) 2/95 (2.1%) 0/39 (0.0%) 
MDM2 8/95 (8.4%) 1/95 (1.1%) 0/95 (0.0%) 0/39 (0.0%) 
ATR 2/95 (2.1%) 3/95 (3.2%) 3/95 (3.2%) 3/39 (7.7%) 
CDKN1A 1/95 (1.1%) 2/95 (2.1%) 9/95 (9.5%) 0/39 (0.0%) 
CDKN2A 1/95 (1.1%) 11/95 (11.6%) 8/95 (8.4%) 0/39 (0.0%) 
ATM 12/95 (12.6%) 0/95 (0.0%) 2/95 (2.1%) 2/39 (5.1%) 
CHEK1 4/95 (4.2%) 7/95 (7.4%) 6/95 (6.3%) 0/39 (0.0%) 
Table 5.4 - A table summarising TP53 pathway gene abnormalities in a cohort of 
paediatric B-NHL patients. Gain, loss and CNN-LOH were investigated in 95 patients 
with array data. Coding mutations were screened for in 39 patients with paired 
tumour and normal exome sequencing data. 
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Remarkably, mutations in these genes were found at very low incidence in a subset 
of 39 patients with paired tumour and normal exome sequencing data. Previous 
investigation into p53 pathway abnormalities in paediatric BL by Leventaki et al. 
(2012) suggested that abrogation of functional p53 protein occurs through multiple 
mechanisms, including MDM2 amplification, but this was not observed. Somatic 
missense mutations in ATM were identified in two cases; one BLL-11q and one 
DLBCL case. Three cases harboured single missense mutations in the ATR gene, 
two of which were cases with mutated ATM. The additional ATR mutant case 
harboured an L1191F mutation and was a BL case that went on to relapse, 15/310. 
This patient had heterozygous G245S TP53 mutation at diagnosis but no other TP53 
abnormality. No other coding mutations in p53 pathway genes were detected. MDM4 
copy number gains were recurrent, occurring in 15.8% of the cohort. The gene is 
located on 1q in a region of recurrent copy number gain in B-NHL as described in 
Chapter 4. Copy number gain of MDM4 has been shown to correlate with high 
expression of both long and short forms of the MDM4 protein (Leventaki et al., 2012).  
 
5.3.9 B-NHL samples with TP53 abnormalities are associated with 
chromosomal complexity 
 
Investigation of the genomic landscape of cases with biallelic TP53 aberrations 
revealed that this subset of patients had more complex genomes than cases who 
were TP53 normal and harboured complex chromosomal abnormalities (Table 5.5). 
Statistical analysis by one-way t-test confirmed that this association was significant 





















6.44 0.3776 48.13 0.08502 1.038462 0.003633 
Biallelic 6.04 0.4422 39.62 0.2328 1.576923 0.006518 
Monoallelic 6.85 0.5304 56.65 0.162 0.5 0.1446 
TP53 
Normal 
4.57 - 29.49 - 0.2790698 - 
Table 5.5 - Investigation of the association between genomic complexity and TP53 
status in paediatric B-NHL. P values were calculated using an unpaired t-test. 
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For an abnormality to be considered a complex chromosomal abnormality based on 
copy number array data it needed to exhibit fluctuation between two or more copy 
number states with two or more individual altered segments on one arm. The 
segments had to be at least 250kb in size to rule out common germline CNVs and 
technical noise. This includes abnormalities resembling the characteristic 11q 
abnormality seen in BL cases and MYC-negative BLL-11q cases, as well as 
instances of chromothripsis and complex stepwise gain similar to those seen in 
iAMP21 abnormalities seen in B-ALL cases (Rand et al., 2011). iAMP21 
(intrachromosomal amplification of chromosome 21) is a complex genomic 
abnormality that defines a subtype of paediatric B cell precursor acute lymphoblastic 
lymphoma (B-ALL). The mechanism driving this aberration has been characterised 
through extensive FISH analysis as a breakage-fusion-bridge mechanism followed in 
many cases by chromothripsis (Robinson et al., 2007).  
 
Out of 64 BL cases in the cohort, 40 patients (62.5%) had TP53 abnormalities (21 
biallelic, 19 monoallelic) of which 22 (55.0%) had complex CNA. In contrast, only 
1/24 (4.2%) BL cases without a TP53 abnormality demonstrated complex 
chromosomal aberrations. Conversely, there was no association between TP53 
abnormalities and complex abnormalities in DLBCL. Five DLBCL cases harboured 
complex chromosomal aberrations, which only included one monoallelic and one 
biallelic case. The single biallelic case had Li-Fraumeni syndrome and demonstrated 
the highest number of complex CNA within the whole cohort with 11 chromosome 
arms affected.  
 
5.3.10 Complex Chromosomal Aberrations 
 
More detailed analysis showed a specific and significant association between TP53 
alterations and complexity of chromosomes 1q, 11q and 13q (Figure 5.8A-C). 66 
complex chromosomal abnormalities were identified on 22 different chromosome 
arms (Figure 5.8B). The most frequently altered arm was 13q, with complex 
aberrations observed in 15 cases. 1q and 11q abnormalities were both seen in 10 
cases. The majority of complex chromosomal abnormalities were found in MYC-
rearranged BL cases with TP53 abnormalities. Of 35 cases with chromosomal 
complexity, 24 (68.6%) were MYC-rearranged BL with TP53 abnormality, compared 
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to 16/56 (28.6%) MYC-rearranged BL cases with TP53 abnormality and no 
chromosomal complexity (p<0.001, Fisher exact test).  
 
Figure 5.8  A pattern of associations between complex chromosomal aberrations 
and TP53 and MYC statuses. (A)  An oncoplot showing the association between 
specific complex chromosomal abnormalities and TP53 abnormalities. (B) Histogram 
displaying the frequency of complex abnormalities of each chromosome arm in 
biallelic, monoallelic and TP53 normal groups. As a diagnosis of BLL-11q is 
determined by the presence of a complex 11q rearrangement, these 4 cases were 
excluded from this analysis. (C) Summary of the incidence of complex chromosomal 
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abnormalities in TP53 biallelic or monoallelic cases compared to TP53 normal cases 
(F e  E ac  e  *= <0.05, **= <0.01).  
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5.3.11 Chromosome Arm Abnormalities 
 
13q abnormalities were primarily observed in BL with the exception of one DLBCL 
case and one B-NHL, NOS case.13/64 (20.3%) BL cases exhibited complex 
chromosomal aberrations on 13q compared to 1/19 (5.3%) DLBCL cases. The 
pattern of centromeric gain followed by telomeric loss on 13q resembles the 11q 
aberration seen in some BL cases in Chapter 4 and also MYC-negative Burkitt-like 
Lymphomas (Salaverria et al., 2014) that were recognised as a provisional subtype 
of B-NHL in the 2016 WHO Classification of Haematological Malignancies (Swerdlow 
et al., 2016). Ten cases with this pattern of aberration were found to have complex 
patterns of gain in addition to the gain-loss pattern, which were termed 13qplex in this 
thesis, distinguishing them from complex chromosomal abnormalities that did not 







Figure 5.9 - A summary of complex chromosomal aberrations on chromosome arm 
13q. (A) Segmented copy number data depicting the size and breakpoint of 13q 
complexity in ten cases with 13qplex pattern aberrations and five with non-13qplex 
aberrations.  Kaplan Meier plots for MIR17HG gain for (B) time to progression and 
(C) overall survival 
 
 
13qplex cases harboured between 1 and 6 distinct segments of copy number gain 
(median 4). All ten 13qplex cases included amplification of the MIR17HG locus, which 
mapped within the highest peak of copy number gain in 9/10 cases (Figure 5.9A). 
Telomeric breakpoints across the 13qplex cases, or the transition point between gain 
and loss, mapped within a 12.1 Mb region, with recurrent breakpoints involving the 
HS6ST3 and MIR4501 loci at 13q32.1. Many of the cases had stepwise copy number 
gains that did not always correlate with an absolute copy number, suggesting that 
some of these aberrations are subclonal. This pattern of gain was distinct from 
 146 
chromothripsis, which is the result of chromosome shattering and manifests as a 
uniform switching between two copy number states along a chromosome arm. 13qplex 
aberrations more closely resembled the iAMP21 abnormality seen in paediatric B cell 
precursor acute lymphoblastic leukaemia (BCP-ALL) (Harewood et al., 2003), which 
arises due to a breakage-fusion-bridge cycle and is regularly followed by 
chromothripsis. 
 
The minimally gained region in 13qplex abnormalities harboured the MIR17HG 
microRNA cluster at 13q31.3. Previous published studies have reported an 
association between gain of MIR17HG and relapse (Schiffman et al., 2011) and the 
cluster has been implicated in the biology of B-NHL in the past (Dal Bo et al., 2015). 
Amplification of MIR17HG was observed more frequently in BL (19/64, 30.0%) than 
DLBCL (3/19, 15.8%, p=0.375, Fisher exact test) cases, although this difference was 
not statistically significant. Amplification of 13q31.3 has previously been shown to be 
associated with paediatric disease by a previous copy number array investigation 
(Havelange et al., 2016b).  
 
Strikingly, the presence of complexity on 13q had the strongest association with 
biallelic TP53 abnormalities (p=0.001, Fisher exact test) (Figure 5.8C), but despite 
this observation, MIR17HG amplification was not associated with disease 
progression or overall survival in the cohort (Figure 5.9B-C). Whilst the biological 
relevance of the 13qplex abnormality identified here remains unclear, the association 
with TP53 abnormalities may offer an explanation for the postulated prognostic 
importance of MIR17HG amplification in previous smaller cohorts of relapsing BL 
(Schiffman et al., 2011). Further investigation of 13q abnormalities is required to 
increase our understanding of how these events occur and whether they have a role 
in driving disease progression or whether they are simply passenger events; helpful 
markers of increased genetic instability. Previous studies in other cancers have 
implicated TP53 aberration in genomic complexity, and specifically chromothripsis. 
Sonic-hedgehog medulloblastoma cases with TP53 aberrations had a high 
propensity to undergo catastrophic DNA rearrangements such as chromothripsis 
(Rausch et al., 2012). TP53 aberrations are also associated with complex karyotypes 
and specific copy number abnormalities in acute myeloid leukaemia (AML), namely 
loss of chromosomes 5, 7, 16, or 18 and additional copies of chromosome 1 and 11 
(Rucker et al., 2012). 
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The 11q abnormalities identified in this cohort were mostly typical of those seen in 
BLL-11q cases (Salaverria et al., 2014) and described in Chapter 4. Two cases had 
the hallmark gain followed by telomeric loss but had more complex breakpoints 
between gain and loss with additional aberrations (Figure 5.10).  
 
Figure 5.10 - Segmented copy number data showing breakpoints and size of 11q 
complexity in paediatric B-NHL. 
 
Additionally, one case had a complex pattern of copy number gain but did not 
harbour the telomeric loss seen in the majority of cases (Figure 5.10). Remarkably, 
while 11q abnormalities were associated with a biallelic TP53 status in B-NHL, the 
four BLL-11q cases had no TP53 abnormalities. There was a clear difference 
between breakpoints in BLL-11q cases when compared with BL cases with 11q 
pattern abnormalities. In BLL-11q cases the breakpoints between gain and loss 
spanned a 0.6Mb region, while the region in other B-NHL cases was considerably 
larger (5.2Mb). Further characterisation of 11q abnormalities is presented in Chapter 
4.   
 
Chromosome 1q is recurrently gained in aggressive B-NHL cases, including 49/95 
cases analysed in this project. Of those, 10 cases had complex copy number gains of 
1q (Figure 5.11). Unlike 13q and 11q complexity, deletions on 1q were not as 
frequent. Instead complex patterns of copy number gain were seen in most cases.  
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Figure 5.11 - A copy number plot depicting segmented copy number data for cases 
with 1q complexity. 
 
Complex gain of 1q primarily involved the centromeric region of the arm and typically 
manifested as fluctuations between copy number states above of three or more. Two 
cases had telomeric deletions similar to those seen in 13qplex abnormalities in 
addition to centromeric gain.  
 
One case in the cohort was diagnosed as DLBCL with underlying Li-Fraumeni 
Syndrome. The extensive complexity observed in the Li-Fraumeni case is further 
evidence for TP53 aberration driving genomic instability and complexity in B-NHL 
(Figure 5.12), as the entire clonal population of the tumour harboured at least one 
TP53 abnormality from the initiating clone onwards. Deletion of 17p in this case 
contributed to the biallelic TP53 status of the tumour, but it was not known whether 




Figure 5.12 - Complex copy number changes observed in a DLBCL tumour from a 
patient with Li-Fraumeni Syndrome. (A) Ideogram depicting segmented copy number 
data from the tumour sample. (B) Raw log ratio and B-allele frequency data depicting 






Genomic analyses of BL and DLBCL have reported that TP53 mutations are among 
the most recurrent mutations in B-NHL (Giulino-Roth et al., 2012; Love et al., 2012) 
and that 17p copy number abnormalities are recurrent (Poirel et al., 2009; Scholtysik 
et al., 2010; Schiffman et al., 2011; Scholtysik et al., 2015) but the clinical relevance 
and impact on patient outcome has not previously been elucidated.  
 
This study has identified, for the first time, an association between TP53 
abnormalities and both disease progression and poor overall survival for UK children 
diagnosed with mature B cell non-Hodgkin lymphoma. We showed that over half of 
paediatric B-NHL patients harboured at least one abnormality affecting the TP53, and 
that those harbouring aberrations on both alleles were at the highest risk of disease 
progression and death. The exciting and novel findings of this investigation have the 
potential to improve outcome for B-NHL patients as we present a prognostic genomic 
marker that is strongly associated with disease progression that can be easily 
screened for in the clinic.  
 
Equally remarkable is the finding that patients with normal TP53 status at diagnosis 
did exceedingly well on standard frontline therapy. Only one patient out of 40 without 
TP53 aberrations at diagnosis went on to develop progressive disease, and this case 
went on to acquire clonal TP53 abnormalities by the point of disease progression. 
Using TP53 status to stratify patients highlights a subset of patients who could 
benefit from treatment de-escalation. There is precedent in the literature for 
integrating TP53 mutation and copy number status with treatment strategy in the 
setting of in CLL in a practical way (Campo et al., 2018). The foundations for 
comprehensive investigation of TP53 status already exist in haematological 
laboratories across Europe as a result of the TP53 Network implemented by the 
European Research Initiative on CLL (ERIC) (Malcikova et al., 2018).  
 
It has been hypothesised that inhibition of p53 protein is functionally required in all BL 
cases to bypass pro-apoptotic signals from deregulated MYC expression, which is a 
common mechanism in other MYC+ tumours (Eischen et al., 1999). High expression 
of MDM4 has previously been demonstrated in TP53wt BL suggesting that 
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abrogation of the p53 pathway is an important requirement for BL development 
(Leventaki et al., 2012).  
 
Recent studies and trials have assessed and suggested the therapeutic potential of 
MDM2/MDMX inhibitors in paediatric cancer and haematological malignancies, 
including B-NHL (Tisato et al., 2017). The work detailed in this study casts doubt on 
the relevance of these inhibitors in the treatment of relapsed/refractory paediatric B-
NHL, as the cases with the worst outcome on current clinical protocols are almost all 
TP53 abnormal. MDM2/MDMX inhibition is still a promising candidate for the 
treatment of B-NHL in the TP53 normal group to reduce the intensity of 
chemotherapy in low-risk patients. This is further supportive evidence for ascertaining 
the TP53 status of paediatric B-NHL at the point of diagnosis. 
 
Genome complexity associated with TP53 abnormality in paediatric B-NHL has not 
been described previously. This association was strongest in MYC-rearranged BL 
patients with TP53 aberration. Despite the association between genomic complexity 
and TP53 abnormalities, complexity was not in itself associated with poor outcome. 
Chromosome arms 13q, 11q and 1q were most frequently affected and are known to 
be the sites of recurrent non-complex copy number alterations in paediatric B-NHL 
(Scholtysik et al., 2010; Schiffman et al., 2011; Salaverria et al., 2014; Scholtysik et 
al., 2015; Havelange et al., 2016b). It is noteworthy that non-complex abnormalities 
of 13q and 1q were more frequent in the cohort but were not associated with TP53 
status. MIR17HG amplification was a common factor of all but one complex 13q 
aberration, and all 13qplex pattern cases. While it was determined that MIR17HG 
amplification was not a marker of poor outcome in this cohort, the strong association 
between 13qplex pattern aberrations and TP53 abnormality, as well as its established 
biological role in B-NHL, may explain why previous studies have suggested 
MIR17HG as a prognostic marker. Both 1q and 11q harbour p53 pathway-associated 
genes which may synergise with TP53 aberrations to aid lymphoma development 
and progression. However it is very likely that a large proportion of complex 
chromosomal aberrations identified in this cohort were passenger abnormalities and 
did not contribute to the pathogenesis of the malignancy.  
 
TP53 status is the first clinically actionable genomic prognostic marker for paediatric 
B-NHL patients. Patients could be routinely screened for aberration using an existing 
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infrastructure within UK hospitals. The next step is to validate the findings of this 
study in a large, clinically annotated cohort from a prospective trial to facilitate 
translating these findings to the clinic. The results of this study have the potential to 
advance the development of more efficacious and less toxic treatment options for 
patients. Diagnostic TP53 status testing will improve our ability to stratify patients in a 
clinically meaningful way and improve their outcome during treatment and beyond.  
 
The significance of TP53 aberrations is still not understood in other BL subtypes, 
particularly endemic BL. A recent study by Grande et al. (2019) identified a significant 
difference between subgroups in the frequency of TP53 mutations based on EBV 
status, with EBV negative BL having twice the rate of TP53 mutation compared to 
EBV positive cases. Despite recent improvements in survival rates of paediatric 
endemic BL at the Queen Elizabeth Central Hospital in Blantyre, Malawi, cure rates 
still lag behind those seen in the UK. Effective prognostic markers of disease 
progression are urgently needed to improve outcomes for patients without increasing 
treatment toxicity. Chapter 6 of this thesis details copy number analysis of endemic 











Endemic Burkitt lymphoma represents the first subtype of BL that was characterised. 
Initially described in 1958 by Denis Burkitt in Africa, endemic BL frequently presents 
as swelling of the jaw or eye socket (Burkitt, 1958). The disease is the most common 
childhood cancer in sub-Saharan Africa, found in the warmer, wetter regions of the 
continent. The incidence of endemic BL was found to be consistent with the 
occurrence of the malarial parasite Plasmodium falciparum, leading to a longstanding 
belief that the parasite was instrumental in the pathogenesis of BL. Investigations into 
BL shortly later revealed the presence of a novel oncogenic virus, the Epstein-Barr 
virus (Epstein et al., 1964). It is believed that both play a role in disease through 
inducing AID (activation induced cytidine deaminase) (Figure 6.1).  
 
 
Figure 6.1  Proposed synergistic mechanisms by which Malarial infection may 
contribute to increased AID expression in an EBV infected B cell in Burkitt 
Lymphoma development. Adapted from (Moormann and Bailey, 2016) 
 
Patients diagnosed with endemic Burkitt Lymphoma generally have a poorer 
prognosis than those diagnosed with the sporadic subtype in the UK and there are a 
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number of factors contributing to this inferior outcome. Patients treated at the Queen 
Elizabeth Central Hospital, Blantyre, Malawi are given a significantly reduced 
treatment protocol compared to patients in the UK. Several protocols exist in different 
clinical and geographical settings and there is little consistency in these protocols, 
resulting in event-free survival rates ranging from 50-80%. FAB/LMB96-based 
chemotherapy administered to patients in the UK comes with severe toxicity and 
requires a high degree of supportive care for months. Reduced-intensity therapy in 
lower income countries lowers supportive care needs for the patient, reducing the 
likelihood of severe adverse events, as well as the cost of treatment per patient 
(Hesseling et al., 2003).  
 
We hypothesised that while the highly chemotherapy-resistant BL cases have poor 
outcomes in a sporadic setting still occur in the endemic subtype, they are currently 
indistinguishable from a larger population of patients who are not sufficiently treated 
by endemic protocols. Intensifying therapy for all patients is not feasible due to the 
cost of chemotherapeutic agents and supportive care (Hesseling et al., 2008), 
however if patients with poorer risk could be identified at diagnosis then an intensified 
regimen could be administered to patients who need it. Previous studies (Poirel et al., 
2009; Schiffman et al., 2011) and work in chapters 4 and 5 have identified prognostic 
genomic markers that confer a poorer outcome in sporadic BL and B-NHL. If these or 
other genomic markers can be used in the endemic setting then the outcome of 
patients with endemic BL could be significantly improved by more targeted treatment.  
 
Independently of the treatment prescribed to the different subtypes, it is well 
understood that sporadic and endemic are biologically distinct (Ferry, 2006). The 
genetic profiles of both subtypes share many features, such as the hallmark IG/MYC 
translocation and mutations of the ID3, TCF3 and CCDN3 axis, but distinct 
differences have been described in the incidence of such mutations (Abate et al., 
2015). IGH-MYC translocation breakpoints are different between subtypes, with the 
majority of rearrangements in sporadic BL truncating the first exon while endemic 
cases harbour rearrangements adjacent to the MYC gene (Pelicci et al., 1986). Abate 
et al. (2015) performed variant calling on RNA-Seq data from 20 endemic BL cases 
and identified TP53 mutations at a lower incidence in endemic BL (3/20, 15.0%) than 
in the sporadic form (14/41, 34.1%). This finding is significant given the finding 
reported in Chapter 5 that TP53 aberrations are associated with disease progression 
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and poor outcome in paediatric B-NHL treated in a UK setting. Conversely, ARID1A 
mutations were shown to be more common in endemic BL (Abate et al., 2015) 
leading to a loss of expression, a finding which has also been reported in other EBV 
positive cancers (Abe et al., 2012).  
 
It has been repeatedly reported that differences in genomic profiles between 
subtypes is thought to driven by EBV status, rather than geographical factors (Abate 
et al., 2015; Grande et al., 2019). Over 90% of endemic BL cases are EBV+ while 
the number is under 30% in the sporadic subtype (Ferry, 2006) and even as low as 
5% in some studies (Zhou et al., 2019). A recent study found that there were a 
significantly higher number of mutations in the EBV+ cases, primarily endemic BL, 
but that they featured fewer driver mutations (Grande et al., 2019). This was 
attributed to a lower incidence of SMARCA4 and CCND3 mutations in EBV+ cases 
as well as fewer apoptosis-associated gene mutations, including TP53 and USP7. 
The authors of the study postulated that EBNA1 expression, driven by EBV+ 
infection, compensates for the anti-apoptotic signal that these mutations would 
provide. Non-coding mutations were identified at a significantly higher rate in EBV 
positive BL cases and this was shown to be associated with higher AID activity and 
aberrant somatic hypermutation (Grande et al., 2019). A more recent whole genome 
sequencing study of BL subtypes also observed a higher mutational load in EBV 
positive BL that was attributed to AID-associated mutations (Panea et al., 2019).  
 
FOXO1 is a commonly mutated gene in DLBCL (Trinh et al., 2013) and BL (Kabrani 
et al., 2018) but recent work in our lab has shown that the rate of mutation between 
endemic and sporadic subtypes are significantly different (Zhou et al., 2019). 
Mutations in FOXO1 are commonly found within a hotspot in the AKT recognition 
motif. However, mutations were found at different residues within the hotspot 
depending on the subtype.  
 
6.2 Chapter Aims 
 
The specific aims of the work detailed in this chapter were as follows: 
x Analyse copy number data from eBL and sBL cohorts to identify recurrent 
copy number analysis using integrative bioinformatics.  
x Evaluate the prognostic significance of recurrent abnormalities in the endemic 
cohort. 
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x Investigate TP53 abnormalities in eBL and compare findings with those in 








6.3.1 Patient cohorts and demographics 
 
Fine needle aspirates (FNA) from paediatric patients diagnosed at the Queen 
Elizabeth Central Hospital (QECH), Blantyre, Malawi were obtained and reviewed by 
pathologists at the Royal Victoria Infirmiary in Newcastle, UK. Of these, 245 were 
determined to be BL after diagnostic pathology was performed on cases with 
sufficient material. Affymetrix Oncoscan v2 MIP arrays were initially generated for a 
core set of 60 cases (Batch 1), with a second batch of 45 arrays generated to give a 
total of 105 cases with copy number data. Endemic BL patients were treated with one 
of four protocols described in Figure 6.2.  
 
 
Figure 6.2 - Treatment protocols used at frontline therapy for endemic BL patients 
treated at the Queen Elizabeth Central Hospital, Blantyre, Malawi. 
 
The addition of doxorubicin brought the existing endemic BL protocol closer to those 
used in the UK with superior overall survival and lower risk of relapse (Miles et al., 
2012). EBER status was known for 51/105 (48.6%) patients and all patients screened 
were EBV positive. EBER status was comprehensive for batch 1, with 51/60 (85.0%) 
patients screened. Data for Batch 2 was mostly unavailable; one case was screened 
and was found to be EBV positive.  
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The sporadic BL cohort analysed in this study involved all 75 BL cases acquired from 
the CCLG biobank that were analysed in chapters 4 and 5. An additional four 
samples were added from patients treated at the Great North Children s Hospital. 
DNA was extracted from viable cells. Three additional BL cases were identified from 
the CCLG cohort that did not have material available when the original copy number 
study was performed.  
 
6.3.2 Segmentation and Quality Control of Copy Number Data from SNP Arrays  
 
Copy number data from Oncoscan arrays for 105 eBL cases was analysed using 
Nexus Copy Number 10.0. Compared to Oncoscan array data generated from the 
sporadic CCLG cohort the data generated from Malawi cases had more intra-assay 
variability in log ratio values. There were 170 frequently seen copy number gains 
called by the segmentation algorithm that were recurrent in the cohort regardless of 
when the array was hybridised. The false positive segments of copy number gain 
were characterised by non-distinct breakpoints and no discernible change in the BAF 
track. The regions were identified manually, and a custom BED file was used to filter 
the region out of analysis within Nexus Copy Number 10.0 and GISTIC2.0.  
 
Waviness  in aCGH and copy number/SNP array data is a well-known occurrence 
and source of noise (Lepretre et al., 2010). Systematic correction performed using 
Nexus Copy Number 10.0 corrects for this array-specific pattern of noise. Despite 
this waviness was still observed in some regions for the majority of samples. This 
coincided with the majority of the additional regions of gain that were filtered out. 
Sporadic BL cases did not exhibit waviness or recurrent gains seen in the eBL 
cohort. Noise identified in sBL cases was characterised previously in chapter four, 
and the CNV filter file used in GISTIC2.0 analysis was re-used in this study.  
 
In endemic cases the mean number of copy number events and CNN-LOH events 
was 58.4 (range 0-331) and 0.8 (range 0-4) respectively. The mean number of copy 
number aberrations and CNN-LOH events in sporadic BL was 71.2 (range 0-761) 
and 1.6 (range 0-20) respectively. Segmented copy number data for both subtypes is 




Figure 6.3 - A heatmap showing segmented copy number data for 105 endemic and 
79 sporadic Burkitt Lymphoma. Blue denotes gain and red denotes loss.  
 
6.3.3 GISTIC2.0 Analysis of Significant Targets in Diagnostic eBL and sBL 
Samples 
 
GISTIC2.0 analysis was performed separately on 105 eBL and 79 sporadic BL 
patients to identify the most frequent copy number aberrations in both subtypes. 
CNN-LOH was also run through GISTIC2.0 to determine frequently affected 
chromosome arms which may be sites of recurrent driver mutations. Results for both 










cytoband Event q value 
residual q 
value wide peak boundaries 
3q29 Gain <0.0001 <0.0001 
chr3:195331537-
198022430 
1q21.1-1q21.3 Gain 0.035982 0.035982 
chr1:145734732-
150974161 
1q31.2-1q31.3 Gain 0.035982 0.035982 
chr1:191709542-
193922252 




22q13.31 Gain 0.035982 0.035982 chr22:41375250-44298893 
1p34.3 Gain 0.037794 0.037794 chr1:35085667-36767600 
5q12.3 Gain 0.037794 0.037794 chr5:64670271-66311589 
2q24.1-2q33.2 Gain 0.035982 0.039698 
chr2:155305838-
204450312 
9q34.3 Gain 0.050387 0.050387 
chr9:138189380-
139554402 
17q11.2 Gain 0.066473 0.066473 chr17:26880986-28944928 
13q31.1-13q32.2 Gain 0.07831 0.07831 chr13:86730661-98383041 
2p21 Gain 0.090581 0.090581 chr2:42651748-46242712 
3p21.2-3p21.1 Gain 0.091593 0.091593 chr3:51370934-52705478 
11q23.3-11q25 Loss <0.0001 <0.0001 
chr11:120850978-
135006516 
2p24.3-2p24.2 Loss <0.0001 <0.0001 chr2:15695921-16738751 
17p12 Loss <0.0001 <0.0001 chr17:10741335-11886863 
2q13-2q24.1 Loss 0.0049636 0.0049636 
chr2:114253448-
157186561 
18q21.31-18q23 Loss 0.0087277 0.0088288 chr18:55462713-78077248 
1q43-1q44 Loss 0.058405 0.058405 
chr1:241676066-
249250621 
13q12.3-13q31.1 Loss 0.058405 0.058405 chr13:30521044-86372843 
10p11.22-
10q23.31 Loss 0.068386 0.068386 chr10:33623137-91458197 
1p36.33-1p36.11 
CNN-
LOH <0.0001 <0.0001 chr1:1-25226220 
17q24.2-17q25.3 
CNN-
LOH 0.00010378 0.00010377 chr17:65042756-81195210 
Chromosome 1 
CNN-
LOH <0.0001 1 chr1:1-249250621 











cytoband Event q value 
residual q 
value wide peak boundaries 
13q31.3 Gain <0.0001 <0.0001 chr13:91686078-94356987 
1q23.1 Gain 0.0059876 0.0059876 
chr1:157410003-
157601372 
3q29 Gain 0.02211 0.02211 
chr3:195539955-
198022430 
9p21.3 Loss <0.0001 <0.0001 chr9:21860429-22448736 
13q33.3-13q34 Loss <0.0001 <0.0001 
chr13:108512716-
115169878 
3q13.31-3q13.32 Loss <0.0001 <0.0001 
chr3:116160574-
118627418 
2p22.2-2p16.3 Loss 0.00038927 0.00042946 chr2:36753571-50591528 
4q13.3-4q22.1 Loss 0.0015957 0.0015957 chr4:62351341-89645650 
1p36.12-1p36.11 Loss 0.0074315 0.0074164 chr1:23733994-23955103 
6q22.33-6q27 Loss 0.038012 0.04168 
chr6:129880109-
171115067 
6q13-6q21 Loss 0.044396 0.047302 chr6:73316478-109641966 
3q26.31-3q26.33 Loss 0.084724 0.079414 
chr3:175520336-
181332410 
1p36.33-1p34.3 CNN-LOH 0.0017775 0.0017775 chr1:704575-36603388 
Chromosome 17 CNN-LOH 0.0094264 0.0094264 chr17:1-81195210 
1q25.2-1q32.1 CNN-LOH 0.075857 0.075617 
chr1:179880905-
204174327 
Table 6.2 - Focal regions identified by GISTIC2.0 analysis in sBL. 
 
In total, 27 regions were identified in the eBL cohort by focal GISTIC2.0 analysis. 
After manual investigation of the regions, three were excluded for being likely 
noise/CNV regions: 17q11.2 gain, 8p23.2 gain and 15q11.2 loss (Figure 6.2A-B). A 
total of 35 regions were highlighted in the sBL cohort, which were reduced to 15 after 
manual checks (Figure 6.4A-B).   
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Figure 6.4 - GISTIC2.0 plots showing recurrent regions of (A) copy number gain and (B) deletion in eBL. 
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Figure 6.5 - GISTIC2.0 plots showing recurrent regions of (A) copy number gain and (B) deletion in sBL.The following regions were 
identified by GISTIC2.0 but were excluded after manual analysis: Two separate peaks of copy number gain at 14q32.33 and copy 
number loss at 1p32.1, 1p22.3, 2q31.1, 3p13, 5q31.1, 6p22.1, 7p15.2, 8q24.21, 10p21.31, 11p15.4, 11q24.3, 12p13.33, 12p13.2, 
12q13.13, 14q21.22, 14q32.33, 16p11.2 and 17q21.32.
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Regions of copy number gains were more prevalent in the eBL cohort (13/24 regions 
identified in eBL, 54.2% vs 3/15 regions identified in sBL 20.0%, p=0.049, Fisher 
exact test), while CNN-LOH was infrequently observed in both cohorts. Only three 
recurrent regions of focal copy number gain were observed in the sBL cohort; 





Figure 6.6 - Copy number aggregate plot showing the copy number profiles of sBL and eBL analysed by copy number array. Blue 
peaks denote copy number gain and red peaks denote copy number loss. 
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Figure 6.6 shows that the most frequently observed regions of copy number gain 
were on 1q and 3q29 in both cohorts (Table 6.1, Table 6.2, Figure 6.6). 1q gain is 
reported as the most frequent genomic aberration in BL after MYC rearrangement 
(Poirel et al., 2009) and the minimal common region was adjacent to the centromere 
in each subgroup. 24/105 (22.9%) eBL cases had gain of 1q compared to 35/79 
(44.3%) sBL cases (p=0.002, Fisher exact test) (Figure 6.6). In sBL the region most 
frequently gained was 1q23.1 while in eBL 1q21.1-1q21.3 was most prevalent. 3q29 
amplification was commonly seen in both cohorts (Figure 6.6) and represents a 
region of interest in paediatric B-NHL as a prognostic marker identified in Chapter 4. 
The minimal common region of gain on 3q29 was similar in both cohorts, involving to 
the telomere in both cases. Chromosome 13 gain involving the MIR17HG miRNA 
cluster at 13q31.3 was seen in both cohorts but was significantly more frequent in 
sBL (10/105, 9.5% eBL and 21/79, 26.6% sBL, p=0.003, Fisher exact test). The 
minimal common region of copy number gain at 13q31.3 was larger in the eBL cases 
at 11.7Mb compared to 2.7Mb in sBL. Loss of 6q frequently observed in sporadic BL 
but was seen in only one patient with eBL and additional copies of chromosome 12 
were almost exclusively seen in eBL. 17p deletion involving TP53 was present at a 
similar frequency in eBL and sBL (16/105, 15.2% eBL vs 12/79, 15.2% sBL, p=1, 
Fisher exact test).  
 
 
6.3.4 Abnormalities associated with disease progression in eBL 
 
Relapse was more common in endemic BL than sBL. 27 patients experienced 
relapse disease while 58 were known to not experience any progression. Outcome 
data was unavailable for 20 eBL cases. Risk of relapse (RR) analysis included only 
patients who completed front-line therapy and time to relapse was measured from 
date of diagnosis to date of relapse. Patients that did not have a documented relapse 
event but went on to die, either from disease or other causes, were excluded.  
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Table 6.3 - Clinical characteristics of sBL and eBL cohorts. ND= Not done. 
 
A copy number aggregate plot comparing the genomic profiles of cases that 
progressed and did not progress is shown in Figure 6.7. Abnormalities in regions 




sporadic BL endemic BL
Total Cases 79 105
Median Age at Diagnosis (range), years 8 (0-19) 7 (2-16)
Sex Male 61 (77.2%) 60 (57.1%)
Female 13 (16.5%) 43 (41.0%)
U 5 (6.3%) 2 (1.9%)
Tumour Stage                                      High (3 or 4) 46 (58.2%) 73 (69.5%)
Low (1 or 2) 8 (10.1%) 23 (21.9%)
U 25 (31.6%) 9 (8.6%)
CSF Involvement Y 2 (2.5%) 9 (8.6%)
N 50 (63.3%) 70 (66.7%)
U 27 (34.2%) 26 (24.8%)
BM Involvement Y 17 (21.5%) 11 (10.5%)
N 44 (55.7%) 59 (56.2%)
U 18 (10.1%) 35 (33.3%)
CNS Involvement Y 5 (6.3%) ND
N 53 (67.1%) -
U 21 (26.6%) -
EBV Positive Y 2 (2.5%) 51 (48.6%)
N 39 (49.4%) 0 (0.0%)
U 38 (48.1%) 54 (51.4%)
MYC  translocation Y 70 (88.6%) 105 (100.0%)
N 5 (6.3%) 0 (0.0%)
U 4 (5.1%) 0 (0.0%)
Treatment FAB/LMB 96 Protocol 62 (78.5%) -
Group A 2 (2.5%) -
Group B 42 (53.2%) -
Group C 13 (16.5%) -
Group unknown 22 (27.8%) -
Malawi 28 day protocol† - 88 (83.8%)
with doxorubicin - 76 (72.4%)
reduced protocol - 6 (5.7%)
No Treatment - 0 (0.0%)
U 17 (21.5%) 13 (12.4%)
Follow-up Number of cases with follow-up data 72 (91.1%) 85 (81.0%)
          Disease progression Relapse/refractory disease 16 (20.3%) 27 (25.7%)
4.8 (2.8-6.7) 5.3 (1.6-10.9)
          Overall survival Dead 15 (19.0%) 28 (26.7%)
Median time to death (range), months 5.3 (0.1-11.1) 3.8 (0-14.1)






Figure 6.7 - A copy number aggregate plot showing the copy number profile at diagnosis of cases with and without disease 
progression. Blue peaks denote copy number gain and red peaks denote copy number loss. 
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The most frequent abnormality observed at relapse was copy number gain of 1q21.2-
1q23.3, which is within a region identified by GISTIC2.0. The region was gained in 
9/27 (33.3%) of relapse cases and 7/58 (12.1%) in the non-progression group 
(p=0.034, Fisher exact test). 7q gain was also slightly more common in the poor 
outcome group with 3/27 cases (11.1%) compared to 2/58 (3.5%) in the group 
without events (p=0.321, Fisher exact test), although this was not statistically 
significant. This is noteworthy as cytogenetic analysis of the FAB/LMB96 trial cohort 
highlighted 7q gain as prognostic but it was not prognostic in the UK B-NHL cohort in 
this analysis (Poirel et al., 2009). Gain of chromosome 12 was only seen in cases 
without disease progression, present in 13.8% of this group. The disparity in 
incidence was not significant (p=0.051, Fisher exact test) but may highlight an 
important role for genes on chromosome 12 in disease progression and sensitivity to 
treatment.  
 
Chapter 4 highlighted three significant prognostic markers in paediatric B-NHL; 17p 
CNN-LOH, 17q CNN-LOH and gain of 3q29 and all three aberrations were observed 
in the eBL cohort. 17p CNN-LOH was significantly associated with relapse in the 
sporadic cohort while it was present in only 3.7% of relapse cases (1/27) in eBL and 
5.2% of cases without disease progression (3/58, p=1, Fisher exact test). It is 
noteworthy that 17p CNN-LOH was not associated with disease progression in eBL 
when it is a strong prognostic marker in a cohort consisting of primarily the sporadic 
subtype. This highlights the important of identifying subtype-specific prognostic 
markers and may refute the idea that prognostic markers in one BL subtype are 
applicable to others, as suggested by Panea et al. (2019).  
 
Conversely to 17p aberration, 17q CNN-LOH was more common in the relapse group 
of the eBL cohort, although this association with relapse was not significant (7/27, 
25.9% vs 7/58, 12.1% p=0.13, Fisher exact test). 17q CNN-LOH in the eBL cohort 
was most frequently affecting 17q23.1-17q25.3 and the telomere, overlapping the 
17q22-17q24.1 region seen in the sBL cohort and including the GNA13 gene, 
characterised in Chapter 4.  
 
3q29 gain was common in eBL as well as being a marker of poor outcome in sBL 
(HR 3.8 95% CI 1.1-13, p=0.041, Cox proportional hazard method). In contrast, gain 
 171 
at 3q29 was most common in the patients without disease progression (9/58, 15.5% 
vs 1/27, 3.7%, p=0.16, Fisher exact test). Only one relapse case had gain at 3q29 
itself, but there was a peak in five relapse cases with copy number gain involving 
BCL6 at 3q27.3-3q28. The hazard ratio of 3q29 gain in eBL was 0.26 (95% CI 0.035-
1.9, p=0.18, Cox proportional hazard method).  
 
 
6.3.5 Univariate survival analysis of genomic and clinical factors in eBL 
 
Univariate survival analysis was performed by Cox proportional hazards method on 
genomic markers identified in eBL. For the endemic cohort two survival metrics were 
utilised: overall survival (OS) and risk of relapse (RR). RR follow up was defined as 
the time from diagnosis to either last follow up or relapse event. RR was used instead 
of TTP to investigate genomic associations with relapse specifically as only patients 
who completed frontline therapy were included as part of RR analysis. Refractory 
disease was excluded from analysis. Survival estimates for the cohort at 12 months 
was 61.3% (CI 95% 50.9-73.9) for RR analysis and 64.3% (CI 95% 54.4-76.0) for OS 
(Figure 6.8A-B). There were 85 patients with sufficient data for RR analysis and 86 
with data to perform OS analysis. 
 
Figure 6.8 - Kaplan Meier plots showing (A) Risk of Relapse Survival and (B) Overall 
Survival for the eBL cohort. 
 
Focal regions identified by GISTIC2.0 in the eBL cohort were included as univariate 
factors as well as patient gender, the three prognostic markers identified in chapter 
four (17p CNN-LOH, 17q CNN-LOH and 3q29 gain) and gain of two genes of 
interest; MCL1 and FOXO1. MCL1 is a putative gene of interest in the gained region 
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of chromosome arm 1q and overexpression in B-NHL cell lines has been shown to 
exert resistance to multiple chemotherapeutic agents (Vrana et al., 2002). 
Amplification of MCL1 was a recurrent abnormality reported by Panea et al. (2019) 
associated with endemic BL. FOXO1 gain was commonly observed but segments of 
copy number gain covering the region were considered to be the result of noise and 
not considered a somatic event. Previous work in the lab has shown an important 
role for FOXO1 in eBL so this aberration was included in analysis (Zhou et al., 2019). 
As expected, prognostic markers identified in Chapter 4 3q29 gain, 17p CNN-LOH 
and 17q CNN-LOH were all significant at univariate analysis in this sporadic BL 
cohort (Table 6.4).  
 
Factor HR (95% CI for HR) p.value 
17q CNN-LOH 4.8 (1.5-15.0) 0.007 
17p CNN-LOH 3.6 (1.1-11.0) 0.029 
3q29 Gain 3.8 (1.1-13.0) 0.041 
Table 6.4 - Genomic abnormalities associated with prognosis in chapter four were 
significantly associated with a poorer time to progression by univariate survival 
analysis in the sporadic BL cohort. 
 
Three factors were identified to be significantly associated with higher risk of relapse 
by univariate survival analysis with a p value < 0.1; 17q11.2 gain, patient gender and 
MCL1 gain. Genomic abnormalities with prognostic value identified by univariate Cox 
Proportional Hazard modelling are summarised in Table 6.5. Prognostic markers 
where p<0.1 in univariate survival analysis were taken forward for multivariate 
modelling.  
 
Factor HR (95% CI for HR) p value 
17q11.2 Gain 3.1 (1.1-9) 0.038 
Gender (F) 3.4 (1.2-9.5) 0.088 
MCL1 Gain 2 (0.88-4.6) 0.097 
Table 6.5 - Significant factors by univariate survival analysis in the eBL cohort. 
 
Patient gender was shown to be associated with relapse in the eBL cohort, with 
female patients having the highest risk of relapse (Figure 6.9A). The gender was not 
prognostic in itself, but the p value was below the threshold (detailed in Chapter 




Figure 6.9 - Kaplan Meier plots showing (A) Risk of Relapse Survival (p=0.083, Log 
rank test) and (B) Overall Survival (p=0.420, Log rank test) for gender. 
 
Of 105 patients in the cohort, 58 patients were male and 47 were female and the 
hazard ratio for female patients was 3.4 (CI 95% 1.2-9.5, p=0.088, Cox proportional 
hazard method). This suggests that patient gender is not a significant prognostic 
marker but may improve a multivariate model. The separation of Kaplan Meier curves 
suggests that any prognostic value of patient gender is small and the correlation was 
not seen in OS analysis (Figure 6.9B).  
 
17q11.2 gain was observed infrequently in the cohort (6/105, 5.7%) but was 
associated with a significantly higher risk of relapse with a HR 3.1 (CI 95% 1.1-9, 
p=0.038, Cox proportional hazard method). The region involved 52 genes and was 
2.1Mb in size. Of the six patients with copy number gain of this region, four relapsed 





Figure 6.10 - Kaplan Meier plots showing (A) Risk of Relapse Survival (p=0.029, Log 
rank test) and (B) Overall Survival (p=0.310, Log rank test) for 17q11.2 gain.  
 
The region of gain at 17q11.2 identified by GISTIC2.0 and significant by univariate 
survival analysis covered 52 genes (Figure 6.11). Gene ontology analysis using Kegg 
Pathway Mapper (Kanehisa et al., 2019) highlighted the MIR451A tumour suppressor 
gene, which has been implicated in drug resistance in breast cancer. The relevance 
of copy number gain of this gene in eBL is unclear. The TRAF4 gene was also 
gained in these samples and is known to drive metastasis in breast cancer through 
TGF-  signalling (Zhang et al., 2013).  
 
 
Figure 6.11  A copy number plot showing copy number gain of 17q11.2 in eBL. Blue 
denotes copy number gain and red denotes copy number loss. 
 
MCL1 gain on cytoband 1q21.3 was recurrently seen in both sBL and eBL as part of 
larger 1q copy number gains and was present in the second most significant region 
of amplification identified by GISTIC2.0. Gain of the gene itself was associated with a 
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higher risk of relapse in the eBL cohort with a HR of 2.0 (CI 95% 0.88-4.6, p=0.097, 
Cox proportional hazard method), but similarly to gender, this may only be significant 
in the context of a multivariate model (Figure 6.12A-B).  
 
 
Figure 6.12  Kaplan Meier plots showing (A) Risk of Relapse Survival. (p=0.090, 
Log rank test) and (B) Overall Survival (p=0.690, Log rank test) for MCL1 gain.  
 
The MCL1 gene is well-studied in B-NHL and has been shown to be important in 
sensitivity and resistance to therapy (Vrana et al., 2002). Previous studies have 
shown that loss of MCL1 in B-NHL cell lines results in sensitivity to BCL2 inhibitor 
Venetoclax (Phillips et al., 2015). MCL1 was gained in 21.0% of the eBL. Patterns of 




Figure 6.13 - A copy number plot showing copy number gains involving the MCL1 




Univariate analysis was repeated on a subset of the eBL cohort treated more 
uniformly on the NL3 protocol with doxorubicin to confirm whether these markers 
were still prognostic in a cohort treated using current treatment protocols (Appendix 
G). In 71/76 (93.4%) patients treated with the NL3 protocol, RR analysis identified 
gender as the only significant marker of higher risk of relapse with the HR of female 
patients as 3.4 (CI 95% 1.2-9.5, p=0.021, Cox proportional hazard method). In 
contrast, MCL1 gain and 17q11.2 gain were not associated with RR in patients 
uniformly treated on NL3 protocols (p=0.67 and 0.14 respectively, Fisher exact test).  
 
 
6.3.6 Multivariate survival analysis 
 
Multivariate analysis was performed on the whole eBL cohort regardless of treatment 
protocols using factors with a p value of 0.1 or less by univariate survival analysis of 
eBL patients; gender, 17q11.2 gain and MCL1 gain (Table 6.5). These factors were 
included as they were significant at p<0.1 by univariate analysis. Model fit 1 (gender 
and 17q11.2 gain) was compared against model fit 2 (17q11.2 gain and MCL1 gain). 
Model 2 had a more significant likelihood ratio test p value at p=0.01 compared to 
p=0.03, meaning that it was the better model. Adding gender to the model to create 
model 3 improved the likelihood ratio p value to p=0.007 (Table 6.6).  
 
Covariate Hazard ratio (95% CI) p value 
17q11.2 Gain 1.24 (1.15-10.40) 0.027 
MCL1 Gain 1.00 (1.15-6.51) 0.023 
Gender (F) 0.76 (0.97-4.72) 0.058 
Table 6.6 - Cox proportional hazard multivariate model 4 in eBL patients. 
 
Comparing the models with using the likelihood ratio test also suggested that model 
3 may have been a better than model 2, although the p value was not significant 
(p=0.052).  
 
6.3.7 TP53 abnormalities in eBL 
 
The TP53 status of BL was determined to be the most important genomic factor in 
predicting and driving relapse in paediatric B-NHL and specifically sporadic BL in 
Chapter 5. The effect of TP53 abnormalities on outcome in the endemic subtype is 
less well understood. A study by Grande et al. (2019) showed that TP53 mutations 
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were less frequent in EBV positive BL cases compared to EBV negative BL, but no 
study has investigated TP53 aberrations in the context of patient outcome or relapse.  
 
17p deletion involving TP53 was observed at similar incidences in both subtypes 
(12/79, 15.2% sBL and 16/105, 15.2% eBL, p=1, Fisher exact test). In contrast, 17p 
CNN-LOH affected 10.1% (8/79) of sBL patient samples and 3.8% (4/105) of eBL 
(p=0.130, Fisher exact test). In the sporadic cohort 17p CNN-LOH was associated 
with an inferior time to progression (HR 3.6 95% CI 1.1-11.0, p=0.029, Cox 
proportional hazard method). The hazard ratio in the eBL cohort was not calculable, 
as there were too few cases in the relapse group.  
 
Work performed in parallel to this project by Dr Peixun Zhou using Sanger 
sequencing had characterised the TP53 gene mutations in the cohort for 101/105 
cases (96.2%). In total, 40 mutations were identified in 37/101 diagnostic samples 
screened (36.6%) and 3/37 samples had a second mutation. By Sanger sequencing 
it was not possible to determine whether two mutations in a sample were on the 
same allele. However, the assumption was made that this was the case given the 
evidence observed in the sporadic cohort in Chapter 5, where two cases were shown 
to have compound heterozygous mutations in TP53. The TP53 mutation status was 
known for 70/79 sBL cases, with 42/70 (60.0%) harbouring at least one mutation, and 
7/42 having two mutations, totalling 49 mutations identified. Of these, two were 
R213R silent mutations and the remainder were missense mutation. The locations of 




Figure 6.14 - A lollipop plot showing TP53 mutations identified in eBL and sBL. 
 
 
The incidence of TP53 mutation was significantly higher in the sporadic cohort 
(42/70, 60.0% vs 37/101, 36.3%, p=0.003, Fisher exact test) which was consistent 
with the findings of both the Grande et al. (2019) and Panea et al. (2019) studies. In 
sBL the most common mutations were R175H, G245S, R248Q and variants at 
R273.While all four were observed in the eBL cohort, G245 mutation was only seen 
in one case, with a different amino acid change to those seen in the sporadic cohort. 
The most frequently mutated residue in the eBL cohort was Y234, which was not 
seen in any sporadic patients. Y234 mutations were found in the IARC TP53 
database and reported to give rise to non-functional p53 protein (Petitjean et al., 
2007). Other mutations in surrounding residues were seen infrequently between 
amino acids 231 and 240 in the eBL cohort, but the area did not harbour mutations in 
the sporadic cohort.  
 
Integrating this data with the array data to take 17p deletion and CNN-LOH into 
account allowed for investigation into the clinical relevance of biallelic and 
monoallelic TP53 aberrations in eBL compared to sBL. In total, 47/101 (46.5%) eBL 
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patients had TP53 aberrations, with 35 (34.7%) having only one monoallelic 
abnormality and 12 (11.9%) having biallelic aberrations. 54/101 (53.5%) cases had 
no detectable TP53 aberrations. Of those with monoallelic aberrations 25/35 (71.4%) 
had a single mutation and 10/35 (28.6%) had deletion without mutation. Of the 
biallelic cases, 4/12 (33.3%) had a single mutation and with CNN-LOH, 6/12 (50.0%) 
had hemizygous mutations alongside 17p deletion. A further two biallelic cases 
harboured two mutations which were considered to be compound heterozygous. In 
the sporadic cohort 44/70 (62.9%) had at least one TP53 aberration, with 23/44 
(52.3%) having only one monoallelic aberration and 21/44 (47.7%) harbouring 
biallelic abnormalities of the TP53 gene. TP53 abnormal cases were significantly less 
frequent in eBL compared to sBL (47/101, 46.5% vs 44/70, 62.9% p=0.043, Fisher 
exact test).  
 
Biallelic aberration of the TP53 gene was relatively infrequent in the eBL cohort 
compared to the sBL group (12/101, 11.9% vs 21/70, 30%; p=0.005, Fisher exact 
test). In contrast, 23/70 (32.9%) sporadic patients had monoallelic abnormalities 
which was consistent between cohorts (35/101, 34.7% vs 23/70, 32.9%, p=1, Fisher 
exact test). The presence of any TP53 aberration was not associated with risk of 
relapse or overall survival in eBL by Cox Proportional Hazards modelling (RR HR 1.1 
95% CI 0.5-2.3, p=0.89, OS HR 1.1 95% CI 0.5-2.3, p=0.81, Cox proportional hazard 
method) (Figure 6.15A-B).  
 
 
Figure 6.15 - Kaplan Meier plots showing the (A) Risk of Relapse (p=0.89, Log rank 
test) and (B) Overall Survival (p=0.82, Log rank test) analysis for eBL patients with 
TP53 abnormalities.  
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Biallelic or monoallelic status were also not associated with an inferior risk of relapse 
when compared against patients without any TP53 aberrations (Biallelic RR HR 1.1 
95% CI 0.3-4.0, p=0.84, Monoallelic RR HR 1.0 95% CI 0.5-2.4, p=0.93, Cox 
proportional hazard method). Despite this, it was shown by OS analysis that TP53 
biallelic cases eBL do worse than both monoallelic and TP53 normal subgroups (HR 
2.3 (95% CI 0.9-6.0), p=0.098, Cox proportional hazard method) (Figure 6.16).  
 
 
Figure 6.16 - Kaplan Meier plots showing the (A) Risk of Relapse (Biallelic vs Normal 
p=0.842, Biallelic vs Monoallelic p=0.875, Monoallelic vs Normal p=0.932, Log rank 
test) and (B) Overall Survival (Biallelic vs Normal p=0.089, Biallelic vs Monoallelic 
p=0.043, Monoallelic vs Normal p=0.590, Log rank test) analysis for eBL patients 
with monoallelic, biallelic and normal TP53 status. 
 
The association was not significant when comparing biallelic cases against TP53 
normal cases, but it was significant when comparing the biallelic patients against the 
rest of the cohort, including monoallelic and normal cases (HR 2.5 95% CI 1.0-6.2, 
p=0.048, Cox proportional hazard method). Comparing the impact of TP53 
abnormalities on outcome in the endemic and sporadic subgroups showed that the 
presence of TP53 biallelic aberrations in eBL does not predict relapse disease in the 
endemic setting but that regardless of relapse status, these patients were more likely 
to die of disease. This is in contrast to sBL where biallelic TP53 status was shown to 
be a potential prognostic marker for disease progression but was not associated with 




Figure 6.17 - Kaplan Meier plots showing the (A) Time to progression (Biallelic vs 
Normal p=0.014, Biallelic vs Monoallelic p=0.133, Monoallelic vs Normal p=0.266, 
Log rank test) and (B) Overall Survival (Biallelic vs Normal p=0.208, Biallelic vs 
Monoallelic p=0.843, Monoallelic vs Normal p=0.183, Log rank test) analysis for 
sporadic BL patients with monoallelic, biallelic and normal TP53 status. 
 
6.3.8 Copy Number Aberrations associated with TP53 status in eBL 
 
Copy number profiles for eBL patients with TP53 abnormalities were compared with 
the profiles of patients with normal TP53 (Figure 6.18) and statistical analysis 





Figure 6.18 - Copy number aggregate plot showing the copy number profiles of eBL patients both with and without TP53 
abnormalities. Blue peaks denote copy number gain and red peaks denote copy number loss. 
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Two regions identified by GISTIC2.0 analysis in the eBL cohort were significantly 
associated with TP53 status. The 11.7Mb region spanning 13q31.1 to 13q32.2 was 
significantly associated with TP53 abnormality (8/47, 17.0% vs 2/54, 3.7%; p=0.04, 
Fisher exact test). This correlates with the finding that MIR17HG amplification and 
13qplex pattern were associated with TP53 aberration in sBL in chapter 5. 
Additionally, focal 1q31.2-1q31.3 gain was recurrent in the TP53 normal group. 
Larger 1q gains were also more common in the TP53 normal group (12/54, 22.2% vs 
4/47, 8.5%; p=0.1, Fisher exact test). Gain of 7q most commonly occurred in the 
TP53 normal group (6/54, 11.1% vs 1/47, 2.1%; p=0.12, Fisher exact test). While 
these abnormalities were not significantly associated with TP53 status, there was a 
clear association between both 1q and 7q gain with TP53 in eBL which should be 






Analysis performed in this chapter determined that TP53 aberrations were markedly 
less common in endemic BL when compared to sporadic BL, which supports the 
hypothesis that TP53 abnormality plays a diminished role in endemic BL. This is 
further supported by the lack of association between TP53 status and relapse in the 
eBL cohort, in contrast to sporadic BL. EBV infection in BL is known to inhibit MYC-
driven pro-apoptotic signals, including p53-mediated apoptosis. EBNA3C nuclear 
antigen coded for by the EBV genome acts to inhibit p53 function, including p53-
mediated apoptosis via interaction with and stabilisation of ING4, ING5 and MDM2 
protein (Saha et al., 2009). Considering this in the context of the findings of our 
study, it is possible that TP53 aberrations are largely redundant in EBV positive BL, 
with p53 function abrogated through viral mediated mechanisms (Fitzsimmons and 
Kelly, 2017). It is remarkable that patients with biallelic TP53 abnormalities had a 
significantly worse overall survival, suggesting that even in the presence of EBV 
infection TP53 plays an important role in chemotherapy resistance.  The poor 
outcome for these patients is to be expected, as a course of intensive chemotherapy 
in the form of FAB/LMB96 protocols with extensive supportive care is insufficient to 
treat this subgroup of TP53 biallelic cancers, as demonstrated by analysis in Chapter 
5. Whole genome and transcriptomic characterisation of these patients from both 
patients would allow for a better understanding of the prognostic role of TP53 and 
determine whether TP53 biallelic subgroup of eBL with a poorer overall survival 
resemble the cases seen in the sporadic cohort that undergo disease progression. 
 
This study investigated the genomic profiles of 105 eBL patients with copy number 
array data. Recurrent abnormalities involving 1q, 7q and 13q were consistent with 
what was previously identified in sporadic B-NHL cases in chapter 4, and specifically 
sBL in this chapter. Copy number analysis also highlighted regions which were 
associated more strongly with a subtype. For example, 6q loss was recurrent in sBL 
but almost entirely absent in the eBL cohort. Conversely, gain of chromosome 12 
was common in the eBL cohort but seen in only one sBL patient. As would be 
expected, the genomic aberrations linked to poor outcome in eBL differed to those 
identified in sBL. None of the three prognostic markers identified in sporadic BL or 
the larger sporadic B-NHL cohort were shown to be prognostic in the endemic cohort.  
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Underlying biological differences associated with EBV infection may also explain the 
disparity of prognostic markers between disease subtypes. There is evidence that, in 
BL, EBV infection promotes genomic instability, including the occurrence of complex 
chromosomal rearrangements similar to those observed in cases with TP53 
aberrations in the sporadic cohort in Chapter 5 (Kamranvar et al., 2007). Genomic 
complexity in the sporadic B-NHL cohort (Chapter 5) was not itself associated with 
poorer outcome, so even if EBV and TP53 aberration play complementary roles in 
driving genomic instability, this may not fully explain the difference in outcome 
between cohorts. 
 
Treatment of endemic Burkitt lymphoma is a significant clinical challenge and an 
important focus for the field of B-NHL research. A combination of a lack of large 
cohort genomic studies into eBL, a reduced capacity for high-intensity chemotherapy 
and unique socioeconomic variables creates a complex clinical problem. Survival 
rates have been increasing steadily over recent years, particularly after the 
introduction of doxorubicin to treatment protocols in Malawi for stage III and IV 
disease (Molyneux et al., 2017). Despite this, rates of survival have fallen short of the 
results seen in sporadic BL in the UK. A recent study was undertaken to determine 
the feasibilit  of eBL being treated with standard chemotherap  in a resource 
constrained setting, with greater efforts made to provide supportive care and 
medication to counteract side effects of the chemotherapy, reduce malnutrition in 
patients and supported patients in transportation to reduce abscondment (McGoldrick 
et al., 2019). While supportive care was successfully administered to paediatric 
patients receiving treatment with intense chemotherapy, 4-year OS for the cohort 
remained low at 44%. Unless paediatric eBL can be successfully treated using 
intense FAB/LMB-based protocols then there will be a clinical need for prognostic 
markers specific to eBL. 
 
 
3q29 was the most significantly gained region identified by GISTIC2.0 analysis of the 
genome in endemic BL in this analysis. The aberration also had no impact on 
prognosis, despite being identified as a strong predictor of inferior time to progression 
and lower overall survival in sporadic B-NHL in chapter 4. The region of gain seen in 
each subtype were comparable in size and both involved the 3q telomere. The 
presence of the aberration in both cohorts suggests that 3q29 gain is important in a 
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pathway or process common to BL subtypes. Scholtysik et al. (2010) suggested that 
copy number gains involving the 3q telomere in their cohort were likely driving BCL6 
expression which is located at 3q27.3. However the majority of 3q29-gained cases in 
both cohorts associated with this analysis, as well as in the analysis in Chapter 4, did 
not involve copy number gain of this gene. Elucidation of a driver gene within this 
region will pave the way for better understanding of universal BL biology and the 
nature of treatment resistance in different subtypes. 17q CNN-LOH was also 
recurrent in eBL but shown not to be associated with progression or death in the 
endemic setting.  
 
A major drawback of investigating the role of TP53 and other genomic markers in 
disease progression and patient outcome is the analysis of diagnostic samples alone. 
Tumours evolve with time and treatment plays a key role in providing selection 
pressures for development of the tumour. TP53 status at diagnosis may not be 
maintained at the point of disease progression. It is entirely feasible that endemic BL 
cases with no detectable TP53 mutation, loss or CNN-LOH may acquire additional 
aberrations involving the gene which change the clonal makeup of the tumour, 
spurring therapy resistance. In Chapter 7 a panel of B-NHL patients with paired 
diagnostic and relapse material is analysed to further investigate this question. Four 
of these patients were sporadic BL cases from the TP53 biallelic high-risk subgroup 
investigated in this chapter as well as Chapter 5. Copy number analysis of these 
patients as their chemotherapy-resistant disease progresses will increase our 












The genetic landscape of disease progression in paediatric B-NHL is poorly 
understood. The lack of understanding and research into the mechanisms of disease 
progression in paediatric B-NHL is primarily due to a lack of usable sequential 
biopsies available for research. Even when a diagnostic biopsy is banked from a 
case who goes on to relapse it is still often uncommon for the sequential biopsy or 
biopsies to be banked. The clinical team generally take minimal tissue at biopsies of 
progressive disease leaving very little to be banked for research purposes. In this 
study material was acquired for 11 B-NHL patients at diagnosis and relapse.  
 
Studies into the clonal evolution of DLBCL by VDJ sequencing identified two distinct 
patterns of relapse (Jiang et al., 2014). A pattern of early-divergent or branching  
evolution involving two distinct clones at diagnosis and relapse with a common 
ancestor arising early in disease development according to phylogenetic analysis of 
somatic hypermutation (SHM) data (Figure 7.1A), and a second pattern of late 
divergent linear  evolution, where the diagnostic and relapse major clones closel  





Figure 7.1  Visual representation of two patterns of disease progression and tumour 
evolution in DLBCL. (A) The Early-divergent scenario involves two clones that have a 
shared ancestor but do not strongly resemble each other. (B) The Late-divergent 
scenario shows a major clone at relapse which shares many features with the 
diagnostic major clone. From Jiang et al. (2014). 
 
Comparison of the mutational distance between diagnostic and relapse clones 
revealed that tumours with the early-divergent model of progression had significantly 
higher rates of SHM at relapse compared to diagnosis. There was no association 
between DLBCL subtype and pattern of evolution, although GCB-like DLBCL patients 
did relapse significantly later than ABC-like DLBCL patients (Jiang et al., 2014). A 
later study of 20 DLBCL diagnostic and relapse pairs successfully determined the 
evolutionary pattern of 18/20 pairs from copy number array data (Juskevicius et al., 
2016). Characterisation of genetic determinants of evolutionary pattern may offer 
new targets for therapy.  
 
The most significant study of disease progression and evolution in sequential BL 
samples investigated 6 paediatric and 1 adult cases with karyotyping data (Aukema 
et al., 2015). The major findings were that samples taken at the point of disease 
progression had significantly more complex karyotypes and that BL cases progress 
in a linear/late-branching pattern of evolution. A later study of relapsed/refractory 
DLBCL pairs postulated that late-divergence is a strategy of tumour survival in 
response to the selection pressure of therapy (Juskevicius et al., 2017) and as such 
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is not a pre-existing feature of the tumour but is acquired rapidly during treatment, 
regardless of B-NHL subtype. This would preclude the relevance of prognostic 
markers, as by this definition the genomic driver of chemotherapy resistance would 
not be present at diagnosis. The prognostic markers identified as part of Chapters 4 
and 5 were significant in a large cohort of patients, particularly in BL cases. This is 
significant, considering that Aukema et al. (2015) report that over 80% of BL 
relapse/refractory cases exhibited a late-branching/linear pattern of evolution. The 
fact that TP53 aberration, as well as 3q29 copy number gain and 17q CNN-LOH 
were significant, independent prognostic markers is incompatible with the concept of 
late acquisition of genomic aberrations driving treatment resistance in BL. One 
possible explanation for this is that prognostic markers identified at diagnosis in our 
cohort represent enabling events that predispose the tumour to further evolution 
through genomic instability, evidence for which is provided in Chapter 5.    
 
In Chapter 4, the largest clinically annotated cohort of paediatric B-NHL patients with 
copy number data was analysed to identify genomic markers of prognosis. Besides 
MYC rearrangements, all copy number abnormalities that were detected were 
present in a relatively small numbers of cases (<30%) and only three abnormalities 
were found to be prognostic in the sporadic cohort. Conversely, in Chapter 5 we 
showed that aberrations of the TP53 gene, including mutations, were present in over 
50% of cases, and were significantly associated with poor outcome. This suggests 
that the vast majority of copy number aberrations in paediatric B-NHL may be 
passenger abnormalities that do not play a vital role in maintenance of the 
malignancy or drive disease progression in poor outcome cases.  
 
In Chapter 6 it was reported that in endemic BL TP53 aberrations had a less 
significant impact in outcome. While TP53 biallelic aberrations were significantly 
associated with poor outcome, there was no association between abnormalities 
involving TP53 and relapse. The most likely explanation for this is the different 
treatment received by each cohort.  
 
It is important to investigate the genomic profile of tumours throughout cancer 
development and progression in order to identify the aberrations present at diagnosis 
which are driving the disease. Tracking these abnormalities in matched diagnostic 
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and relapse samples will identify those that persist at the point of disease 
progression to determine which abnormalities confer chemoresistance to the cancer.  
 
Despite over 90% of paediatric BL and DLBCL cases being successfully cured at 
frontline treatment without high rates of relapse, it is hypothesised that driver 
aberrations are present at the point of diagnosis that allow the lymphoma to survive 
treatment in the small number of cases who relapse or have refractory disease. For 
this reason, it is important to compare multiple samples both before and after 
treatment where possible. In CLL it has been shown that TP53 abnormalities at 
diagnosis are prognostic markers of disease progression and are actively selected 
for during chemotherapy in longitudinal studies of sequential biopsies from the same 
patient. These subclones with TP53 aberrations were shown present at diagnosis 
and arose before treatment was administered (Malcikova et al., 2015). Analysis of 
subclones showed that patients with small TP53 abnormal clones had the same 
inferior outcome as those with major TP53 aberrant clones at diagnosis (Rossi et al., 
2014). In CLL patients with subclonal TP53 aberrant populations at diagnosis that 
subclone expanded after treatment with conventional chemotherapy. Current 
knowledge of clonal expansion in B-NHL is limited with no sequencing- or array-
based studies conducted on paediatric B-NHL or BL.  
 
7.2 Chapter Aims 
 
The specific aims of the work detailed in this chapter were as follows: 
x Compare the genomic landscape of relapsed/refractory paediatric B-NHL in 
both pre-treatment and post-treatment biopsies and track changes in profiles 
between both samples.  
x Investigate the pattern of clonal evolution exhibited in disease progression in 
paediatric B-NHL.  
x Determine whether genomic abnormalities are associated with patterns of 





7.3.1 Patient Cohort 
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A total of 11 diagnostic and relapse pairs were analysed in this study. Nine patients 
from the CCLG cohort who experienced relapsed/refractory disease for whom there 
were both diagnostic and relapse biopsies available via the CCLG biobank. Seven 
CCLG cases were diagnosed BL and diagnosed were DLBCL. One DLBCL case 
harboured an IGH-MYC translocation while the other did not. Two additional cases 
were obtained from the Queen Elizabeth Central Hospital in Blantyre, Malawi. One of 
these cases was diagnosed BL and was analysed as part of the eBL cohort in 
Chapter 6, while the other was considered to be a HGBL, NOS case in line with the 
WHO 2016 classification (Swerdlow et al., 2016).  
 
In sBL, 4/7 relapse cases died of disease and three were alive at last follow up of 
17.3, 123.1 and 45.7 months respectively (Figure 7.2). All four BL patients that died 
did so within 12 months of initial diagnosis at 7.1, 5.3, 11.1 and 11.1 months 
respectively. Of the two DLBCL cases one died of disease at 17.1 months after 
diagnosis while the other was still alive at 36 months.  
 
 
Figure 7.2 - A Forest plot displaying the clinical course for 11 relapsed/refractory B-
NHL patients with copy number array data generated from paired diagnostic and 
sequential progressive sample. 
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Both DLBCL relapses occurred later than any sBL relapse and death occurred later 
after relapse than in sBL (relapse at 8.2 and 7.7 months, death at 17.1 months after 
diagnosis). Both endemic patients relapsed quickly (2.3 and 4.3 months) and death 
occurred in both cases rapidly thereafter (1.1 months later and 0.5 months later 
respectively). 
 
7.3.2 Sporadic Burkitt lymphoma pair 1 - 10/10065 
 
Case 10/10065 from the CCLG cohort was diagnosed as stage III BL at presentation 
with an IGH/MYC translocation confirmed by FISH. The 1-year old patient was male 
was treated on the Inter B-NHL trial with a FAB/LMB96 protocol in group B and 
rituximab. At the end of frontline therapy, a thymic cyst was biopsied. Relapse was 
confirmed within one month of remission, and the patient was alive and disease free 
at last follow up 17 months after diagnosis (Figure 7.2). The patient had gain of 1q, 
telomeric deletion of 6q, gain of the 16q telomere and deletion of 17p at diagnosis, as 
well as CNN-LOH affecting 1p (Figure 7.3). All copy number abnormalities identified 
in the diagnostic sample were present at relapse. 
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Figure 7.3 - Copy number profile of sporadic BL patient 10/10065 at diagnosis and 
relapse. Summary of segmented copy number aberrations at (A) diagnosis and (B) 
relapse. Processed log ratio data and B-allele frequency data for both (C) diagnostic 
and (D) relapse samples. 
 
A gain on chromosome 1 is maintained from diagnosis to relapse (Figure 7.3A-B), 





Figure 7.4 - ID3 deletion on 1p was identified in patient samples from 10/10065 at 
both diagnosis and relapse. 
 
The breakpoint of 1q gain differed between samples, with a median lower log ratio at 
diagnosis suggesting a smaller population of cells harboured the aberration but 
spanning more of the 1q arm. 1q gain at relapse had a higher log ratio suggesting 
that the abnormality is present in a larger proportion of subclones within the relapse 
sample and the B-allele frequency plot showed a stronger separation of the central 
track which supports this suggestion (Figure 7.3C-D).  
 
The relapse sample has a loss at 3q13.31 with 3 distinct steps involving the genes 
TUSC7, LINC00903, LSAMP (and LSAMP-AS1), MIR4447 and LINC00901. The log 
ratio was -1.1 at the lowest point within the segment, strongly suggesting that the 
loss occurred in more than one subclonal population and that both copies were 
deleted in the majority of the tumour (Figure 7.5). The deletion of the TUSC7 gene 




Figure 7.5 - Homozygous TUSC7 deletion at 3q13.31 was identified in the relapse 
sample from 10/10065 only. 
 
Gain of 7q was observed in the relapse sample and not the diagnostic sample. 7q 
gain is common in B-NHL and has previously been considered a putative prognostic 
marker in the paediatric setting, however not in an analysis of 162 cases in chapter 4. 
The region gained stretched from 7q11.23 to the 7q telomere, involving the majority 
of the arm (Figure 7.6). There was no evidence of the abnormality being present at 
diagnosis, even in a small subpopulation. However, the sensitivity of copy number 
arrays is not sufficient to completely rule out presence of the abnormality in a very 
small subclonal population. Both samples had gains on 16q which had identical 
breakpoints and similar log ratio values between timepoints which suggests this 




Figure 7.6 - 7q gain was acquired at relapse in patient 10/10065 but was absent at 
diagnosis. 
 
The diagnostic sample of this BL patient had a heterozygous 17p deletion involving 
the whole arm. The arm was still deleted at the time of relapse, but a complex pattern 
of gain and loss was observed at the 17p centromeric region. TP53 was still deleted 
despite this new pattern of copy number change arising. This event was not seen at 
diagnosis, even at low levels. There was no karyotyping data or 
constitutional/matched normal DNA sample meaning that it was not possible to 
screen for rearrangements with other chromosomes.  
 
Given the early relapse experienced by this patient, it was assumed that there was 
not ample opportunity for extensive tumour evolution and for diverse subclonal 
populations to arise which would explain the overall consistency in genomic profiles 
between diagnosis and relapse. Specific copy number aberrations were seen that 
showed the genomic profile changed at relapse, suggesting that these abnormalities 
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were beneficial to the tumour while being treated with intensive chemotherapy. 
Numerous candidate genes reside on chromosome arm 7q which may confer the 
survival advantage to the subclone. Deletion of the TUSC7 gene itself is a candidate 
tumour suppressor gene that requires further investigation. 
 
7.3.3 Sporadic Burkitt lymphoma pair 2 – 16/818 
 
Patient 16/818 was a 3-year-old female diagnosed with BL in the pelvis and 
abdomen. The malignancy was IGH-MYC positive by FISH but tumour stage and 
other clinical factors were unknown due lost clinical notes. The patient underwent an 
early relapse at four months after diagnosis and died of disease three months after 
relapse. The diagnostic sample had a quiet genome with deletions of the 1p telomere 
and 17p as the only large aberrations. At relapse both deletions were maintained, 
and multiple other copy number abnormalities were acquired. Copy number gain of 
3q, the 8q telomere and chromosome 12 were observed at relapse. Two complex 
chromosomal aberrations involving 17q and 18q were also acquired. There was no 
evidence from the copy number array data that acquired aberrations were present in 
a subclonal population of the diagnostic sample. Oncoscan array data for the relapse 
sample was noisy meaning that some allelic calls were unclear during analysis, 
however copy number changes could be confidently called (Figure 7.7).  
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Figure 7.7 - Copy number profile of sporadic BL patient 16/818 at diagnosis and 
relapse. Summary of copy number aberrations at (A) diagnosis and (B) relapse. 
Processed log ratio data and B-allele frequency data for both (C) diagnostic and (D) 
relapse samples.  
 
 
An 8.1Mb deletion of the 1p telomere was observed at diagnosis and maintained at 
relapse. The log ratio was consistently -0.69 in both samples suggesting now 
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expansion or contraction of the abnormality and that it was likely present in the clonal 
population in each case. It is likely this aberration, that involved deletion of TP73, 
occurred early on in lymphoma development. The relapse case exhibited copy 
number gain of the majority of chromosome 3 involving all of 3q and the centromeric 
region of 3p. The log ratio was 0.31 and copy number gain was not seen at all in the 
diagnostic sample. The region involved 3q29 which was shown to be a prognostic 
marker associated with relapse in chapter 4. There was no focal amplification in this 
region suggesting a candidate gene.  
 
A region 33.6Mb on 8q toward the telomere stretching from 8q23.3-8q24.3 was 
gained in the relapse sample. Within this region of copy number gain was a smaller 
region with a higher copy number containing 27 genes in a 5.2Mb region at 8q24.21-
8q24.22. This segment of copy number gain can be seen in a small upward shift in 
the log ratio in the diagnostic, but below the threshold for the segmentation algorithm 
to call. This supports the likelihood that a gene in this region was beneficial to 
lymphoma survival in this patient and that tumour cells with this aberration survived 
frontline chemotherapy. It is also possible that these cells had a different 
chemoresistance-inducing genetic alterations and that 8q gain was just a passenger 
aberration.  
 
Chromosome arm 17p was lost at diagnosis and this deletion was maintained at 
relapse. The log ratios were similar at -0.79 and -0.72 at diagnosis and relapse 
respectively (Figure 7.8A-B). This suggests the deletion is clonal and occurred early 
in lymphomagenesis. Chromosome 17q was also aberrant in the relapse sample, but 
not the diagnostic. A complex pattern of gain and loss was seen on 17q including a 
high copy number amplification region with a log ratio of 1.61 (TuScan estimation = 8 
copies) which includes TBX2 and TBX4, often amplified in cancer (Figure 7.8B). 
TBX2 is involved in senescence and is known to inhibit CDKN2A (p19ARF) and 
abrogates the TP53 pathway (Vance et al., 2005). CNN-LOH on 17q was shown in 
chapter 4 to be associated with poor outcome and a higher risk of relapse but copy 
number changes were not common. TBX2 and TBX4 may be candidate genes for 
mutation analysis within the 17q region. Another region of amplification on 17q was 
seen with an estimated copy number of 6 involving several HOX family genes 
(HOXB5, HOXB6, HOXB7, HOXB8, HOXB9 and HOXB13). Chromosome arm 18q 
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also harboured complex aberrations involving six regions of amplification and four 
regions of deletion that were specific to relapse (Figure 7.8).  
 
 
Figure 7.8 - Chromosome 18 was not aberrant at diagnosis but acquired a complex 
pattern of copy number aberration at relapse on the 18q arm. The aberration involved 
high level amplification of the BCL2 gene with an estimated 25 copies present. 
 
Copy number gains occurred in a step wise pattern which culminated in the highest 
level of amplification with a log ratio of 2.90, estimated to be 25 copies of BCL2 which 
was one of three genes in this region alongside PHLPP1 and KDSR. Immediately 
after this segment sat a region of deletion, suggesting a complex rearrangement 
similar to those associated with TP53 aberration described in chapter 5.  
 
The pattern of clonal evolution in this case of early relapse resembled that of 
10/10065 in that the diagnostic and relapse samples were closely related 
genomically. Abnormalities on chromosome 12, 17q and 18q arose at relapse 
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presenting putative candidate genes that are known to play a role in lymphoma that 
may be responsible for driving disease progression. Some evidence of subclonal 
populations was detected on chromosome 8 and chromosome 12, suggesting that 
the resistant clone had expanded and given rise to further subclones with biallelic 
inactivation of TP53, 17q and 18q aberrations in common.  
 
7.3.4 Sporadic Burkitt lymphoma pair 3 – 15/353 
 
Patient 15/353 was diagnosed with stage III IGH/MYC-positive BL at the age of 11. 
The patient was male and masses in the abdomen and mediastinum and there was 
no involvement in the bone marrow or central nervous system. He was treated on 
FAB/LMB96 protocols in group B the patient relapsed one month after final frontline 
chemotherapy and died of disease three months after relapse. At diagnosis the 
patient had multiple small aberrations as well as 6p CNN-LOH that was maintained at 
relapse. The relapse sample acquired a complex pattern of copy number gain and 





Figure 7.9 - Copy number profile of sporadic BL patient 15/353 at diagnosis and 
relapse. Summary of segmented copy number aberrations at (A) diagnosis and (B) 
relapse. Processed log ratio data and B-allele frequency data for both (C) diagnostic 
and (D) relapse samples. 
 
Gain of the chromosome 1 centromere was seen at relapse but not diagnosis (Figure 
7.9), involving the majority of 1q and 52.5Mb of 1p. Gain on 1q was paired with 
telomeric loss and there were two distinct copy number segments in 1q. The region 
adjacent to the centromere appeared to have gained two additional copies while the 
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rest of the arm had one additional copy with the exception of the telomere which was 
deleted. Aberration within the ALK gene in both samples was observed on 
chromosome 2. Both cases had deletion of exon 1 of the gene followed by gain of an 
additional copy of exons 2-11, followed again by deletion of exon 12-15. The 
remaining exons were unaffected, and breakpoints were consistent between 
samples. The ALK gene is a recurrent translocation partner in rearrangements in 
anaplastic large cell lymphoma (ALCL) and encodes a tyrosine kinase receptor 
(Ferreri et al., 2012). The diagnostic sample harboured a focal 3q29 gain involving 
only the TFRC gene (transferrin receptor 1) or CD71 which is highly expressed in BL 
and expression is a believed to be a poor prognostic marker in follicular lymphoma 
(FL) treated with rituximab (de Fontbrune, 2019). The remainder of chromosome 3q 
was unaffected by copy number aberrations in the diagnostic sample but was highly 
complex in the relapse sample. A complex pattern of 10 gain and 10 loss segments 
spanning 87.8Mb stretched from 3q11.1 to 3q26.33 (Figure 7.10). Within this region 
was a small focal homozygous deletion involving the TUSC7 gene, as was seen in 




Figure 7.10 - Complex aberration on 3q involving multiple regions of copy number 
gain and loss was observed in the relapse sample of 15/353 that was not present in 
the diagnostic biopsy. 
 
A low-level gain of chromosome 7 was seen at relapse which could not have been 
present in the major clone as the log ratio was low at 0.17 and the was no evidence 
of this aberration in the diagnostic sample. The relapse sample had an additional 
copy number gain at 8q24.22 to 8q24.3. The breakpoint furthest from the telomere 
was adjacent to the MYC gene, which was found within a focal deletion involving only 
the gene.  
 
Two deletions on 9p at 9p24.1 and 9p21.3 were present at diagnosis involving the 
JAK2 and CDKN2A genes. Both deletions were present at relapse with similar log 
ratios in each case (JAK2: -0.86 vs -0.62, CDKN2A: -1.13 vs -0.92) suggesting that 
the aberrations occurred early during the development of the malignancy. CDKN2A 
deletions in both samples were entirely focal involved no other genes (Figure 7.11). 
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In addition, exon 1 of PTEN was deleted in both samples on chromosome 10 and 
focal amplification of the CBL gene on 11q was maintained at relapse.  
 
 
Figure 7.11 - Partial CDKN2A deletion identified at diagnosis and maintained at 
relapse in patient 15/353. Region shown spanned chr9:21889358-22084295. 
 
A region of copy number gain on 14q telomere was seen in the relapse sample that 
was present in the diagnostic sample but involving copy number gain of more of the 
chromosome. The breakpoint region of the gain on 14q sat within the MYC gene 
which may suggest that MYC rearrangement in this case involved an imbalanced 
translocation that is more complex than those typically found in BL. No karyotyping 
data was available for either sample and no constitutional DNA was present for 
structural analysis by whole genome sequencing. 16p gain was seen in both samples 
with the same breakpoints, but a 11.3Mb gain on 16q at the telomere was seen only 
at relapse. Chromosome 19p gain was seen only in the relapse sample, affecting 
19p13.3 to 19p13.2 involving a region identified by GISTIC2.0 analysis in Chapter 4. 
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Clonal evolution in this relapse case resembled that of both 10/10065 and 16/818 as 
the two samples were closely related in their genomic profiles. The additional 
abnormalities arising at the point of relapse that could not be identified as subclonal 





7.3.5 Sporadic Burkitt lymphoma pair 4 – 16/391 
 
Patient 16/391 was a 13-year-old male diagnosed with MYC positive BL. The tumour 
had no bone marrow or central nervous system involvement and was diagnosed an 
abdominal stage III BL. After successful treatment on FAB/LMB96 protocols in group 
B the patient relapsed 3 months on from remission. The patient remains alive and 
disease-free 10 years on from diagnosis. The diagnostic tumour had copy number 
gains of 1q, chromosome 7, chromosome 9, chromosome 19 and 21q, and a 
complex aberration on chromosome 11q, typical of those seen in BLL-11q cases. 
The relapse sample acquired an additional copy of chromosome 12 as well as 
complex chromosomal aberrations of 14q and 18q. 4q deletion was also acquired, 
and 9q gain was not seen at relapse. Both diagnostic and relapse samples had CNN-
LOH across the whole of chromosome 17. 
 
A stepwise pattern of gain on chromosome 1q was seen in the diagnostic sample 
and was maintained at relapse with the same breakpoint. The highest point of gain 
was seen at 1q25.2 involving nine genes, none of which are known to be involved in 




Figure 7.12 - Copy number profile of sporadic BL patient 16/391 at diagnosis and 
relapse. Summary of segmented copy number aberrations at (A) diagnosis and (B) 
relapse. Processed log ratio data and B-allele frequency data for both (C) diagnostic 
and (D) relapse samples.  
 
4q deletion was not present at diagnosis but was observed at relapse spanning 4q12 
to 4q35.2. Chromosome 7 was gained at both diagnosis and relapse. The log ratio 
remained effectively unchanged throughout the two timepoints (Diagnosis 0.40, 
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Relapse 0.39). A subclonal population at diagnosis had an additional copy of 
chromosome 9 with a log ratio of 0.14. At relapse 9p gain was still observed with a 
slightly higher log ratio, but 9q was not gained or altered at all. It is possible that 9p 
and 9q gains were present within different subpopulations at diagnosis and that the 
9q gained clone was lost during treatment (Figure 7.13).  
 
 
Figure 7.13 - Chromosome 9 gain at diagnosis and relapse in patient 16/391. 
Aberrations in both samples were barely detectable and likely affected a small 
subclone in each biopsy. 
 
The copy number gains in both samples were almost undetectable but comparison of 
the median log ratio of probes across chromosome 9 in each sample against other 
chromosomes shows a clear upward shift in intensity (Figure 7.12C-D). 
 
Chromosome 11q was aberrant at diagnosis in a pattern typical of BLL-11q cases 
described recently (Salaverria et al., 2014). The gain spanned 22.2Mb at 11q22.1-
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11q24.1 but a peak of copy number gain was observed at 11q22.1-11q22.3 involving 
18 genes including multiple matrix metalloproteases (MMP) genes as well as BIRC2 
and BIRC3 which both play a role in TNF signalling and resistance to apoptosis 
(Figure 7.14). The breakpoint between gain and loss sits within the JHY gene. The 
log ratio of gain was higher in the diagnostic sample which was likely a result of the 
relapse sample being small and having to be macrodissected. 
 
 
Figure 7.14 - Chromosome 11q abnormality at diagnosis and relapse in patient 
16/391. 
 
At relapse the tumour acquired a low-level gain of chromosome 12. This was 
considered to be a subclonal event as the log ratio of 0.13 was considerably lower 
than that of the gain on chromosome 1q (log ratio 0.38). Gain on 13q was likely 
subclonal also with a log ratio of 0.21, but in a larger subclonal population of cells. 
There was a complex pattern of gain and loss on chromosome 14 in the relapse 
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sample which involved a high copy amplification of a 1.3Mb region within 14q12 
involving G2E3 (G2/M phase specific E3 ubiquitin ligase).  
 
Chromosome 17 was aberrant in both diagnostic and relapse samples from the 
patient. The diagnostic tumour sample had CNN-LOH across both 17p and 17q. The 
BAF showed that the CNN-LOH was not present in all of the tumour sample and may 
have been a subclonal event at both diagnosis and relapse. However due to the 
macrodissected nature of the relapse sample it cannot be ruled out that the 17p 
CNN-LOH-bearing clone expanded into the niche left by chemosensitive clones yet 
was diluted in array analysis by contaminating normal tissue. 
 
Complex aberrations on chromosome 18 involved almost the entirety of the 18q arm 
and was comprised of two regions of high copy gain separated by two regions of 
loss. Unlike the 18q complexity seen at relapse in 16/818, this aberration did not 
involve gain of BCL2. The TCF4 and POLI genes were found in the regions of high 
copy number gain. A subclonal gain of chromosome 19 was seen at diagnosis which 
is present in part at relapse. In the relapse sample the abnormality was also 
subclonal but did not involve the majority of 19q. Similar to the aberration on 
chromosome 9 it is likely that there were multiple chromosome 19 events that 
occurred in separate subclones, some of which were not maintained at relapse. 
Chromosome 21 gain was seen at diagnosis but not at relapse. The gain was likely 
subclonal with a log ratio of 0.21. The B allele frequency track separated by a small 
amount on chromosome 22 in the relapse sample which suggests allelic imbalance. 
No change in log ratio was observed however, suggesting that instead of a subclonal 
copy number gain or loss it was more likely caused by a subclonal CNN-LOH event.  
 
16/391 followed the trend of other BL relapse pairs in that copy number events at 
diagnosis were mostly maintained at diagnosis while new aberrations arose at 
relapse from subclonal populations.  
 
7.3.6 Sporadic Burkitt lymphoma pair 5 – 18/721 
 
Patient 18/721 was a 6-year-old male patient diagnosed with BL with an IGH-MYC 
rearrangement. The patient presented with an abdominal mass and was negative for 
bone marrow and CNS involvement. The patient was treated with FAB/LMB-based 
treatment protocols but treatment group was unknown. There was residual active 
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disease at the end of frontline therapy signalling primary refractory disease. Despite 
this the patient was still alive three years after the end of treatment. Diagnostic 
biopsy material was present in the form of an FFPE block only, while relapse biopsy 
material was split into one fresh frozen mass and one FFPE block with the same 
pathology number. All three samples were investigated by copy number array. 
Additional constitutional DNA was available and analysed by array. The genome of 
the diagnostic sample was relatively quiet with CNN-LOH on 2p and 17q only (Figure 
7.15, Figure 7.16). The relapse samples harboured more aberrations and were not 
identical to each other. 2p and 17q CNN-LOH were not seen at relapse.  
 
Chromosome 1 was aberrant at diagnosis and relapse, with a 1pter deletion that was 
maintained as well as a focal deletion of ID3. A small low-level copy number gain at 
1q22-1q23.3 was seen at diagnosis falling within the region called by GISTIC2.0 
analysis in chapter 4, but at diagnosis the aberrations on 1q were much more 
complex with a stepwise gain of 1q with 13 distinct segments of copy number change 




Figure 7.15 - Copy number profile of sporadic BL patient 18/721 at diagnosis and 
relapse. Summary of segmented copy number aberrations at (A) diagnosis and 




Figure 7.16 - Processed log ratio data and B-allele frequency data for (A) the 
diagnostic sample and relapse (B) FFPE sample and (C) FF sample from the same 
biopsy from 18/721. 
 
The telomere of 1q was deleted also, but likely only in a subclone as the log ratio was 
only -0.16 in the FFPE relapse sample. Strikingly, the loss was not observed in the 
FF relapse sample. This difference between arrays represents spatial heterogeneity 
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within the tumour sample where different subclonal populations likely made up 
varying proportions of the tumour cells in each sample.  
 
 
Figure 7.17 - Log ratio and B-allele frequency data for chromosome 1 depicting a 
complex pattern of copy number gain and amplification at 1q acquired at relapse. 
The abnormality was not present at (A) diagnosis but present in both (B) FFPE and 
(C) FF relapse samples taken from 18/721.  
 
At diagnosis chromosome 2p was shown to have a subclonal CNN-LOH event 
highlighted by the four tracks observed in the BAF track. There were two distinct 
segments of adjoined CNN-LOH that had different BAF profiles suggesting that while 
both were subclonal, they were present at different proportions at diagnosis. The 
CNN-LOH aberrations were not seen in either relapse sample, implying that 2p CNN-
LOH is not advantageous to the tumour cell in a therapeutic setting. On chromosome 
3 the diagnostic sample was quiet with no copy number changes, but both relapse 
samples acquired low level loss of 3p and gain of 3q24 to 3q29. These segments 
indicated a low level event in a subclonal population as the log ratio did not deviate 
strongly from the baseline (gain log ratio 0.12 FF, 0.15 FFPE, loss log ratio 0.12 FF, 
0.15 FFPE). In contrast, a focal deletion of TUSC7 at 3q13.31 was most likely clonal 
with a log ratio of -0.73. Intriguingly the FFPE relapse sample showed a subclonal 
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deletion in the middle of 4q while the FF sample had a high copy gain near the 
centromere, with neither sample harbouring both abnormalities. This further implies a 
more complex tumour heterogeneity at relapse.  
 
Chromosome 7 was quiet at diagnosis but gain of 7p was seen at relapse, but only in 
the FFPE sample. The 7p gain was subclonal with a log ratio of 0.13, and a small 
gain on 7q21.11-7q21.3 which appeared to be present at a higher incidence within 
the tumour at 0.28 log ratio. Chromosome 10 held another aberration that was seen 
in one relapse sample but not the other at 10q21.1-10q25.1 which was deleted in the 
FF relapse sample only. The region involved the PTEN gene.  
 
Chromosome 13 was aberrant in both relapse samples while the diagnostic sample 
harboured no aberrations. Both relapse samples had stepwise gain with a peak 




Figure 7.18 - Log ratio and B-allele frequency data for chromosome 13q depicting a 
complex copy number gain acquired at relapse in the (A) FFPE sample and (B) FF 
sample from 18/721. Both samples have amplification of 13q but the patterns are 
distinct. 
 
The pattern of gain was different in both samples: the FF sample started from a high 
copy number gain at 13q31.3 that tailed off with segments of reducing log ratio 
toward the telomere, while in the FFPE sample there were multiple stepwise 
segments of gain on either side of the peak. It is likely that the two relapse samples 
represent multiple occurrences of 13q gain, with a common region of amplification 




Case 18/721 was distinct from other BL relapse pairs analysed in that the diagnostic 
sample bore little resemblance to the relapse sample. Only a deletion on 1p was 
maintained from diagnosis to relapse which suggests that this was an aberration that 
occurred early in the development of lymphoma. The dominant clone at diagnosis 
was eliminated by frontline therapy, but multiple resistant clones arose with little in 
common, alluded to by the variety of copy number profiles seen between the FF and 
FFPE relapse samples. These clones may have only had 13q gain and TP53 biallelic 
inactivation in common. 18/721 experienced disease progression quicker than all but 
one BL relapse pairs, which is remarkable as it is generally assumed that the quicker 
relapses seen in paediatric BL patients lead to a linear model of clonal evolution. In 
this model the relapse/refractory tumour strongly resembles the tumour at diagnosis, 
which accurately describes BL pairs 1-4. This case however shows evidence of an 
later divergence of BL clones which is the alternative model recognised in B-NHL 
(Juskevicius et al., 2017), despite there being very little time for the heterogeneity 
that was observed to arise.  
 
 
7.3.7 Sporadic Burkitt lymphoma pair 6 – 15/310 
 
Patient 15/310 was a 10-year-old male diagnosed with BL in multiple sites. There 
was no evidence of bone marrow or CNS involvement and IG-MYC translocation was 
confirmed by FISH. The patient was treated with FAB/LMB-based protocols in group 
B and was in remission at the end of CYM1. Relapse was confirmed three months 
after the end of treatment, or 5.8 months after diagnosis. Salvage therapy at relapse 
was ultimately unsuccessful and the patient died 5 months after relapse was 
confirmed.  
 
A deletion of 1p35.3-1p35.1 was present at diagnosis but not observed in the relapse 
sample. Allelic frequency data from the array indicated the region was hemizygous 
and that the deletion was clonal (Figure 7.19A-D). The relapse sample had an 
additional copy of chromosome 7 in a small subclonal population that was not 
observed at diagnosis. The log ratio was very low at 0.09 but is clearly discernible 
when compared to the rest of the genome at relapse (Figure 7.19C-D). At diagnosis 
the patient had 13q CNN-LOH affecting the entirety of the arm affecting the clonal 




Figure 7.19 - Copy number profile of sporadic BL patient 15/310 at diagnosis and 
relapse. Summary of segmented copy number aberrations at (A) diagnosis and (B) 
relapse. Processed log ratio data and B-allele frequency data for both (C) diagnostic 
and (D) relapse samples.  
 
 
This case of relapsed BL was noteworthy for its extremely quiet genome at both 
diagnosis and relapse. There were no copy number aberrations present at diagnosis 
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that were maintained at relapse. The fact that both abnormalities detected by array at 
relapse were subtle and also did not appear clonal suggests either that the sample 
has a low tumour content compared to the diagnostic sample, or that the copy 
number aberrations were subclonal. This case further supports the need for TP53 
aberration in disease progression with a G245S mutation being the only abnormality 
screened for that was detected at both timepoints. The pattern of evolution 
resembles the early diverging type as the diagnostic and relapse profiles were so 
different. Exome sequencing analysis could only be performed on the diagnostic 
sample as the FFPE DNA quality was insufficient. If this sample could be sequenced 
then more complex tracking of the resistant subclones could be performed by looking 
at the differences in VAF of mutations or employing more sophisticated tools.  
 
 
7.3.8 Sporadic Burkitt lymphoma pair 7 – 4/136 and 10/136 
 
Patient 4/136 was a 4-year-old male diagnosed with BL. The stage II tumour was 
abdominal, and the patient had no bone marrow or CNS involvement of the disease. 
The primary tumour was treated on FAB/LMB-based protocols in group B and 
completed CYM1 in remission. Three months later the patient relapsed, followed by 
another relapse four months after that. The patient died two months after the second 
documented relapse. Tumour material was available for the diagnostic sample and 
the two relapses, but the fragment size of the DNA from the second relapse was 
insufficient for array analysis or sequencing. The was also insufficient DNA remaining 
from the diagnostic sample for sequencing. The diagnostic sample harboured a gain 
of chromosome 7 and 17q CNN-LOH that were both maintained at relapse and 
deletion on 16p that was not present at relapse. 1q gain and 8p telomeric loss were 




Figure 7.20 - Copy number profile of sporadic BL patient 4/136 and 10/136 at 
diagnosis and relapse. Summary of segmented copy number aberrations at (A) 
diagnosis and (B) relapse. Processed log ratio data and B-allele frequency data for 
both (C) diagnostic and (D) relapse samples. 
 
A region of copy number gain on chromosome arm 1q typical of the abnormalities 
identified by GISTIC2.0 was present in the relapse sample but not the diagnostic 
sample, even at low level. This is surprising as 1q is a common abnormality in BL but 
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not prognostic and is likely a passenger abnormality. A 2q12.1-2q14.1 deletion was 
also present at diagnosis but not relapse. The BAF tracks in both cases suggest that 
the aberrations were present in the entire sample. The whole of chromosome 7 was 
gained at diagnosis and this was maintained at relapse. However, an additional event 
occurred between the diagnostic sample being taken and the first relapse biopsy 
where one copy of the region between 7p22.1 and 7p15.1 was deleted, making it 
copy number normal (Figure 7.21). This was confirmed by CNN-LOH arising in the 
region that was originally deleted. This arose due to the non-duplicated copy of the 
region being deleted, leaving behind the original and duplicated version. This 
provides some evidence of a model of tumour evolution with an ancestral clone that 
had already acquired the extra copy of chromosome 7 at diagnosis.  
 
 
Figure 7.21 - Log ratio and B-allele frequency data for chromosome 7 depicting a 
copy number gain present at diagnosis in the relapse. Subsequent events led to the 
loss of one copy of 7p22.1-7p15.1 at relapse with associated CNN-LOH in the region. 
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A 9p deletion from the telomere to 9p21.3 was found at relapse in which the 
breakpoint was adjacent to CDKN2A and one copy of the gene was lost. The allelic 
frequency track showed that the deletion was not fully clonal and that a proportion of 
the tumour sample still retained heterozygosity at the site. A deletion was seen on 
16p at diagnosis but was not maintained at relapse, despite being present in almost 
the entire tumour population. 17p was normal in both samples while 17q CNN-LOH 







7.3.9 DLBCL paired analysis 
 
DLBCL is most comprehensively studied in an adult setting where most diagnoses 
occur, while paediatric relapsed/refractory DLBCL is poorly understood. In a study of 
20 DLBCL relapse pairs 65% of cases were found to be late divergent or linear in 
nature (Juskevicius et al., 2016), similar to the BL relapses observed in this 
investigation. 35% of DLBCL cases in that study had early divergent evolutionary 
patterns where the relapsed tumour bore little resemblance to the original diagnostic 
sample, and three cases (15%) had entirely unrelated relapses. Two DLBCL relapse 
cases were available for analysis in this investigation and both had sequential 
biopsies at both diagnosis and relapse. As the two relapse/refractory DLBCL pairs 
underwent disease progression early (2.3 and 4.3 months respectively) it was not 
expected that either would be clonally unrelated recurrences.  
 
 
7.3.10 DLBCL pair 1 – 16/547 
 
Patient 16/547 was diagnosed at age 16 with DLBCL localised to the intestines. Case 
notes suggested that the patient had an underlying common variable 
immunodeficiency, which was likely an important driver for lymphomagenesis in this 
patient. The stage III DLBCL was negative for MYC, BCL2 and BCL6 
rearrangements. The patient was treated at frontline on an adult protocol of R-CHOP 
alongside with rituximab at relapse. There was no recorded date of remission, but 
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clinical data suggested the patient relapsed rather than developed primary refractory 
disease. The patient died from disease nine months after relapse. The diagnostic and 
relapse samples did not resemble each other, with 1p CNN-LOH, 17p CNN-LOH and 
a deletion on chromosome 10 maintained from diagnosis to relapse (Figure 7.22). 
 
 
Figure 7.22 - Copy number profile of DLBCL patient 16/547 at diagnosis and relapse. 
Summary of segmented copy number aberrations at (A) diagnosis and (B) relapse. 
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A small region of CNN-LOH at the 1p telomere from 1p36.33 to 1p35.3 was observed 
at diagnosis and maintained at relapse. On top of this at diagnosis it was clear that a 
small subclonal population had CNN-LOH of the whole chromosome, which was 
maintained within a slightly higher proportion of cells at relapse but still not the clonal 
majority. The frequency of 1p CNN-LOH within the relapse simple was higher than at 
diagnosis. A complex pattern of gain around the centromere of chromosome 6 was 
seen at diagnosis, involving high copy number amplification between 6p21.2 and 
6q12. An additional region of amplification at 6q14.1 was also seen at diagnosis 
involving the TTK and BCKDHB genes. None of the amplified regions seen at 
diagnosis were amplified at relapse. Instead the majority of 6q was deleted from 
6q16.1 to the telomere, which equally was not present at diagnosis.  
 
Chromosome 9 had aberrations at both diagnosis and relapse that were not 
consistent between timepoints. The diagnostic sample harboured low level CNN-LOH 
on 9q with three well defined copy number gains on the arm at 9q32-9q33.1, 9q33.3-
9q34.11 and 9q34.3 respectively. The amplification had consistent log ratio values of 
0.18, 0.15 and 0.17 respectively, suggesting that they coexisted in the same cell 
population, possibly as a result of a chromothripsis-like event. These aberrations 
were not present at relapse, but the whole of chromosome 9 had acquired CNN-LOH 
in a subpopulation, not just 9q. The proportion of the tumour with CNN-LOH was 
higher than at diagnosis, alluded to by the BAF track data. Chromosome 13q was 
gained at relapse, but there is some suggestion that the aberration was present at 
diagnosis in a very small population and went undetected by the segmentation 
algorithm. The whole chromosome was gained in three segments with the highest 
point of gain at relapse occurring from 13q31.3 to the 13q telomere.  
 
17p CNN-LOH was visible in a small population at diagnosis. This was seen at 
relapse also, but the CNN-LOH affected both arms of the chromosome at this 
timepoint. Interestingly TP53 was not mutated at both diagnosis and relapse, which 
may suggest an alternative gene of interest was mutated at diagnosis to confer the 
survival advantage to cells that had acquired 17p CNN-LOH. CNN-LOH on 17p at 
diagnosis developed into CNN-LOH of the whole of chromosome 17. This may have 
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occurred as a secondary event within the subclone that harboured 17p CNN-LOH at 
diagnosis or may be the result of a distinct subpopulation arising.  
 
The evolution of disease progression within this case appeared to be early divergent, 




7.3.11 DLBCL pair 2 – 5/894 
 
Patient 5/894 was a 4-year-old female diagnosed with DLBCL. They were diagnosed 
with a stage III DLBCL of the abdomen and pelvis with no bone marrow or CNS 
involvement and IG-MYC rearrangement was confirmed by FISH. The patient was 
treated on FAB/LMB-based protocols in group B but was escalated to group C after a 
lack of complete response to COP1 treatment. The patient did not achieve remission 
following CYM1/CYVE2 therefore was moved to salvage therapy for refractory 
disease, comprised of RICE and BEAM protocols. This salvage treatment was 
successful, and the patient has gone three years since diagnosis without further 
progression. An additional copy of chromosome 12 was observed at diagnosis and 
relapse, while the relapse sample also acquired deletions of chromosomes 6 and 10 




Figure 7.23 - Copy number profile of DLBCL patient 5/894 at diagnosis and relapse. 
Summary of segmented copy number aberrations at (A) diagnosis and (B) relapse. 




5/894 harboured a low-level copy number gain of chromosome 3 at diagnosis that 
was not detected by the TuScan segmentation algorithm with a low log ratio of 0.11. 
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This abnormality spanned from 3p12.3 to the entirety of 3q. The relapse sample 
showed no evidence of this event, inferring that the population involved did not 
survive treatment. Conversely, chromosome 4 was deleted in a subclone of the 
relapse tumour but not at diagnosis. 7q11.23 to 7q22.1 was amplified at relapse but 
not diagnosis and  This region has been previously associated with outcome in B-
NHL in cytogenetic studies (Poirel et al., 2009; Nelson et al., 2010). The miniscule 
deviations in log ratio from the origin in these samples suggests a low tumour cell 
content within the samples. The exception to this finding was gain of chromosome 12 
which was shared by both diagnostic and relapse samples. At diagnosis the log ratio 
of chromosome 12 was significantly higher than at relapse and was clearly present in 
significantly more of the sample than gain on chromosome 3, suggesting that 
chromosome 12 gain was common to a large portion of the tumour and that tumour 
content was high in this sample. It was not possible to comment on the tumour 
content of the relapse sample from array data alone as there were no aberrations 
with high deviations in log ratio to determine the approximate log ratio of a clonal 
abnormality.  
 
A small copy number gain at 9p21.3 was seen in the diagnostic biopsy but was not 
maintained. The telomeric breakpoint was adjacent to the CDKN2A gene and eight 
genes were within the segment. A subclonal deletion of chromosome 10 was seen at 
relapse but not diagnosis, meaning that gain of chromosome 12 was the only 




7.3.12 Endemic Burkitt Lymphoma paired analysis 
 
Paired material from diagnostic and relapse biopsies was available for two patients 
diagnosed at Queen Elizabeth Central Hospital in Blantyre, Malawi. The time at 
which relapse was identified in the endemic cohort may have been later than in the 
UK and the disease could have progressed further as the patient would not have 
received regular scans to screen for recurrent disease. Selection pressure on the 
tumour cells exerted by therapy was different to that of the B-NHL cases seen in the 
UK, so the pattern of clonal evolution cannot be directly compared. However, 
common factors may be identified between endemic and sporadic BL cases which 
are shown to drive disease progression. Other co-morbidities including HIV infection, 
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EBV infection, malarial infection, malnutrition and other confounding factors were 
more common in the endemic cohort, further separating the clinical situation between 
analyses.  
 
7.3.13 Endemic Burkitt lymphoma pair 1 - B266/B300 
 
Patient B266/B300 was a 3-year-old male diagnosed with a MYC-positive Burkitt-like 
lymphoma. IHC performed at Newcastle University retrospectively confirmed that the 
patient likely had a high-grade B cell lymphoma and not BL. The patient received one 
course of treatment out of four, consisting of vincristine, cyclophosphamide, 
methotrexate, hydrocortisone and doxorubicin (Molyneux et al., 2017). The patient 
then absconded for two months which is not uncommon in this clinical setting. After 
two months the patient returned to the clinic with active disease and died shortly 
after. As the patient did not complete frontline therapy the disease cannot be 
considered to have relapsed. It is conceivable that the malignancy would have been 
successfully treated if frontline therapy had been completed. However, the case was 
informative with regard to the development of the tumour after a small amount of 
treatment. The patient also represents a significant clinical challenge in the Malawi 




Figure 7.24 - Copy number profile of endemic HGBL patient B266/B300 at diagnosis 
and relapse. Summary of segmented copy number aberrations at (A) diagnosis and 
(B) relapse. Processed log ratio data and B-allele frequency data for both (C) 
diagnostic and (D) relapse samples. 
 
 
The copy number profile of the diagnostic sample was almost completely normal with 
no large abnormalities (Figure 7.24A-D). There was a baseline level of noise that was 
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higher than in the CCLG tumour samples which was most probably a result of the 
different sample processing and storage technique at the QECH in Malawi. There 
were 177 small regions of copy number gain that were not supported by changes in 
the BAF track, suggesting that they were the result of natural noisy waviness in the 
data and not biological. The relapse sample for this patient, B300, harboured two 
abnormalities not present at diagnosis. The sample at relapse had a single extra 
copy of chromosomes 7 and 12 (Figure 7.24A-D). This is significant as both 
chromosomes were recurrently gained at relapse in the sporadic and endemic 
cohorts. No other aberrations were present in the relapse sample. It is clear, 
however, that chromosomes 7 and 12 play an important role in the development of 
non-Hodgkin s l mphoma.  
 
7.3.14 Endemic Burkitt lymphoma pair 2 - B558/B594 
 
Patient B558/B594 was a female patient who was 7 years old when diagnosed with 
typical endemic BL at QECH, Malawi. FISH confirmed 98.2% of cells had an 
IGH/MYC translocation. The patient received additional prednisolone as well as 
cyclophosphamide, vincristine, doxorubicin, methotrexate and hydrocortisone 
(Molyneux et al., 2017). The patient relapsed four months after initial diagnosis where 
they received three courses of salvage therapy, before being palliated with morphine 




Figure 7.25 - Copy number profile of endemic BL patient B558/B594 at diagnosis and 
relapse. Summary of segmented copy number aberrations at (A) diagnosis and (B) 
relapse. Processed log ratio data and B-allele frequency data for both (C) diagnostic 
and (D) relapse samples. 
 
The diagnostic sample harboured few abnormalities and had a quiet copy number 
profile (Figure 7.25-D). A copy number gain on chromosome 13 involving the FOXO1 
gene was observed but the log ratio was low (probe median 0.11) and the allelic ratio 
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did not support any change of copy number in the region. In the relapse sample there 
was a subclonal gain of 13q, but this did not align with the putative region seen at 
diagnosis. The gain of 13q did not appear clonal in the relapse sample as the log 
ratio was 0.13 and the BAF track was not strongly affected. There was also deletion 
at the centromeric end of 15q involving a 10.1Mb region from 15q11.1 to 15q13.1 
that was maintained at relapse. At relapse there were gain of the whole of 
chromosomes 7 and 12, similarly to B266. The gains appeared to be clonal with high 
log ratios (chr7: 0.47, chr12: 0.46) and the BAF data showed a clear deviation.  
 
17p was deleted at diagnosis involving the whole chromosome arm. The aberration 
was not seen across the entire sample but affected a large portion of cells with a log 
ratio of -0.45. Remarkably the relapse sample had 17p CNN-LOH without loss that 
was entirely clonal, meaning that two distinct subclones arose that harboured 17p 
aberrations involving TP53.  
 
7.3.15 Recurrent abnormalities in progressive disease 
 
Figure 7.26 compares the copy number profiles of diagnostic and relapse samples 
diagnosed with sporadic BL. Gain on 3q involving 3q29 was seen in three relapse 
samples but was absent from diagnostic samples. Given that 3q29 gain was a 
recurrent copy number abnormality and was identified as a prognostic marker at 
diagnosis in Chapter 4, the fact that it was acquired in three relapse samples 
strengthens evidence for its prognostic value in B-NHL and suggests that it confers 




Figure 7.26 - Comparison of copy number profiles of paired diagnostic and relapse 
samples from seven paediatric sporadic Burkitt Lymphoma patients. 
 
Chromosome 7 gain was seen in two cases at diagnosis and was maintained in both 
respective relapse samples. Three cases also acquired gains on chromosome 7 
involving one 7p gain, one 7q gain and one gain of the whole chromosome. This 
strongly suggests a role for chromosome 7 in disease progression and resistance to 
chemotherapy. While a gain of chromosome 7 was not in itself prognostic in the 
cohort of 162 paediatric B-NHL diagnostic samples screened in chapter four, the 
abnormality was highlighted as a putative prognostic marker in the FAB/LMB96 trial 
(Poirel et al., 2009). Chromosome 7 aberrations may arise frequently at relapse as 
passenger abnormalities, but do not confer a protective advantage to the lymphoma.  
 
Three out of seven sBL relapse/refractory cases (42.9%) harboured a deletion of the 
TUSC7 gene that arose at relapse (Figure 7.27). Deletion of this gene was seen in 
19 diagnostic samples analysed in Chapter 4, primarily BL (12/19, 63.2%), but it is 
remarkable that the abnormality arose at relapse in 3/7 sBL relapse pairs. A recent 
whole genome sequencing study identified aberrations of the 3q13.31 locus involving 
LSAMP and TUSC7 and determined they did not co-occur with CCND3 mutations 
(Lopez et al., 2019). The role of TUSC7 aberration in relapse remains to be 




Figure 7.27 - Deletion on 3q involving TUSC7 was acquired in three relapse samples. 
Region shown spanned chr3:115723703-117327885. 
 
Gain of 1q has long been known to be a common aberration in B-NHL, particularly 
BL (Lones et al., 2004; Poirel et al., 2009; Scholtysik et al., 2010; Scholtysik et al., 
2015). Copy number gain of the region identified by GISTIC2.0 was seen in the 
diagnostic sample of two sBL pairs and maintained at relapse, with three additional 
cases with 1q gain events acquired at relapse. 1q gain has not been shown to be 
prognostic in large clinical trial cohorts (Poirel et al., 2009) nor was it prognostic in 
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this paediatric diagnostic cohort of B-NHL cases and was determined to be a likely 
passenger abnormality. Investigation of 95 paediatric B-NHL cases with known TP53 
status showed that complex aberrations of 1q involving copy number gain were 
significantly associated with TP53 status, which is a possible explanation for the 
increased incidence of 1q gain at relapse. MDM4 amplification on 1q may confer a 
survival advantage to the tumour at during therapy, explaining the higher incidence of 
1q gain at relapse as it may inhibit p53, but is also likely that 1q gain is a passenger 
abnormality, given the high frequency at which it was observed in the diagnostic 
cohort in Chapter 4. 
 
17q CNN-LOH was present in three diagnostic samples of seven sBL pairs, however 
it was only maintained at relapse in two of these and no cases acquired 17q CNN-
LOH. In the sBL case (case 18/721) where 17q CNN-LOH was lost at relapse, the 
pattern of evolution resembled the early-divergent/branching form that has been 
described previously in DLBCL (Juskevicius et al., 2016). In this sample 17p CNN-
LOH arose instead at relapse which may suggest that while both aberrations were 
prognostic in a diagnostic cohort, 17p CNN-LOH involving TP53 biallelic inactivation 
conferred a stronger survival advantage to the tumour than 17q CNN-LOH.  
 
 
7.3.16 TP53 Aberrations in Disease Progression 
 
Work described in Chapter 5 of this thesis showed that TP53 aberrations at diagnosis 
are significantly associated with a higher risk of disease progression and poor 
outcome in paediatric B-NHL. The exception to this observation was in endemic BL, 
where TP53 abnormalities were not associated with a higher risk of relapse, but 
TP53 was a prognostic marker of poorer overall survival. We hypothesise, therefore, 
that TP53 abnormalities identified at diagnosis are maintained at relapse as they 
drive disease progression in a therapeutic setting. Where material was available, the 
TP53 status of diagnostic and relapse pairs were investigated by copy number array 
and sequencing.   
 
In patient 10/10065 the TP53 status was stable throughout timepoints, with 17p loss 
and hemizygous G266E mutations with a VAF of 85% at diagnosis and 92% at 
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relapse (Figure 7.28C), meaning that both alleles of the TP53 gene were aberrant at 
both diagnosis and relapse.  
 
 
Figure 7.28 - Deletion of 17p was seen at both (A) diagnosis and (B) relapse in 
patient 10/10065, but a distinct pattern of copy number gain adjacent to the deleted 
region arose at relapse. (C) A G266E mutation in the TP53 gene was identified at 
diagnosis and maintained at relapse. 
 
Similarly to 10/10065, both the diagnostic and relapse samples of 16/818 harboured 
a deletion of 17p and a mutation in on the remaining allele. The hemizygous V216G 
mutation in TP53 identified at diagnosis was maintained at relapse and the VAF was 
slightly higher from 86% of reads to 92% (Figure 7.29C). The breakpoint of loss on 
17p was different between samples with the diagnostic sample spanning just 
17p13.3-17p11.2 and the relapse sample having loss of the whole arm all the way to 




Figure 7.29 - Deletion of 17p was seen at both (A) diagnosis and (B) relapse in 
patient 16/818, but a distinct pattern of copy number gain and loss arose on 17q at 
relapse. (C) A V216G mutation in TP53 was identified at diagnosis and was 
maintained at relapse.  
 
 
No copy number abnormalities involving chromosome 17 were seen in either sample 
from patient 15/353, but the diagnostic sample exhibited two TP53 mutations at 
R248Q and R273C. The mutations were maintained at relapse, but the VAF 
increased significantly in one mutation. The R248Q mutation only increased from 
44% to 49% suggesting that it was common to the majority of the tumour cells. In 
contrast the R273C mutation was only seen in 20% of reads at diagnosis and at 
relapse this population had expanded to 44%. Comparing this to the R248Q mutation 
which remained stable suggests that the R273C mutation was present in a subclonal 
population that already had a R248Q mutation in TP53. The two variants could not 
be shown to be present on different alleles, but this assumption was made based on 
the findings of Chapter 5. This is further evidence for TP53 biallelic aberration being 
selected for by intensive chemotherapy, giving this subclone an advantage over 
those without TP53 aberrations in the context of therapy.  
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Patient 16/391 harboured a R248Q mutation that we identified by whole exome 
sequencing of the diagnostic fresh frozen tumour sample and was confirmed to be 
present in the FFPE relapse sample by both Sanger sequencing and Haloplex 
targeted sequencing (Figure 7.30). This suggests that the resistant clone in this case 
harboured TP53 biallelic aberrations.  
 
 
Figure 7.30 - Deletion of 17p was seen at both (A) diagnosis and (B) relapse in 
patient 16/391 but a distinct pattern of copy number gain and loss on 17q arose at 
relapse. (C) A V216G mutation in TP53 identified at diagnosis was maintained at 
relapse. 
 
While a small deletion on 17p was seen at diagnosis in patient 18/721, it did not 
involve the TP53 gene (Figure 7.31A). The diagnostic sample harboured CNN-LOH 
across the whole of the 17q arm with two distinct segments overlapping. Remarkably 
the relapse tumour samples both show a clonal 17p loss involving TP53 that 
appeared to be clonal in both samples (Figure 7.31B-C) and exome sequencing of 
the FF sample revealed the presence of an R248W TP53 mutation (Figure 7.31D). 
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Exome sequencing confirmed that there was no mutation in TP53 at the point the 
diagnostic biopsy was taken, nor was there loss or CNN-LOH of the 17p arm (Figure 
7.31D). This suggests that genomic evolution occurred between the point of 
diagnosis and relapse. The major clone at diagnosis was not maintained and 
receded during therapy.  
 
 
Figure 7.31 - Log ratio and B-allele frequency data for chromosome 17 in the (A) 
Diagnostic sample, (B) FFPE sample and (C) FF sample from 18/721. Both relapse 
sample harboured deletion of the 17p arm while the diagnostic sample showed a 
small deletion of 17p13.1-17p12 adjacent to but not involving TP53. The diagnostic 
sample also harboured 17q CNN-LOH which was not present in either relapse 
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sample. (D) Aligned whole exome sequencing showing the presence of an R248W 
mutation in TP53 that arose at relapse and was not detectable at diagnosis. 
 
Between diagnosis and relapse the patient went from having two unaltered alleles of 
TP53 to biallelic abrogation through two separate events. Given the fact that the 17p 
loss clonal line likely expanded from an undetectable subclonal population at 
diagnosis to a clonal effacement of the relapse tumour it is a sensible assumption to 
make that TP53 was a vital driver of chemotherapy resistance in this case. The TP53 
mutation observed at relapse was not detected in a single read of the exome 
sequencing data at diagnosis. 
 
The only abnormality that was acquired at relapse by patient 15/310 was 17p CNN-
LOH in a small subpopulation of the relapse sample. There was no evidence of 17p 
aberration at diagnosis and the CNN-LOH was only present in a small subclone of 
the tumour at relapse (Figure 7.32). Exome sequencing analysis revealed that the 
patient had a somatic heterozygous G245S mutation in TP53 at diagnosis which was 




Figure 7.32 - CNN-LOH of 17p was not present at (A) diagnosis but was acquired at 
(B) relapse in case 15/310. A G245S mutation was present at (C) diagnosis in 39% 
of reads and confirmed to be present at (D) relapse by Sanger sequencing.F = 
Forward direction, R = Reverse direction.  
 
Combined comparison of seven sBL relapse pairs highlights a strikingly recurrent 
element of disease progression: TP53 abnormalities. All BL relapses that were 
screened had at least one TP53 aberration at some point during their disease 
development and were always maintained as the lymphoma progressed. This further 
supports the suggestion that abrogation of p53 protects the cancer cell from 
FAB/LMB-based treatment and shapes the evolution of the tumour. Tumours that 
acquired TP53 aberration at diagnosis followed a linear pattern of evolution with a 
relapse tumour that was closely related to the dominant diagnostic clone. With the 
exception of 4/136 all BL pairs either had biallelic aberration of TP53 at diagnosis or 
acquired it at relapse, and in the exception, there was a TP53 mutation at relapse 




In 16/547 there was no aberration involving TP53 at diagnosis or relapse, which was 
a hallmark of BL relapsed pairs and a significant prognostic marker at diagnosis. It is 
possible that mutation in another gene on 17p is responsible for resistance to 
treatment in this case. 17p CNN-LOH was the only abnormality that was maintained 
from diagnosis through to relapse, although this may be coincidental as the context 
of 17p CNN-LOH was different at relapse with all of chromosome 17 affected and not 
just the p arm. Similarly, chromosome 17 of 5/894 was normal by array at both 
timepoints, with no CNN-LOH or deletion observed. A G187S mutation in TP53 was 
identified at diagnosis by exome sequencing with a VAF of 39% and while this was 
maintained at relapse, the VAF dropped to 20%, suggesting that TP53 was not a 
driver of disease progression and chemoresistance in this case.  
 
Given that the TP53 status of both 16/547 and 5/894 remained stationary between 
diagnosis and relapse gives credence to the hypothesis that TP53 is important in 
tumour survival in BL but not DLBCL in the paediatric setting. This is particularly 
interesting as both malignancies are treated uniformly with FAB/LMB-based protocols 
in the UK, where these patients were sourced. It is possible that the strong pro-
apoptotic signalling in BL caused by high MYC expression requires a stronger anti-
apoptotic driver to overcome the stress of intensive chemotherapy, while in DLBCL 
alternative pathways give rise to disease progression independent of TP53. The ant-
apoptotic pressure conferred by a heterozygous TP53 mutation in this patient may 
provide a small survival advantage to the lymphoma as it was shown to have an IG-
MYC translocation. However, it is clear that in the two paediatric DLBCL cases 
investigated that TP53 is not as important in tumour survival as it is in the setting of 
paediatric BL.  
 
Sanger sequencing of TP53 performed previously in the lab showed that the 
diagnostic sample of endemic BL patient B558 had a heterozygous R248W mutation. 
Additional Sanger sequencing of the relapse sample confirmed that the R248W 
mutation in TP53 was maintained at relapse and was homozygous. This suggested 
strongly that the mutation and deletion of 17p seen at diagnosis existed in distinct 
subclones and that mutation of TP53 conferred a stronger survival advantage than 
hemizygous deletion, further intensified by a subsequent CNN-LOH event at relapse, 
leading to biallelic inactivation of the TP53 gene. Frontline therapy to treat BL in 
Malawi is much less intensive than that which is given in the UK which means higher 
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relapse rates and lower overall survival (Molyneux et al., 2012). The selection 
pressure conferred by treatment is therefore weaker than that in sBL relapse cases, 







Comparing diagnostic and relapse samples in a non-paired manner allowed for 
identification of aberrations that were selected for at relapse, and that are likely 
candidates to drive disease progression and confer resistance to chemotherapy. It 
was clear through analysis of the seven sporadic BL relapse/refractory pairs that 
TP53 aberration was the strongest factor associated with BL relapse, with particular 
emphasis on biallelic aberrations. Six out of seven pairs had biallelic aberrations at 
relapse making TP53 abnormalities an important biomarker for screening. TP53 
status was also the most important factor in determining the evolutionary model that 
drove disease progression in sporadic BL. All four of the sporadic BL cases that had 
already established biallelic abnormalities involving TP53 progressed in a late-
diverging/linear evolutionary pattern. The two sBL patients that did not have biallelic 
aberrations at diagnosis but acquired them at relapse had early-diverging/branching 
clonal progression.  
 
Copy number abnormalities identified at diagnosis in sBL were consistent with those 
at relapse, although additional events were seen in most cases with a more complex 
genome at relapse. No case lost a TP53 aberration that was present at diagnosis; all 
were maintained at relapse, strongly supporting the idea that TP53 is vital for BL 
survival. Interestingly, TP53 status did not correlate with time to progression, as 
might be expected given the linear evolution pattern that biallelic TP53 aberrations 
were associated with. Patient 16/391 took 6.1 months from diagnosis to relapse 
which was longer than either of the sporadic BL cases without biallelic TP53 
aberrations at diagnosis. Of these two cases, it is remarkable that both acquired 
additional TP53 abnormalities, showing that even when the main clonal population of 
the tumour has monoallelic aberrations affecting the gene, further aberrations are still 
selected for in a treatment setting.  
 
This is the first genomic study of disease progression across multiple timepoints in 
sporadic BL using copy number arrays. The only study to previously investigate the 
genomics of BL progression enlisted traditional cytogenetic techniques to compare 
sequential samples (Aukema et al., 2015). The key findings of the study were the 
identification of a linear pattern of clonal evolution and an increase in genome 
complexity. Seven cases, including six paediatric and one adult case, were 
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compared between sequential biopsies. Five had diagnostic and relapse biopsies 
while two were compared at first and second relapse. An additional 18 BL cases with 
karyotype data from the Mitelman Database were analysed alongside their in-house 
cases, totalling 25 cases. Copy number abnormalities that have previously been 
reported in B-NHL were common at diagnosis and relapse, specifically gain of 1q, 
trisomy 7/7q and abnormalities involving 13q (Poirel et al., 2009; Nelson et al., 2010; 
Aukema et al., 2015). Abnormalities on 11q, loss of 17p and loss of 19q were only 
seen at relapse. The findings of our study do not correlate directly with the genomic 
aberrations reported by Aukema et al. (Aukema et al., 2015) as we identified two 
instances of 17p deletion and one case with 11q aberration at diagnosis. We do 
however report one instance of 17p deletion being acquired at relapse. We also 
report more complex genomes in sequential biopsies which may be driven by the 
increased incidence of biallelic TP53 aberrations in sBL relapses, which we showed 
to be strongly associated with genomic instability in Chapter 5.  
 
Despite clear evidence for a key role in sporadic BL progression, TP53 status was 
stable in both DLBCL pairs. Both harboured one aberration that encompassed the 
TP53 gene with 16/547 exhibiting 17p CNN-LOH and 5/894 having a somatic 
heterozygous G187S mutation. Previous studies into the clonal evolution of DLBCL 
relapse have reported an enrichment for TP53 and CDKN2A aberrations at relapse 
(Juskevicius et al., 2017), but this was not seen in either of our cases. No 
abnormalities could be shown to be significantly associated with relapse in DLBCL 
which highlights that a larger patient cohort is required.  
 
In endemic B-NHL both patients acquired additional copies of chromosomes 7 and 
12 at relapse with no evidence of the abnormalities at diagnosis. Previous studies in 
B-NHL into chromosome 7 gain, as well as analysis as part of chapter 4, have 
suggested that a minimal common region at 7q22.1 involves a gene of interest in B-
NHL, most likely MIR106B, a paralogue of MIR17HG. p53 is a direct target of 
MIR106B, and inhibition of the constituents of the mir106b~25 miRNA cluster has 
been shown to increase endogenous p53 expression and causes cell cycle arrest 
and apoptosis (Kumar et al., 2011; Mehlich et al., 2018). Similarly, upregulation of 
MDM2 on chromosome 12 at 12q15 may drive p53 inhibition via increased 
ubiquitination and degradation. More samples with matched diagnostic and 
relapse/refractory are required to comprehensively investigate disease evolution in 
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endemic BL. While TP53 status for B266/B300 was unknown, the gene was 
sequenced in both samples from B558/B594. This patient had the most complex 
pattern of TP53 aberration within the cohort, as the diagnostic sample had 
undergone a subclonal 17p loss as well as harbouring an R248W mutation in the 
TP53 gene. At relapse the tumour acquired a 17p CNN-LOH, yet 17p deletion was 
still detected. Allelic frequency data from the copy number array data showed that the 
17p CNN-LOH event was present in the vast majority of tumour clones, while 17p 
deletion remained in a subclonal population. It is possible that the subclonal 
population with a TP53 mutation at diagnosis did not coexist with 17p deletions in the 
sample and acquired CNN-LOH at relapse. Without next generation sequencing data 
and the ability to compare allelic frequencies of TP53 variants across samples, it is 
not possible to ascertain the pattern of development.  
 
In this study we showed that disease progression in paediatric B-NHL follows one of 
two models previously reported and characterised in the literature (Jiang et al., 2014; 
Juskevicius et al., 2016; Juskevicius et al., 2017). Remarkably, biallelic TP53 
aberrations were a strong determinant of the pattern of clonal evolution of relapse in 
sBL, suggesting that TP53 aberrations are beneficial to the tumour survival under 
treatment. In DLBCL TP53 abnormalities were present in both cases but were stable 
throughout disease progression. There was also evidence of TP53 aberrations being 
involved in eBL relapse, with additional TP53 abnormalities arising at relapse. In 
combination with the findings reported in Chapters 5 and 6, it clear that TP53 is an 









Chapter 8: General Discussion 
 
Disease progression and treatment resistance represent the most significant clinical 
challenges in treating paediatric aggressive B-NHL (Kim et al., 2014). Event-free 
survival in paediatrics is over 90% but the outcome for those that undergo disease 
progression is dire, with salvage rates as low as 17% (Fujita et al., 2008; Poirel et al., 
2009; Anoop et al., 2012). It is not currently possible to reliably predict which patients 
will be successfully treated on frontline therapy and who will undergo 
relapse/refractory disease, so prognostic markers are urgently needed that can be 
utilised in the clinic. Prognostic markers have been successfully used in the clinic in 
other cancers to stratify patients, for example in breast cancer HER2 and ER 
expression are both used clinically to predict poor outcome in patients (Mass et al., 
2005). This has been particularly successful in paediatric B-ALL, in which patients 
are stratified based on cytogenetic subgroups that are significantly associated with 
outcome (Rand et al., 2011; Moorman, 2016).   
 
Previous studies have attempted to address this requirement. A study of karyotyping 
data from 238 patients of the FAB/LMB-96 trial reported that additional copies of 
chromosome arm 7q and deletion of 13q were prognostic markers of disease 
progression and poor outcome (Poirel et al., 2009). This represents the largest 
investigation of genomic markers of disease progression to date. A later study of 28 
BL patients using copy number arrays investigated genomic aberrations associated 
with outcome. This was the first study of prognostic markers using high resolution 
arrays in aggressive B-NHL (Schiffman et al., 2011). The study did not observe 
recurrent 13q loss or additional copies of 7q, instead reporting that MIR17HG 
amplification at 13q31.3 was associated with relapse. The observation was based on 
the finding that 2/3 relapse cases within the cohort had 13q31.3 amplification at 
diagnosis. However, no statistical analysis was performed due to small patient 
numbers. As with other genomic prognostic markers in B-NHL, this has not been 
translated to the clinic. The study also highlights the difficulty of identifying prognostic 
markers in small patient cohorts. No genomic studies involving meaningful cohort 
sizes have yet investigated outcome in paediatric B-NHL, with the majority of studies 
performed largely without clinical annotation or survival analysis, precluding the 
identification of useful prognostic markers.  
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Analysis performed in this thesis aimed to improve our ability to detect patients who 
were at risk of undergoing relapse/refractory disease at diagnosis. We hypothesised 
that copy number abnormalities detected by copy number arrays would be 
associated with disease progression and poor outcome. By combining our UK-based 
cohort of clinically-annotated patient samples with data from the literature the power 
of our investigation could be increased to create the largest clinically annotated 
dataset of high-resolution copy number data in paediatric B-NHL.  
 
The pilot project described in Chapter 3 demonstrated that copy number data 
identified from the literature could integrated with in-house datasets to perform 
analysis on paediatric and adult B-NHL. The literature search highlighted the 
abundance of adult DLBCL copy number data, which is to be expected given the 
demographics of the disease (HMRN - Incidence, 2019). Conversely, paediatric 
cases were less common in the literature, with only 52 cases with copy number data 
identified. We expanded our cohort further by processing as many cases from the 
CCLG biobank as possible, expanding the patient cohort from 25 cases to 110 for 
analysis in Chapter 4. It was also clear that a systematic pathology review of patient 
material was required to validate the working diagnoses provided by the treating 
centre of treatment. Due to the fact that treatment of paediatric B-NHL in the UK is 
uniform, regardless of histopathological subtype, many patients in the CCLG cohort 
had incomplete diagnoses or were diagnosed using earlier editions of the WHO 
Classification (Swerdlow et al., 2016). This initial pilot study highlighted significant 
data analysis hurdles that needed to be overcome, as well as issues regarding 
patient diagnosis and pathology review that informed and improved the later stages 
of the project. 
 
Comprehensive analysis of copy number data from 162 paediatric B-NHL samples 
identified three independent prognostic markers: 3q29 copy number gain, 17q copy 
number neutral loss of heterozygosity (CNN-LOH) and 17p CNN-LOH. 3q29 copy 
number gain had been reported in BL previously (Scholtysik et al., 2010) but was not 
shown to be prognostic. Copy number gains observed on 3q in the Scholtysik et al. 
study peaked at 3q27.2 and so were assumed to be associated with BCL6 
amplifications. However, in Chapter 4 we narrowed down the minimal common 
region of copy number gain to 3q29, and only 13/17 cases with this abnormality also 
harbouring an additional copy of BCL6. This suggests a different driver gene in the 
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region is responsible for increasing the risk of disease progression. Whole-exome 
sequencing data of a cohort of 39 B-NHL cases with paired tumour and normal 
sequencing data was analysed for mutations within 3q29. These data showed that 
somatic mutations involving PAK2 and OPA1 were recurrent in a cohort of 39 B-NHL 
cases with paired tumour and normal sequencing data, both of which were in the 
region of copy number gain in 17/17 cases with 3q29 gain. A study into PAK2 in 
haematological malignancies reported that expression was highest in high-risk 
patients in BL and DLBCL (Edlinger et al., 2017). Given this finding, the role of PAK2 
should be further investigated in paediatric B-NHL.  
 
17q CNN-LOH was observed in 20/162 cases screened in Chapter 4. Two distinct 
focal regions were identified spanning 17q22-17q24.1 and 17q11.2-17q21.32. 
Investigating variants across 17q identified 57 recurrently mutated genes. RNF213 
was most frequently mutated but was not covered by a region identified by 
GISTIC2.0. GNA13 was identified as a candidate gene within the region as mutations 
in GNA13 are reported to be recurrent in both BL and GCB-like DLBCL (Love et al., 
2012; Schmitz et al., 2012). 16/73 cases screened harboured a mutation in the gene, 
and 4/6 cases with CNN-LOH spanning the gene harboured mutations. Despite this 
association between 17q CNN-LOH and GNA13 mutation, mutations of the gene 
were not associated with disease progression or outcome, but it may suggest that 
mutations in GNA13 may cooperate with other abnormalities in disease progression.  
 
Chapter 4 was performed to provide a genome wide screen of copy number 
abnormalities in a cohort of paediatric B-NHL patients and to integrate this analysis 
with well-annotated clinical data to identify markers of poor prognosis. A major 
downside to this analysis was the availability of clinical data. Every effort was made 
early in the project to acquire time to follow up, relapse status and a key set of clinical 
parameters. In particular, relatively few centres could supply information regarding 
bone marrow and central nervous system involvement, as well as LDH levels with 
paired normal range data. These clinical factors are currently used to decide what 
treatment arm patients are registered to, and as a result should be included as 
cofactors in multivariate survival analysis. It would be beneficial to perform this 
analysis with more clinical information available. Focused analysis of whole exome 
sequencing data was performed as part of the work reported in this chapter to 
prioritise regions believed to be associated with significantly inferior outcomes in 
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paediatric B-NHL. However the study would benefit from an exome-wide analysis of 
the same data to identify prognostic genetic variants which are not associated with 
copy number abnormalities.  
 
17p CNN-LOH involving the TP53 gene was also found to be a significant prognostic 
marker associated with disease progression and poor outcome. In Chapter 5 I 
investigated the role of TP53 aberrations in paediatric B-NHL to determine whether 
this explained the prognostic value of 17p CNN-LOH. Mutations were present in 
46/95 cases screened (48.4%). Sequencing and copy number array data were 
integrated to determine the TP53 status of all 95 patients in the analysis. Overall, 
54.7% (52/95) of cases had at least one aberration involving the TP53 gene, with half 
of those (26/95, 27.4%) harbouring abnormalities affecting both alleles.  
 
Remarkably, TP53 aberrations were associated with lower overall survival and a 
shorter time to progression. TP53 mutations alone were also a significant prognostic 
marker. In fact, the TP53 normal group of the cohort had such a favourable prognosis 
that only one case underwent disease progression, and in Chapter 7 this case was 
shown to acquire two distinct aberrations involving the gene at relapse. The role of 
TP53 in B-NHL has been investigated previously but has not been discussed in the 
context of outcome. Leventaki et al. (2012) postulated that all BL patients must have 
abrogated TP53 function as CDKN1A expression was negative in 30/30 cases that 
they screened. Further characterisation of the cohort is required to determine 
whether functional p53 is still expressed in the cases without TP53 aberrations or 
whether regulators including MDM2 and MDM4 are involved. Regardless of this, we 
have identified a clear association between genetic abnormalities of the TP53 gene 
and a subsequent poor outcome. In chronic lymphocytic leukaemia, TP53 mutations 
are routinely screened for at diagnosis and are used to direct treatment decisions 
(Campo et al., 2018). This could easily be implemented in paediatric B-NHL, as the 
facilities already exist in hospitals across Europe (Malcikova et al., 2018). TP53 
abnormalities are not targetable directly, but in chronic lymphocytic leukaemia (CLL) 
these cases respond well to PI3K signalling inhibitors (Idelalisib) and BCL2 inhibitors 
(Venetoclax) (Brown et al., 2014; Stilgenbauer et al., 2016). A clinical trial 
investigating the efficacy of Venetoclax in combination with PI3K inhibitor Copanlisib 
in relapsed/refractory B-NHL is currently recruiting in Switzerland, the results of 
which may provide supporting data for TP53 aberrant lymphoma being a targetable 
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subgroup (ClinicalTrials.gov Identifier: NCT03886649). An important consideration 
with the potential use of these drugs on TP53 aberrant BL is that it is not clear 
whether CLL patients respond well to Idelalisib and Venetoclax due to the TP53 
aberrant nature of the malignancy, or whether TP53 simply highlights a high-risk 
group, meaning that targeted therapy is administered earlier. It is also important to 
mention that Idelalisib has been shown to be ineffective in BL. The key finding from 
the analysis performed during this project is that TP53 identified a subgroup of 
approximately 50% of patients with extremely low risk of relapse/refractory disease 
who might be candidates for treatment de-escalation. Treatment toxicity is a major 
problem in treating paediatric B-NHL (Cairo et al., 2018) and identifying patients who 
do not require the full protocol will help to reduce toxic effects. 
 
The increased risk of disease progression conferred by TP53 aberrations in 
paediatric B-NHL may function through increased genomic instability. We observed 
frequent complex chromosomal aberrations in patients with biallelic abnormalities of 
TP53 using copy number arrays. Aberrations in the TP53 gene are associated with 
genomic instability in medulloblastoma (Rausch et al., 2012) and has been shown to 
drive chromothripsis in these patients. TP53 mutations have also been shown to 
drive genomic instability in ovarian cancer, which directly drives chemoresistance 
and disease progression (Zhang et al., 2017). Complex chromosomal abnormalities 
affecting chromosome arms 1q, 11q and 13q were significantly more frequent in the 
TP53 biallelic group, but none of these were independently associated with outcome. 
Future investigations into the mutational profile of TP53 abnormal vs normal 
subgroups will allow us to characterise these patients and the complex aberrations 
they harbour more comprehensively.  
 
The work presented in Chapter 5 could be further improved by the inclusion of 
additional clinical data in the same way as Chapter 4. Considerable gaps in bone 
marrow, CNS and LDH data hampers the survival analysis and translation to the 
clinic and the study would be improved by reanalysis with more clinical data 
available. Additionally the cohort could be improved by securing constitutional DNA 
from more patients so that mutations could be confirmed to be somatic. Analysis of 
complex chromosomal aberrations highlighted an important association between 
TP53 status and these aberrations. However, it was not possible to properly 
characterise these complex genomic changes using copy number arrays alone. Copy 
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number arrays are not able to define breakpoints in complex aberrations, and are 
relatively low resolution. To account for this, a sequencing-based approach would be 
necessary. Whole genome sequencing would be ideal as many of the breakpoints 
would not be within exons, and long read sequencing would allow for accurate 
mapping of aberrations. O ford Nanopore s MinION technolog  would be an effective 
tool for analysing these aberrations. 
 
An important finding from survival analysis in paediatric B-NHL was the observation 
that 6q deletion was associated with cases that did not undergo disease progression. 
In fact, no case with deletion of PRDM1 died or experienced relapse/refractory 
disease. PRDM1 codes for BLIMP1 which is an important driver of B cell terminal 
differentiation (Shaffer et al., 2002). PRDM1 deletion has been reported previously in 
adult ABC-like DLBCL but not in GCB-like DLBCL (Pasqualucci et al., 2006), 
suggesting that it would be associated with a poor prognosis. In contrast, we 
identified PRDM1 in 0/18 (0.0%) cases of disease progression and 18/119 (15.1%). It 
is possible that this disparity in prognostic value is explained by the fact that 
Pascqualucci et al. (2006) screened primarily adult DLBCL patients while our cohort 
is primarily paediatric BL. The identification of a marker of good risk in paediatric B-
NHL opens up the possibility for treatment de-escalation.  
 
Our investigation of 105 endemic BL cases is the largest genomic study of this 
disease subtype. Recent studies have described the genetics of endemic BL without 
relating these findings to outcome (Grande et al., 2019; Panea et al., 2019). We 
described genomic markers detectable by copy number array that could be 
implicated in disease progression. Perhaps most significantly, genomic events that 
were significant prognostic markers of progression in the sporadic cohort were shown 
to be unrelated to relapse in the endemic setting, including TP53 aberration. TP53 
abnormalities were less common in endemic BL compared to sporadic BL (47/101, 
46.5% vs 44/70, 62.9%, p=0.043, Fisher exact test), but more striking was the 
dramatic difference in biallelic abnormalities (12/101, 11.9% vs 21/70, 30%; p=0.005, 
Fisher exact test) and the lack of association with disease progression. We 
hypothesise that this is primarily due to a different clinical setting and treatment 
protocols. It is likely, given this data, that the survival advantage conferred to the 
tumour by TP53 aberration in sBL is important in the setting of dose intense 
FAB/LMB-based treatment. Treatment given to eBL patients in Malawi is 
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substantially less intensive (Molyneux et al., 2017) and development of therapy 
resistance more likely, even in the absence of TP53 aberration.  
 
The clinical setting in Malawi provided unique difficulties to this analysis. Relatively 
high abscondment rates and changes in treatment protocols complicated the analysis 
and limited the size of the cohort that could be interrogated in survival analysis. 
Further sample collection is ongoing from patients diagnosed with B-NHL in Malawi, 
so a larger cohort is achievable in the future. Another challenge presented by the 
setting of the study was patient sample quality. The requirement to transport patient 
samples back to the UK at room temperature imposed limits on what could be 
achieved. Whole exome sequencing on DNA from PreservCyt-fixed samples was not 
possible at the point of the project s inception. Since the completion of this part of the 
project, other members of the lab have begun a pilot project to perform library preps 
on this DNA. Once this process has been fully optimised it is the plan to generate 
whole exome sequencing data for a large part of the Malawi cohort.  
 
The evolution of progressive disease in paediatric B-NHL is poorly understood but is 
known to progress either in a late-diverging/linear pattern or an early-
diverging/branching pattern.  Only one study has investigated clonal evolution in BL 
relapses (Aukema et al., 2015) and did not utilise high resolution genomic tools. In 
BL the majority of patients have been shown to exhibit the linear pattern of evolution. 
Our study of seven sBL patients with paired diagnostic and relapse material showed 
that cases who had biallelic TP53 abnormalities at diagnosis followed this pattern of 
evolution. All six patients sBL with TP53 mutation data had biallelic aberrations at the 
point of disease progression, which supports the discovery that TP53 aberrations are 
a key driver of disease progression in paediatric BL. When the major diagnostic 
subclone harboured TP53 biallelic aberrations the copy number profile of the relapse 
sample strongly resembled that of the diagnostic sample, supporting the hypothesis 
that clonal evolution in these cases was linear. The copy number profile was more 
aberrant at relapse compared to the diagnostic sample, which corroborates the 
findings of the karyotyping study into BL relapses (Aukema et al., 2015). Increased 
genomic complexity is likely driven by TP53 aberration at relapse, as we showed that 
cases with aberrations involving both alleles had significantly more complex 
genomes in Chapter 5. A significant limitation to the scope of this work is the use of 
log ratio as a proxy measurement for clonal fraction. This could be improved further 
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by the use of high-depth whole genome sequencing which would allow for analysis 
using bioinformatics tools such as ClonEvol to robustly identify subpopulations in 
paired diagnostic and relapse samples. This would address several limitations to the 
analysis presented in this thesis.  
 
In summary, this PhD project has identified and characterised an important genomic 
prognostic marker that plays an important role in the development of treatment-
resistant paediatric B-NHL. These findings may shape the way that patients are 
screened at diagnosis and managed through treatment. TP53 aberrations play a 
major role in resistance to chemotherapy and genomic instability. Additional 
prognostic markers, detectable by copy number arrays, were also shown to be 
associated with disease progression in the paediatric setting. A good-prognostic 
marker, del6q, was also identified. No patients with del6q underwent disease 
progression. As a leading candidate within the minimal region of deletion, PRDM1 
would be amenable to clinical analysis by FISH or copy number arrays and may 
identify patients suitable for treatment de-escalation to reduce the toxic effects of 
therapy. However, to enable our findings to have significant impact in the clinic, 
further validation of prognostic markers is required in an additional, comparable 
cohort. Access to a prospective trial cohort with extensive clinical annotation would 
allow us to confirm the prognostic role of TP53 aberrations in disease progression 
and allow us to better stratify patients based on their risk, as is done routinely in other 
paediatric malignancies such as B-ALL (Moorman, 2016) and medulloblastoma 
(Schwalbe et al., 2017).  
 
The findings of this study have given us the opportunity to ameliorate treatment-
related morbidity in a large subgroup of paediatric B-NHL patients. While the 
introduction of rituximab to frontline therapy has all but eliminated relapsed/refractory 
disease, meaning that validation of TP53 aberration as a prognostic marker cannot 
be validated on a prospective trial cohort. However, the control arm of the inter-B-
NHL trial, who did not receive rituximab, are an ideal retrospective cohort to validate 
our ability to identify low-risk patients with a good-prognostic marker, such as TP53 
wildtype status, or del6q (Minard-Colin et al., 2016). In addition, projects such as the 
ACCELERATE trial now exist to aid in the development and design of clinical trials in 
paediatric B cell malignancies (Pearson et al., 2019). The ACCELERATE project 
highlights the need for combining resources worldwide to bring together all available 
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data and samples from patients with relapsed/refractory disease. This trial platform 
represents an exciting opportunity to develop prognostication in paediatric lymphoma 
and validate the clinical impact of TP53 status.  
 
The next steps to improve the outcome for patients will not simply focus on those 
with poor risk prognostic markers, but will heavily focus on the patients who are 
cured with standard therapy and have good risk markers, as the recent introduction 
of rituximab to frontline therapy has significantly reduced the incidence of disease 
progression in paediatric B-NHL (V et al., 2020). Patients now experience higher-
than-ever progression-free survival rates but this still comes at the cost of significant 
toxicity. The results presented in this thesis highlight that approximately half of the 
cohort without TP53 abnormalities do not require rituximab to achieve excellent 
progression-free survival rates, and are candidates for treatment de-escalation. With 
confirmation of the findings of this project, we can significantly change how diagnosis 
and management of disease is performed and bring about a positive change for 
patient outcome. 
 









Minimum and maximum 
cap values on analyzed 
data. 
-cap  2 Regions with a log2 ratio greater than the cap are set to the cap value; 
regions with a log2 ratio less than -cap value are set to -cap. Values must 
be positive.  
1.5 
Smallest number of 
markers to allow in 
segments from the 
segmented data. 
-js  4 Segments that contain fewer than this number of markers are joined to the 
neighboring segment that is closest in copy number. 
4 
Threshold for copy 
number amplifications.   
-ta  0.15 Regions with a copy number gain above this value are considered 
amplified.  
0.1 
Threshold for copy 
number deletions.   
-td  0.15 Regions with a copy number loss below this value are considered 
deletions.  
0.1 
Significance threshold for 
q-values.   
-qvt  0.1 Regions with q-values below this number are considered significant.  0.25 
Gene GISTIC -genegistic  1 Flag indicating that the gene GISTIC algorithm should be used to calculate 
the significance of deletions at a gene level instead of a marker level. 




-smallmem 1 Flag indicating that the SegArray memory compression scheme should be 
used to reduce the memory requirements of the computation for large data 
sets. Computation is somewhat slower with memory compression 
enabled. Allowed values= (1,0).  
1 
Broad Level Analysis -broad  1 Flag indicating that an additional broad-level analysis should be 




-twosides  1 Flag indicating that a two-dimensional quadrant figure should be created 
as part of a broad analysis. Allowed values = (1,0).  
0 
Broad Length -brlen  0.5 Threshold used to distinguish broad from focal events, given in units of 
fraction of chromosome arm.  
0.98 
Confidence Interval -conf  
 
0.99 Confidence level used to calculate the region containing a driver.  0.75 
Arm Peel Off -armpeel  1 Flag set to enable arm-level peel-off of events during peak definition. The 
arm-level peel-off enhancement to the arbitrated peel-off method assigns 
all events in the same chromosome arm of the same sample to a single 
0 
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peak. It is useful when peaks are split by noise or chromothripsis. Allowed 
values= (1,0).  
Gene Tables -savegene  
 
1 Flag indicating that gene tables should be saved. Allowed values= (1,0).  0 
Remove Sex 
Chromosomes 
-rx  1 Flag indicating whether to remove data from the sex chromosomes before 
analysis.  Allowed values= (1,0).  
1 
Gene Collapse Method -gcm  extreme Method for reducing marker-level copy number data to the gene-level copy 
number data in the gene tables. Markers contained in the gene are used 
when available, otherwise the flanking marker or markers are used. 
Allowed values are mean, median, min, max or extreme. The extreme 
method chooses whichever of min or max is furthest from diploid.  
mean 









Time to progression (TTP) Overall survival (OS)   
HR (95% CI) p value HR (95% CI) p value No. cases with abnormality (%) 
Univariate analysis           
7q21q22 Gain (Poirel et al.) 0.54 (0.16-1.9) 0.33 0.42 (0.13-1.4) 0.17 37/162 (22.8%) 
13q34 Loss (Nelson et al., Poirel et al.)  1.8 (0.6-5.6) 0.29 1.4 (0.49-4.3) 0.5 19/162 (11.7%) 
13q31.3 Gain (Schiffman et al.) 0.86 (0.28-2.6) 0.79 1.3 (0.55-3.3) 0.51 41/162 (25.3%) 
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13 - benign(0) 












13 - benign(0.095) 
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13 - benign(0.152) 
14/136 Paired 17:63010694 
missense_var









14/325 Paired 17:63010541 
missense_var
iant 1214/4922 968/1134 
Q323





















13 - benign(0.218) 



























13 - benign(0.05) 
14/400 Paired 17:63052633 stop_gained 325/4922 79/1134 Q27* Cag/Tag COSM982995 HIGH 
GNA1
3 - - 
14/414 Paired 17:63049634 stop_gained 742/4922 496/1134 R166* Cga/Tga COSM6081726 HIGH 
GNA1














ag/ag - HIGH 
GNA1
3 - - 
15/360 Paired 17:63052527 
missense_var





















13 - benign(0.014) 
16/511 Paired 17:63052529 
missense_var
























21/153 Paired 17:63052633 stop_gained 325/4922 79/1134 Q27* Cag/Tag COSM982995 HIGH 
GNA1
3 - - 



























13 - benign(0.001) 
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5/796 Paired 17:63010556 
missense_var




















































































10/45 Unpaired 17:63052630 stop_gained 328/4922 82/1134 Q28* Caa/Taa - HIGH 
GNA1
3 - - 


























































































18/721 Unpaired 17:63010916 
missense_var



































































































12/760 Unpaired 17:63014381 
missense_var









12/760 Unpaired 17:63014381 
missense_var





























































7* Cag/Tag - HIGH 
RNF2
13 - - 




























































15/156 Unpaired 17:63010848 
missense_var
















































































































































16/817 Unpaired 17:63014390 stop_gained 788/4922 542/1134 L181* tTg/tAg COSM4170816 HIGH 
GNA1
3 - - 















































































































2 Unpaired 17:63010775 
missense_var























21/199 Unpaired 17:63052633 stop_gained 325/4922 79/1134 Q27* Cag/Tag COSM982995 HIGH 
GNA1
3 - - 

















































































































































































































































































































































































































































































































































































































































































































































































































































































classification** Mutation type TP53 status 
1/49 BL 
no 
abnormality     no mutation         no mutation 
no 
abnormality 
10/10065 F1 BL 17p Loss 22.2 99.6% G266E G>A 85 Inactive non-functional Homozygous Biallelic 
10/134 DLBCL 
no 





abnormality     R249T G>C 21 Inactive non-functional Heterozygous Monoallelic 
10/28 BL 17p Loss 20.5 91.9% no mutation         no mutation Monoallelic 
10/45 BL 
no 





abnormality     D208G A>G 39 Fully active functional Heterozygous Monoallelic 
11/602 BNHL 
no 
abnormality     E286K G>A 41 Inactive non-functional Heterozygous Monoallelic 
11/634 BL 
no 





abnormality     S241P T>C 38 Inactive non-functional Heterozygous Monoallelic 
12/195 BNHL 
no 










abnormality     no mutation         no mutation 
no 
abnormality 
12/709 F1 BL 
no 






























abnormality     L289fs TC>* 89 
The activity of 
truncated p53 is 






abnormality     C176F G>T 40 Inactive partially functional Heterozygous Monoallelic 
14/165 BL 
no 
abnormality     R248Q G>A 44 Inactive non-functional Heterozygous Monoallelic 
14/167 BL 
no 











abnormality     E258D A>C 48 Inactive non-functional Heterozygous Monoallelic 
14/325 BL 
no 





14/334 DLBCL 17p Loss 22.2 99.6% no mutation         no mutation Monoallelic 
14/36 BL 
no 
abnormality     no mutation         no mutation 
no 
abnormality 
14/400 BL 17p Loss 19.7 88.3% V122fs Gdel 
40 
The activity of 
truncated p53 is 













abnormality     R248W C>T 49 Inactive non-functional Heterozygous Monoallelic 
14/486 BL 
no 
abnormality     V173M G>A 36 Inactive non-functional Heterozygous Monoallelic 
14/502 DLBCL 
no 

















abnormality     G245S G>A 39 Inactive non-functional Heterozygous Monoallelic 
15/314 BL 
no 







abnormality     no mutation         no mutation 
no 
abnormality 
15/353 F1 BL 
no 

















abnormality     Y205F A>T 
39 
The activity of 
truncated p53 is 











abnormality     no mutation         no mutation 
no 
abnormality 
16/391 F1 BL 
17p CNN-
LOH 22.2 99.6% R248Q G>A 40 Inactive non-functional Homozygous Biallelic 
16/488 BL 
no 
abnormality     G266E G>A 39 Inactive non-functional Heterozygous Monoallelic 
16/511 BL 
no 








% no mutation         no mutation Monoallelic 
16/611 BL 
no 





abnormality     no mutation         no mutation 
no 
abnormality 
16/816 BL 17p Loss 20.6 92.4% R175H G>A 31 Inactive non-functional Hemizygous Biallelic 
16/817 BL 
no 
abnormality     no mutation         no mutation 
no 
abnormality 
16/818 F1 BL 17p Loss 17.9 80.3% V216G T>G 92 Inactive non-functional Hemizygous Biallelic 
16/827 BL 17p Loss 20.6 92.4% D281G A>G 24 Inactive non-functional Hemizygous Biallelic 
16/847 DLBCL 17p Loss 21.5 96.4% R248Q G>A 56 Inactive non-functional Hemizygous Biallelic 
18/721 P1 BL 
no 
abnormality     no mutation         no mutation 
no 
abnormality 
20/3020 DLBCL 17p Loss 19 85.2% no mutation         no mutation Monoallelic 
20/4012 BL 
no 





abnormality     Y126S A>C 96 Inactive non-functional Homozygous Biallelic 
21/199 BL 
no 
abnormality     R282W C>T 18 Inactive non-functional Heterozygous Monoallelic 
21/224 DLBCL 
no 

















abnormality     no mutation         no mutation 
no 
abnormality 
21/322 BL 17p Loss 22.2 99.6% R273H G>A 59 Inactive non-functional Hemizygous Biallelic 
21/37 BL 
no 
abnormality     R248Q G>A 41 Inactive non-functional Heterozygous Monoallelic 
21/55 BL 
no 
abnormality     C135R T>C 38 Inactive non-functional Heterozygous Monoallelic 
22/22 BL 
no 
abnormality     R175H G>A 50 Inactive non-functional Heterozygous Monoallelic 
22/9 BL 
17p CNN-
LOH 14 62.8% T155N C>A 84 Inactive non-functional Homozygous Biallelic 
3/95 DLBCL 
no 





















LOH 21.8 97.8% G245S G>A 88, 90 Inactive non-functional Homozygous Biallelic 
4/283 DLBCL 17p Loss 22.2 99.6% R213Q G>A 71 Inactive non-functional Hemizygous Biallelic 
4/297 BL 
no 










abnormality     no mutation         no mutation 
no 
abnormality 
4/830 BNHL 17p Loss 22.2 99.6% L257P, R282W T>C, C>T  65, 30 Inactive, Inactive non-functional Hemizygous Biallelic 
4/911 BL 
17p CNN-
LOH 17.2 77.1% R175H G>A 91 Inactive non-functional Homozygous Biallelic 
5/212 DLBCL 
no 





abnormality     R333P G>C 36 Partial activity partially functional Heterozygous Monoallelic 
5/311 BL 
no 
abnormality     no mutation         no mutation 
no 
abnormality 
5/437 BL 17p Loss 22.2 99.6% R196P G>C 88 Inactive non-functional Hemizygous Biallelic 
5/685 BL 
17p CNN-
LOH 12.9 57.8% no mutation         no mutation Monoallelic 
5/686 BL 
no 







abnormality     R273C C>T 45 Inactive non-functional Heterozygous Monoallelic 
5/796 BL 
no 
abnormality     no mutation         no mutation 
no 
abnormality 
5/894 P1 DLBCL 
no 
abnormality     G187S G>A 39 Fully active functional Heterozygous Monoallelic 
5/915 BL 17p Loss 18.5 83.0% no mutation         no mutation Monoallelic 
5/96 BL 
no 
abnormality     no mutation         no mutation 
no 
abnormality 
6/475 BL 17p Loss 19.4 87.0% R273C C>T 86 Inactive non-functional Hemizygous Biallelic 
7/146 BL 
no 
abnormality     P151A C>G 20 Inactive non-functional Heterozygous Monoallelic 
7/550 BL 
17p CNN-
LOH 22.2 99.6% R175H G>A 92 Inactive non-functional Homozygous Biallelic 
9/25 BL 
17p CNN-
LOH 16.4 73.5% H179R A>G 92 Inactive non-functional Homozygous Biallelic 





Time to progression (TTP) Overall survival (OS) 
HR (95% CI) p value HR (95% CI) p value No. cases with abnormality (%) 
CNS involvement 1.53 (0.2-12.3) 0.686  4.40 (0.9-22.0)  0.072  4/47 (8.5%)* 
BM involvement 1.68 (0.5-6.0) 0.421  3.40 (0.9-13.0)  0.067  14/48 (29.2%)* 
TP53 deletion 1.60 (0.4-6.0) 0.470 0.44 (0.1-3.4) 0.430 10 (17.2%) 
TP53 CNN-LOH 4.80 (1.4-16.0) 0.011 3.40 (0.9-13.0) 0.069 6 (10.3%) 
TP53 mutation 8.30 (1.1-64.0) 0.043 7.20 (0.9-56.0) 0.060 35 (60.3%) 
Any TP53 abnormality 7.00 (0.9-54.0) 0.062 6.20 (0.8-48.0) 0.083 37 (63.8%) 
TP53 monoallelic abnormality 4.40 (0.5-42.0) 0.200 7.10 (0.8-61.0) 0.074 16 (27.6%) 
TP53 biallelic abnormality  8.80 (1.1-70.0) 0.041 5.20 (0.6-45.0) 0.130 21 (36.2%) 
Appendix F - Survival analysis of TP53 abnormalities in subsets of the paediatric B-NHL cohort. * Value calculated as a percentage 








































B095 NA M 10 NA NA NA MYC/IGL 1 No No 1 No Yes No No No 
B105 L (BL Protocol) M 3 1 0 0 IGH/MYC 1 No Yes 1 No No No No No 
B121 L (BL Protocol) M 6 2 0 0 MYC/IGL 1 Yes Yes 1 No No No No No 
B150 NL (BL Protocol 1) M 12 3 0 0 IGH/MYC 1 Yes Yes 1 No No No No No 
B153 NL (BL Protocol 1) F 5 4 1 0 IGH/MYC 1 Yes Yes 1 No Yes No Yes Yes 
B156 NL (BL Protocol 1) F 9 2 0 0 IGH/MYC NA No No 1 No Yes No Yes No 
B160 NL (BL Protocol 1) M 12 4 1 1 IGH/MYC 1 Yes Yes 1 No No Yes No Yes 
B172 NL (BL Protocol 1) F 3 4 1 1 IGH/MYC 1 Yes Yes 1 No No Yes No Yes 
B174 NL (BL Protocol 1) M 6 1 0 0 IGH/MYC NA Yes Yes 1 No No Yes No Yes 
B186 
NL (Protocol 2) no 
dox M 5 2 0 0 MYC/IGL 1 Yes Yes 1 No No Yes No No 
B190 
NL (Protocol 2) no 
dox F 11 1 0 0 IGH/MYC 1 Yes Yes 1 No No No No No 
B195 
NL (Protocol 3)  + 
dox F 5 3 NA NA IGH/MYC 1 Yes Yes 1 No No No No No 
B201 
NL (Protocol 3)  + 
dox M 4 4 NA 0 IGH/MYC 1 Yes Yes 1 No No No No No 
B210 NA M 7 NA NA NA MYC/IGL 1 No No 1 No No No No Yes 
B216 NA M 2 NA NA NA IGH/MYC 1 No No 1 No Yes No No Yes 
B232 L (BL Protocol) M 12 2 0 0 IGH/MYC 1 Yes Yes 1 No Yes Yes No Yes 
B264 
NL (Protocol 3)  + 
dox M 8 3 0 NA IGH/MYC NA Yes Yes 1 No No No No No 
B272 NA F 6 1 0 0 IGH/MYC 1 No No 1 No No No Yes No 
B273 
NL (Protocol 3)  + 
dox F 13 4 1 0 MYC/IGL 1 Yes Yes 1 No No No No No 
B282 
NL (Protocol 3)  + 
dox M 5 4 1 0 IGH/MYC 1 Yes Yes 1 Yes No No No No 
B284 NA F 5 4 NA NA MYC/IGK 1 No No 1 No No No No No 
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B285 
NL (Protocol 3)  + 
dox F 4 3 0 0 IGH/MYC 1 Yes Yes 1 No No Yes No No 
B286 
NL (Protocol 2) no 
dox M 6 2 NA NA IGH/MYC 1 Yes Yes 1 No Yes No No Yes 
B287 
NL (Protocol 3)  + 
dox M 5 4 1 NA IGH/MYC 1 Yes Yes 1 No No No No No 
B288 NA F 9 3 NA NA IGH/MYC 1 No No 1 No No No No No 
B289 
NL (Protocol 3)  + 
dox F 7 3 NA NA IGH/MYC 1 Yes Yes 1 No Yes No No No 
B294 
NL (Protocol 3)  + 
dox F 6 3 0 NA IGH/MYC 1 Yes Yes 1 No No No No No 
B298 
NL (Protocol 3)  + 
dox M 6 3 0 0 MYC/IGK 1 Yes Yes 1 No Yes No No No 
B309 
NL (Protocol 3)  + 
dox F 6 4 NA 1 IGH/MYC NA No No 1 No Yes No No No 
B311 
NL (Protocol 3)  + 
dox F 8 2 0 0 IGH/MYC 1 Yes Yes 1 No No No No No 
B313 NA F 4 3 0 NA MYC/IGL 1 No No 1 No No No No No 
B314 
NL (Protocol 3)  + 
dox F 4 4 0 0 IGH/MYC 1 Yes Yes 1 No No No No No 
B321 
NL (Protocol 3)  + 
dox M 3 3 0 NA MYC/IGL 1 Yes Yes 1 No No No No No 
B324 NA F 3 NA NA NA IGH/MYC 1 No No 1 No No No No Yes 
B326 
NL (Protocol 3)  + 
dox F 6 3 NA NA IGH/MYC 1 Yes Yes 1 No No No No No 
B330 
NL (Protocol 2) no 
dox M 6 2 0 0 IGH/MYC 1 Yes Yes 1 No No No No No 
B343 
NL (Protocol 3)  + 
dox M 10 1 0 NA IGH/MYC NA Yes Yes 1 No No No No No 
B346 
NL (Protocol 3)  + 
dox M 7 3 0 NA IGH/MYC 1 Yes Yes 1 No No No Yes No 
B347 
NL (Protocol 3)  + 
dox M 7 3 NA NA IGH/MYC NA Yes Yes 1 No No No Yes No 
B349 
NL (Protocol 3)  + 
dox F 6 3 0 NA IGH/MYC 1 Yes Yes 1 No No No No Yes 
B361 
NL (Protocol 3)  + 
dox M 9 3 0 0 IGH/MYC NA No No 1 No No No No No 
B363 L (BL Protocol) F 12 1 0 0 MYC/IGL 1 Yes Yes 1 No No Yes No No 
B370 
NL (Protocol 3)  + 
dox M 8 3 NA NA IGH/MYC 1 Yes Yes 1 No No No No No 
B371 
NL (Protocol 3)  + 
dox M 10 3 0 0 IGH/MYC 1 Yes Yes 1 No No No No Yes 
B374 
NL (Protocol 2) no 
dox M 5 1 0 0 IGH/MYC 1 Yes Yes 1 No No No No Yes 
B375 
NL (Protocol 3)  + 
dox M 8 3 0 0 MYC/IGL 1 Yes Yes 1 No No No No No 
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B389 
NL (Protocol 3)  + 
dox F 11 NA NA NA IGH/MYC 1 No No 1 No No No No No 
B391 
NL (Protocol 3)  + 
dox M 8 4 0 1 MYC/IGK 1 Yes Yes 1 No No No No No 
B397 
NL (Protocol 3)  + 
dox F 10 3 0 0 MYC/IGL 1 Yes Yes 1 No No No No No 
B409 
NL (Protocol 3)  + 
dox M 3 NA NA NA IGH/MYC NA No No 1 No No No No No 
B410 
NL (Protocol 3)  + 
dox M 3 3 NA NA IGH/MYC 1 No No 1 No No No No No 
B413 
NL (Protocol 3)  + 
dox M 12 4 NA 1 IGH/MYC 1 Yes Yes 1 No No No No No 
B420 NA M 6 NA NA NA MYC/IGL NA No No 1 No No No No Yes 
B422 
NL (Protocol 3)  + 
dox M 5 3 0 NA IGH/MYC 1 Yes Yes 1 No No Yes Yes No 
B423 
NL (Protocol 3)  + 
dox M 6 3 NA NA IGH/MYC 1 Yes Yes 1 No No No No No 
B428 
NL (Protocol 2) no 
dox M 7 2 0 0 IGH/MYC 1 Yes Yes 1 No No No No No 
B436 
NL (Protocol 3)  + 
dox M 7 3 0 0 IGH/MYC 1 Yes Yes 1 No Yes No No No 
B453 NA NA NA NA 1 NA IGH/MYC 1 No No 1 Yes Yes No No No 
B459 NA F 9 3 NA NA IGH/MYC 1 No No 1 No No No No Yes 
B463 
NL (Protocol 3)  + 
dox M 8 3 0 0 IGH/MYC 1 Yes Yes 1 No No No No No 
B483 
NL (Protocol 3)  + 
dox M 9 4 0 0 IGH/MYC NA Yes Yes 2 No No No Yes No 
B492 
NL (Protocol 3)  + 
dox M 11 1 0 0 IGH/MYC NA Yes Yes 2 No Yes No No Yes 
B495 
NL (Protocol 3)  + 
dox F 7 3 or 4 0 0 IGH/MYC NA Yes Yes 2 No No No No No 
B498 
NL (Protocol 3)  + 
dox F 5 1 0 0 IGH/MYC NA Yes Yes 2 No Yes No No No 
B501 
NL (Protocol 3)  + 
dox F 10 3 0 0 IGH/MYC NA Yes Yes 2 No No No No No 
B505 
NL (Protocol 3)  + 
dox M 5 1 0 0 IGH/MYC NA Yes Yes 2 No No No No No 
B509 
NL (Protocol 3)  + 
dox M 10 3 0 0 IGH/MYC NA Yes Yes 2 No Yes No No No 
B516 
NL (Protocol 3)  + 
dox M 9 3 0 0 MYC/IGL NA Yes Yes 2 No No No No Yes 
B520 
NL (Protocol 3)  + 
dox M 16 4 1 NA IGH/MYC NA Yes Yes 2 No No No No No 
B536 
NL (Protocol 3)  + 
dox M 10 3 0 NA IGH/MYC NA Yes Yes 2 No No No No No 
B538 
NL (Protocol 3)  + 
dox M 10 3 0 1 IGH/MYC NA Yes Yes 2 No Yes No Yes No 
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B550 
NL (Protocol 3)  + 
dox F 5 3 or 4 0 0 MYC/IGL NA Yes Yes 2 No No No No No 
B555 NA NA NA NA NA NA IGH/MYC NA No No 2 No No No No No 
B558 
NL (Protocol 3)  + 
dox F 7.5 3 0 0 IGH/MYC NA Yes Yes 2 No No Yes No No 
B570 
NL (Protocol 3)  + 
dox F 12 3 0 0 IGH/MYC NA Yes Yes 2 No No No No Yes 
B572 
NL (Protocol 3)  + 
dox F 7 3 or 4 NA NA IGH/MYC NA Yes Yes 2 No No No No No 
B583 
NL (Protocol 3)  + 
dox F 7 4 NA 1 IGH/MYC NA Yes Yes 2 No No Yes Yes No 
B595 
NL (Protocol 3)  + 
dox F 6 1 0 0 MYC/IGL NA Yes Yes 2 No No Yes Yes No 
B618 
NL (Protocol 3)  + 
dox F 5 3 0 0 MYC/IGL NA Yes Yes 2 No No No No No 
B624 
NL (Protocol 3)  + 
dox F 8 1 0 0 IGH/MYC NA Yes Yes 2 No No No No No 
B631 
NL (Protocol 3)  + 
dox F 7 3 0 0 IGH/MYC NA Yes Yes 2 No No No No No 
B643 
NL (Protocol 3)  + 
dox F  12 4 1 0 IGH/MYC NA Yes Yes 2 No Yes Yes No No 
B648 
NL (Protocol 3)  + 
dox M 8 3 0 0 IGH/MYC NA Yes Yes 2 No No No No No 
B667 
NL (Protocol 3)  + 
dox M 7 3 or 4 0 0 MYC/IGL NA Yes Yes 2 No No No No No 
B674 
NL (Protocol 3)  + 
dox M 7 3 0 0 IGH/MYC NA Yes Yes 2 No Yes No Yes No 
B676 
NL (Protocol 3)  + 
dox F 7 3 0 0 IGH/MYC NA Yes Yes 2 No No No No No 
B678 
NL (Protocol 3)  + 
dox F 9 4 0 0 MYC/IGL NA Yes Yes 2 No No No No No 
B679 
NL (Protocol 3)  + 
dox M 11 4 0 1 IGH/MYC NA Yes Yes 2 No No No No No 
B680 
NL (Protocol 3)  + 
dox M 9 4 NA 0 IGH/MYC NA Yes Yes 2 No No No No No 
B681 
NL (Protocol 3)  + 
dox F 12 4 0 1 IGH/MYC NA Yes Yes 2 No No No No Yes 
B686 
NL (Protocol 3)  + 
dox M 3 3 0 0 IGH/MYC NA Yes Yes 2 No No Yes No No 
B697 
NL (Protocol 3)  + 
dox F 9 3 0 0 IGH/MYC NA Yes Yes 2 No Yes No No Yes 
B709 
NL (Protocol 3)  + 
dox M 4 3 0 NA IGH/MYC NA Yes Yes 2 No No No No No 
B721 
NL (Protocol 3)  + 
dox M 6 4 0 1 IGH/MYC NA Yes Yes 2 No No No No No 
B730 
NL (Protocol 3)  + 
dox M 9 3 0 NA IGH/MYC NA Yes Yes 2 No No No No No 
B738 
NL (Protocol 3)  + 
dox M 3 3 0 0 IGH/MYC NA Yes Yes 2 No No No No Yes 
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B755 
NL (Protocol 3)  + 
dox M 8 3 0 0 IGH/MYC NA Yes Yes 2 No No No No No 
B766 
NL (Protocol 3)  + 
dox F 8 3 0 0 IGH/MYC NA Yes Yes 2 No No Yes No No 
B767 NA F 5 3 or 4 NA NA IGH/MYC NA No No 2 Yes Yes No Yes Yes 
B773 
NL (Protocol 3)  + 
dox M 14 3 0 0 MYC/IGL NA Yes Yes 2 No No No No No 
B779 
NL (Protocol 3)  + 
dox M 13 1 0 0 IGH/MYC NA Yes Yes 2 No No No No No 
B780 
NL (Protocol 3)  + 
dox M 8 3 0 0 MYC/IGL NA Yes Yes 2 No Yes Yes Yes No 
B800 
NL (Protocol 3)  + 
dox F 4 1 0 0 IGH/MYC NA Yes Yes 2 No No No No No 
B803 
NL (Protocol 3)  + 
dox M 10 4 0 1 MYC/IGL NA Yes Yes 2 No No No Yes Yes 
B808 
NL (Protocol 3)  + 
dox M 5 1 0 0 MYC/IGL NA Yes Yes 2 No No Yes No No 















abnormality None       Normal No   
B105 
No 
abnormality None       Normal No   
B121 
No 
abnormality None       Normal No   
B150 
No 
abnormality None       Normal No   
B153 
No 
abnormality None       Normal No   
B156 
No 
abnormality None       Normal No   
B160 17p deletion None       Monoallelic Yes 
Loss + No 
mutation 
B172 17p deletion None       Monoallelic Yes 
Loss + No 
mutation 
B174 17p deletion None       Monoallelic Yes 
Loss + No 
mutation 
B186 17p deletion None       Monoallelic Yes 





c.529C>T Probably damaging Deleterious 
Monoallelic Yes 1 Mutation only 
B195 
No 
abnormality None       Normal No   
B201 
No 
abnormality None       Normal No   
B210 
No 
abnormality None       Normal No   
B216 
No 
abnormality None       Normal No   
B232 17p deletion p.R248W 
c.742C>T Probably damaging Deleterious 
Biallelic Yes Hemizygous 
B264 
No 
abnormality None       Normal No   
B272 
No 
abnormality None       Normal No   
B273 
No 
abnormality None       Normal No   
B282 17p CNN-LOH p.Y234C 
c.701A>G Probably damaging Deleterious 
Biallelic Yes Homozygous 
B284 
No 
abnormality None       Normal No   
B285 17p deletion None       Monoallelic Yes 






c.848G>C Probably damaging Deleterious 
Monoallelic Yes 1 Mutation only 
B287 
No 




c.770T>A Probably damaging Deleterious 




c.838A>G Probably damaging Deleterious 
Monoallelic Yes 1 Mutation only 
B294 
No 




c.700T>A Probably damaging Deleterious 
Monoallelic Yes 1 Mutation only 
B309 
No 
abnormality None       Normal No   
B311 
No 
abnormality None       Normal No   
B313 
No 
abnormality None       Normal No   
B314 
No 
abnormality None       Normal No   
B321 
No 
abnormality None       Normal No   
B324 
No 
abnormality None       Normal No   
B326 
No 






c.817C>T, c.613T>C Probably damaging, Probably 
damaging 
Deleterious, 
Neutral Biallelic Yes 2 Mutations 
B343 
No 




c.638G>A Probably damaging Deleterious 




c.405C>G Probably damaging Deleterious 
Monoallelic Yes 1 Mutation only 
B349 
No 
abnormality None       Normal No   
B361 
No 
abnormality None       Normal No   
B363 17p deletion None       Monoallelic Yes 





c.706T>A Probably damaging Deleterious 
Monoallelic Yes 1 Mutation only 
B371 
No 




c.700_701delTAinsCG Possibly damaging No Data 
Monoallelic Yes 1 Mutation only 
B375 
No 
abnormality None       Normal No   
B389 
No 





c.718A>C Probably damaging Deleterious 




c.523C>T Probably damaging Deleterious 




c.524G>A Possibly damaging Deleterious 




c.742C>T Probably damaging Deleterious 




c.734G>A Probably damaging Deleterious 
Monoallelic Yes 1 Mutation only 
B420 
No 
abnormality None       Normal No   
B422 17p deletion p.R248Q 
c.743G>A Probably damaging Deleterious 
Biallelic Yes Hemizygous 
B423 
No 




c.695T>C Benign Neutral 






c.691A>G, c.745A>G Benign, Probably damaging Neutral, 
Deleterious Biallelic Yes 2 Mutations 
B453 17p CNN-LOH p.Y205F 
c.613_614ins(1) No data (Frameshift) No data 
(Frameshift) Biallelic Yes Homozygous 
B459 
No 




c.736A>G Probably damaging Neutral 
Monoallelic Yes 1 Mutation only 
B483 
No 
abnormality NA       NA     
B492 
No 




c.536A>T Benign Deleterious 
Monoallelic Yes 1 Mutation only 
B498 
No 
abnormality NA       NA     
B501 
No 




c.700_701delTAinsCG Possibly damaging No Data 
Monoallelic Yes 1 Mutation only 
B509 
No 
abnormality None       Normal No   
B516 
No 
abnormality NA       NA     
B520 
No 
abnormality None       Normal No   
B536 
No 




c.524G>A Possibly damaging Deleterious 
Monoallelic Yes 1 Mutation only 
B550 
No 




abnormality None       Normal No   
B558 17p deletion p.R248W 
c.742C>T Probably damaging Deleterious 
Biallelic Yes Hemizygous 
B570 
No 




c.546C>A No data (nonsense) No data 
(nonsense) Monoallelic Yes 1 Mutation only 
B583 17p deletion None       Monoallelic Yes 
Loss + No 
mutation 
B595 17p deletion None       Monoallelic Yes 





c.569C>T Possibly damaging Neutral 
Monoallelic Yes 1 Mutation only 
B624 
No 




c.569C>T Possibly damaging Neutral 
Monoallelic Yes 1 Mutation only 
B643 17p deletion None       Monoallelic Yes 








c.395A>G Probably damaging Deleterious 
Monoallelic Yes 1 Mutation only 
B674 
No 




c.455C>T Probably damaging Deleterious 
Monoallelic Yes 1 Mutation only 
B678 
No 
abnormality None       Normal No   
B679 
No 
abnormality None       Normal No   
B680 17p CNN-LOH p.R282W 
c.844C>T Probably damaging Deleterious 
Biallelic Yes Homozygous 
B681 
No 
abnormality None       Normal No   
B686 17p deletion p.R175H 
c.524G>A Possibly damaging Deleterious 
Biallelic Yes Hemizygous 
B697 
No 
abnormality None       Normal No   
B709 
No 
abnormality None       Normal No   
B721 
No 
abnormality None       Normal No   
B730 
No 
abnormality NA       NA     
B738 
No 
abnormality None       Normal No   
B755 
No 
abnormality None       Normal No   
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B766 17p deletion None       Monoallelic Yes 
Loss + No 
mutation 
B767 17p CNN-LOH p.Y236C 
c.707A>G Probably damaging Deleterious 
Biallelic Yes Homozygous 
B773 
No 




c.817C>T Probably damaging Deleterious 
Monoallelic Yes 1 Mutation only 
B780 17p deletion p.C176S 
c.526T>A Possibly damaging Deleterious 
Biallelic Yes Hemizygous 
B800 
No 
abnormality None       Normal No   
B803 
No 
abnormality None       Normal No   
B808 17p deletion p.Y234C, p.M237I 
c.701A>G, c.711G>A Probably damaging, Probably 
damaging 
Deleterious, 
Deleterious Biallelic Yes Hemizygous 
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